{
  "data": [
    {
      "paragraphs": [
        {
          "qas": [
            {
              "id": "61f80d5d882a024a1000003c_001",
              "question": "Do only changes in coding regions of MEF2C cause developmental disorders?"
            }
          ],
          "context": "de novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\nclinical genetic testing of protein - coding regions identifies a likely causative variant in only around half of developmental disorder ( dd ) cases\npossible mutations within highly conserved fetal brain - active elements cause neurodevelopmental disorders with a domi \" \" t mechanism.\n. here we show that de novo mutations in highly evolutionarily conserved fetal brain - active elements are significantly and specifically enriched in neurodevelopmental disorders\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\nmissense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy.\n. we identified de novo mutations in three classes of putative regulatory elements in almost 8, 000 patients with developmental disorders\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\n. we also show how non - coding variants can help inform both the disease - causing mechanism underlying protein - coding variants and dosage tolerance of the gene."
        },
        {
          "qas": [
            {
              "id": "62211c853a8413c65300006d_001",
              "question": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?"
            }
          ],
          "context": ". circrnas are generally produced by a noncanonical splicing event called backsplicing that is dependent on the canonical splicing machinery, giving rise to circrnas classified into three main categories : exonic circrna, circular intronic rna, and\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\nrecent studies have identified a new class of ncrnas called circular rnas ( circrnas ), which are produced by back - splicing and fusion of either exons, introns, or both exon - intron into covalently closed loops.\ncompared to the linear rna, circrnas are produced differentially by backsplicing exons or lariat introns from a pre - messenger rna ( mrna ) forming a covalently closed loop structure missing 3'poly - ( a ) tail or 5'cap, rendering them immune to\nhuman transcriptome contains a large number of circular rnas ( circrnas ) that are mainly produced by back splicing of pre - mrna.\nexonic circrna, circular intronic rna, and exon - intron circular rna.\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\ncircrnas are a large class of endogenous single - stranded rna that is different from other linear rna, which are produced by back - splicing and fusion of either exons, introns, or both exon - intron into covalently closed loops.\nexonic circular rnas ( circrnas ) are rna molecules that are covalently closed by back - splicing via canonical splicing machinery.\nfor either a new type of circrna ( including only part of the exon : sub - exonic circrnas ) or, even more rarely, mono - exonic canonical circrnas."
        },
        {
          "qas": [
            {
              "id": "620c27e93a8413c653000006_001",
              "question": "Is METTL1 overexpression associated with better patient survival?"
            }
          ],
          "context": "here we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n. conversely, mettl1 overexpression induces oncogenic cell transformation and cancer.\n. furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\n. immunohistochemical staining using 406 nsclc and 265 escc specimens confirmed that ly6k overexpression was associated with poor prognosis for patients with nsclc ( p = 0. 0003 ), as well as escc ( p = 0. 0278 ), and multivariate analysis confirmed its\nour data revealed that the amount of especially cd204 + tams increases with malig \" \" cy grade. in grade iii - iv, high cd204 expression was associated with shorter survival, while high iba - 1 intensity correlated with a longer survival\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\n. in grade iv, cd204 showed independent prognostic value when adjusting for clinical data and the methylation status of o6 - methylguanine - dna methyltransferase.\ngrhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\n. in addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 hgsocs ( hr = 0. 74, 95 % ci = 0. 61 - 0. 90, log - rank p = 0. 002 ) and 675 high - figo stage hgsocs ( hr = 0. 76, 95 % ci = 0. 61 - 0. 96, log - rank p\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells."
        },
        {
          "qas": [
            {
              "id": "61f80c37882a024a1000003b_001",
              "question": "Do mutations in KCNT2 only cause phenotypes with epilepsy?"
            }
          ],
          "context": "kcnt2 variants resulting in substitutions affecting the arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt\n. this is the first report of pathogenic variants in kcnt2 causing a developmental phenotype without epilepsy.\n. notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\nchromosome aberrations in which epilepsy is a major and consistent finding include angelman syndrome due to loss of the maternal 15q11. 2 - q12 segment, tetrasomy of the maternal segment 15pter - q13 due to an additional inv dup chromosome, miller - dieker\n. our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\nde novo truncating mutations in wasf1 cause intellectual disability with seizures.\nmissense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy.\nto investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\n. these gain - of - function effects are likely to increase neuronal excitability consistent with the epileptic potential of fhf2 variants\n. we report two additional individuals with intellectual disability, dysmorphic features, hypertrichosis, macrocephaly and the same de novo kcnt2 missense variants affecting the arg190 residue as previously described"
        },
        {
          "qas": [
            {
              "id": "61f593f8882a024a1000000f_001",
              "question": "Is there an association between pyostomatitis vegetans and Crohn's disease?"
            }
          ],
          "context": "[ pyostomatitis vegetans and crohn's disease. a specific association of 2 diseases ].\npyostomatitis vegetans is frequently associated with chronic inflammatory bowel diseases and can, thus, give a diagnostic hint at an existing ulcerative colitis or crohns disease.\noral crohn's disease and pyostomatitis vegetans. an unusual association.\npyostomatitis vegetans is a specific marker for ulcerative colitis and crohn's disease.\npyostomatitis vegetans : a clue for diagnosis of silent crohn's disease.\npyostomatitis vegetans ( pv ) is a rare, chronic mucocutaneous disorder associated with inflammatory bowel disease ( ibd )\nsuccessful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with crohn's disease.\npyostomatitis vegetans, and bowel - associated dermatosis - arthritis syndrome.\nintroduction : pyostomatitis vegetan ( pv ) is often associated with chronic inflammatory bowel disease ( ibd ). observation : tw\n. clinical manifestations improved dramatically with prednisone. discussion : this case of pyostomatitis - pyodermatitis vegetans involved several aspects rarely reported in the literature : a ) the cutaneomucosal signs were inaugural ; b ) the association"
        },
        {
          "qas": [
            {
              "id": "6217e1ac3a8413c653000031_001",
              "question": "Is serotonin transported by platelets?"
            }
          ],
          "context": "platelets transport and store virtually all plasma serotonin in dense granules\nactivated platelets, which carry peripheral serotonin,\nplatelet serotonin response was measured by serotonin augmented platelet aggregation and platelet serotonin receptor density.\nplatelet - dense granules contain neurotransmitters such as serotonin and gamma - aminobutyric acid. molecular players controlling granule formation and secretion are\nsert was studied in the 1970s and 1980s using membrane vesicles isolated from blood platelets.\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nsoluble transferrin receptor - 1 ( stfr1 ) concentrations are increased in the plasma under two conditions that are associated with increased iron absorption, i. e. iron deficiency and increased erythropoiesis.\nthese data indicate that iron delivered via transferrin and its receptor is intrinsically involved in oligodendrocyte maturation and thus plays a critical role in the onset of myelination.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney."
        },
        {
          "qas": [
            {
              "id": "61f59592882a024a10000010_001",
              "question": "Is Sotrovimab effective for COVID-19?"
            }
          ],
          "context": "the food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness.\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nms that monoclonal antibodies ( e. g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab ) are a better choice for treating severe or non - severe covid - 19 patients. clini\nin patients with non - severe covid - 19, casirivimab - imdevimab probably reduces hospitalisation ; bamlanivimab - etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. convalescen\ntecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\ncurrently, evidence on efficacy and safety of ivermectin for prevention of sars - cov - 2 infection and covid - 19 treatment is conflicting.\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\ntherefore, many - but not all - of the antibody products with emergency use authorization should retain substantial efficacy against the prevailing variant strains of sars - cov - 2.\nwe collected serological data of patients with covid - 19 who were treated with regn - cov 1200 mg ( casirivimab 600 mg / imdevimab 600 mg )."
        },
        {
          "qas": [
            {
              "id": "621b5bcc3a8413c65300003d_001",
              "question": "Is Otolin-1 a matrix protein?"
            }
          ],
          "context": "otoconia matrix protein, otolin - 1\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\nmammalian otolin : a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein otoconin - 90 and cerebellin - 1\nbinds to otolin - 1 and forming matrix protein architectures\netrin - 1 is a laminin - related secreted protein, is highly induced after tissue injury, and may serve as a marker of injury.\nthe essential role of iron in the development of oligodendrocytes.\nexpression of \u03b1 - taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.\nprecise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility.\naccumulating evidence demonstrates the involvement of asporin in oa pathogenesis.\nthe collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease."
        },
        {
          "qas": [
            {
              "id": "620aedee3a8413c653000001_001",
              "question": "Is AGO2 related to cytokinesis?"
            }
          ],
          "context": "ago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\nautophagy is a homeostatic process involved in the turnover or elimination of cytoplasmic components, damaged organelles, and protein aggregates via a lysosomal degradation mechanism.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\n. the tumor - suppressing function of cyld is associated with its deubiquitinating activity, which maps to the carboxyl - terminal region of the protein\nautophagy is a cellular survival pathway that is necessary for the degradation of cellular constituents such as long - lived proteins and damaged organelles.\nautophagy is a lysosome - associated, degradative process that catabolizes cytosolic components to recycle nutrients for further use and maintain cell homeostasis.\nnotably, the expression of nanog, a key pluripotency regulator and repressor of extraembryonic endoderm specification in es cells, was significantly reduced in zic3 knockdown cells.\nautophagy is known as a catabolic process for the recycling of the cytoplasmic macromolecules.\nautophagy is a self - eating process, in which the damaged or excessed cell organelles and misfolded protein aggregates are removed from the cellular microenvironment.\n, it is largely unknown how misfolded polypeptides form aggresomes and are eventually cleared by the aggresome - macroautophagy / autophagy pathway, so - called aggrephagy."
        },
        {
          "qas": [
            {
              "id": "621b61833a8413c65300003e_001",
              "question": "Is the protein HOXA11 associated with endometrial disease?"
            }
          ],
          "context": "both cd10 and hoxa11 have been implicated in regulation of endometrial homeostasis.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\nendometrial mrna and protein expression levels of hoxa10 and hoxa11 were significantly lower in patients with am than in control patients.\nfoxa1 is a key determi \" \" t of estrogen receptor function and endocrine response.\nfurthermore, knockdown of foxa1 expression blocks the association of er with chromatin and estrogen - induced gene expression demonstrating the necessity of foxa1 in mediating an estrogen response in breast cancer cells.\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\nfoxa1 expression could be a prognostic marker in er - positive breast cancer.\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nfoxa1 determines estrogen receptor action in breast cancer progression"
        },
        {
          "qas": [
            {
              "id": "621ed10f3a8413c653000062_001",
              "question": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?"
            }
          ],
          "context": "regulatory t cells ( tregs ) are cd4 ( + ) cd25 ( bright ) cd62l ( high ) cells that actively down - regulate immune responses.\ncd4 + cd25 + t regulatory cells ( tregs ) are classified as a subset of t cells whose role is the suppression and regulation of immune responses to self and non - self.\ncd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are negative regulators of the immune system that induce and maintain immune tolerance.\ncd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are potent modulators of immune responses.\nregulatory cd4 ( + ) cd25 ( + ) t ( treg ) cells with the ability to suppress host immune responses against self - or non - self antigens play important roles in the processes of autoimmunity, transplant rejection, infectious diseases and cancers.\ncd4 ( + ) cd25 ( + ) regulatory t cells ( treg ) play a central role in the prevention of autoimmunity and in the control of immune responses by down - regulating the function of effector cd4 ( + ) or cd8 ( + ) t cells.\ncd4 + cd25 + regulatory t cells ( tregs ) are essential negative regulators of immune responses.\naccumulating evidence has demonstrated that naturally occurring cd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are critical for mainte \" \" ce of immunological tolerance and have been shown to be important in regulating the immune responses in many diseases\nobjectives : cd4cd25 regulatory t cells ( tregs ) play a key role in the prevention of various inflammatory and autoimmune disorders by suppressing immune responses.\nnaturally occurring cd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are essential for the active suppression of autoimmunity."
        },
        {
          "qas": [
            {
              "id": "5fdb4100a43ad31278000015_001",
              "question": "Is Mediator present at super enhancers?"
            }
          ],
          "context": "super - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\nfurthermore, the binding of sim2 marks a particular sub - category of enhancers known as super - enhancers. these regions are characterized by typical dna modifications and mediator co - occupancy ( med1 and med12 ).\nbrd4 and mediator were found to co - occupy thousands of enhancers associated with active genes.\nthe term'super - enhancer'has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of mediator binding, as measured by chromatin immunoprecipitation and sequencing ( chip - seq ).\nmany genes determining cell identity are regulated by clusters of mediator - bound enhancer elements collectively referred to as super - enhancers.\nthese domains, which we call super - enhancers, consist of clusters of enhancers that are densely occupied by the master regulators and mediator\nmediator kinase inhibition further activates super - enhancer - associated genes in aml.\na number of studies have recently demonstrated that super - enhancers, which are large cluster of enhancers typically marked by a high level of acetylation of histone h3 lysine 27 and mediator bindings, are frequently associated with genes that control\nsuper - enhancers and preventing cross talk between distinct regulatory elements.\n. we show that setd1a binds both promoters and enhancers with a striking overlap between setd1a and mef2 on enhancers"
        },
        {
          "qas": [
            {
              "id": "62057b35c9dfcb9c0900002d_001",
              "question": "Does atemoya juice inhibit the CYP1A2 enzyme?"
            }
          ],
          "context": "the results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nepoxyeicosatrienoic acids ( eets ) are formed from arachidonic acid by the action of p450 epoxygenases ( cyp2c and cyp2j ).\nepoxyeicosatrienoic acids ( eets ) are generated from arachidonic acid by cytochrome p450 ( cyp ) epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are epoxides of arachidonic acid generated by cytochrome p450 ( cyp ) epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are arachidonic acid metabolites produced by cytochrome p450 epoxygenases which are highly expressed in hepatocytes.\ncitrus fruits, and its aglycone hesperetin using cell - free bioassay system and primary cultured rat cortical cells.\nepoxyeicosatrienoic acids ( eets ) are potent lipid mediators formed by cytochrome p450 epoxygenases from arachidonic acid."
        },
        {
          "qas": [
            {
              "id": "6217dc9d3a8413c65300002d_001",
              "question": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?"
            }
          ],
          "context": "neurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\nserum neurofilament light chain ( snfl ) is a marker of neuroaxonal injury.\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nneurofilament light chain ( nfl ) has recently been proposed as a promising biomarker in frontotemporal dementia ( ftd )\nneurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with alzheimer's dementia, and psychiatric disorders.\nbnfl can be used as a potential biomarker to predict disease onset, severity, and progression of genetic ataxia.\nhere we report that, following sciatic nerve injury, mlkl, a pseudokinase known to rupture cell membranes during necroptotic cell death, is induced and targets the myelin sheath membrane of schwann cells to promote myelin breakdown.\nrecently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\nsystematic quantification of neurotrophic adipokines rbp4, pedf, and clusterin in human cerebrospinal fluid and serum."
        },
        {
          "qas": [
            {
              "id": "621ebec63a8413c65300005d_001",
              "question": "Is Epistaxis associated with dental implant placement?"
            }
          ],
          "context": ". this could be associated with minor complications ranging from epistaxis to sinusitis, which are manageable.\n. the most frequent clinical complication was the epistaxis,\nthe overall survival rate of the implants into the sinus cavity was 95. 6 %, without statistical differences according to the level of penetration. the clinical and radiological complications were 3. 4 % and 14. 8 % respectively\nin a healthy adolescent male as a possible complication of subclinical frontal sinusitis.\nimplant placement and protrusion of the implant up to 3mm beyond the sinus floor does not alter the stability and outcome of dental implants, one year post - restoration\nacute and chronic sinusitis can give rise to a wide array of intracranial and orbital complications. these complications include brain abscess, subdural empyema,\na 26 year old patient with a history of locally recurrent mandibular ameloblastoma who developed a temporal intracranial ameloblastoma tumor requiring a collaborative neurosurgical and maxillo - facial radical surgical approach. conclusion : although\nchronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.\nameloblastoma is the most common odontogenic tumor of epithelial origin, and though it is of a benign nature, it frequently infiltrates the bone, has a high rate of recurrence and could potentially become malig \" \" t.\nintracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures."
        },
        {
          "qas": [
            {
              "id": "61f58a1a882a024a10000009_001",
              "question": "Is Daprodustat effective for anemia?"
            }
          ],
          "context": "daprodustat for the treatment of anemia in patients not undergoing dialysis.\nand daprodustat may become an effective alternative for treatment of anemia with ckd.\ndaprodustat for the treatment of anemia in patients undergoing dialysis.\ndaprodustat is one of the orally administrated small - molecule hif - ph inhibitors, leading to an increase in erythropoietin production, which is regulated by hif. also, daprodustat is expected to improve iron metabolism\ndaprodustat is under development as an emerging new class of agents for the treatment of anemia associated with chronic kidney disease ( ckd ).\ndaprodustat is an oral hypoxia - inducible factor prolyl hydroxylase inhibitor developed for treating anemia of chronic kidney disease.\ndaprodustat, an oral hypoxia - inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease.\nbackground : daprodustat ( gsk1278863 ) is an oral hypoxia - inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease ( ckd ).\nconclusions : oral daprodustat was noninferior to cera in achieving and maintaining target hemoglobin levels in japanese nd patients.\nbackground : the anemia studies in chronic kidney disease ( ckd ) : erythropoiesis via a novel prolyl hydroxylase inhibitor ( phi ) daprodustat - dialysis ( ascend - d ) trial will test the hypothesis that daprodustat is non - inferior to comparator epoetin alfa"
        },
        {
          "qas": [
            {
              "id": "621218353a8413c653000013_001",
              "question": "Is REGN5458 a single-targeted antibody?"
            }
          ],
          "context": ". here we describe a fully human bsab ( regn5458 ) that binds to b - cell maturation antigen ( bcma ) and cd3, and compare its antitumor activities vs those of anti - bcma car t cells to identify differences in efficacy and mechanism of action.\ncd3 - engaging bispecific antibodies ( bsabs ) and chimeric antigen receptor ( car ) t cells are potent therapeutic approaches for redirecting patient t cells to recognize and kill tumors\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nanother cd20 directed mab, ofatumumab, is in phase 3.\nwe here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by bcma pyrrolobenzodiazepine ( pbd ) antibody drug conjugate ( adc ) medi2228 which can augment efficacy of these immunotherapies.\nresults from a phase i / ii trial suggest that an antibody - drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple - negative breast cancer. a\nmacroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti - cd20 - based therapy.\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\nthe emerging b - cell depleting therapies, particularly anti - cd20 agents such as rituximab, ocrelizumab, as well as the fully human ofatumumab, have shown promising clinical and magnetic reso \" \" ce imaging benefit.\nsacituzumab govitecan ( sg ), the first antibody - drug conjugate ( adc ) approved for triple - negative breast cancer, incorporates the anti - trop2 antibody hrs7 conjugated to a topoisomerase - 1 ( top1 ) inhibitor payload. we so"
        },
        {
          "qas": [
            {
              "id": "6020a7391cb411341a00007e_001",
              "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?"
            }
          ],
          "context": "finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti - il - 5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce csu symptoms.\n. the treatments that are under clinical trials for csu are anti - ige treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec - 8,\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\normation on the effects of the off - label use, in csu, of biologics licensed for the treatment of other diseases, including dupilumab, benralizumab, mepolizumab, reslizumab, and secukinumab. finally, we discuss\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nsmall molecules ( e. g. ligustrazine and sp600125 ) and large molecule antibodies ( e. g. lebrikizumab, benralizumab, dupilumab ) are being considered as novel agents for the pharmacotherapy of asthma.\nthe appropriate use of these biologics, and of those in development ( e. g., benralizumab and dupilumab ), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.\n. no adverse events were observed. routinely administered bel shows clinical efficacy on non - approved manifestations, but careful patient selection is warranted.\nalthough treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis."
        },
        {
          "qas": [
            {
              "id": "6217dd013a8413c65300002f_001",
              "question": "Do the proteins Talin and Amot interact?"
            }
          ],
          "context": "we show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\nwe show that menin physically interacts with proteins involved in the canonical wnt signaling pathway, including beta - catenin, tcf3 ( tcfl1 ), and weakly with tcf4 ( tcfl2 ).\nbinds to otolin - 1 and forming matrix protein architectures\nwhile analyzing chromatin immunoprecipitation data sets from 21 sequence - specific transcription factors active in the drosophila embryo, we found that binding of all factors exhibits a dose - dependent relationship with \" tagteam \" sequence motifs bound\n. we demonstrate that tiam1 shuttles between the cytoplasm and nucleus antagonizing taz / yap by distinct mechanisms in the two compartments\nhowever, the model requires a motor to generate the loops, and although cohesin is a strong candidate for the extruding factor, a suitable motor protein ( or a motor activity in cohesin itself ) has yet to be found\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\nhydin was recently identified as an axonemal protein ; however, its function is as yet unknown.\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\nthe results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs."
        },
        {
          "qas": [
            {
              "id": "6220cbf83a8413c653000067_001",
              "question": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?"
            }
          ],
          "context": "secondly, the degradation of some mrnas related to immune responses has been reported to be regulated by binding of rna - binding proteins to adenylate uridylate - rich elements ( au - rich elements, ares ) located in the 3'- untranslated region ( 3'- utr ).\nin the 3'- untranslated region, the destabilizing adenine - uridine ( au ) - rich elements ( ares ) control the expression of several transcripts through interactions with are - binding proteins ( aubps ) and rna degradation machinery.\npost - transcriptional mrna regulation by rna binding proteins ( rbps ) associated with au - rich elements ( ares ) present in the 3'untranslated region ( 3'utr ) of specific mrnas modulates transcript stability and translation in eukaryotic cells.\nthese proteins bind to adenine uridine - rich element ( are ) in the 3'untranslated region of target messenger rna and stimulate target degradation.\nt mrnas. rna - binding proteins can control mrna stability by binding to au - and u - rich elements located in the 3'- untranslated regions ( 3'- utrs ) of target\nhu proteins are rna - binding proteins that are implicated in the control of stabilization, nuclear export, and / or translation of specific mrnas with au - rich elements ( ares ) in the 3'- untranslated region. th\nmber of the elav family of rna - binding proteins, has been implicated in this pathway through its binding to adenine and uridine ( au ) - rich stability elements ( are ) located in the 3'untranslated regions ( 3'- utrs ) of the mrna. whereas three\nthe au / u - rich element - binding protein hur has been shown to bind to p53 mrna 3'utr and enhance translation in response to dna - damaging uvc radiation.\nhu proteins have been shown to bind to au - rich elements ( ares ) in the 3'- untranslated region of unstable mrnas.\nadenylate / uridylate - rich elements ( ares ) are the most common cis - regulatory elements in the 3'- untranslated region ( utr ) of mrnas, where they fine - tune turnover by mediating mrna decay."
        },
        {
          "qas": [
            {
              "id": "6211566a3a8413c653000010_001",
              "question": "Has CPX-351 been approved by the FDA and the EMA?"
            }
          ],
          "context": "cpx - 351 ( united states : vyxeos\u00ae ; europe : vyxeos\u00ae liposomal ), a dual - drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1 : 5 molar ratio, is approved by the us fda and the ema for the treatment of adults with newly diagnosed\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\nin august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\nthe responses seen with venetoclax in rrmm with t ( 11 ; 14 ) ( high bcl - 2, low bcl - xl and mcl - 1 ) and selinexor in penta - refractory myeloma which fulfills the fda category of unmet need, opens up newer options for these patients.\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nchimeric antigen receptor t cells demonstrate efficacy in b - cell malig \" \" cies, leading to us food and drug administration approval of axicabtagene ciloleucel ( october 2017 ) and tisagenlecleucel ( may 2018 ) for large b - cell lymphomas after 2 prior lines\nthe fda granted accelerated approval to selinexor plus low - dose dexamethasone for triple - class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data."
        },
        {
          "qas": [
            {
              "id": "6217dc173a8413c65300002b_001",
              "question": "Do we find bacteriophages in the gut?"
            }
          ],
          "context": "bacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nalready without exogenous intervention, a multitude of phage - bacterial interactions occur within the human gut, some of which might play a direct role in disease progression\nwe are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies.\n. despite their high prevalence, we have an incomplete understanding of how crassphages shape and respond to ecological and evolutionary dynamics in the gut.\ncrassphages are a broad group of diverse bacteriophages in the order caudovirales that have been found to be highly abundant in the human gastrointestinal tract\nour findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\nirradiation profoundly impacted gut microbiota profiles in both animals.\n. our study describes a distinct mutational signature in colorectal cancer and implies that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin - producing pks pathogenicity island.\n. here we expose human intestinal organoids to genotoxic pks + e. coli by repeated luminal injection over five months\na multitude of symbiotic bacteria and bacteriophages are decreased in abundance in patients with covid - 19"
        },
        {
          "qas": [
            {
              "id": "601d6fe11cb411341a000033_001",
              "question": "Is tirabrutinib effective for lymphoma?"
            }
          ],
          "context": ". this article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in japan.\nhistological verification of the treatment effect of tirabrutinib for relapsed / refractory primary central nervous system lymphoma.\nin march 2020, oral tirabrutinib was approved in japan for the treatment of recurrent or refractory primary central nervous system lymphoma.\ntirabrutinib was well tolerated and showed promising efficacy for b - cell nhl / cll.\nhere, we provide a comprehensive review of the preclinical and clinical activity of tirabrutinib, a drug approved in japan for relapsed or refractory primary central nervous system lymphoma and all lines of waldenstrom\n. tirabrutinib is also under regulatory review in japan for the treatment of waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma\nconclusion : these data indicate favorable efficacy of tirabrutinib in patients with relapsed / refractory pcnsl.\nprimary central nervous system lymphoma ( pcnsl ). methods : patients with relapsed / refractory pcnsl, karnofsky performance status \u226570, and normal end - organ function received tirabrutinib 320 and 480\nthe phase ii juliet trial suggests that the cd19 - targeting car t - cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large b - cell lymphoma.\nor refractory diffuse large b - cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel."
        },
        {
          "qas": [
            {
              "id": "621ea5a53a8413c653000055_001",
              "question": "Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?"
            }
          ],
          "context": "epoxyeicosatrienoic acids ( eets ), synthesized from arachidonic acid by cytochrome p450 epoxygenases, are converted to dihydroxyeicosatrienoic acids by soluble epoxide hydrolase.\nepoxyeicosatrienoic acids ( eets ), synthesized by cytochrome p450 epoxygenases from arachidonic acid.\nepoxyeicosatrienoic acids ( eets ) are synthesized from arachidonic acid by cytochrome p450 epoxygenases in endothelial cells.\nepoxyeicosatrienoic acids ( eets ) are generated from arachidonic acid by cytochrome p450 ( cyp ) epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are epoxides of arachidonic acid generated by cytochrome p450 ( cyp ) epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are arachidonic acid metabolites produced by cytochrome p450 epoxygenases which are highly expressed in hepatocytes.\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nepoxyeicosatrienoic acids ( eets ) are bioactive eicosanoids produced from arachidonic acid by cytochrome p450 epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are formed from arachidonic acid by the action of p450 epoxygenases ( cyp2c and cyp2j ).\nbiologically active epoxyeicosatrienoic acid ( eet ) regioisomers are synthesized from arachidonic acid by cytochrome p450 epoxygenases of endothelial, myocardial, and renal tubular cells."
        },
        {
          "qas": [
            {
              "id": "6027446d1cb411341a0000dd_001",
              "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?"
            }
          ],
          "context": "interpretation : our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful pci, does not influence the recurrence of angina or the outcome ; these\nthe recurrence of angina or the outcome ; these findings should be taken into account when considering the place of trimetazidine in clinical practice.\nconclusions : tranexamic acid did not affect a patient's functional status at 90 days after ich, despite there being significant modest reductions in early death ( by 7 days ), haematoma expansion and saes, which is consistent with an antifibrinolytic\nconclusions simvastatin showed no benefits in decreasing the incidence of vasospasm, dci, or all - cause mortality after aneurysmal sah. we conclude that patients with sah should not be treated routinely with simvastatin during the acute stage.\nthese findings suggest that greater exposure to isradipine might slow disease progression.\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah ).\n. none of the deaths was considered related to study medication. interpretation : our study does not provide evidence that tranexamic acid prevents intracerebral haemorrhage growth, although the treatment was safe with no increase in thromboembolic\naceis / arbs are protective factors against mortality in covid - 19 patients with htn, and these agents can be considered potential therapeutic options in this disease.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\ninterpretation : functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events."
        },
        {
          "qas": [
            {
              "id": "62211d6f3a8413c65300006f_001",
              "question": "Are circRNAs susceptible to degradation by RNase R?"
            }
          ],
          "context": "as circular rnas ( circrnas ) are resistant to degradation by exonucleases, their abundance relative to linear rnas can be used as a surrogate marker for mrna stability in the absence of transcription.\n. in comparison to linear rnas, circrnas are more resistant to exonuclease rnase r - mediated degradation with a much stronger stability due to the absence of 3'terminals\nis stable, difficult to cleave and resistant to rna exonuclease or rnase r degradation. circrn\n. due to lack of 3'termini, circrnas are more resistant to degradation by exonuclease rnase r and possess greater stability than linear rnas.\ndue to lack of 3'termini, circrnas are more resistant to degradation by exonuclease rnase r and possess greater stability than linear rnas.\nbecause circrnas are not easily degraded by exonuclease rnase r, they can exist more stably in body fluids than linear rnas.\ncircrnas are a kind of closed circular rna molecule widely existing in transcriptomes. due to lack of free ends, they are not easily cleaved by rnase r, thus avoiding degradation.\nwe propose that such an r - loop dependent cirna degradation likely represents a mechanism that on one hand limits cirna accumulation by recruiting rnase h1 and on the other hand resolves r - loops for transcriptional elongation at some gc - rich\nis a strong 3'to 5'exoribonuclease, which efficiently degrades linear rnas, such as mrnas and rrnas ; therefore, the circular parts of lariat rnas and the circrnas can be segregated from eukaryotic total rnas by their rnase r resistance. thus, rnase\nthe unique structures, circrnas are resistant to exonuclease rnase r and maintain stability more easily than linear rnas. rece"
        },
        {
          "qas": [
            {
              "id": "62057f1ec9dfcb9c0900002e_001",
              "question": "Does atemoya juice inhibit tye CYP3A4 enzyme?"
            }
          ],
          "context": "the results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\nepoxyeicosatrienoic acids ( eets ) are potent lipid mediators formed by cytochrome p450 epoxygenases from arachidonic acid.\nepoxyeicosatrienoic acids ( eets ) are epoxides of arachidonic acid generated by cytochrome p450 ( cyp ) epoxygenases.\nepoxyeicosatrienoic acids ( eets ) are arachidonic acid metabolites produced by cytochrome p450 epoxygenases which are highly expressed in hepatocytes.\nepoxyeicosatrienoic acids ( eets ) are formed from arachidonic acid by the action of p450 epoxygenases ( cyp2c and cyp2j ).\nepoxyeicosatrienoic acids ( eets ) are generated from arachidonic acid by cytochrome p450 ( cyp ) epoxygenases."
        },
        {
          "qas": [
            {
              "id": "6217db763a8413c653000028_001",
              "question": "Is Mycobacterium abscessus a human pathogen?"
            }
          ],
          "context": "mycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non - tuberculous mycobacteria ( ntm ) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost.\nmycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug resistance.\nmycobacterium abscessus lung disease is difficult to treat due to intrinsic drug resistance and the persistence of drug - tolerant bacteria.\nmycobacterium abscessus is unique in terms of its high morbidity and treatment failure rates\nlemierre's syndrome secondary to fusobacterium necrophorum infection, a rare cause of hepatic abscess.\nlemierre's disease : postanginal bacteremia and pulmonary involvement caused by fusobacterium necrophorum.\nclostridium difficile is a spore - forming obligate anaerobe that is a leading cause of healthcare - associated infections\n. pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombit protein, patient - derived fibroblasts, plasma, and erythrocytes\nthese infectious yeast amyloidoses are outstanding models for the many common human amyloid - based diseases that are increasingly found to have some infectious characteristics. < br >\nmucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies."
        },
        {
          "qas": [
            {
              "id": "62121c583a8413c653000016_001",
              "question": "Is MEDI2228 a bispecific antibody?"
            }
          ],
          "context": ". sacituzumab govitecan is an antibody - drug conjugate composed of an antibody targeting the human trophoblast cell - surface antigen 2 ( trop - 2 ), which is expressed in the majority of breast cancers, coupled to sn - 38 ( topoisomerase i inhibitor ) through\nresults from a phase i / ii trial suggest that an antibody - drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple - negative breast cancer. a\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer.\nwe here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by bcma pyrrolobenzodiazepine ( pbd ) antibody drug conjugate ( adc ) medi2228 which can augment efficacy of these immunotherapies.\nis a monoclonal antibody that works directly against the spike protein of sars - cov - 2 to block its attachment and entry into a human cell.\n6 receptor ( il - 6r ) monoclonal antibody ( tocilizumab ), represents a major breakthrough for the treatment of immune - mediated disorders.\nsacituzumab govitecan ( sg ) is a novel antibody - drug conjugate ( adc ) that has shown promising efficacy in mtnbc\n. here we describe a fully human bsab ( regn5458 ) that binds to b - cell maturation antigen ( bcma ) and cd3, and compare its antitumor activities vs those of anti - bcma car t cells to identify differences in efficacy and mechanism of action.\nbiological ( b ) dmards ( tumour necrosis factor inhibitors ( adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ), abatacept, rituximab, tocilizumab, sarilumab and biosimilar ( bs ) dmards ) and targeted synthetic ( ts ) dmards ( the janus\na phase ii study indicates that sacituzumab govitecan ( immu - 132 ), a trop - 2 - specific antibody linked to the irinotecan metabolite sn - 38, prolongs the progression - free survival of patients with advanced triple - negative breast cancer. i"
        },
        {
          "qas": [
            {
              "id": "601c4ff61cb411341a000022_001",
              "question": "Is proton beam therapy used for treatment of craniopharyngioma?"
            }
          ],
          "context": "reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull - base sarcomas, and unresectable meningiomas. conclusions : use of proton beam th\ninitial experience with proton beam therapy in childhood - onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment.\nlts : published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull - base sarcomas, and unresectable meningiomas. conc\npencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation - induced cerebral vasculopathies : a dosimetric and linear energy transfer ( let ) evaluation.\nwe hereby report a case of a 7 - year - old boy with a craniopharyngioma which had been subtotally resected and was subsequently treated with modern pencil beam proton therapy under high - precision image guidance.\nproton therapy for craniopharyngioma in adults : a protocol for systematic review and meta - analysis.\npurpose : we report the results of the early cohort of patients treated for craniopharyngioma with combined proton - photon irradiation at the massachusetts general hospital and the harvard cyclotron laboratory. methods and materials : between 1981 and\nproton radiation has been used safely and effectively for medulloblastoma, primitive neuro - ectodermal tumors, craniopharyngioma, ependymoma, germ cell intracranial tumors, low - grade glioma, retinoblastoma, rhabdomyosarcoma and other soft tissue\nclinical equipoise : protons and the child with craniopharyngioma.\npopulation. we evaluated the outcomes of all adult craniopharyngioma patients treated at our institution using proton therapy to report outcomes for disease control, treatment - related toxicity, and tumor response. methods : we analyzed 14 adult patie"
        },
        {
          "qas": [
            {
              "id": "601d73261cb411341a00003a_001",
              "question": "Is there a genetic cause of craniostenosis?"
            }
          ],
          "context": "recent genetic studies have identified several novel genes and pathways that cause nonsyndromic craniosynostosis, providing genetic evidence linking the causes of syndromic and nonsyndromic craniosynostoses, and allowing for genotype - based prediction\n[ genetic counseling in craniostenosis. results of a prospective study performed with a group of studies on craniofacial malformations ].\nidentification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis.\nand the embryological period in which the mutation itself occurs, a type of craniosynostosis arises that may involve one or more cranial sutures.\n. it is becoming clearer that in most patients with craniosynostosis, there is regional imbalance of skull growth, which co - exists with a variety of other equally important factors, such as genetic defects, raised intracranial pressure, venous\n. craniostenosis and developmental retardation were the primary presenting features in this patient.\nthe risk of both nonsyndromic and syndromic presentations of craniosynostosis, especially metopic synostosis\n1, 000 annual paediatric ct investigations of the skull will lead to about 3 excess neoplasms in the head region, i. e., the probability of an induced late effect must be suspected in the range of some thousandths.\nthrough which skull growth abnormalities are seen\n. characteristic malformations of the apert syndrome are early craniostenosis, microviscerocranium and ii - v finger syndactyly of hand and toes with proximal phalanx of the bilateral thumb \" in delta \"."
        },
        {
          "qas": [
            {
              "id": "620586a8c9dfcb9c09000032_001",
              "question": "Can bergapten cross the blood-brain barrier?"
            }
          ],
          "context": "good penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nthe blood - brain barrier ( bbb ) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.\nseveral brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro bbb model.\nthe blood - brain barrier ( bbb ) consists of endothelial cells, astrocytes, and pericytes embedded in basal lamina ( bl ).\nthe results showed the bbb penetration of azd3759 was decreased within 24 hr after radiation, however, the free concentration of azd3759 in brain kept at a high level in the context of radiation.\nfurthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\nwe report the discovery and early clinical development of azd3759, a selective egfr inhibitor that can fully penetrate the blood - brain barrier ( bbb ),\nhowever, the preliminary equivocal cognitive results obtained with bapineuzumab as well as the detrimental cognitive effects observed with semagacestat, a potent \u03b3 - secretase inhibitor, raise the possibility that targeting a\u03b2 may not be clinically\nthe next generation egfr tkis osimertinib and azd3759 have improved bbb penetration and the bloom study of osimertinib and azd3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically"
        },
        {
          "qas": [
            {
              "id": "620be4fd3a8413c653000002_001",
              "question": "Does TIMELESS-TIPIN participate in replisome disassembly?"
            }
          ],
          "context": "timeless - tipin and ubxn - 3 promote replisome disassembly during dna replication termination in caenorhabditis elegans.\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n. here, we show that the mcm2 - ctf4 - pol\u03b1 axis facilitates the transfer of parental ( h3 - h4 ) 2 tetramers to lagging - strand dna at replication forks\nthe tousled - like kinases ( tlks ) are involved in chromatin assembly, dna repair, and transcription. two tlk genes exist in humans, and their expression is often dysregulated in cancer. tlks phosphorylate asf1\n. in the cytoplasm, tiam1 localizes to the destruction complex and promotes taz degradation by enhancing its interaction with \u03b2trcp\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nthese structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\n. to investigate the molecular basis of tad formation, we performed hi - c experiments on cells depleted for the forkhead transcription factors, fkh1 and fkh2, previously associated with replication timing\ntwist - open mechanism of dna damage recognition by the rad4 / xpc nucleotide excision repair complex."
        },
        {
          "qas": [
            {
              "id": "60570fe494d57fd879000026_001",
              "question": "Is hemoglobin antimicrobial?"
            }
          ],
          "context": "beyond its physiological activity, hemoglobins are able to inhibit the growth of several microorganisms.\nthe \u03b1137 - 141 peptide, a natural antimicrobial peptide, can be obtained after hydrolysis of hemoglobin, the main constituent of blood red part\na novel amp, t. granosa hemoglobin - derived peptide ( tgh1 ), was identified and its antimicrobial effect\nwe determine that hbcs have the capacity to play a defensive role, where they are responsive to toll - like receptor stimulation and are microbicidal.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\n. this antimicrobial enzyme forms the part of the innate defense system of nearly all animals and exists in their somatic discharges such as milk, tears, saliva and urine.\nit is also the most studied bee product, aimed at unravelling its bioactivities, such as antimicrobial, antioxidant, anti - aging, immunomodulatory, and general tonic action against laboratory animals, microbial organisms, farm animals, and clinical\nlysozyme ( lzm ) is a natural anti - bacterial protein that is found in the saliva, tears and milk of all mammals including humans.\n. pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombit protein, patient - derived fibroblasts, plasma, and erythrocytes\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins."
        },
        {
          "qas": [
            {
              "id": "620588f9c9dfcb9c09000033_001",
              "question": "Can bergapten cause phototoxicity?"
            }
          ],
          "context": "furthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned.\n: we found evidence for low cardenolides by hplc, but substantial toxicity when extracts were assayed on na + / k + - atpases.\nit is possible, however, that the low incidence of clinically significant and fatal pulmonary toxicity, as experienced in this group of patients, may be related to the infusion of bleomycin.\nbleomycin might cause pulmonary fibrosis at higher cumulative doses as toxic effect directly to the lungs or most likely in addition by the formation of vascular microthrombi.\nfact that although intravesical administration of bacillus calmette - guerin is generally considered to be safe, it is not exempt from complications and these could appear immediately after treatment or as a delayed complication many years later.\ne in vivo determination of the spf. evidence of anti - inflammatory activity of the sunscreen antiphlogistics bisabolol and panthenol was also not apparent in the uv model over a time course of 48 h\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nmay be a candidate agent for neuroprotective treatment in the retina, after screening 41 materials for anti - oxidative properties in a primary retinal cell culture under oxidative stress.\nbleomycin sometimes causes fatal pulmonary toxicity, including bleomycin - induced pneumonitis.\npotential anti - inflammatory effects of hesperidin from the genus citrus."
        },
        {
          "qas": [
            {
              "id": "6217d9bf3a8413c653000024_001",
              "question": "Can IFNg induce the expression of IDO?"
            }
          ],
          "context": "ifng - induced up - regulation of indoleamine 2, 3 - dioxygenase ( ido )\nifn - \u03b3 - induced indoleamine - 2, 3 - dioxgenase ( ido )\nthe tryptophan - degrading activity of ido1 was not induced significantly by chlamydia infection alone, but the addition of ifng greatly increased its activity.\nstrong and positive correlation between ido1 and ifng mrna expression levels\nifng inducible ido / gtpch inflammation cascade\nwe found that cdcs from prediseased tcsle male mice express the ifn signature as female tcsle cdcs do. estrogens are necessary but not sufficient to express this ifn signature, but high doses of e2 can compensate for other steroidal components.\ngene expression and increased resistance to differentiation - inducing inflammatory stimuli\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\nactivated pscs expressed il - 33 in the nucleus, and the expression was increased by il - 1\u03b2, tnf - \u03b1, pdgf - bb, and ifn - \u03b3, but not tgf - \u03b21."
        },
        {
          "qas": [
            {
              "id": "602c2ade1cb411341a000124_001",
              "question": "Are TAMs good anticancer therapeutic targets?"
            }
          ],
          "context": "integrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nthe intercellular adhesion molecules ( icams ) are members of the immunoglobulin superfamily and have been identified to play major roles in inflammation and immune responses.\nthe immunosuppressive effects of cd4 + cd25 high regulatory t cells ( tregs ) interfere with antitumor immune responses in cancer patients.\nthalidomide and its immunomodulatory analogues have numerous effects on the body's immune system, including potential anti - cancer and anti - inflammatory activities.\nt regulatory cells ( tregs ) have a role in immunosuppression and control of autoimmunity, and are currently an important topic in the study of immune response to tumor cells.\ntherefore, we propose that cd4 ( + ) t cells that recognize secreted tsa may be superior for immunotherapy by t cell transfer, because the local extracellular antigen concentration will be higher for secreted tsa.\nwe found immune activation coexistent with elevation of multiple targetable immune checkpoint molecules, including pd - l1, pd - l2, pd - 1, tim - 3, b7 - h3, btla, and ctla - 4, along with increases in tumor infiltration by cd4 ( + ) foxp3 ( + ) regulatory t cells in"
        },
        {
          "qas": [
            {
              "id": "6027434c1cb411341a0000dc_001",
              "question": "Is gabapentin effective for chronic pelvic pain?"
            }
          ],
          "context": "gabapentin not effective for chronic pelvic pain in women.\ninterpretation : erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and cgrp probably does not have an important role in paroxysmal pain.\n. the mean average nrs pain score was 4 \u00b7 3 ( sd 2 \u00b7 3 ) in the gabapentin group and 4 \u00b7 5 ( sd 2 \u00b7 2 ) in the placebo group\ntreatment for crampsthere is evidence ( 13 rcts, n = 4012 ) that for the treatment of cramps in mnd, compared to placebo : - memantine and tetrahydrocannabinol ( thc ) are probably ineffective ( moderate - quality evidence ) ; - vitamin e may have little or no\n. the mean worst nrs pain score was 7 \u00b7 1 ( standard deviation [ sd ] 2 \u00b7 6 ) in the gabapentin group and 7 \u00b7 4 ( sd 2 \u00b7 2 ) in the placebo group\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion.\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for acute treatment of migraine, but have not yet been submitted to the fda for this indication.\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the fda for this indication.\nthe efficacy and safety of calcitonin gene - related peptide monoclonal antibody for episodic migraine : a meta - analysis. based on the results of this meta - analysis, cgrp monoclonal antibodies significantly reduced the monthly migraine days and acute"
        },
        {
          "qas": [
            {
              "id": "6056fbfc94d57fd87900001d_001",
              "question": "Does the royal jelly contain proteins?"
            }
          ],
          "context": "major royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\nnutrients such as 24 - methylenecholesterol, major royal jelly proteins, and 10 - hydroxy - 2 - decenoic acid.\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nwe observed differences in the metabolome, proteome, and phytosterol compositions of royal jelly synthesized by nurse bees from multi - pesticide exposed colonies, including significant reductions of key nutrients such as 24 - methylenecholesterol, major\nanalysis of drosophila yellow - b cdna reveals a new family of proteins related to the royal jelly proteins in the honeybee\njelleines, isolated as novel antibacterial peptides from the royal jelly ( rj ) of bees, exhibit broad - spectrum protection against microbial infections.\ntwo - dimensional electrophoresis was used for the fractionation of royal jelly proteins\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\nlysozyme ( lzm ) is a natural anti - bacterial protein that is found in the saliva, tears and milk of all mammals including humans."
        },
        {
          "qas": [
            {
              "id": "6217c0b63a8413c65300001e_001",
              "question": "Does UBE4B promote renal cancer?"
            }
          ],
          "context": "ube4b might act as an oncogene in regulating rcc development. therefore it could be served as an effective indicator to predict os and a potential biomarker for targeted therapy of rcc patients.\nthe au / u - rich element - binding protein hur has been shown to bind to p53 mrna 3'utr and enhance translation in response to dna - damaging uvc radiation.\npecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\nrecurrent superficial urothelial bladder cancer seem to be linked to immunological effector mechanisms.\n. since the human orthologue of ubxn - 3, faf1, is a candidate tumour suppressor, these findings suggest that manipulation of cmg disassembly might be applicable to future strategies for treating human cancer.\nbladder cancer ( bc ) is a major clinical issue. methods : we performed immunohistochemistry to assess the role of human epidermal growth factor receptor - 2 ( her - 2 ) and microsatellite instability ( msi ) factors mutl homologue 1 ( mlh1 ) and muts homologue 2\nfive new pd - 1 / pd - l1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma ( uc ) : pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\nthis result indicates that they may be used as putative biomarkers for monitoring changes in bladder carcinogenesis in response to bcg immunotherapy.\nand approved in the setting of metastatic refractory urothelial cancer ( gupta et al."
        },
        {
          "qas": [
            {
              "id": "6025d9e41cb411341a0000b7_001",
              "question": "Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\nevent - free survival and overall survival of patients not treated with valproic acid were 6. 5 and 7. 8 months\n. a preliminary report of a randomized phase iii trial, the pacific trial, demonstrated an impressive increase in median progression - free survival with consolidative durvalumab, a pd - l1 inhibitor, compared with observation after ccrt.\nprolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with\ndnx - 2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas : a case report.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\noverall survival for recurrent high - grade glioma was 13. 6 months ( 95 % confidence interval, 10. 8 to 20. 0 ) and was statistically improved relative to an external control ( hazard ratio, 0. 45 ; p = 0. 003 ).\nvariable response of cns hemangioblastomas to pazopanib in a single patient with von hippel - lindau disease : case report.\ndiffuse intrinsic pontine gliomas ( dipg ) are the most aggressive brain tumors in children with 5 - year survival rates of only 2 %"
        },
        {
          "qas": [
            {
              "id": "621b950f3a8413c653000044_001",
              "question": "Is SMOC2 expressed during wound healing?"
            }
          ],
          "context": ". quantitative real - time polymerase chain reaction analysis revealed that the expression of t - ucr uc. 63 + was increased in pc tissues. mtt assay and wound healing assay revealed that uc. 63 + was involved in cell growth and cell migration\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\ndeficiency of the smoc2 matricellular protein impairs bone healing and produces age - dependent bone loss.\nmesenchymal - epithelial transition in sarcomas is controlled by the combinatorial expression of microrna 200s and grhl2.\nmucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\nour studies located the position of wnts, downstream lef1 and tcf3 and stem cell marker proteins, which provide new information in understanding the role of the wnt singaling pathway in whisker follicles'growth.\nin hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition.\n. in the normal mouse mammary gland, tcf3 is highly expressed in terminal end buds, structures that lead duct development\nwe found that in contrast to es cells, where it represses wnt - pathway target genes, tcf3 promotes the expression of a subset of wnt - responsive genes in breast cancer cells while repressing another distinct target subset.\nour study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis."
        },
        {
          "qas": [
            {
              "id": "620580afc9dfcb9c0900002f_001",
              "question": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?"
            }
          ],
          "context": "the results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nepoxyeicosatrienoic acids ( eets ) are formed from arachidonic acid by the action of p450 epoxygenases ( cyp2c and cyp2j ).\nepoxyeicosatrienoic acids ( eets ) are epoxides of arachidonic acid generated by cytochrome p450 ( cyp ) epoxygenases.\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\nepoxyeicosatrienoic acids ( eets ) are generated from arachidonic acid by cytochrome p450 ( cyp ) epoxygenases.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\nanother enzymatic pathway, the cytochrome p450 ( cyp ) system."
        },
        {
          "qas": [
            {
              "id": "61f602a3882a024a1000001f_001",
              "question": "Is Cabotegravir effective for HIV prevention?"
            }
          ],
          "context": "cabotegravir for hiv prevention in cisgender men and transgender women.\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\nan evaluation of cabotegravir for hiv treatment and prevention.\nbackground : the hiv prevention trials network ( hptn ) 083 trial demonstrated that long - acting cabotegravir ( cab - la ) was more effective than tenofovir disoproxil fumarate - emtricitabine ( tdf / ftc ) in preventing human immunodeficiency virus ( hiv ) in\nlong - acting injectable cabotegravir for the prevention of hiv infection\ndesign and testing of a cabotegravir implant for hiv prevention.\ncabotegravir long - acting for hiv - 1 prevention.\ncabotegravir is an investigational integrase inhibitor in development for the treatment and pre - exposure prophylaxis of hiv - 1 infection.\ncabotegravir : its potential for antiretroviral therapy and preexposure prophylaxis.\ncabotegravir is a novel human immunodeficiency virus integrase enzyme inhibitor used for prevention and treatment of hiv infection."
        },
        {
          "qas": [
            {
              "id": "62211b973a8413c65300006c_001",
              "question": "Are G-quadruplexes(G4) possible drug targets for glioblastoma?"
            }
          ],
          "context": "the g - quadruplex ( g4 ) dna, which has been developed as a potential anticancer target in drug screening and design, plays a crucial role in the oncogene transcription and translation.\nthese observations indicate that 6otd targets gscs through g4 stabilization and promotion of dna damage responses. therefore, g4s are promising therapeutic targets for glioblastoma.\ntherefore, a novel g4 - directed therapeutic strategy could specifically target cancer stem cells in gbm.\ntelomestatin, a strong telomerase inhibitor with g - quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers.\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia.\n. emerging evidence in recent years authenticated that g4 dna structures exist both in cell - free and cellular systems, and function in different diseases, especially in various cancers, aging, neurological diseases, and have been considered novel\ng - quadruplex ( g4 ) dna is a type of quadruple helix structure formed by a continuous guanine - rich dna sequence\nactivity of a novel g - quadruplex - interactive telomerase inhibitor, telomestatin ( sot - 095 ),\nructure has been yet resolved for the complex with telomestatin, one of the most promising g - quadruplex - targeting anticancer drug candidates. here\n. tp53 mutations are frequent in low - grade gliomas and secondary glioblastomas derived therefrom."
        },
        {
          "qas": [
            {
              "id": "622608ea3a8413c653000079_001",
              "question": "Is RUNX1T1 associate with obesity?"
            }
          ],
          "context": "runx1t1 rs34269950 is associated with obesity and metabolic syndrome.\nwhile research in this area is growing, our knowledge of obesity - related cognitive dysfunction and brain alterations has not yet been synthesized.\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\n. specifically, compared to aa genotype, rs34269950 del / del genotype was associated with a 1. 47 [ 95 % confidence interval ( ci ) : 1. 01 - 2. 14, p = 0. 042 ] fold higher rate of obesity risk.\nobesity in the pre - school years was associated with poorer outcomes for some cognitive measures in this study. stronger relationships between obesity and cognition or educational attainment may emerge later in childhood.\nfurthermore, knockdown of foxa1 expression blocks the association of er with chromatin and estrogen - induced gene expression demonstrating the necessity of foxa1 in mediating an estrogen response in breast cancer cells.\noverweight and obesity are associated with an increased risk of subnormal intellectual performance in young adult males. subjects with low birth weight and adolescent overweight / obesity are at particular risk of subnormal performance.\nimpairments in cognitive function have been associated with obesity in both people and rodents.\nobesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition - related brain areas in patients with mdd.\nresults : currently, the fda has approved several molecules for the treatment of obesity, both in monotherapy and in combination"
        },
        {
          "qas": [
            {
              "id": "61f9cb19c9dfcb9c09000002_001",
              "question": "Is Adamts18 deficiency associated with cancer?"
            }
          ],
          "context": ". these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. in aom / dss - induced colitis - associated colorectal cancer, the deficiency of adamts18 in mice resulted in enhanced tumorigenesis and colon inflammation that could be attributed in part to enhanced nuclear translocation of \u03b2 - catenin and elevated\n. however, the underlying mechanism is not clear. here we generated an adamts18 - deficient mouse strain as an in vivo model to investigate the role of adamts18 in the pathogenesis of colorectal cancer\nadamts18 is a novel tumor suppressor and is critical to the pathology of human colorectal cancer. however, the underlying mechanism is not clear\n. moreover, increased p38mapk and erk1 / 2 activities were detected in colon cancer cells from adamts18 - deficient mice\n. further studies revealed that adamts18 deficiency reduced intestinal e - cadherin levels in mice, which ultimately led to intestinal barrier dysfunction\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\nmoreover, inhibition of atm kinase or deficiency in nuclear actin polymerization causes carcinogenic ret / ptc chromosome rearrangements after dsbs induction in human cells.\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes.\nadenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response."
        },
        {
          "qas": [
            {
              "id": "61f5f89b882a024a10000019_001",
              "question": "Is Ozanimod effective for Ulcerative Colitis?"
            }
          ],
          "context": "sions : ozanimod was more effective than placebo as induction and mainte \" \" ce therapy in patients with moderately to severely active ulcerative colitis. ( fun\nozanimod interferes with migrations of activated t cells to the site of inflammation and is a promising drug for the uc treatment. key words : crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.\nozanimod : a first - in - class sphingosine 1 - phosphate receptor modulator for the treatment of ulcerative colitis.\n. additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\nconclusions : there was a high rate of continued study participation and long - term benefit with ozanimod hcl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active uc in the touchstone ole\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\nof relapsing multiple sclerosis and ulcerative colitis\n. colchicine, an inhibitor of nlrp3 inflammasome formation, and il - 1 - targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.\nexpert opinion : avelumab has shown clinical efficacy for metastatic and advanced uc in phase i studies after the failure of platinum - based therapy with a well - tolerated safety profile.\nozanimod ( rpc1063 ) is a specific and potent small molecule modulator of the sphingosine 1 - phosphate receptor 1 ( s1pr1 ) and receptor 5 ( s1pr5 ), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative"
        },
        {
          "qas": [
            {
              "id": "621bd38d3a8413c653000046_001",
              "question": "Is esophageal adenocarcinoma associated with aberrant glycosylation?"
            }
          ],
          "context": "igg glycosylation profile was independently associated with esophageal precancerosis beyond inflammation, which could be an early biomarker for esophageal cancer.\naltered glycoprotein expression has been demonstrated in tissue from patients with barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.\ncomparative glycomic profiling of esophageal adenocarcinoma reveals a subset of glycans that can be selected as candidate biomarkers\nesophageal adenocarcinoma represents a highly morbid and mortal cancer with a defined progression from metaplasia ( barrett's esophagus ) to dysplasia to neoplasia\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\nmuc1 is a membrane glycoprotein, which in adenocarninomas is overexpressed and exhibits truncated o - glycosylation.\ndisease - free states in esophageal cancer are more dramatic than in other cancers.\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\nmucin - type o - linked glycosylation\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases."
        },
        {
          "qas": [
            {
              "id": "622629d13a8413c65300007e_001",
              "question": "Can FTO promote pancreatic cancer development?"
            }
          ],
          "context": "m6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\ninvasion, and metastasis of pancreatic cancer cells.\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\noncogenic myc, a master transcription factor that turns on anabolic metabolism to promote cell growth in many cancers.\nthe anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\ntnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\nltf is likely to be a candidate tumor suppressor and downregulates the development of npc by inhibiting npc proliferation through induction of cell cycle arrest and modulation of the mapk signaling pathway.\nsuggesting that these pathways do not predispose cyld - deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and / or pro - inflammatory stress. conclusions : our findings underscore a critical tumor - suppressing role\npten is a potent tumour suppressor"
        },
        {
          "qas": [
            {
              "id": "621b8dee3a8413c653000042_001",
              "question": "Is Lysozyme abundant in human tears?"
            }
          ],
          "context": "lysozyme in tears, saliva, sweat, and other body fluids,\nlysozyme present in the natural tear\ntear lysozyme\nin this study we quantify lysozyme, the most prevalent protein in tear fluid,\nlysozyme ( lzm ) is a natural anti - bacterial protein that is found in the saliva, tears and milk of all mammals including humans.\n. this antimicrobial enzyme forms the part of the innate defense system of nearly all animals and exists in their somatic discharges such as milk, tears, saliva and urine.\nlysozyme ( lyz ) is a naturally occurring enzyme that operates against gram - positive bacteria and leads to cell death\ncollagen is the most abundant protein family in mammals.\nthe \u03b1137 - 141 peptide, a natural antimicrobial peptide, can be obtained after hydrolysis of hemoglobin, the main constituent of blood red part\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells."
        },
        {
          "qas": [
            {
              "id": "6052715494d57fd87900000e_001",
              "question": "Is FTY720 FDA approved?"
            }
          ],
          "context": ". in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment.\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\nefgartigimod is an fcrn inhibitor recently approved for mg treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development.\n. although the mechanism of fty720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\nresults : currently, the fda has approved several molecules for the treatment of obesity, both in monotherapy and in combination\ndupilumab is the first us fda approved biologic for treatment of atopic dermatitis.\nin march of 2017, the united states food and drug administration ( fda ) approved dupilumab for the treatment of moderate - to - severe atopic dermatitis in adults that is uncontrolled with topical medications, becoming the first biologic agent approved to\ntecovirimat : first global approval.\n. new fda - approved therapies for ad are crisaborole and dupilumab."
        },
        {
          "qas": [
            {
              "id": "621d19cc3a8413c65300004a_001",
              "question": "Is cytokeratin a tumor marker?"
            }
          ],
          "context": "the immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\nevels of inflammatory and tumor markers, including carbohydrate antigen ( ca ) 19 - 9, ca125, carcinoembryonic antigen ( cea ), ca153, and cytokeratin 19 fragments ( cyfra21 - 1 ),\ncytokeratin fragment antigen 21 - 1 ( cyfra21 - 1 ) in patients with laryngeal squamous cell carcinoma ( lscc ) and its correlation with tumorigenesis and progression\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\ncytokeratin fragment 19 ( auc = 0. 6882, p < 0. 0001 ) proved best in detecting relapse.\n. cyld expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\ntumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\nbladder cancer ( bc ) is a major clinical issue. methods : we performed immunohistochemistry to assess the role of human epidermal growth factor receptor - 2 ( her - 2 ) and microsatellite instability ( msi ) factors mutl homologue 1 ( mlh1 ) and muts homologue 2"
        },
        {
          "qas": [
            {
              "id": "602596691cb411341a0000ad_001",
              "question": "Is tofacitinib a JAK inhibitor?"
            }
          ],
          "context": "and targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\ntwo different janus kinase ( jak ) inhibitors - baricitinib and tofacitinib - are effective and licensed in active rheumatoid arthritis ( ra ).\npacritinib ( pac ), a multi - kinase inhibitor with specificity for jak2, flt3, and irak1 but sparing jak1, has demonstrated clinical activity in mf with minimal myelosuppression.\nobjective baricitinib is an oral, once - daily selective janus kinase ( jak1 / jak2 ) inhibitor for adults with moderately to severely active rheumatoid arthritis ( ra ).\n< b > objective < / b > : baricitinib is an orally administered inhibitor of jak1 and jak2 that has been shown to be effective in treating rheumatoid arthritis ( ra ).\npacritinib, a dual jak2 and flt3 inhibitor which also inhibits irak1, has demonstrated the ability to favorably impact mf - associated splenomegaly and symptom burden, while having limited myelosuppression with manageable gastrointestinal toxicity.\ndevelopments of jak inhibitors, such as ruxolitinib, pacritinib, momelotinib, and febratinib enabled the effective management in mf patients.\nthe janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours m1 macrophage development.\nexpert opinion jak inhibitors are effective in the treatment of rheumatoid arthritis as evidenced by several inhibitors enabling the majority of treated patients to achieve acr20 responses, with baricitinib and incb - 039110 both effective when\nother jakis, such as fedratinib and pacritinib, proved to be useful in mf."
        },
        {
          "qas": [
            {
              "id": "60292dc61cb411341a000110_001",
              "question": "\u0391re plants from the genus Strychnos the original source of curare?"
            }
          ],
          "context": "velopment : curare is prepared by boiling the roots, bark and stalks of different plants belonging to the loganiaceae ( strychnos ) and menispermaceae families ( chondrodendron, curarea and abuta ).\nthe ethnobotanical uses of south american species of strychnos l. ( loganiaceae ) are reviewed, with the exception of their major role in the preparation of curare, which will be dealt with in detail elsewhere.\nthe history to about 1850 of the muscle - relaxant poison curare is discussed, especially the developments leading to the botanical identification of the plants that yield the alkaloidal active principles : loganiaceae ( strychnos species ) and\n. the study reviews the historical and ethnographic aspects of the use of curares and timbos in the amazonian region. development : curare is prepared by boiling the roots, bark and stalks of different plants belonging to the loganiaceae ( strychnos )\n. owing to their poisonous properties, some species of strychnos genus have been employed mainly in hunting and fishing, as an adjunct to weapons used not only in the search of food and clothes, but also for preventing depredation by wild animals\nprinciples : loganiaceae ( strychnos species ) and menispermaceae ( abuta, chondrodendron, and curarea species ).\n. they have been employed for martial and criminal purposes and also as a means of determining guilt or innocence. by their nature, poisons such as strychnine and curare affect the functioning of the victim's body ;\nin aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ach receptor, but rather to be a specific blocking agent for a class of receptor - activated na + and cl - responses.\nthe variants are the curaremimetic toxin alpha from naja nigricollis and erabutoxin a or b from laticauda semifasciata\nusual clinical concentrations of curare cause competitive inhibition of muscle nicotinic acetylcholine receptors while higher concentrations may induce open channel blockade."
        },
        {
          "qas": [
            {
              "id": "61f9605f882a024a1000004f_001",
              "question": "Are variants in FHF2 (also known as FGF13) associated with encephalopathy?"
            }
          ],
          "context": "missense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy.\n. our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\n. the x - linked fhf2 gene ( also known as fgf13 ) has alternative first exons which produce multiple protein isoforms that differ in their n - terminal sequence\n. these gain - of - function effects are likely to increase neuronal excitability consistent with the epileptic potential of fhf2 variants\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nreciprocal h3. 3 gene editing identifies k27m and g34r mechanisms in pediatric glioma including notch signaling.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nfamilial als is associated with mutations in all exons of sod1 : a novel mutation in exon 3 ( gly72ser )."
        },
        {
          "qas": [
            {
              "id": "602c26171cb411341a000122_001",
              "question": "Is AZD9668 a VEGF mRNA drug?"
            }
          ],
          "context": "azd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\n. these include the pikfyve kinase inhibitor apilimod, cysteine protease inhibitors mdl - 28170, z lvg chn2, vby - 825, and ono 5334, and the ccr1 antagonist mln - 3897\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\nwe report the discovery and early clinical development of azd3759, a selective egfr inhibitor that can fully penetrate the blood - brain barrier ( bbb ),\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\n. azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay\n. signaling was tested by western blotting assay. the nude mice pc - 3 xenograft model was applied to test azd5153's activity in vivo. results : azd5153 inhibited proliferation and survival of established and primary prostate cancer cells\n. azd5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. azd5153 was non - cytotoxic to the prostate epithelial cells\nmidostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor."
        },
        {
          "qas": [
            {
              "id": "603400051cb411341a00014e_001",
              "question": "Is histone variant H3.3K27M associated with gliomas?"
            }
          ],
          "context": "well - known oncohistones, with mutations on both h3. 1 and h3. 3, include h3k36m in chondroblastoma, h3k27m in glioma\nreciprocal h3. 3 gene editing identifies k27m and g34r mechanisms in pediatric glioma including notch signaling.\n. about 85 % of all dipg are characterized by a lysine - to - methionine substitution in histone 3, which leads to global h3k27 hypomethylation accompanied by h3k27 hyperacetylation.\n. tp53 mutations are frequent in low - grade gliomas and secondary glioblastomas derived therefrom.\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\nhic1 is a candidate tumor suppressor gene which is frequently hypermethylated in human tumors, and its location within the miller - dieker syndrome's critical deletion region at chromosome 17p13. 3 makes it a candidate gene for involvement in this gene\nsuch as h3k9me, h3k27me, h2aub, or active marks such as h3k4me, h3k36me, h3ac ), and chromatin remodeling ( nucleosome composition, occupancy, and location ).\n. it is marked with the histone variant h2a. z and h4k16 acetylation in active state\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks )."
        },
        {
          "qas": [
            {
              "id": "6081a83f4e6a4cf630000007_001",
              "question": "Is FKBP52 encoding a chaperone ?"
            }
          ],
          "context": "the co - chaperone fk506 - binding protein 51 ( fkbp51 )\nhsp90 co - chaperones pp5 and fkbps\nco \u2011 chaperone fkbp52\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces.\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nthe schizosaccharomyces pombe fbp1 gene, which encodes fructose - 1, 6 - bis - phosphatase, is transcriptionally repressed by glucose through the activation of the camp - dependent protein kinase a ( pka ) and transcriptionally activated by glucose starvation\ntlk1 substrates were identified as the histone h3 and asf1 ( a histone h3 / h4 chaperone )\nof bound peptides that identify the tissue of origin of the hsp.\nthat encode a highly conserved region of 54 amino acids flanked by val3527 and lys3583, were identified and phenotyped"
        },
        {
          "qas": [
            {
              "id": "62004357c9dfcb9c09000015_001",
              "question": "Does \u03b1CGRP have amyloidogenic properties?"
            }
          ],
          "context": ". these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention.\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\npurpose of review : monoclonal antibodies ( mabs ) targeting the calcitonin - gene - related peptide ( cgrp ) pathway have been developed for episodic and chronic migraine prevention, either through binding the cgrp ligand ( eptinezumab, fremanezumab,\nthe efficacy and safety of calcitonin gene - related peptide monoclonal antibody for episodic migraine : a meta - analysis. based on the results of this meta - analysis, cgrp monoclonal antibodies significantly reduced the monthly migraine days and acute\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nwithin the past few years, new and promising drugs such as more specific 5 - ht 1f receptor agonists ( that is, lasmiditan ) and monoclonal calcitonin gene - related peptide ( cgrp ) receptor antibodies entered advanced development phases while non - invasive\ngalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide, has demonstrated in previous phase 2 and phase 3 clinical studies ( \u22646 - month of treatment ) a reduction in the number of migraine headache\nfour monoclonal antibodies have been developed : one targeting the calcitonin gene - related peptide receptor ( erenumab ) and three targeting the calcitonin gene - related peptide ( eptinezumab, fremanezumab, and galcanezumab )."
        },
        {
          "qas": [
            {
              "id": "60282c3f1cb411341a0000fe_001",
              "question": "Is istiratumab effective for pancreatic cancer?"
            }
          ],
          "context": "expert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer.\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\na phase ii study indicates that sacituzumab govitecan ( immu - 132 ), a trop - 2 - specific antibody linked to the irinotecan metabolite sn - 38, prolongs the progression - free survival of patients with advanced triple - negative breast cancer. i\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\nshown to be effective for advanced biliary tract cancer.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study."
        },
        {
          "qas": [
            {
              "id": "601efda31cb411341a000069_001",
              "question": "Does bleomycin cause lung toxicity?"
            }
          ],
          "context": "bleomycin might cause pulmonary fibrosis at higher cumulative doses as toxic effect directly to the lungs or most likely in addition by the formation of vascular microthrombi.\nbleomycin is a cancer therapeutic known to cause lung injury which progresses to fibrosis.\nbleomycin sometimes causes fatal pulmonary toxicity, including bleomycin - induced pneumonitis.\nbleomycin, a widely used anti - cancer drug, may give rise to pulmonary fibrosis, a serious side effect which is associated with significant morbidity and mortality.\nbleomycin lung toxicity is well established and can manifest as bleomycin - induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications.\nprevious studies have proposed that the lung toxicity caused by bleomycin is related to the c - terminal regions of these drugs, which have been shown to closely interact with dna in metal - bleomycin - dna complexes.\nbleomycin is an antineoplastic agent that causes a dose - related lung fibrosis that limits its therapeutic effectiveness.\npulmonary toxicity is a devastating complication of bleomycin chemotherapy.\npulmonary toxicity is an important adverse effect of bleomycin treatment.\nbleomycin is potentially capable of inducing a diffuse interstitial fibrosis of the lung, the pathogenesis of which has not yet been elucidated."
        },
        {
          "qas": [
            {
              "id": "6082f4374e6a4cf63000000f_001",
              "question": "Is Keutel syndrome a common genetic disorder?"
            }
          ],
          "context": "keutel syndrome ( omim 245150 ) is a very rare syndrome\nkeutel syndrome is a rare autosomal - recessive condition characterized by abnormal cartilage calcification.\nintroduction : werner syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the werner syndrome gene belonging to the family of recq helicase.\nthe 22q11. 2 deletion syndrome ( di george syndrome ) is one of the most prevalent genetic disorders.\nmgp - deficiency in humans leads to keutel syndrome, a rare genetic disease hallmarked by abnormal soft tissue calcification.\namong them, the most studied is werner's syndrome, \" adult progeria \", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in dna repair.\napert syndrome - acrocephalosyndactyly - is a rare autosomal domi \" \" t disorder representing 1 : 65 000 cases of living newborns\nli - fraumeni syndrome ( lfs ) is a rare, autosomal domi \" \" t, hereditary cancer predisposition disorder.\nli - fraumeni syndrome ( lfs ) is a rare hereditary autosomal domi \" \" t cancer disorder.\nhutchinson - gilford progeria syndrome is an autosomal domi \" \" t, rare, fatal pediatric segmental premature aging disease."
        },
        {
          "qas": [
            {
              "id": "601d724a1cb411341a000035_001",
              "question": "Is fusobacterium associated with Lemierre's syndrome?"
            }
          ],
          "context": "fusobacterium necrophorum is aaerobic gram - negative bacillus and is the most common organism reported to cause lemierre's syndrome which usually occurs one to three weeks post pharyngitis or oropharyngeal surgery.\nfusobacterium necrophorum, a well \u2010 known cause of lemierre's syndrome, was identified.\nfusobacterium necrophorum is a gram - negative anaerobic bacterium that is the causative agent of the invasive disease lemierre's syndrome.\nfusobacterium necrophorum is a rare infection most notable for causing lemierre's syndrome.\nfusobacterium necrophorum plays a causal role in a rare and life - threatening condition, lemierre's syndrome.\nlemierre's syndrome due to fusobacterium necrophorum.\nfusobacterium species is known for being a causative agent for lemierre's syndrome, which is characterized by thrombophlebitis of the jugular vein.\nlemierre's syndrome is a rare disorder of young adults caused by the anaerobic bacterium, fusobacterium necrophorum and occasionally by other fusobacterium species ( f. nucleatum, f. mortiferum and f. varium etc ).\nwe report an unusual case of lemierre's syndrome due to a rare species of fusobacterium, that is, fusobacterium nucleatum preceded by mycoplasma pneumoniae pharyngitis and followed later by epstein - barr virus infectious mononucleosis.\nfusobacteria are most often associated with the classic presentation of lemierre's syndrome consisting of a sore throat, internal jugular vein thrombophlebitis, and septic emboli to the lungs."
        },
        {
          "qas": [
            {
              "id": "621fd6083a8413c653000066_001",
              "question": "Unlike DNA, RNA is not methylated, yes or no?"
            }
          ],
          "context": "the detection and quantification of methylated rna can be beneficial to understand certain cellular regulation processes such as transcriptional modulation of gene expression, immune response, or epigenetic alterations.\na combined genetic and biochemical approach revealed that human dnmt2 did not methylate dna but instead methylated a small rna ; mass spectrometry showed that this rna is aspartic acid transfer rna ( trna ( asp ) ) and that dnmt2 specifically methylated\nthe accessibility of dna is regulated by epigenetic processes, including methylation of cytosine. in these circumstances the nucleic sequence of the dna does not change.\nhere, we propose that rna methylation began prior to dna methylation in the early forms of life evolving on earth.\nepigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in dna sequence.\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\nmethylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications."
        },
        {
          "qas": [
            {
              "id": "620155b6c9dfcb9c09000024_001",
              "question": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?"
            }
          ],
          "context": "disruption of nuclear architecture as a cause of covid - 19 induced anosmia.\nin our retrospective cohort study comparing the clinical presentation of covid - 19 and other respiratory viral infections, we found that anosmia and dysgeusia were symptoms independently associated with covid - 19 and can be important differentiating\nchromatin conformation capture using in situ hi - c on fluorescence - activated cell - sorted olfactory sensory neurons and their progenitors shows that olfactory receptor gene clusters from 18 chromosomes make specific and robust interchromosomal contacts\n. a likely explanation for the reduction of or transcription is the striking reorganization of nuclear architecture observed in the osn lineage, which disrupts multi - chromosomal compartments regulating or expression in humans and hamsters\n. here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish covid - 19 from other respiratory diseases, yet such essential information is largely unavailable.\n. our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of covid - 19.\nit is difficult to distinguish coronavirus disease - 2019 ( covid - 19 ) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.\ncovid - 19 and can be important differentiating symptoms in patients presenting with acute respiratory illness\nalthough covid - 19 has been extensively characterized clinically, the factors distinguishing sars - cov - 2 from other respiratory viruses are unknown.\n. functional tests were performed to study their pathogenicity and understand the disease mechanism. results : the consistent clinical features of the affected individuals, from seven unrelated families, included choanal atresia, athelia or hypoplastic"
        },
        {
          "qas": [
            {
              "id": "622dd1433a8413c6530000a5_001",
              "question": "Is taxilin a cancer marker?"
            }
          ],
          "context": "\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\nexpression of \u03b1 - taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.\nexpression of \u03b1 - taxilin in hepatocellular carcinoma correlates with growth activity and malig \" \" t potential of the tumor.\n\u03b1lpha - taxilin ( \u03b1 - taxilin ) has been found as one of the novel, significantly up regulated protein in ra\nexpressed exosomal marker tumor susceptibility gene ( tsg ) 101 and flotillin ( flot ) 1.\nthe axon guidance cues netrin - 1 is a secreted protein overexpressed in many different cancer tissues\nflotillin 1 and tumor susceptibility gene 101 ( tsg101 ), two exosomal marker proteins,\nnetrin - 1, a laminin - related secreted protein, displays proto - oncogenic activity in cancers.\nfoxa1 expression could be a prognostic marker in er - positive breast cancer.\nthe library of integrated network - based cellular signatures ( lincs ) l1000 data set currently comprises of over a million gene expression profiles of chemically perturbed human cell lines."
        },
        {
          "qas": [
            {
              "id": "622668313a8413c653000087_001",
              "question": "Is PCAT6 a microRNA?"
            }
          ],
          "context": "in this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\n. among these noncoding rnas are short rnas, such as micrornas, snornas, and piwi - interacting rnas, and the functions of those are relatively well understood\nour objective was to characterize non - canonical circrnas, namely not originating from back splicing and circrna produced by non - coding genes.\nhere, we profiled gene expression following sciatic nerve crush in mice and identified long noncoding rnas ( lncrnas ) that act in the regenerating neurons and which are typically not expressed in other contexts\nit is now evident that noncoding rnas play key roles in regulatory networks determining cell fate and behavior, in a myriad of different conditions, and across all species\nthis study aimed to explore the regulatory mechanism of methyltransferase3 ( mettl3 ) - mediated long non - coding rna ( lncrna ) n6 - methyladenosine ( m6a ) modification in the osteogenic differentiation of human adipose - derived stem cells ( hascs ) induced by\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\nour results suggest that 3'utr sequences can function not only in cis to regulate protein expression, but also intrinsically and independently in trans, likely as noncoding rnas, a conclusion supported by a number of previous genetic studies.\nwe found that : i ) the circrna expression profile revealed 1, 285 significant differences in circrna expression, with circrna expression downregulated in 594 samples and upregulated in 691 samples via interactions with mirnas."
        },
        {
          "qas": [
            {
              "id": "6201a4edc9dfcb9c09000028_001",
              "question": "Is HDAC1 required for GATA-1 transcriptional activity?"
            }
          ],
          "context": "hdac1 is required for gata - 1 transcription activity, global chromatin occupancy and hematopoiesis.\n. thus, gata - 1 deacetylation and its interaction with hdac1 modulates gata - 1 chromatin binding and transcriptional activity that control erythroid / megakaryocyte commitment and differentiation.\nfurthermore, knockdown of foxa1 expression blocks the association of er with chromatin and estrogen - induced gene expression demonstrating the necessity of foxa1 in mediating an estrogen response in breast cancer cells.\n. our results indicate that tissue - specific chromatin conformation is not necessary for tissue - specific gene expression but rather acts as a scaffold facilitating gene expression when enhancers become active.\nthese different timing classes each associate with binding sites for two transcription factors, gaga - factor and zelda, previously implicated in controlling chromatin accessibility at zga.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\neuchromatin and heterochromatin have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. thus, dna accessibility is not likely to be the primary determi \" \" t of gene regulation."
        },
        {
          "qas": [
            {
              "id": "623a24d6f0baec9a1b000002_001",
              "question": "Is telomestatin, a novel statin drug used to treat high cholesterol?"
            }
          ],
          "context": "telomestatin, a strong telomerase inhibitor with g - quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers.\na novel telomerase inhibitor, telomestatin, isolated from streptomyces anulatus is the most potent telomerase inhibitor so far.\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia.\ntelomestatin is a natural product isolated from streptomyces anulatus 3533 - sv4 and has been shown to be a very potent telomerase inhibitor.\nactivity of a novel g - quadruplex - interactive telomerase inhibitor, telomestatin ( sot - 095 ),\ngsk2140944 is a novel bacterial topoisomerase inhibitor in development for the treatment of bacterial infections.\nructure has been yet resolved for the complex with telomestatin, one of the most promising g - quadruplex - targeting anticancer drug candidates. here\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd )."
        },
        {
          "qas": [
            {
              "id": "61f7d4da882a024a10000033_001",
              "question": "Is there an association between Guillain\u2013Barr\u00e9 syndrome and covid vaccine?"
            }
          ],
          "context": "to date, cases of guillain - barre syndrome ( gbs ) following a covid vaccine ( pfizer, johnson & johnson, janssen, astrazeneca ) have been reported.\nguillain - barre syndrome associated with covid - 19 vaccination.\ncovid - 19 vaccine causing guillain - barre syndrome, a rare potential side effect.\ncase of guillain - barre syndrome following covid - 19 vaccine.\nassociation of receipt of the ad26. cov2. s covid - 19 vaccine with presumptive guillain - barre syndrome, february - july 2021.\nwe report a case of guillain - barre syndrome after the first dose of sars - cov - 2 vaccine and believe this is a temporal, rather than causal association.\nwe report a case of guillain - barre syndrome ( gbs ) following the first dose of oxford / astrazeneca covid - 19 vaccine with papilledema as atypical onset.\nguillain - barre syndrome after covid - 19 vaccination.\nguillain - barre syndrome associated with covid - 19 : a close relationship or just a coincidence? ( review ).\nguillain - barre syndrome following chadox1 ncov - 19 covid - 19 vaccination : a case series."
        },
        {
          "qas": [
            {
              "id": "61fa904fc9dfcb9c09000004_001",
              "question": "Is Erythropoietin effective for neuroprotection of Preterm Infants."
            }
          ],
          "context": "erythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\nor death or in the frequency of serious adverse events. conclusions : high - dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe\ninterpretation : erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis.\nbased on existing evidence, it is still too early to recommend epo as the standard treatment for preterm brain injury.\nthere was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age ( 97 children [ 26 % ] vs\nsafety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.\nthis study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection ( recombi \" \" t human erythropoietin injection, rhuepo ) for the treatment of anemia associated with chronic kidney failure\nbackground : the anemia studies in chronic kidney disease ( ckd ) : erythropoiesis via a novel prolyl hydroxylase inhibitor ( phi ) daprodustat - dialysis ( ascend - d ) trial will test the hypothesis that daprodustat is non - inferior to comparator epoetin alfa\nuremic toxins affect erythropoiesis during the course of chronic kidney disease : a review.\nuse of epogen for treatment of anemia associated with chronic renal failure."
        },
        {
          "qas": [
            {
              "id": "6226317a3a8413c653000080_001",
              "question": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?"
            }
          ],
          "context": "ameloblastoma ( ab ) is the most common benign epithelial odontogenic tumor occurring in the jawbone.\nameloblastoma is the most common clinically significant epithelial odontogenic tumor, and is considered a benign but locally aggressive tumor of the craniofacial region.\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\nameloblastoma is the most common odontogenic tumor of epithelial origin, and though it is of a benign nature, it frequently infiltrates the bone, has a high rate of recurrence and could potentially become malig \" \" t.\nameloblastoma is the second most common benign epithelial odontogenic tumor and though it is of a benign nature, it is locally invasive, has a high recurrence rate and could potentially become malig \" \" t.\nameloblastoma is a benign epithelial odontogenic tumor that typically arises in the mandible or maxilla or, rarely, in the immediate adjacent soft tissues\nbackground : the ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo - fac\nameloblastoma ( am ) is a slow growing and aggressive benign tumor with an odontogenic epithelial origin arising from the mandible or maxilla.\nameloblastoma ( ab ) is an aggressive and slow - growing tumor with high recurrence rate, which arises from odontogenic epithelium.\nbackground : ameloblastoma is a neoplasm classified as a benign epithelial odontogenic tumor of the jaws, grow slowly and are locally invasive"
        },
        {
          "qas": [
            {
              "id": "622901d23a8413c65300008c_001",
              "question": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?"
            }
          ],
          "context": "ameloblastoma, a benign but locally aggressive odontogenic tumor, often demonstrates metastasis despite benign histological features and this variant is termed as metastasizing ameloblastoma ( metam ).\nameloblastoma is a locally invasive, histologically nonmalig \" \" t tumor that may on very rare occasions give rise to metastases.\nameloblastoma is an odontogenic tumor, usually benign, which rarely metastasizes to distant organs.\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\nobjectives : ameloblastoma is a benign, slow - growing, locally invasive epithelial tumor of odontogenic origin, with unlimited growth capacity and a strong tendency to recur.\nbackground : ameloblastoma is a frequent odontogenic benign tumor characterized by local invasiveness, high risk of recurrence and occasional metastasis and malig \" \" t transformation\nameloblastomas are benign but locally invasive neoplasms which may grow to massive proportions and cause significant morbidity\nbackground : ameloblastoma is a rare benign odontogenic tumor with a metastasis rate estimated at 2 % of cases, mainly involving the lung ( 80 % ) and lymph nodes ( 20 % ). methods : we hereby present the case of a 26 year old patient with a history of locally\nbackground : ameloblastoma is a neoplasm classified as a benign epithelial odontogenic tumor of the jaws, grow slowly and are locally invasive\n. although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat."
        },
        {
          "qas": [
            {
              "id": "620157bec9dfcb9c09000025_001",
              "question": "Is there any role of the 'Greek islands' in olfactory receptor choice?"
            }
          ],
          "context": ". these contacts are orchestrated by intergenic olfactory receptor enhancers, the'greek islands ', which first contribute to the formation of olfactory receptor compartments and then form a multi - chromosomal super - enhancer that associates with the\n. the greek - island - bound transcription factor lhx2 and adaptor protein ldb1 regulate the assembly and maintece of olfactory receptor compartments, greek island hubs and olfactory receptor transcription, providing mechanistic insights into and\nchromatin conformation capture using in situ hi - c on fluorescence - activated cell - sorted olfactory sensory neurons and their progenitors shows that olfactory receptor gene clusters from 18 chromosomes make specific and robust interchromosomal contacts\nsuper - enhancer that associates with the single active olfactory receptor gene\n. our results indicate that different types of mutational events in the brca1 and brca2 genes are responsible for the hereditary component of breast / ovarian cancer in the greek population\nreceptors ( ors ) as well as key components of their signaling pathway\n. meta - analysis of published data indicates that mouse adar3 expression is highest in the hippocampus, thalamus, amygdala, and olfactory region\n. their function and distribution around important regulatory genes raises the question of how they relate to 3d conformation of these loci\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes."
        },
        {
          "qas": [
            {
              "id": "622dc4b63a8413c6530000a4_001",
              "question": "Is paxillin affected by RANKL?"
            }
          ],
          "context": "paxillin levels induced by rankl in murine bone marrow cells.\nrankl promotes paxillin serine and tyrosine phosphorylation,\nwestern blotting assays presented upregulated expressions of tnf receptor - activating factor 6 ( traf6 ) and integrin \u03b23 induced by gingipains and rankl compared to rankl alone\n. moreover, the pit resorption assays showed that gingipains augmented bone resorptive function of osteoclasts induced by rankl.\nwe also find that tcf3 phosphorylation is triggered by canonical wnt ligands, lrp6, and domi \" \" t negative mutants for axin and gsk3, indicating that this process shares the same upstream regulators with \u03b2 - catenin stabilization.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\ninteraction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\nour study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis.\nb - cell precursor acute lymphoblastic leukemia ( bcp - all ) with tcf3 - pbx1 fusion gene expression has constitutively elevated levels of wnt16b and ror1 ( receptor tyrosine kinase - like orphan receptor ), a ligand and a receptor from the wnt signaling\nthe activation of mixed lineage kinase - like ( mlkl ) by receptor - interacting protein kinase - 3 ( ripk3 ) results in plasma membrane ( pm ) disruption and a form of regulated necrosis, called necroptosis."
        },
        {
          "qas": [
            {
              "id": "622b95dc3a8413c653000092_001",
              "question": "Is retinol binding protein 4 an adipokine?"
            }
          ],
          "context": "retinol - binding protein 4 ( rbp4 ) is a prominent adipokine i\nfetuin - a and retinol - binding protein 4 ( rbp4 ) are secreted as both hepatokine and adipokine.\nsystematic quantification of neurotrophic adipokines rbp4, pedf, and clusterin in human cerebrospinal fluid and serum.\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\nthe human vitamin e - binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome\nspecial at - rich sequence - binding protein 1 ( satb1 ) is a cell type - specific matrix attachment region binding protein, functioning as a global genome organizer.\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\nadipose - derived stem cells ( hascs ) induced by nel - like 1 protein ( nell - 1 )."
        },
        {
          "qas": [
            {
              "id": "622ce21d3a8413c65300009c_001",
              "question": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?"
            }
          ],
          "context": "precise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility.\nhydin was recently identified as an axonemal protein ; however, its function is as yet unknown.\nnetrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nthe axon guidance cues netrin - 1 is a secreted protein overexpressed in many different cancer tissues\nnetrins are a family of secreted protein related to laminin and act as tropic cues directing axon growth and cell migration during neural development.\nnetrin - 1, a laminin - related secreted protein, displays proto - oncogenic activity in cancers.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\n. functional characterization of mutant fhf2a co - expressed with wild - type nav1. 6 ( scn8a ) revealed that mutant fhf2a proteins lost the ability to induce rapid - onset, long - term blockade of the channel while retaining pro - excitatory properties"
        },
        {
          "qas": [
            {
              "id": "621e62c33a8413c653000050_001",
              "question": "Are there any R packages that help with visualizing data on spirals?"
            }
          ],
          "context": ". here we present the r package spiralize that provides a general solution for visualizing data on spirals. spiralize implements numerous graphics functions so that self - defined high - level graphics can be easily implemented by users\nspiral layout has two major advantages for data visualization. first, it is able to visualize data with long axes, which greatly improves the resolution of visualization. second, it is efficient for time series data to reveal periodic patterns\n. the flexibility and power of spiralize are demonstrated by five examples from real - world datasets.\n. the core of all graph kernels is implemented in c + + for efficiency. using the kernel matrices computed by the package, we can easily perform tasks such as classification, regression and clustering on graph - structured samples.\n. here we provide graphkernels, the first r and python graph kernel libraries including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and the state - of - the - art weisfeiler - lehman graph\nwe review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high - dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.\nmeasuring the similarity of graphs is a fundamental step in the analysis of graph - structured data, which is omnipresent in computational biology\n. the scripts are compatible with linux, mac os and the ms windows 10 subsystem for linux and are available as a graphical user interface, a web service at http : / / \" \" oplot. bioinf. be and command line tools.\n. we demonstrate the ability of slic - cage to generate data for genome - wide promoterome with 1000 - fold less material than required by existing cage methods, by generating a complex, high - quality library from mouse embryonic day 11. 5 primordial germ\nvariant review with the integrative genomics viewer."
        },
        {
          "qas": [
            {
              "id": "61faa3bac9dfcb9c0900000b_001",
              "question": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?"
            }
          ],
          "context": "the advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\n. during the 24 - month follow - up, hiv - 1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group ( hazard ratio, 1. 02 ; 95 % confidence interval, 0. 81 to 1. 30 ; p = 0. 84 ). conclusions : the alvac - gp120 regimen did not\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\nthe alvac - gp120 regimen did not prevent hiv - 1 infection among participants in south africa d\nwe assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus ankara expressing antigen 85a ( mva85a ), in adults infected with hiv - 1.\nmodified vaccinia ankara was safe and immunogenic in subjects infected with hiv and represents a promising smallpox vaccine candidate for use in immunocompromised populations.\nerratum : safety and immunogenicity of modified vaccinia ankara - bavarian nordic smallpox vaccine in vaccinia - naive and experienced human immunodeficiency virus - infected individuals : an open - label, controlled clinical phase ii trial.\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\nan evaluation of cabotegravir for hiv treatment and prevention.\nbackground : the hiv prevention trials network ( hptn ) 083 trial demonstrated that long - acting cabotegravir ( cab - la ) was more effective than tenofovir disoproxil fumarate - emtricitabine ( tdf / ftc ) in preventing human immunodeficiency virus ( hiv ) in"
        },
        {
          "qas": [
            {
              "id": "622baf3f3a8413c653000099_001",
              "question": "Do Afamin bind Vitamin E?"
            }
          ],
          "context": "the human vitamin e - binding protein afamin\nafamin, a vitamin e - binding protein in human plasma\nthe plasma glycoprotein afamin has been previously identified as an alternative carrier protein for vitamin e in extravascular fluids such as plasma and cerebrospinal, ovarian follicular, and seminal fluids.\nafamin is a plasma vitamin e - binding glycoprotein\nthe human vitamin e - binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nevidence ) ; - vitamin e may have little or no effect ( low - quality evidence ) ; and - the effects of l - threonine, gabapentin, xaliproden, riluzole, and baclofen are uncertain as the evidence is either very low quality or the trial specified the outcome\ncytoprotective effects of hesperetin and hesperidin against amyloid \u03b2 - induced impairment of glucose transport through downregulation of neuronal autophagy.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker."
        },
        {
          "qas": [
            {
              "id": "622632483a8413c653000081_001",
              "question": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?"
            }
          ],
          "context": "disruption of complex immune regulation mechanisms is associated with adverse preg \" \" cy outcomes, including preeclampsia ( pe ).\ndisruption of well - controlled immune functions leads to infertility, placental inflammation, and numerous preg \" \" cy complications, including preeclampsia ( pe ).\nin addition, it has been demonstrated that immune disturbance may be responsible for some adverse preg \" \" cy outcomes such as preeclampsia ( pe ), recurrent spontaneous abortion ( rsa ) and intrauterine growth restriction ( iugr ).\ndisruption of this immune balance and / or inadequate placental perfusion is believed to be associated with a lot of preg \" \" cy - related complications, such as recurrent spontaneous abortion, pre - eclampsia, and fetal intrauterine growth restriction.\nhowever, immune maladaptation and hemostatic imbalance have been suggested to be responsible for adverse preg \" \" t outcomes, such as preeclampsia ( pe ), miscarriage, recurrent spontaneous abortion ( rsa ) and intrauterine growth restriction ( iugr ).\npreeclampsia can thus be considered a hyperinflammatory state associated with defective regulation of the immune system proposed as a key element in the pathological events of the placental subtype of this disorder.\ntherefore, a delicate immune balance is critical for the mainte \" \" ce of a successful preg \" \" cy, while disruption of this balance can induce complications such as implantation failure, miscarriage, preterm birth / labor, preeclampsia and fetal growth\nesponse. in previous models of preeclampsia ( pe ), defective immune function caused by disruption of lymphangiogenesis was shown to be involved in the disease pathophy\nmaternal immune tolerance is important for maintaining preg \" \" cy, and researchers have increasingly focused on the critical roles of cytokines in the pathogenesis of pe in recent years.\nobjective : increased oxidative stress and immune dysfunction are implicated in preeclampsia ( pe ) and may contribute to the two - to fourfold increase in pe prevalence among women with type 1"
        },
        {
          "qas": [
            {
              "id": "62266c353a8413c65300008a_001",
              "question": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?"
            }
          ],
          "context": "the new arlncrna - based model predicts crc patient prognosis and provides new research ideas regarding potential mechanisms regulating the biological behavior of crc. arlncrnas may play important roles in personalized cancer treatment.\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\ncircrnas are a subclass of lncrnas that have been found to be abundantly present in a wide range of species, including humans"
        },
        {
          "qas": [
            {
              "id": "621e9aa13a8413c653000053_001",
              "question": "Are there roles for cohesin mutations in AML?"
            }
          ],
          "context": ". these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\n. inflammatory signals limit hspc self - renewal and drive hspc differentiation. consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for aml progression.\n. emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. among these mechanisms is a role for cohesin in the control of inflammatory responses in hspcs and myeloid cells\nwell - known oncohistones, with mutations on both h3. 1 and h3. 3, include h3k36m in chondroblastoma, h3k27m in glioma\naccumulated evidence implies that mutations in the gene coding for cu / zn superoxide dismutase ( sod ) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis ( als ).\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\nconsistent with a role for inflammatory signals in promoting myeloid differentiation of hematopoietic stem and progenitor cells ( hpscs ), cohesin mutations in hspcs led to reduced inflammatory gene expression and increased resistance to\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes."
        },
        {
          "qas": [
            {
              "id": "622d0aa63a8413c6530000a0_001",
              "question": "Is ASF1 phopshorylated by  the Tousled-like kinases?"
            }
          ],
          "context": "asf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nthe tousled - like kinases ( tlks ) are involved in chromatin assembly, dna repair, and transcription. two tlk genes exist in humans, and their expression is often dysregulated in cancer. tlks phosphorylate asf1\nthe tousled - like kinases 1 and 2 ( tlk1 / 2 ) control histone deposition through the asf1 histone chaperone\ntlks interact specifically ( and phosphorylate ) with the chromatin assembly factor asf1, a histone h3 - h4 chaperone\ntlk1 substrates were identified as the histone h3 and asf1 ( a histone h3 / h4 chaperone )\nof the mixed lineage kinase domain - like protein ( mlkl ) upon its phosphorylation.\nwe also find that tcf3 phosphorylation is triggered by canonical wnt ligands, lrp6, and domi \" \" t negative mutants for axin and gsk3, indicating that this process shares the same upstream regulators with \u03b2 - catenin stabilization.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\n. the stress - activated protein kinase ( sapk ) pathway and its effectors, sty1 mapk and transcription factor atf1, play a critical role in the adaptation of fission yeast to grow on alternative non - fermentable carbon sources by inducing the expression\n. to investigate the molecular basis of tad formation, we performed hi - c experiments on cells depleted for the forkhead transcription factors, fkh1 and fkh2, previously associated with replication timing"
        },
        {
          "qas": [
            {
              "id": "6237a6e93a8413c6530000b1_001",
              "question": "Does sphingosine-1 phosphoate suppress epiregulin?"
            }
          ],
          "context": "s1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\nwe demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation.\nthe pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\npten is a potent tumour suppressor\nsurface inhibitory molecules such as siglec - 8, anti - il - 1s such as canakinumab, bruton kinase ( btk ) inhibitors such as gdc - 0853 and anti - il - 5s such as benralizumab and mepolizumab. summary : the ongoing clinical trials on new targets of treatment hold\n. we then focus on one of these, silc1, and show that it regulates neuroregeneration in cultured cells and in vivo, through cis - acting activation of the transcription factor sox11.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins."
        },
        {
          "qas": [
            {
              "id": "62068e67c9dfcb9c09000038_001",
              "question": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?"
            }
          ],
          "context": "whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31 % after exclusion of common causes\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes.\nmapping, and segregation analysis for novel disease - causing gene discovery\nthe whole exome sequencing, further verified with sanger sequencing and parental background.\n. heteroplasmy of mtdna was independently examined by high - depth whole mtdna sequencing analysis in our research laboratory and in two clinical laboratory improvement amendments and college of american pathologists - accredited laboratories using\n. many tools have been developed to analyze genomic variation ranging from single nucleotide variants to whole chromosomal aberrations. as sequencing throughput increases, the number of variants called by such tools also grows\n. we performed molecular analysis of the brca1 and brca2 genes in 898 greek families, using sanger sequencing or next generation sequencing for the detection of small insertion / deletion frameshift, nonsynonymous, truncating and splice - site\nusing massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in bcl11b\nbiparental inheritance of mitochondrial dna in humans.\nand allowing for genotype - based prediction of risk of recurrence in some nonsyndromic families."
        },
        {
          "qas": [
            {
              "id": "622662e13a8413c653000085_001",
              "question": "Can METTL3 methylate long noncoding RNAs?"
            }
          ],
          "context": "this study aimed to explore the regulatory mechanism of methyltransferase3 ( mettl3 ) - mediated long non - coding rna ( lncrna ) n6 - methyladenosine ( m6a ) modification in the osteogenic differentiation of human adipose - derived stem cells ( hascs ) induced by\nthe methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation.\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\nn6 - methyladenosine ( m6a ) is the most abundant internal modification on messenger rnas ( mrnas ) and long noncoding rnas ( lncrnas ) in eukaryotes\n. m6a regulates rna processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6a methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis.\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\nour results suggest that 3'utr sequences can function not only in cis to regulate protein expression, but also intrinsically and independently in trans, likely as noncoding rnas, a conclusion supported by a number of previous genetic studies.\na combined genetic and biochemical approach revealed that human dnmt2 did not methylate dna but instead methylated a small rna ; mass spectrometry showed that this rna is aspartic acid transfer rna ( trna ( asp ) ) and that dnmt2 specifically methylated\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna"
        },
        {
          "qas": [
            {
              "id": "622f6ad13a8413c6530000aa_001",
              "question": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?"
            }
          ],
          "context": "has been shown that helminth infections including schistosoma mansoni may modulate atopic diseases including asthma. i\ntherefore, we hypothesize that schistosoma japonicum egg antigens, a type of native antigen, can induce production of cd4 ( + ) cd25 ( + ) t cells with regulatory activity, modulating airway inflammation and inhibiting asthma development.\nve found that schistosoma infection or schistosoma related products can improve or prevent some immune and inflammatory diseases, such as severe asthm\nin areas where schistosomiasis is endemic, a negative correlation is observed between atopy and helminth infection, associated with a low prevalence of asthma.\nschistosoma japonicum infection downregulates house dust mite - induced allergic airway inflammation in mice\nhelminths and their products can regulate immune response and offer new strategies to control and alleviate inflammation, including asthma.\n. japonicum infection ( allergen sensitization before infection ) on asthma were rarely investigated.\nhese results reveal a novel form of immune protective mechanism, which may play an important role in the modulating effect of helminth infection on allergic asthmatic reactions.\nhelminths and their products can shape immune responses by modulating immune cells, which are dysfunctional in inflammatory diseases such as asthm\nwe found that lung - stage s. japonicum infection significantly ameliorated ova - induced aai, whereas post - lung - stage infection did not."
        },
        {
          "qas": [
            {
              "id": "6212c25c3a8413c653000019_001",
              "question": "Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?"
            }
          ],
          "context": "together with the frequent simultaneous deletions of kmt2a, atm and cbl and mutations of asxl1, sf3b1 and cbl, we show that cadm1 may be important in the physiopathology of the del ( 11q ) mds, extending its role as tumor - suppressor gene from solid\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\ndkk1 has been implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic breast cancer, and osteoblastic metastases of prostate cancer.\nthe cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\ntumours to dna - damaging agents and to deletion of the anti - apoptotic protein mcl1\nmxa, ifitm1 ) in cd14 + monocytes of csle patients and healthy controls ( hcs )\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\nboth deletions have overlapped with the critical region of miller - dieker syndrome ( mds ) and involved candidate genes such as pafah1b1, ywhae and crk\n. the variant is associated with expression of cadm2 in the cingulate cortex ( p - value = 4 \u00d7 10 ( - 4 ) )"
        },
        {
          "qas": [
            {
              "id": "625374a8e764a53204000027_001",
              "question": "Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy"
            }
          ],
          "context": "periampullary adenocarcinomas are rare neoplasm that originates from the pancreatic head, the ampulla of vater, the distal bile duct or the duodenum.\ndefinition : periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors. methods : in the present study, we retrospectively reviewed the medical records of 16 patients\npancreaticobiliary subtype of periampullary carcinoma ( pac ) has a poor prognosis in comparison to the intestinal subtype.\nwhereas periampulary adenocarcinoma ( pac ) having four anatomic subtypes, pancreatic, common bile duct ( cbd ), ampullary and duodenum shows relative better prognosis\nsome 20 - 40 % of the periampullary carcinoma is irresectable at the time of diagnosis. biliary stenting and surgical bypass are commonly used palliative procedure.\n. it is most commonly performed for periampullary malig \" \" cy but may also be indicated in select cases of chronic pancreatitis or benign periampullary tumors.\npatients with periampullary tumour has not been reported to date.\nreviewed the medical records of 16 patients with periampullary carcinomas over 10 years. results : 16 patients, 10 men and 6 women ( median age 66. 7 years, range 42 - 80 ) had a\npancreatic and psoas abscesses as a late complication of intravesical administration of bacillus calmette - guerin for bladder cancer : a case report and review of the literature. this case illustrates the fact that although intravesical administration\nin patients suspected of pancreatic or periampullary cancer, abdominal contrast - enhanced computed tomography ( ct ) is the standard diagnostic modality."
        },
        {
          "qas": [
            {
              "id": "62015485c9dfcb9c09000023_001",
              "question": "Do SETD1A mutations predispose to schizophrenia?"
            }
          ],
          "context": ". our findings advance understanding of how setd1a mutations predispose to schizophrenia ( scz ) and point to novel therapeutic interventions.\n. notably, evolutionarily conserved setd1a targets are associated with neuropsychiatric genetic risk burden. reinstating setd1a expression in adulthood rescues cognitive deficits\nrecapitulation and reversal of schizophrenia - related phenotypes in setd1a - deficient mice.\ninteracting partners bcl11b and gatad2a are also schizophrenia risk genes indicating that other genes interacting with or are regulated by satb2 are making a contribution to schizophrenia and cognition.\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\nmutations in the superoxide dismutase - 1 ( sod1 ) gene have been found in 12 % - 23 % of patients diagnosed with familial als.\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\nmutations in the cu / zn superoxide dismutase 1 ( sod1 ) gene have been reported to cause adult - onset autosomal domi \" \" t amyotrophic lateral sclerosis ( fals ).\nmutations in the cu, zn superoxide dismutase ( sod1 ) gene have been reported in some pedigrees with familial amyotrophic lateral sclerosis ( fals )."
        },
        {
          "qas": [
            {
              "id": "61f7cca7882a024a1000002b_001",
              "question": "Is Sotatercept effective for Pulmonary Arterial Hypertension?"
            }
          ],
          "context": "sotatercept for the treatment of pulmonary arterial hypertension.\n. it is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis - associated lung fibrosis.\nnewer agents with anti - fibrotic properties, such as pirfenidone or nintedanib, might hold promise also for the pulmonary fibrosis seen in sarcoidosis.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\n< b > objective < / b > : baricitinib is an orally administered inhibitor of jak1 and jak2 that has been shown to be effective in treating rheumatoid arthritis ( ra ).\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\nefforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a sirna product against glycolate oxidase, which has become the first effective therapy to treat ph1.\n. it is an adenosine receptor a2a antagonists that will represent an important option for patients with advanced pd where it has been demonstrated efficacy in decreasing daily off time and is well tolerated.\nthe 5 - ht1f receptor agonist lasmiditan, a drug acting through non - vasoconstrictive mechanisms, represents a promising safe, effective and tolerated acute migraine therapy also for patients at cardiovascular risk."
        },
        {
          "qas": [
            {
              "id": "624f2355e764a5320400000b_001",
              "question": "Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?"
            }
          ],
          "context": "the sino - nasal - outcome - test - 22 ( snot - 22 ) represents the reference questionnaire to assess symptoms, health - related quality - of - life ( hrqol ) and treatment - response in patients with chronic rhinosinusitis ( crs ).\nbackground : the 22 - item sino - nasal outcome test ( snot - 22 ) is a commonly utilized outcome measure for chronic rhinosinusitis ( crs\ntcomes included scores on the crs disease severity visual analog scale ( vas ), 22 - item sino - nasal outcome test ( snot - 22 ), 5 - dimension euroqol ( eq - 5d ) general health status vas, and 36 - item short - form health survey ( sf - 36 ) for hrqol and nasal\nobjectives : we set out to determine the psychometric validation of a disease - specific health related quality of life instrument for use in chronic rhinosinusitis, the 22 item sinonasal outcome test ( snot - 22 ), a modification of a pre - existing\nobjectives / hypothesis : sinonasal outcomes test - 22 ( snot - 22 ) is used widely as a patient - reported sinonasal quality - of - life ( qol ) instrument for endoscopic endonasa\nbackground : the 22 - item sino - nasal outcome test ( snot - 22 ) is a widely used and powerful patient - reported outcomes measure for chronic rhinosinus\n. responses from the sinonasal outcomes test - 22 ( snot - 22 ), a measure of patient hrqol, as well as the lund - kennedy and lund - mackay scores were recorded at enrollment\nbackground : prior study demonstrated that baseline 22 - item sino - nasal outcome test ( snot - 22 ) aggregate scores accurately predict selection of surgical intervention in patients with chronic rhinosinus\nact of crs. we sought to determine if 22 - item sino - nasal outcome test ( snot - 22 ) score is predictive of patient - perceived crs symptom control. methods : prospective cross - sectional study of 2\ndevelopment of sinonasal outcome test ( snot - 22 ) domains in chronic rhinosinusitis with nasal polyps."
        },
        {
          "qas": [
            {
              "id": "626aa563e764a53204000036_001",
              "question": "Is pRETRO-SUPER an adenoviral vector?"
            }
          ],
          "context": "in this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\nlong - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\none of the most advanced and most promising vectors is the attenuated, non - replicating poxvirus mva ( modified vaccinia virus ankara ), a safer derivative of the uniquely successful smallpox vaccine\nsimian parainfluenza virus 5 ( sv5 ) is a prototype of the paramyxoviridae family of nonsegmented negative - sense rna viruses.\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nof posttranscriptional tpr gene silencing by rna interference ( rnai ).\ncircular retrotransposition products generated by a line retrotransposon\nthe e1a gene of adenovirus encodes two proteins, 289 and 243 amino acids long, which have positive ( transactivator ) and negative ( enhancer repressor ) rna polymerase ii transcriptional regulatory properties and cell transformation activities including\nof a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development."
        },
        {
          "qas": [
            {
              "id": "6201a85cc9dfcb9c0900002a_001",
              "question": "Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?"
            }
          ],
          "context": "independence of chromatin conformation and gene regulation during drosophila dorsoventral patterning.\nwhile analyzing chromatin immunoprecipitation data sets from 21 sequence - specific transcription factors active in the drosophila embryo, we found that binding of all factors exhibits a dose - dependent relationship with \" tagteam \" sequence motifs bound\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\n. in drosophila, the dna - binding protein zelda ( also known as vielfaltig ) is required for this transition and for transcriptional activation of the zygotic genome.\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\ntranscription factors and chromatin - remodeling complexes are key determi \" \" ts of embryonic stem cell ( esc ) identity.\n. we define tissue - specific enhancers and link them to expression patterns using single - cell rna - seq. surprisingly, despite tissue - specific chromatin states and gene expression, chromatin organization is largely maintained across tissues\n. our results indicate that tissue - specific chromatin conformation is not necessary for tissue - specific gene expression but rather acts as a scaffold facilitating gene expression when enhancers become active.\nrecent advances in our understanding of the three - dimensional organization of the eukaryotic nucleus have rendered the spatial distribution of genes increasingly relevant"
        },
        {
          "qas": [
            {
              "id": "61faa1fcc9dfcb9c0900000a_001",
              "question": "Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\noverall survival for recurrent high - grade glioma was 13. 6 months ( 95 % confidence interval, 10. 8 to 20. 0 ) and was statistically improved relative to an external control ( hazard ratio, 0. 45 ; p = 0. 003 ).\nof glioblastoma or anaplastic astrocytoma, administration of toca 511 and toca fc, compared with soc, did not improve overall survival or other efficacy end points.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\nthe proteasome inhibitor bortezomib is effective for a variety of tumors, but not for gbm.\nconclusion : the combination of inc280 / buparlisib resulted in no clear activity in patients with recurrent pten - deficient glioblastoma.\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\nexpert opinion : despite the poor global results of dacomitinib in recurrent gb shown in a phase ii trial, some patients had a significant benefit.\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful."
        },
        {
          "qas": [
            {
              "id": "61f93e68882a024a1000004d_001",
              "question": "Should perampanel be used for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "conclusions : perampanel was associated with a significant decline in alsfrs - r score and was linked to worsening of the bulbar subscore in the 8 mg group.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\n. the trial was halted due to the large number of adverse events. discussion : the use of perampanel in this study of als was limited by its poor tolerability\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nconclusions : pentoxifylline is not beneficial in als and should be avoided in patients treated with riluzole.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\ninterpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nneuroprotective agents are screened for use in patients with als."
        },
        {
          "qas": [
            {
              "id": "624c88a1e764a53204000002_001",
              "question": "Is Satb1 a transcription factor?"
            }
          ],
          "context": "the transcription factor satb1 that regulates the t - cell maturation\nchromatin organizers satb2 and satb1\nsatb1 ( special at - rich binding protein 1 ) is a global chromatin organizer regulating the expression of a large number of genes\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\nsatb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\ntranscription factor complexes. these myb complexes assemble aberrantly with lyl1, e2a, c / ebp family members, lmo2, and satb1.\nspecial at - rich sequence - binding protein 1 ( satb1 ) is a cell type - specific matrix attachment region binding protein, functioning as a global genome organizer.\nthe special at - rich sequence binding protein 1 ( satb1 ) and its role in solid tumors.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling."
        },
        {
          "qas": [
            {
              "id": "6228b3553a8413c65300008b_001",
              "question": "Are circular RNAs implicated in diseases of the eye?"
            }
          ],
          "context": "in this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\ncircrna is a rising star in researches of ocular diseases.\nin this review we consider the current state of knowledge regarding the potential role and underlying mechanism of circrnas in ocular diseases including pterygium, age - related cataract, glaucoma, diabetic retinopathy, retinoblastoma, retinal vascular\nwe recently identified a circular rna transcript ( circgrm4 ) that is significantly upregulated in the eye of cystathionine \u03b2 - synthase - deficient mice.\nretinopathy, retinoblastoma, retinal vascular dysfunction and hyperhomocysteinemia induced ocular diseases, emphasizing that circrnas could be promising biomarkers for the diagnosis and prognosis evaluation.\nrecent evidence has demonstrated that circular rnas ( circrnas ) played crucial roles in fine - tuning the levels of gene expression by sequestering the corresponding microrna ( mirnas ).\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\ncircular rnas profiling in the cystathionine - \u03b2 - synthase mutant mouse reveals novel gene targets for hyperhomocysteinemia induced ocular disorders\ncircular rnas ( circrnas ) belong to a recently re - discovered species of rna that emerge during rna maturation through a process called back - splicing.\ncircular rna ( circrna ) is a large class of covalently closed circrna."
        },
        {
          "qas": [
            {
              "id": "626aaaa8e764a5320400003a_001",
              "question": "Can epigenetic modifications be heritable?"
            }
          ],
          "context": "epigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nsome of these epigenetic changes appear to be heritable.\nmore interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nepigenetic alterations are defined as heritable changes in gene expression mediated through mechanisms other than alterations in the dna sequence itself, including dna promoter methylation and various histone covalent modifications.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\nepigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in dna sequence.\nepigenetic alterations, which, by definition, comprise mitotically and meiotically heritable changes in gene expression that are not caused by changes in the primary dna sequence, are increasingly being recognized for their roles in carcinogenesis.\nepigenetic modification refers to heritable changes in the genetic material without any changes in the nucleic acid sequence and results in heritable phenotypic changes.\nepigenetics refers to the heritable, but reversible, regulation of various biological functions mediated principally through changes in dna methylation and chromatin structure derived from histone modification.\nepigenetic mechanisms, which include dna methylation, histone modification, and microrna ( mirna ), can produce heritable phenotypic changes without a change in dna sequence."
        },
        {
          "qas": [
            {
              "id": "61f7d2a5882a024a10000032_001",
              "question": "Is Belimumab used for lupus nephritis?"
            }
          ],
          "context": "a secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.\ncent findings : recently, the belimumab in subjects with systemic lupus erythematosus - lupus nephritis trial tested belimumab, an inhibitor of b - cell activating factor, as an add - on therapy to steroids and either mycophenolate mofetil ( mmf ) or\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\nbelimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis ( including dialysis and transplanted patient ).\ndurable renal response and safety with add - on belimumab in patients with lupus nephritis in real - life setting ( berliss - ln ).\nst implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with sle, specifically lupus nephritis. by targ\nic agents, rituximab may be used for refractory lupus nephritis patients in combination with another dmard, and belimumab was recently approved by the us food and drug administration for csle treatment in children aged > 5 years\nbelimumab and low - doses of mycophenolate mofetil as induction therapy of class iv lupus nephritis : case series and literature review.\nin this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add - on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase iii clinical trials.\nfollowing treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. belimumab might hold promise for this indication."
        },
        {
          "qas": [
            {
              "id": "62507ca3e764a5320400000f_001",
              "question": "Is SOX10 expressed in melanoma cells?"
            }
          ],
          "context": "our study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis.\nmelanocytic markers melan - a and sox10\nthe most commonly used melanocytic markers include s100, melan - a, hmb45 and sox10\nfoxa1 expression can independently predict chemosensitivity of er - positive breast cancer patients.\nmesenchymal - epithelial transition in sarcomas is controlled by the combinatorial expression of microrna 200s and grhl2.\nfoxa1 expression could be a prognostic marker in er - positive breast cancer.\nexpression of \u03b1 - taxilin in hepatocellular carcinoma correlates with growth activity and malig \" \" t potential of the tumor.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\nstaining for the transcription factors foxp2, satb1 and satb2 labeled most ganglion cells in the avian ganglion cell layer."
        },
        {
          "qas": [
            {
              "id": "61f939a5882a024a1000004a_001",
              "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?"
            }
          ],
          "context": "this study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\n. a randomized phase ii trial in second - line hcc showed improved overall survival ( hazard ratio : 0. 38 ; p = 0. 01 ) in patients with met - high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\ncabozantinib in the treatment of hepatocellular carcinoma.\nostic factor in hcc after sorafenib failure. tivantinib demonstrated a nearly doubling of progression free and overall survival in the met high group compared to placebo in a phase ii study in patient\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nexpression ( met - high ) hepatocellular carcinoma previously treated wit\npositive results in recent phase iii clinical trials have confirmed the high value of anti - angiogenic therapies for hcc in both first ( sorafenib and lenvatinib ) and second line ( regorafenib and cabozantinib ) treatment modalities.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo."
        },
        {
          "qas": [
            {
              "id": "6250a545e764a53204000012_001",
              "question": "Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?"
            }
          ],
          "context": "objective : the 6 - question euroqol 5 - dimension health assessment ( eq - 5d ) is a widely used, simple instrument that monitors general health - related quality of life ( hrqol ) in chronic disease.\ntcomes included scores on the crs disease severity visual analog scale ( vas ), 22 - item sino - nasal outcome test ( snot - 22 ), 5 - dimension euroqol ( eq - 5d ) general health status vas, and 36 - item short - form health survey ( sf - 36 ) for hrqol and nasal\nobjectives : we set out to determine the psychometric validation of a disease - specific health related quality of life instrument for use in chronic rhinosinusitis, the 22 item sinonasal outcome test ( snot - 22 ), a modification of a pre - existing\nhealth survey ( sf - 36 ) for hrqol and nasal polyp - related healthcare resource use questionnaires. re\nthe mfm scale was a useful instrument in the follow up of patients with dmd. moreover, it is a more comprehensive scale to assess patients and very good for conducting trials to evaluate treatment.\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\nnorth star ambulatory assessment in brazilian portuguese is a reliable and valid instrument to measure functional capacity in boys with duchenne muscular dystrophy.\nthe sino - nasal - outcome - test - 22 ( snot - 22 ) represents the reference questionnaire to assess symptoms, health - related quality - of - life ( hrqol ) and treatment - response in patients with chronic rhinosinusitis ( crs ).\n. assessments included timed rise from floor, timed 10 m walk / run, six - minute walk distance, north star ambulatory assessment ( nsaa ) and forced vital capacity ( fvc ). mean age at baseline was 5. 9 years ( range 4. 1 - 8. 1 years )\nimprovement over 3 years in a composite outcome comprising measures of motor function, pulmonary function, and satisfaction with treatment"
        },
        {
          "qas": [
            {
              "id": "61f608d4882a024a10000023_001",
              "question": "Is sacituzumab govitecan effective for breast cancer?"
            }
          ],
          "context": "sacituzumab govitecan in metastatic triple - negative breast cancer.\nsacituzumab govitecan has shown promise in cancers outside of tnbc, such as urothelial and lung and is being evaluated in hr - positive breast cancers.\nexpert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\nsacituzumab govitecan was initially approved in april 2020 under accelerated approval for the treatment of patients with metastatic triple - negative breast cancer who received at least two prior therapies for metastatic disease\nsacituzumab govitecan for metastatic triple - negative breast cancer : clinical overview and management of potential toxicities.\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer.\nsacituzumab govitecan ( also known by the brand name trodelvy\u00ae ) is a new and available treatment for metastatic triple - negative breast cancer, or mtnbc for short.\nintroduction : sacituzumab govitecan - hziy, approved in 2020 for treatment of metastatic triple - negative breast cancer, provides a new option for a population with a historically poor prognosis with standard\n. food and drug administration of sacituzumab govitecan - hziy ( trodelvy ) for the treatment of patients with metastatic triple - negative breast cancer who had received at least two prior therapies in the metastatic setting.\n. sacituzumab govitecan is an antibody - drug conjugate composed of an antibody targeting the human trophoblast cell - surface antigen 2 ( trop - 2 ), which is expressed in the majority of breast cancers, coupled to sn - 38 ( topoisomerase i inhibitor ) through"
        },
        {
          "qas": [
            {
              "id": "622905043a8413c65300008e_001",
              "question": "Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?"
            }
          ],
          "context": "acute necrotizing encephalopathy ( ane ) typically affects young, healthy children who develop rapid - onset severe encephalopathy triggered by viral infections.\nacute necrotizing encephalopathy ( ane ) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems.\nacute necrotizing encephalopathy ( ane ) is a recently identified, uncommon encephalopathy affecting children. ane is characterized by a preceding viral illness followed by seizures and rapid progressive neurologic deterioration.\nbackground : acute necrotizing encephalopathy ( ane ) is a rapidly progressive encephalopathy seen commonly in children triggered by various prodromal viral infections, most common being influenza virus and human herpes virus - 6. objective : we report two\nacute necrotizing encephalopathy of childhood ( anec ) is a disease, characterized by a respiratory or gastrointestinal infection, accompanied with fever, rapid alteration of consciousness, and seizures.\nacute necrotizing encephalopathy ( ane ) is a rare but distinctive type of acute encephalopathy with global distribution. occurrence of ane is usually preceded by a virus - associated febrile illness and ensued by rapid deterioration.\nacute necrotizing encephalopathy ( ane ) presents in children after common viral infections.\nacute necrotizing encephalopathy of childhood ( anec ) is a disease characterized by respiratory or gastrointestinal infection and high fever accompanying with rapid alteration of consciousness and seizures\nacute necrotizing encephalopathy ( ane ) is a specific type of encephalopathy usually followed by febrile infection\nsince it was first recognized, neurological complications including acute necrotizing encephalopathy ( ane ) have been globally documented in association with this viral infection."
        },
        {
          "qas": [
            {
              "id": "6251465ae764a53204000017_001",
              "question": "Is Phospholemman a membrane protein?"
            }
          ],
          "context": "phospholemman ( fxyd1 ) is a single - transmembrane protein regulator of na, k - atpase, expressed strongly in heart, skeletal muscle, and brain and phosphorylated by protein kinases a and c at ser - 68 and ser - 63, respectively.\nthe transmembrane lipoprotein phospholemman ( fxyd1 )\n. several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),\nve - cadherin protein levels were also increased in the plasma membrane fraction.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nthe plasma membrane - bound e - cadherin protein\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\nmembrane \" \" otubes play important functional roles in numerous cell activities such as cellular transport and communication.\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3"
        },
        {
          "qas": [
            {
              "id": "61f93c38882a024a1000004b_001",
              "question": "Can Isradipine slow progression of Early Parkinson Disease?"
            }
          ],
          "context": "however, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\nthese findings suggest that greater exposure to isradipine might slow disease progression.\nresults : isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy - adjusted unified parkinson's disease rating scale parts i - iii score over 36 months ( spearman rank correlation coefficient, rs :\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nconclusion : long - term treatment with immediate - release isradipine did not slow the clinical progression of early - stage p\nisd might represent an alternative option for patients with advanced pd.\nibudilast slowed brain atrophy in ppms and spms patients in a multicenter phase 2b study.\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nlong - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial."
        },
        {
          "qas": [
            {
              "id": "625144c9e764a53204000016_001",
              "question": "Is neurofilament light marker for disease?"
            }
          ],
          "context": "neurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\nneurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with alzheimer's dementia, and psychiatric disorders.\nserum neurofilament light chain ( snfl ) is a marker of neuroaxonal injury.\nneurofilament light chain ( nfl ) has recently been proposed as a promising biomarker in frontotemporal dementia ( ftd )\nrecently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\n. we investigated the correlation of both cerebrospinal fluid ( csf ) and serum nfl with detailed neuropsychological data and cognitive decline in a cohort of sporadic and familial ftd.\n. using light as a probe for selective neuronal activation or inhibition and as a means to read out neural activity has dramatically enhanced our understanding of complex neural circuits.\nsystematic quantification of neurotrophic adipokines rbp4, pedf, and clusterin in human cerebrospinal fluid and serum."
        },
        {
          "qas": [
            {
              "id": "62532d42e764a53204000022_001",
              "question": "Is resistance training usually associated with increasing muscle hypertrophy?"
            }
          ],
          "context": "resistance training increases muscle size ( i. e., causes hypertrophy ) and muscle strength, particularly in untrained individuals.\nit is universally accepted that resistance training promotes increases in muscle strength and hypertrophy in younger and older populations\nin resistance training, it has been empirically accepted that muscle hypertrophy is developed by low intensity and high volume training, while muscle strength and power are developed by high intensity and low volume training.\nit has been proposed that protein supplementation during resistance exercise training enhances muscle hypertrophy.\nthe rate and amount of muscle hypertrophy associated with resistance training is influenced by a wide array of variables including the training program, plus training experience, gender, genetic predisposition, and nutritional status of the\nresistance training ( rt ) is a popular method of conditioning to enhance sport performance as well as an effective form of exercise to attenuate the age - mediated decline in muscle strength and mass.\nr adaptations caused by resistance training include increased cross - sectional area of the muscle ( hypertrophy, hyperplasia, or both ), selective hypertrophy of fast twitch fibers, decreased or maintained mitochondrial number and capillary density of\nbackground : effects of resistance training on muscle strength and hypertrophy are well established in adults and younger elderly.\nchronic resistance training induces increases in muscle fibre cross - sectional area ( csa ), otherwise known as hypertrophy.\nwe conclude that a program of resistance exercise can be safely carried out by elderly women, such a program significantly increases muscle strength, and such gains are due, at least in part, to muscle hypertrophy."
        },
        {
          "qas": [
            {
              "id": "61f93cc7882a024a1000004c_001",
              "question": "Is nerinetide effective for ischaemic stroke?"
            }
          ],
          "context": "the authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\nconclusions : tirilazad mesylate increases death and disability by about one fifth when given to patients with acute ischemic stroke\n. although the mechanism of fty720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\n. the larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.\nconclusions : in patients with acute ischemic stroke, the dosage regimen of 7. 5 mg over 1 hour followed by 10 mg / d of intravenous lubeluzole is safe and statistically significantly reduced mortality.\n. although further trials of tirilazad are now unwarranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischemic stroke."
        },
        {
          "qas": [
            {
              "id": "61f938e7882a024a10000049_001",
              "question": "Is Algenpantucel-L effective for pancreatic cancer?"
            }
          ],
          "context": "conclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\nconclusions : algenpantucel - l immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable pdac receiving soc neoadjuvant chemotherapy and chemoradiatio\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.\n. grade 3 or higher adverse events occurred in 105 of 140 patients ( 75 % ) in the standard group and in 115 of 142 patients ( 81 % ) in the experimental group ( p > 0. 05 ). conclusions : algenpantucel - l immunotherapy did not improve survival in patients with\nthe anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\nconclusions : panitumumab in combination with chemotherapy does not improve orr, pfs and os in patients with kras wild - type, advanced biliary cancer.\nshown to be effective for advanced biliary tract cancer.\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\ninterpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer."
        },
        {
          "qas": [
            {
              "id": "62515021e764a53204000018_001",
              "question": "Is Mical an oxidoreductase?"
            }
          ],
          "context": "mical is an oxidoreductase\nthe oxidoreductase mical\nwe have recently identified a new family of multidomain oxidoreductase ( redox ) enzymes, the micals,\nthe micals, which are flavoprotein monooxygenase / hydroxylase enzymes that associate with flavin adenine dinucleotide ( fad ) and use the co - enzyme nicotinamide adenine dinucleotide phosphate ( nadph ) in redox reactions\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nhere we report tight genetic linkage between fals and a gene that encodes a cytosolic, cu / zn - binding superoxide dismutase ( sod1 ), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion o2. - to o2 and h2o2 ( ref.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nhave reported point mutations in the cytosolic cu / zn superoxide dismutase ( sod 1 ) gene in some families with familial amyotrophic lateral sclerosis ( als ).\n. a likely explanation for the reduction of or transcription is the striking reorganization of nuclear architecture observed in the osn lineage, which disrupts multi - chromosomal compartments regulating or expression in humans and hamsters\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate."
        },
        {
          "qas": [
            {
              "id": "61fa9a60c9dfcb9c09000007_001",
              "question": "Should istiratumab be used for Pancreatic Cancer?"
            }
          ],
          "context": "antitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\ninterpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.\nexpert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract\nconclusions : panitumumab in combination with chemotherapy does not improve orr, pfs and os in patients with kras wild - type, advanced biliary cancer.\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement."
        },
        {
          "qas": [
            {
              "id": "605b9c2a94d57fd879000035_001",
              "question": "Does Amblyopia affect the eye?"
            }
          ],
          "context": "amblyopia is defined as the reduction of best - corrected visual acuity of one or both eyes caused by conditions that affect normal visual development\namblyopia is a developmental disorder resulting in poor vision in one eye.\namblyopia is a reduced best - corrected visual acuity of one or both eyes that cannot be attributed to a structural abnormality ; it is a functional reduction in the vision of an eye caused by disuse during a critical period of visual development\nobjective : amblyopia or lazy eye is a common visual problem affecting children that cannot correct with lenses.\namblyopia is a disorder of visual acuity in one eye, thought to arise from suppression by the other eye during development of the visual cortex.\namblyopia is a developmental disorder that affects the spatial vision of one or both eyes in the absence of an obvious organic cause ; it is associated with a history of abnormal visual experience during childhood\namblyopia is characterised by decrease in vision in one or both eyes as a result of processing defect in the visual pathways of the brain\namblyopia or \" lazy eye \" represents a disorder of the visual system characterized by poor vision in an eye that is otherwise physically normal.\nocular misalignment or unilateral blur often causes amblyopia, a disorder that has become a standard for understanding developmental plasticity.\namblyopia, commonly known as \" lazy eye, \" is a frequent but preventable cause of decreased vision"
        },
        {
          "qas": [
            {
              "id": "603bc2b61cb411341a00015b_001",
              "question": "Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?"
            }
          ],
          "context": "there has been intensified interest in the neuropeptides oxytocin ( ot ) and arginine vasopressin ( avp ) in autism spectrum disorders ( asd ) given their role in affiliative and social behavior in animals, positive results of treatment studies using ot,\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\ndysfunction of brain - derived arginine - vasopressin ( avp ) systems may be involved in the etiology of autism spectrum disorder ( asd ).\nbackground : arginine vasopressin ( avp ) has been hypothesized to play a role in aetiology of autism based on a demonstrated involvement in the regulation of social\nthe behavioral effects of avp are mediated through the avp receptor 1a ( avpr1a ), making the avpr1a gene a reasonable candidate for autism susceptibility.\nhowever, we recently found that cerebrospinal fluid ( csf ) concentration of the \" social \" neuropeptide arginine vasopressin ( avp ) is significantly lower in pediatric asd cases vs. controls.\nwe therefore hypothesized that avp signaling deficits may contribute to social impairments in children with autism spectrum disorder ( asd ).\nprevious results suggest that oxt and arginine vasopressin ( avp ) may play a role in the etiopathogenesis of asd\nthe contribution of oxytocin and vasopressin to mammalian social behavior : potential role in autism spectrum disorder.\nbackground : dysregulation of the vasopressin ( avp ) system has been implicated in the pathogenesis of autistic spectrum dis"
        },
        {
          "qas": [
            {
              "id": "6278da4456bf9aee6f00000f_001",
              "question": "Is thalidomide used as an immunomodulatory drug nowadays?"
            }
          ],
          "context": "thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno - modulatory drug.\nas immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases\nthalidomide is a drug that, since its development, has made history in the world of medicine - - having been withdrawn and now has returned with a boom as an anticancer and immunomodulatory drug.\nafter nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs ( imids ).\nthalidomide is an immunomodulatory drug ( imid ) with proven therapeutic action in several autoimmune / inflammatory diseases ;\nthalidomide is an immunomodulatory agent ; although its mechanisms of action are not fully understood, many authors have described its anti - inflammatory and immunosuppressive properties\nalthough thalidomide was withdrawn in the 1960s after its teratogenic property was recognized, it was subsequently found that this drug possesses immunomodulatory and anti - inflammatory effects.\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\nthalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malig \" \" cies\nthalidomide is attracting growing interest because of its reported immunomodulatory and anti - inflammatory properties."
        },
        {
          "qas": [
            {
              "id": "6278d0a756bf9aee6f00000e_001",
              "question": "Does p85\u03b1 homodimerize?"
            }
          ],
          "context": "homodimerized p85\u03b1\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\n. here, we show that the mcm2 - ctf4 - pol\u03b1 axis facilitates the transfer of parental ( h3 - h4 ) 2 tetramers to lagging - strand dna at replication forks\nthe crystal structure of this compound with pim1 confirmed the predicted binding mode and protein - ligand interactions except those in the acidic ribose pocket.\nwe also find that tcf3 phosphorylation is triggered by canonical wnt ligands, lrp6, and domi \" \" t negative mutants for axin and gsk3, indicating that this process shares the same upstream regulators with \u03b2 - catenin stabilization.\nhsp90 co - chaperones pp5 and fkbps\nthe crystal structures of pim1 in apo form and bound with amppnp have been solved\npromoter as well as heterologous promoters in an orientation - independent manner\nphospholemman ( fxyd1 ) is a single - transmembrane protein regulator of na, k - atpase, expressed strongly in heart, skeletal muscle, and brain and phosphorylated by protein kinases a and c at ser - 68 and ser - 63, respectively."
        },
        {
          "qas": [
            {
              "id": "6276d2d956bf9aee6f000002_001",
              "question": "Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?"
            }
          ],
          "context": "there are theoretical concerns that angiotensin - converting enzyme inhibitors ( aceis ) and angiotensin receptor blockers ( arbs ) could increase the risk of severe covid - 19.\nthere has been a lot of speculation that patients with coronavirus disease 2019 ( covid - 19 ) who are receiving angiotensin - converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) may be at increased risk for adverse outcomes.\nsome studies of hospitalized patients suggested that the risk of death and / or severe illness due to covid - 19 is not associated with the use of angiotensin - converting enzyme inhibitors ( aceis ) and / or angiotensin ii receptor type 1 blockers ( arbs )\nthese findings suggest that the use of ace - i and arb is not associated with adverse outcomes and may be associated with improved outcomes in covid - 19, which is immediately relevant to care of the many patients on these medications.\nthat aceis and arbs increase the likelihood of contracting covid - 19 or worsen the outcome of sars - cov \u2011 2 infections\naceis / arbs are protective factors against mortality in covid - 19 patients with htn, and these agents can be considered potential therapeutic options in this disease.\naceis and arbs do not promote a more severe outcome of covid - 19.\n. in conclusion, these results suggest that acei / arb medications should not be discontinued for hypertensive patients in the context of covid - 19 pandemic.\n. our analysis demonstrated that acei and / or arb use was associated neither with testing positive rates of covid - 19 nor with mortality of covid - 19 patients.\non the basis of the available evidence, acei / arb therapy should be continued in patients who are at risk for, or have covid - 19, either in general population or hypertension patients."
        },
        {
          "qas": [
            {
              "id": "6278ddfe56bf9aee6f000013_001",
              "question": "Are functional tests a good biomarker for Duchenne Muscular Dystrophy?"
            }
          ],
          "context": "the north star ambulatory assessment ( nsaa ) is a validated 17 - item functional rating scale and widely used to assess motor function in boys with duchenne muscular dystrophy ( dmd ).\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\nthe north star ambulatory assessment is a functional scale specifically designed for ambulant boys affected by duchenne muscular dystrophy ( dmd ).\n. we hypothesised that boys with dmd could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the north star ambulatory assessment ( nsaa ) total score.\nnorth star ambulatory assessment in brazilian portuguese is a reliable and valid instrument to measure functional capacity in boys with duchenne muscular dystrophy.\nhis preliminary investigation describes the relationship between community ambulation measured by the stepwatch activity monitor and the current standard of functional assessment, the 6 - minute walk test, in ambulatory boys with duchenne muscular\nherefore, in our group of ambulant patients with dmd, timed functional testing was the most sensitive parameter to determine the extent of disease progression\nconclusion : the moderate correlation between functional tests, age and baseline mri measures supports mri as a biomarker in duchenne muscular dystrophy clinical trials.\nwe hypothesised that boys with dmd could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the north star ambulatory assessment ( nsaa ) total score.\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures."
        },
        {
          "qas": [
            {
              "id": "627926bc56bf9aee6f00001a_001",
              "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?"
            }
          ],
          "context": "during influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\nfindings indicate that clinical symptoms alone would be insufficient to distinguish between coronavirus disease 2019 and other respiratory infections ( eg, influenza ) and / or to evaluate the effects of preventive interventions ( eg, vaccinations ).\nalthough covid - 19 has been extensively characterized clinically, the factors distinguishing sars - cov - 2 from other respiratory viruses are unknown.\nit is difficult to distinguish coronavirus disease - 2019 ( covid - 19 ) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.\ncovid - 19 and can be important differentiating symptoms in patients presenting with acute respiratory illness\ncovid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\nsince the symptoms are similar to other respiratory infections, differential diagnosis in travellers arriving from countries with wide - spread covid - 19 must include other more common infections such as influenza and other respiratory tract diseases.\n. here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish covid - 19 from other respiratory diseases, yet such essential information is largely unavailable.\nwe show that although covid - 19 and influenza are different in many ways, there are numerous similarities ; thus, in addition to using nucleic acid - based polymerase chain reaction ( pcr ) and antibody - based approaches, clinicians and epidemiologists\ncovid - 19 has a similar pattern of infection, clinical symptoms, and chest imaging findings to influenza pneumonia."
        },
        {
          "qas": [
            {
              "id": "627a6ef856bf9aee6f000020_001",
              "question": "Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?"
            }
          ],
          "context": "lumbar puncture is performed routinely for diagnostic and therapeutic purposes in idiopathic intracranial hypertension, despite lumbar puncture being classically contraindicated in the setting of raised intracranial pressure.\nalthough generally considered innocuous, there may be considerable danger when lumbar puncture is performed in the presence of increased intracranial pressure, especially when a mass lesion is present.\nthere are few abnormal ct scans presenting a contraindication for lumbar puncture and the majority of these patients usually have clinical signs to suggest raised intracranial pressure.\n. patients without focal neurological deficits often undergo cct before lumbar puncture ( lp ) to exclude contraindications to lp including brain herniation or increased csf pressure.\ndeath following lumbar puncture ( lp ) is feared by physicians. many opinions are found in literature on the question whether computed cranial tomography ( ct ) should be performed before lp, to prevent herniation.\nlumbar puncture ( lp ) is usually contra - indicated in situations where the icp is suspected to be high.\nlumbar puncture should be avoided if focal neurologic findings suggest concomitant mass lesion, as in brain abscess, and lumbar puncture should be approached with great caution if meningitis is accompanied by evidence of significant intracranial\nas an emergency diagnostic procedure, spinal puncture is indicated when cns infection is suspected or to establish the diagnosis of subarachnoid hemorrhage when results of cranial computed tomography are normal\n. the major contraindication is elevated intracranial pressure with evidence of a mass lesion.\n. the most serious complication is cerebral herniation and, for its prevention, computed tomography ( ct ) or cerebral magnetic reso \" \" ce imaging ( mri ) must always be performed before lumbar puncture : a lesion with evident mass effect is a"
        },
        {
          "qas": [
            {
              "id": "6402c910201352f04a00000c_001",
              "question": "Can losartan reduce brain atrophy in Alzheimer's disease?"
            }
          ],
          "context": "interpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\nconclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\nthese findings suggest that greater exposure to isradipine might slow disease progression.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\nthere has been a lot of speculation that patients with coronavirus disease 2019 ( covid - 19 ) who are receiving angiotensin - converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) may be at increased risk for adverse outcomes."
        },
        {
          "qas": [
            {
              "id": "63fa13da201352f04a000001_001",
              "question": "Is PRP-40 regulation of microexons a conserved phenomenon?"
            }
          ],
          "context": "prp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n. knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n. surprisingly, the regulatory methylated region is contained in an unusually large intron that is conserved in ibm1 orthologues.\nin several eukaryotic organisms, heterochromatin ( hc ) in the introns of genes can regulate rna processing, including polyadenylation, but the mechanism underlying this regulation is poorly understood.\nin the poly - pyrimidine tract upstream of the regulated microexon.\nin many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by pr domain - containing protein 9 ( prdm9 )."
        },
        {
          "qas": [
            {
              "id": "64178e15690f196b51000020_001",
              "question": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "he approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nan effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures."
        },
        {
          "qas": [
            {
              "id": "640e2616201352f04a00002a_001",
              "question": "Is medical hydrology the same as Spa therapy?"
            }
          ],
          "context": "he worked to improve the status of spa medicine, recasting it as medical hydrology.\nhydrotherapy, \" \" balneotherapy, \" \" spa therapy, \" \" spa treatment, \" \" creno - balneotherapy, \" \" water treatments, \" and \" aqua therapy, \" o\nbath ) or ( balneo * ) or ( hydrotherap * ) or ( mineral water ) or ( thermal water ) or ( spring water ) or ( health resort medicine ) )\nspa therapy is an integral part of the treatment of burn scars. the objective of this systematic review is to provide an overview of the spa therapy used in the treatment of burn scars and analyze its effects reported in clinical studies\n. we used the prisma checklist and queried 8 scientific databases from august 2019 to july 2020 for articles referenced with the specific key words : ( burn ) and ( ( spa ) or ( crenotherap * ) or ( sulfur bath ) or ( balneo * ) or ( hydrotherap * ) or ( mineral\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\n. the patients were divided into two groups, depending on the use of 6 % hes 130 / 0. 4 : group a ( 461 \u00b1 167 ml of saline - based hes was administered ; 43 patients ) and group b ( hes not administered ; 50 patients )\nconclusions \u2022 the review indicates that yoga, aerobic exercise, acupuncture, biofeedback, hypnosis, and inositol and n - acetylcysteine all show promise in the treatment of excoriation disorder and other body - focused repetitive behaviors, such as\nadvanced development phases while non - invasive neuromodulatory approaches were suggested to be potentially effective as non - pharmaceutical interventions for migraine.\n. on the other hand, laboratory abnormalities and radiological findings were not statistically different between the two groups."
        },
        {
          "qas": [
            {
              "id": "64178e73690f196b51000023_001",
              "question": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "esulting in an absence of functional dystrophin protein. viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. herein, long - term ( > 2 years ) functional outcomes in viltolarsen treated pati\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\nat years 3 and 4, eteplirsen - treated patients demonstrated markedly greater mean 6mwt than controls ( difference in change from baseline of 132 m [ 95 % ci ( 29, 235 ), p = 0. 015 ] at year 3 and 159 m [ 95 % ci ( 66, 253 ), p = 0. 002 ] at year 4 )\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nviltolarsen restores the reading frame of the dmd gene by skipping exon 53 and produces a truncated but functional form of dystrophin.\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders."
        },
        {
          "qas": [
            {
              "id": "63f02a82f36125a426000013_001",
              "question": "Does CIDEB mutation protect from liver disease?"
            }
          ],
          "context": "germline mutations in cideb and protection against liver disease.\nin intestinal epithelial carcinogenesis, mice ( iec - cyld ( \u03b49 ) mice ) that carry a mutation that eliminates the deubiquitinating domain of cyld in intestinal epithelial cells ( iec ) were generated by crossing villin - cre transgenic mice to previously\nlow prophylactic doses of mab combinations protected against infection by many variants in k18 - hace2 transgenic mice, 129s2 immunocompetent mice and hamsters, without the emergence of resistance.\nhave reported point mutations in the cytosolic cu / zn superoxide dismutase ( sod 1 ) gene in some families with familial amyotrophic lateral sclerosis ( als ).\nmutations in the cu, zn superoxide dismutase ( sod1 ) gene have been reported in some pedigrees with familial amyotrophic lateral sclerosis ( fals ).\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\nprovides an endogenous mechanism to upregulate hepcidin, leading to sustained iron - restricted erythropoiesis and preventing systemic iron overload in \u03b2 - thalassemic mice.\n. ibudilast may have a role in the treatment of progressive ms phenotypes.\naccumulated evidence implies that mutations in the gene coding for cu / zn superoxide dismutase ( sod ) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis ( als ).\nall mutations in the human gene for cuzn superoxide dismutase ( cuznsod ) reported to date are associated with the disease amyotrophic lateral sclerosis ( als )."
        },
        {
          "qas": [
            {
              "id": "64105502201352f04a00002d_001",
              "question": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?"
            }
          ],
          "context": "the north star ambulatory assessment ( nsaa ) is a validated 17 - item functional rating scale and widely used to assess motor function in boys with duchenne muscular dystrophy ( dmd ).\nintroduction : the north star ambulatory assessment ( nsaa ) tool is a key instrument for measuring clinical outcomes in patients with duchenne muscular dy\nthe north star ambulatory assessment is a functional scale specifically designed for ambulant boys affected by duchenne muscular dystrophy ( dmd ).\n. we hypothesised that boys with dmd could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the north star ambulatory assessment ( nsaa ) total score.\nwe hypothesised that boys with dmd could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the north star ambulatory assessment ( nsaa ) total score.\nnorth star ambulatory assessment in brazilian portuguese is a reliable and valid instrument to measure functional capacity in boys with duchenne muscular dystrophy.\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\nherefore, in our group of ambulant patients with dmd, timed functional testing was the most sensitive parameter to determine the extent of disease progression\nwe have developed a new scale and the associated classification system, to assess the functional ability of children diagnosed with dmd\nallow assessment of high - functioning boys with duchenne muscular dystrophy."
        },
        {
          "qas": [
            {
              "id": "6415ca99690f196b51000019_001",
              "question": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?"
            }
          ],
          "context": "engineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nbackground : tisagenlecleucel is an anti - cd19 chimeric antigen receptor ( car19 ) t - cell therapy approved for the treatment of children and young adults with relapsed / refractory ( r / r ) b - cell acute lymphoblastic leukemia ( b - all ).\nchimeric antigen receptor t cells demonstrate efficacy in b - cell malig \" \" cies, leading to us food and drug administration approval of axicabtagene ciloleucel ( october 2017 ) and tisagenlecleucel ( may 2018 ) for large b - cell lymphomas after 2 prior lines\ncd3 - engaging bispecific antibodies ( bsabs ) and chimeric antigen receptor ( car ) t cells are potent therapeutic approaches for redirecting patient t cells to recognize and kill tumors\n. food and drug administration ( fda ) approved novartis'tisagenlecleucel ( ctl - 019, kymriah ), which is a synthetic bioimmune product of anti - cd19 chimeric antigen receptor ( car ) t cells, for the treatment of relapsed / refractory b - cell acute\nwithin the last one year, two anti - cd19 car t - cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the united states food and drug administration for the treatment of relapsed or refractory large b - cell lymphoma after\nthe phase ii juliet trial suggests that the cd19 - targeting car t - cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large b - cell lymphoma.\nthe emerging b - cell depleting therapies, particularly anti - cd20 agents such as rituximab, ocrelizumab, as well as the fully human ofatumumab, have shown promising clinical and magnetic reso \" \" ce imaging benefit.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well."
        },
        {
          "qas": [
            {
              "id": "64178e4b690f196b51000022_001",
              "question": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "n december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\ngolodirsen is a provisionally approved pmo - based drug for approx. 8 % of all dmd patients amenable to exon 53 skipping.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\nesulting in an absence of functional dystrophin protein. viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. herein, long - term ( > 2 years ) functional outcomes in viltolarsen treated pati\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\nviltolarsen restores the reading frame of the dmd gene by skipping exon 53 and produces a truncated but functional form of dystrophin.\nefforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a sirna product against glycolate oxidase, which has become the first effective therapy to treat ph1."
        },
        {
          "qas": [
            {
              "id": "63f043e4f36125a426000023_001",
              "question": "Is Baricitinib effective for Alopecia Areata?"
            }
          ],
          "context": "we reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata ( aa ) in recent 5 years including clinical trials and case reports.\nconclusions : in two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.\n< b > objective < / b > : baricitinib is an orally administered inhibitor of jak1 and jak2 that has been shown to be effective in treating rheumatoid arthritis ( ra ).\nin patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.\nthus, once - daily baricitinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated emerging treatment for patients with moderate to severe active ra who have responded inadequately to or are intolerant of\nconclusions : the efficacy and safety profile of baricitinib was maintained during long - term treatment of japanese patients with ra and background methotrexate therapy.\nbaricitinib is effective in treatment of ra, and did not appear to have significant safety concerns during the first 6 months of treatment.\nin february 2017, baricitinib was approved in the eu, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant\nconclusion : baricitinib 2 mg and 4 mg administered once daily, in combination with dmard, were efficacious interventions for active ra that had no significant risk of teae development.\nobjective baricitinib is an oral, once - daily selective janus kinase ( jak1 / jak2 ) inhibitor for adults with moderately to severely active rheumatoid arthritis ( ra )."
        },
        {
          "qas": [
            {
              "id": "64137616201352f04a000041_001",
              "question": "Anemia is not associated with chronic kidney failure"
            }
          ],
          "context": "anemia is a common complication of chronic kidney disease.\nanemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.\nanemia is a common and clinically important consequence of chronic kidney disease ( ckd ).\nanemia is an adverse outcome and common complication in chronic kidney disease patient\nanaemia is a common manifestation ofa chronic kidney failure.\nanemia is a frequent complication of kidney disease.\nanemia is a common complication of chronic kidney disease ( ckd ) in predialysis stage.\nanemia in chronic kidney disease is common and iron deficiency is an important cause.\nanemia in children with chronic kidney disease\niron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia."
        },
        {
          "qas": [
            {
              "id": "64163660690f196b5100001d_001",
              "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "though deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\nconclusions selinexor - dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.\ntrial. both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome ( p <. 001 for daily predn\nevidence from randomized clinical trials, prospective studies, meta - analyses, and post - hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving\nfunctional decline compared with those receiving prednisone / prednisolone.\nconclusion the combination of selinexor and dexamethasone has an orr of 21 % in patients with heavily pretreated, refractory myeloma with limited therapeutic options.\nallow assessment of high - functioning boys with duchenne muscular dystrophy.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd )."
        },
        {
          "qas": [
            {
              "id": "64144200201352f04a000043_001",
              "question": "Is anaphylaxis a results of mast cell activation?"
            }
          ],
          "context": "anaphylaxis results from the massive activation of the mast cells ( mcs ).\nanaphylaxis results from severe systemic mast cell activation. in addition to ige - mediated and physical triggers, it may occur with a clonal mast cell\nextensive activation of mast cells is the major switch that triggers systemic anaphylaxis, resulting in the subsequent release of anaphylactic mediators into circulation.\nidiopathic anaphylaxis : a form of mast cell activation syndrome.\npurpose of review : mast cell activation syndrome ( mcas ) and anaphylaxis are the result of a spontaneous or triggered pathological degranulation of mast cells ( mcs ) and might have as substrate normal or pathological mcs ( increased burden, aberrant mcs\nin this chapter, we will describe the mechanisms of mast cell ( and basophil ) activation in anaphylaxis, with a focus on ige - dependent activation, which is thought to be responsible for most examples of antigen - induced anaphylaxis in humans.\nanaphylaxis is a life - threatening syndrome resulting from the sudden release of mast cell - and basophil - derived mediators into the circulation.\nidiopathic anaphylaxis involves mast cell activation ( acutely elevated urine histamine or serum tryptase ) and activated lymphocytes.\nsystemic anaphylaxis arises when mast cells, possibly along with other cell types, are provoked to secrete mediators that evoke a systemic response.\nwhen there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable."
        },
        {
          "qas": [
            {
              "id": "64178e34690f196b51000021_001",
              "question": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "ucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\nviltolarsen restores the reading frame of the dmd gene by skipping exon 53 and produces a truncated but functional form of dystrophin.\nesulting in an absence of functional dystrophin protein. viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. herein, long - term ( > 2 years ) functional outcomes in viltolarsen treated pati\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nallow assessment of high - functioning boys with duchenne muscular dystrophy."
        },
        {
          "qas": [
            {
              "id": "6410f839201352f04a000032_001",
              "question": "Can the concept of digital twins be applied in Precision Nutrition?"
            }
          ],
          "context": "a \" virtual digital twin, \" which could serve to guide nutrition in a personalized manner.\nwe herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \" virtual digital twin, \" which could serve to\nour data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs\n. our data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.\n. we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\nobjective we aimed to integrate neural data and an advanced machine learning technique to predict individual major depressive disorder ( mdd ) patient severity.\n. the flexibility and power of spiralize are demonstrated by five examples from real - world datasets.\nbackground : machine learning - based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them\ntraining protocols are designed dependent on individual t response.\nhere, we introduce the computational framework pines ( phenotype - informed noncoding element scoring ), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype - dependent manner"
        },
        {
          "qas": [
            {
              "id": "64040edf201352f04a000011_001",
              "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?"
            }
          ],
          "context": "interpretation : pioglitazone did not delay the onset of mild cognitive impairment.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\nevidence for the increased prevalence of diabetes and obesity is reviewed as it relates to cognitive decline.\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nconclusions and relevance : minocycline did not delay the progress of cognitive or functional impairment in people with mild ad during a 2 - year period."
        },
        {
          "qas": [
            {
              "id": "63f9cdb033942b094c000012_001",
              "question": "Does silencing of SRRM4 promote microexon inclusion?"
            }
          ],
          "context": "srrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\nwe show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n. knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression."
        },
        {
          "qas": [
            {
              "id": "64040af9201352f04a00000d_001",
              "question": "Is levosimendan effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "interpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nconclusions : levosimendan did not achieve the primary endpoint of improving sitting svc in als. headache and increased heart rate were increased on levosimendan, although it was otherwise well tolerated.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nneuroprotective agents are screened for use in patients with als.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported."
        },
        {
          "qas": [
            {
              "id": "641365f6201352f04a00003a_001",
              "question": "Is Iron deficiency anemia a common complication of chronic kidney disease?"
            }
          ],
          "context": "anemia is a common complication of chronic kidney disease.\nanemia in chronic kidney disease is common and iron deficiency is an important cause.\niron deficiency anemia ( ida ) is a frequent complication of chronic kidney disease ( ckd ) and is associated with adverse outcomes in these patients.\niron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia.\nlimited data suggest that iron deficiency is common in patients with chronic kidney disease with anemia ; this lack of iron can hinder the effectiveness of erythropoiesis.\nanemia is a frequent complication of kidney disease.\nanemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.\niron deficiency, both functional and absolute, is common in patients with chronic kidney disease ( ckd ), especially those requiring dialysis.\nanemia is a common and clinically important consequence of chronic kidney disease ( ckd ).\nbackground : iron deficiency anemia is a common complication in patients with chronic kidney di"
        },
        {
          "qas": [
            {
              "id": "6410ef9b201352f04a000031_001",
              "question": "Can modulation of KCNQ1 splicing prevent arrhythmias?"
            }
          ],
          "context": "amiloride regulates iks and aps with transmural differences and reduces arrhythmogenicity through the modulation of kcnq1 splicing. we suggested that the modulation of kcnq1 splicing may help prevent arrhythmia.\n. notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\n. functional characterization of mutant fhf2a co - expressed with wild - type nav1. 6 ( scn8a ) revealed that mutant fhf2a proteins lost the ability to induce rapid - onset, long - term blockade of the channel while retaining pro - excitatory properties\nin this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nwe identified > 200 significant alternative splicing ( as ) events and distinct as profiles were observed in the right ( rv ) and left ( lv ) ventricles in pln - r14del compared to wt mouse hearts.\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\n. our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces."
        },
        {
          "qas": [
            {
              "id": "6414c124690f196b51000002_001",
              "question": "Is trichotillomania encountered with equali frequency in males and females?"
            }
          ],
          "context": "other body - focused repetitive behaviors, such as trichotillomania.\nfuture studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.\nthe disease affects mainly female patients, who often deny the habit, and it usually presents with a bizarre pattern nonscarring patchy alopecia with short hair and a negative pull test.\ncontrary to what is observed in true hermaphroditism and in male pseudo - hermaphroditism, there is no erroneous transmission of the genetic gonadal differentiation programme in female pseudohermaphroditism.\nsex differences in oncogenic mutational processes.\nfew studies exist on the psychosexual outcome of homogeneous groups of individuals with 5\u03b1 - reductase deficiency type 2 ( 5\u03b1 - rd - 2 ) and the relation between gender changes and parental hostile and benevolent sexism, which are two components of\n. yet evidence of how individuals experience this condition and the psychosocial implications are lacking\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\ntrichomegaly of the eyelashes is a rare adverse effect of egfr inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes.\nthe exposed rats had a greater incidence of pituitary chromophobe adenomas, epithelial and mesothelial cell tumors than the unexposed controls but the excessive occurrence of malig \" \" t gliomas that was observed in the monkeys was absent in the rats."
        },
        {
          "qas": [
            {
              "id": "63f9cd2f33942b094c000011_001",
              "question": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?"
            }
          ],
          "context": "microexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n. knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\nand regulators of protein translation or being translated into peptides in various diseases ; 5 ) circrnas have been identified for their enrichment and stability in exosomes and detected in body fluids such as human blood, saliva, and cerebrospinal\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences."
        },
        {
          "qas": [
            {
              "id": "6411b4a8201352f04a000035_001",
              "question": "Is prosopagnosia also known as lack of auditory recognition?"
            }
          ],
          "context": "visual object agnosia refers to the inability to recognize objects and prosopagnosia to the failure to recognize faces that are well familiar to the patient, when stimuli are visually perceived.\nprosopagnosia ( pa ) or face blindness is characterized by a deficiency in identifying familiar faces.\nprosopagnosia is a selective visual agnosia characterized by the inability to recognize the identity of faces.\nprosopagnosia is a visual agnosia characterized by an inability to recognize previously known human faces and to learn new faces\nprosopagnosia is a type of visual agnosia with inability to identify faces, usually secondary to brain lesion in associative cortex areas, but there is also a congenital form known as developmental prosopagnosia.\nthe apparent selectivity of agnosia for faces is termed prosopagnosia or face blindness.\nin recent years, prosopagnosia is defined as the \" loss of ability to recognize the well - acquainted persons like the family members by their physiognomy. \"\nby \" prosopagnosia \" - namely, by a form of visual agnosia, specifically affecting face recognition.\nprosopagnosia is a selective impairment of the visual learning and recognition of faces.\nintroduction : the prosopagnosia has generally been defined as an incapacity to recognize familiar faces, or faces previously known, due to certain lesions to certain areas of the ce"
        },
        {
          "qas": [
            {
              "id": "641357bc201352f04a000039_001",
              "question": "Do cells undergoing necroptosis show disruption of their cell membranes?"
            }
          ],
          "context": "both necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.\nnecroptosis, a form of programmed cell death, is characterized by the loss of membrane integrity and release of intracellular contents, the execution of which depends on the membrane - disrupting activity of the mixed lineage kinase domain - like protein\nnecroptosis is a form of caspase - independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain - like ( mlkl ) pseudokinase after its activation by the upstream kinases, receptor interacting protein\nnecroptosis is a highly inflammatory form of programmed cell death that results from mlkl - mediated disruption of the cell membrane.\nthus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\nnecroptosis induction leads to cell membrane disruption, inflammation and vascularization.\nchanisms by which the essential, and possibly terminal, necroptotic effector, mlkl, triggers the disruption of cellular membranes to cause cell lysis.\nnecroptosis is a programmed cell death pathway triggered by activation of receptor interacting protein kinase 3 ( ripk3 ), which phosphorylates and activates the mixed lineage kinase - like domain pseudokinase, mlkl, to rupture or permeabilize the plasma\nnon - inflammatory process while necrosis triggers inflammation. recent studies on necroptosis and pyroptosis, two types of programmed necrosis, revealed that plasma membrane rupture is mediated by mlkl channels during necroptosis but depen\nthe activation of mixed lineage kinase - like ( mlkl ) by receptor - interacting protein kinase - 3 ( ripk3 ) results in plasma membrane ( pm ) disruption and a form of regulated necrosis, called necroptosis."
        },
        {
          "qas": [
            {
              "id": "641ad941690f196b5100003d_001",
              "question": "Are LOQ and LOD the same?"
            }
          ],
          "context": "the limit of detection ( lod ) and limit of quantitation ( loq )\n* limit of blank ( lob ), limit of detection ( lod ), and limit of quantitation ( loq ) are terms used to describe the smallest concentration of a measurand that can be reliably measured by an analytical procedure.\n. the limit of quantitation ( loq ), or concentration at which quantitative results can be reported with a high degree of confidence, may likewise be determined by either approach\nlimit of detection ( lqd ) / limit of quantitation ( loq ) : comparison of the empirical and the statistical methods exemplified with gc - ms assays of abused drugs.\nthe limits of detection ( lod ) and quantitation ( loq ) were 0. 6 and 2. 1 microg / l, respectively.\nlimits of detection ( lod ) and quantitation ( loq ) for uv detection are 1 and 2 mg / l, respectively.\nlimits of detection ( lod ) and quantification ( loq ) at 10 and 20 ng / g were achieved,\nthe quantitative parameters of sensor for silver ion are determined as the limit of detection ( lod ) 5. 95 \u00d7 10 - 7 m, and limit of quantitation ( loq ) 1. 98 \u00d7 10 - 8 m in the linear range\nresults indicated that the dynamic ranges of three fur - bearing animals were all from 1 % to 90 % ; the limit of detection ( lod ) and limit of quantification ( loq ) for three fur - bearing animals were same, with lod 0. 1 % ( w / w ) and loq 1 % ( w / w ).\nmissing values caused by the limit of detection or quantification ( lod / loq ) were widely observed in mass spectrometry"
        },
        {
          "qas": [
            {
              "id": "64179337690f196b51000034_001",
              "question": "Do machine learning-based methods outperform statistical methods for survival analysis?"
            }
          ],
          "context": "our results reveal that machine - learning - based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i. e., cox proportional hazard model.\nwe review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high - dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.\nthis analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods - cox model regularized with ridge penalty ( cox - ridge ) and partial least squares\nbackground : machine learning - based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them\nbackground : over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms\nfurthermore, although machine learning and data mining methods are based on statistics, most such techniques do not address the biologist's requirement for sound mathematical confidence measures.\nthese results confirm that clinically useful mdd risk - stratification models can be generated from baseline patient self - reports and that ml methods improve on conventional methods in developing such models\ncan be improved by using machine learning methods.\ndeepsurv models consistently outperformed coxph ; both approaches performed best when provided with all the datasets.\n. the model had high sensitivity and accuracy in predicting the 1 - year overall survival rate ( area under the curve = 0. 717 ). the prediction model risk score was an independent predictor of crc."
        },
        {
          "qas": [
            {
              "id": "6402c868201352f04a00000b_001",
              "question": "Was erythropoietin effective for optic neuritis in the TONE trial?"
            }
          ],
          "context": "interpretation : erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\nerythropoietin rct that failed to demonstrate differences between groups for both primary and secondary outcomes.\nor death or in the frequency of serious adverse events. conclusions : high - dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nthere was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age ( 97 children [ 26 % ] vs\nesistance to erythropoietin therapy is a common complication of the modern management of anemia in chronic kidney disease\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nuse of epogen for treatment of anemia associated with chronic renal failure.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy."
        },
        {
          "qas": [
            {
              "id": "64299b6a57b1c7a315000001_001",
              "question": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?"
            }
          ],
          "context": "however, we found that infections by omicron were significantly less severe than those caused by delta and other previous variants.\ninfection with sars - cov - 2 variant omicron is considered to be less severe than infection with variant delta, with rarer occurrence of severe disease requiring intensive care.\nearly work suggests that infections caused by the omicron variant may be less severe than those caused by the delta variant.\nsevere acute respiratory syndrome coronavirus 2 infection from the omicron variant in children / adolescents is less severe than infection from the delta variant.\nfirst time sars - cov - 2 infections occurring at a time when the omicron variant was rapidly spreading were associated with significantly less severe outcomes than first - time infections when the delta variant predominated.\nin the general population, illness after infection with the sars - cov - 2 omicron variant is less severe compared with previous variants.\nomicron variant infection is associated with significantly lower severity of disease compared with the delta variant.\nearly reports of omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by omicron\nglobally, sars cov - 2 omicron variant has led to a notable increase of covid - 19 diagnoses, although with less severe clinical manifestations and decreased hospitalizations.\nomicron appears to lead to a milder illness for patients compared with previous covid - 19 variants."
        },
        {
          "qas": [
            {
              "id": "64040bd8201352f04a00000e_001",
              "question": "Should be used bexarotene for relapsing-remitting multiple sclerosis?"
            }
          ],
          "context": "interpretation : we do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.\n. it was approved by the food and drug administration ( fda ) in march 2017 for using in adults with relapsing - remitting multiple sclerosis ( rrms ) and primary progressive multiple sclerosis ( ppms ).\nibudilast for the treatment of multiple sclerosis.\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nconclusions : among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.\nselinexor plus low - dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.\nof relapsing forms of ms, to exert beneficial effects in reducing disease progression unrelated to relapses in spms.\nthe fda granted accelerated approval to selinexor plus low - dose dexamethasone for triple - class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data.\n. it summarizes prior and current clinical trials of ibudilast in ms as well as its pharmacology. expert opinion : although ibudilast has not been found to decrease the focal inflammatory activity in relapsing ms, it was shown to have an effect on\nof relapsing multiple sclerosis and ulcerative colitis"
        },
        {
          "qas": [
            {
              "id": "6429ee7457b1c7a31500000b_001",
              "question": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?"
            }
          ],
          "context": "analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\n. some studies revealed changes in certain immune response parameters post - vaccination when analgesics / antipyretics were used either prophylactically or therapeutically. still, there is no evidence that these changes impact vaccine efficacy\nworldwide, paracetamol is administered as a remedy for complaints that occur after vaccination. recently published results indicate that paracetamol inhibits the vaccination response in infants when given prior to vaccination.\nwhile antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.\n. these findings prompt to consider therapeutic instead of prophylactic treatment to ensure maximal vaccination efficacy and retain the possibility to treat pain and fever after vaccination.\nand vaccine recipients that short - term use of analgesics / antipyretics at non - prescription doses is unlikely to affect vaccine - induced immunity.\n. specific data on the impact of analgesic / antipyretic medications on immunogenicity of covid - 19 vaccines are limited\n. only prophylactic paracetamol treatment, and not therapeutic treatment, during vaccination has a negative influence on the antibody concentration after hepatitis b vaccination in adults\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\nthese findings suggest that the use of ace - i and arb is not associated with adverse outcomes and may be associated with improved outcomes in covid - 19, which is immediately relevant to care of the many patients on these medications."
        },
        {
          "qas": [
            {
              "id": "64281a47690f196b5100004f_001",
              "question": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?"
            }
          ],
          "context": "oxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\nlumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.\nlumasiran, an rnai therapeutic for primary hyperoxaluria type 1.\nlumasiran in the management of patients with primary hyperoxaluria type 1 : from bench to bedside.\nrationale & objective : lumasiran reduces urinary and plasma oxalate ( pox ) in patients with primary hyperoxaluria type 1 ( ph1 ) and relatively preserved kidney function\npharmaceuticals for the treatment of primary hyperoxaluria type 1 ( ph1 ).\nthe effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.\nlumasiran is an rna interference ( rnai ) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of ph1.\nphase 3 trial of lumasiran for primary hyperoxaluria type 1 : a new rnai therapeutic in infants and young children.\nhepatocyte - targeted delivery, and with the recent approvals of givlaari ( givosiran ) for the treatment of acute hepatic porphyria, oxlumo ( lumasiran ) for the treatment of primary hyperoxaluria, and leqvio ( inclisiran ) for the treatment of"
        },
        {
          "qas": [
            {
              "id": "6429cfb557b1c7a315000005_001",
              "question": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?"
            }
          ],
          "context": "our study supports the recommendation that patients with chronic pulmonary diseases, including asthma and copd who require treatment with either inhaled or systemic corticosteroids, should continue their use during the covid - 19 pandemic.\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\nhowever, patients with asthma or copd should continue all prescribed inhaled medications.\nadditionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe covid - 19, but there is no evidence guiding the use of biologic therapy.\nthe available recommendations state that patients with asthma should use inhaled glucocorticosteroids ( gcs ) on a regular basis.\nour findings assured the safety of continued use of inhaled corticosteroids during the covid - 19 pandemic.\nthe benefit - risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or copd.\nthese findings should encourage clinicians to continue ics therapy for copd patients during the covid - 19 pandemic.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\n. similarly, the meta - analysis observed no significant difference in the risk for the development of a severe course of covid - 19 with preadmission use of inhaled corticosteroids in patients with covid - 19 relative to non - use of inhaled corticosteroids"
        },
        {
          "qas": [
            {
              "id": "6432f75757b1c7a31500001d_001",
              "question": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?"
            }
          ],
          "context": "in the united states, zanubrutinib, a next - generation btk inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with waldenstrom macroglobulinemia, and for adults with\n. this article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in japan.\nhere, we provide a comprehensive review of the preclinical and clinical activity of tirabrutinib, a drug approved in japan for relapsed or refractory primary central nervous system lymphoma and all lines of waldenstrom\npositive phase iii - study data have been published for lenvatinib as first - line and cabozantinib as second - line therapy.\n. tirabrutinib is also under regulatory review in japan for the treatment of waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma\nine kinase inhibitor tirabrutinib ( for relapsed and refractory pcnsl ) and high - dose chemotherapy with autologous stem cell transplantation support using thiotepa and busulfan ( butt ) were approved by the japanese ministry of health and welfare in\ntirabrutinib was well tolerated and showed promising efficacy for b - cell nhl / cll.\nin march 2020, oral tirabrutinib was approved in japan for the treatment of recurrent or refractory primary central nervous system lymphoma.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy."
        },
        {
          "qas": [
            {
              "id": "63eef94ff36125a426000010_001",
              "question": "Is Cinpanemab effective for Parkinson\u2019s Disease?"
            }
          ],
          "context": "conclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ]."
        },
        {
          "qas": [
            {
              "id": "643306cc57b1c7a315000027_001",
              "question": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?"
            }
          ],
          "context": "the crispr - cas12a system can detect both l858r and t790m with a limit of detection of 0. 005 % in less than three hours.\n. to identify additional therapeutic targets in aml, we optimize a genome - wide clustered regularly interspaced short palindromic repeats ( crispr ) screening platform and use it to identify genetic vulnerabilities in aml cells\n. sensitive and accurate detection of brca1 and brca2 mutations is crucial for personalized clinical management of individuals affected by breast or ovarian cancer, and for the identification of at - risk healthy relatives\nthe detection and quantification of methylated rna can be beneficial to understand certain cellular regulation processes such as transcriptional modulation of gene expression, immune response, or epigenetic alterations.\nof crispr guide rnas and open chromatin sites by assay of transposase - accessible chromatin with sequencing ( atac - seq ).\n. in addition, active enhancers can be detected through signatures of bidirectional transcription initiation. described here is a protocol for performing super - low input carrier - cage ( slic - cage )\ngle cell gel electrophoresis ( e. g., comet assay ) and immunofluoresence microscopy to detect the presence of gamma - h2ax foci, we find that cr [ vi ] induces dna double - strand breaks similar to ionizing radiation ( ir ). we also demo\n. through this strategy, we detected significant cis - eqtls ( i. e., dna variants affecting gene expression ) and selected a few candidates to conduct an association study in a large brazilian cohort ( 624 patients and 668 controls )\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes."
        },
        {
          "qas": [
            {
              "id": "63f9ccdc33942b094c00000f_001",
              "question": "Is PRP-40 involved in microexon splicing?"
            }
          ],
          "context": "prp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\n. knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\nprdm9 methyltransferase activity is essential for meiotic dna double - strand break formation at its binding sites.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nin the poly - pyrimidine tract upstream of the regulated microexon."
        },
        {
          "qas": [
            {
              "id": "6404199d201352f04a000019_001",
              "question": "Is ocrelizumab effective for primary progressive multiple sclerosis?"
            }
          ],
          "context": "ocrelizumab ( ocrevus\u00ae ) is an intravenously administered, humanized anti - cd20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis ( rms ) or primary progressive multiple sclerosis ( ppms ).\nbackground : ocrelizumab is a humanised anti - cd20 monoclonal antibody developed for the treatment of multiple sclerosis ( ms )\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nanti - cd20 agents for multiple sclerosis : spotlight on ocrelizumab and ofatumumab.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\nareas covered : in this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti - cd20 therapies for ms, including rituximab, ocrelizumab, and ofatumumab.\ninterpretation natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper - limb component.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\n. it was approved by the food and drug administration ( fda ) in march 2017 for using in adults with relapsing - remitting multiple sclerosis ( rrms ) and primary progressive multiple sclerosis ( ppms ).\nthe emerging b - cell depleting therapies, particularly anti - cd20 agents such as rituximab, ocrelizumab, as well as the fully human ofatumumab, have shown promising clinical and magnetic reso \" \" ce imaging benefit."
        },
        {
          "qas": [
            {
              "id": "63f9cdcc33942b094c000013_001",
              "question": "Does silencing of SRRM4 inhibit tumor growth across cancers?"
            }
          ],
          "context": "we show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\ntogether, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity. < br >\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nsilencing nuclear pore protein tpr elicits a senescent - like phenotype in cancer cells.\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100."
        },
        {
          "qas": [
            {
              "id": "64041e97201352f04a00001e_001",
              "question": "Is daridorexant effective for insomnia?"
            }
          ],
          "context": ". daridorexant is superior to placebo in improving sleep quality.\ndaridorexant was superior to placebo in reducing wake time after sleep onset ( md = - 13. 26 ; 95 % ci, - 15. 48 to - 11. 03 ; p < 0. 00001 ), latency to persistent sleep ( md = - 7. 23 ; 95 % ci, - 9. 60 to - 4. 85 ; p < 0. 00001 ), with increasing the total sleep time\n. treatment with daridorexant has resulted in a slightly higher incidence of adverse events [ risk ratio ( rr ) = 1. 19 ; 95 % ci, 1. 05 - 1. 35 ;, p = 0. 005 ], specifically somnolence ( rr = 1. 19 ; 95 % ci, 1. 13 - 3. 23 ; p = 0. 005 ) and fatigue ( rr = 2. 01 ; 95 % ci,\ndaridorexant ( quviviq\u2122 ; idorsia pharmaceuticals ltd. ) is an orally administered dual orexin type 1 and type 2 ( ox1 and ox2 ) receptor antagonist ( dora ) being developed for the treatment of insomnia.\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\nconclusion the combination of selinexor and dexamethasone has an orr of 21 % in patients with heavily pretreated, refractory myeloma with limited therapeutic options.\nconclusions selinexor - dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.\nselinexor, an exportin - 1 inhibitor, yielded promising results in quad - or penta - refractory mm including patients resistant to daratumumab.\n. it is an adenosine receptor a2a antagonists that will represent an important option for patients with advanced pd where it has been demonstrated efficacy in decreasing daily off time and is well tolerated.\ndiscussion : intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild - to - moderate ad dementia patients."
        },
        {
          "qas": [
            {
              "id": "64041dae201352f04a00001d_001",
              "question": "Is deucravacitinib effective for psoriasis?"
            }
          ],
          "context": "introduction : deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a phase 2 clinical trial of adults with moderate to severe plaque psoriasis.\nconclusion : deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.\npoetyk pso - 1 and pso - 2 involved 1688 patients with moderate - to - severe psoriasis. after 16 weeks, in both studies, over 50 % of patients treated with deucravacitinib reached pasi75, which was significantly superior to placebo and apremilast\n. deucravacitinib was well tolerated and safe.\nwe reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata ( aa ) in recent 5 years including clinical trials and case reports.\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\ntwo different janus kinase ( jak ) inhibitors - baricitinib and tofacitinib - are effective and licensed in active rheumatoid arthritis ( ra ).\npacritinib ( pac ), a multi - kinase inhibitor with specificity for jak2, flt3, and irak1 but sparing jak1, has demonstrated clinical activity in mf with minimal myelosuppression.\nustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\ninhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast."
        },
        {
          "qas": [
            {
              "id": "6428da47690f196b51000051_001",
              "question": "Can the epigenetic status of introns affect gene expression?"
            }
          ],
          "context": "consistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.\nepigenetics refers to structural modifications to genes that do not change the nucleotide sequence itself but instead control and regulate gene expression.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nthese modifications, also known as epigenetic code, do not change the dna sequence but alter the expression level of specific genes.\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nepigenetic regulation is referred to as changes in gene function that do not involve changes in the dna sequence, it is usually accomplished by dna methylation, histone modifications ( repressive marks such as h3k9me, h3k27me, h2aub, or active marks\nepigenetic changes to the genome are biochemical alterations to the dna that do not change an individual's genome but do change and influence gene expression."
        },
        {
          "qas": [
            {
              "id": "642d4c9b57b1c7a315000013_001",
              "question": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?"
            }
          ],
          "context": "luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.\nbioluminescence - optogenetics is mediated by luminopsin fusion proteins - light - sensing opsins fused to light - emitting luciferases.\nluminopsins by fusing light - sensing opsins with light - emitting luciferases.\nouse ips - npcs were transduced with a novel optochemogenetics fusion protein, luminopsin 3 ( lmo3 ), which consisted of a bioluminescent luciferase, gaussia luciferase, and an opsin, volvox channelrhodopsin 1.\nhere we have expanded and refined the versatility of luminopsin tools by fusing an alternative luciferase variant with high light emission, gaussia luciferase mutant glucm23, to depolarizing and hyperpolarizing channelrhodopsins\noptogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits.\noptogenetics is the use of genetically coded, light - gated ion channels or pumps ( opsins ) for millisecond resolution control of neural activity.\n. it involves exogenous expression of a light - activated protein in a very particular retinal cell enabling regulation ( stimulation vs. inhibition ) of its physiological activity\noptogenetics refers to the genetic modification of cells to express light - sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.\nin optogenetics, as in nature, sensory photoreceptors serve to control cellular processes by light."
        },
        {
          "qas": [
            {
              "id": "6428da98690f196b51000053_001",
              "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?"
            }
          ],
          "context": "during influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\ncovid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\ncovid - 19 and can be important differentiating symptoms in patients presenting with acute respiratory illness\nsince the symptoms are similar to other respiratory infections, differential diagnosis in travellers arriving from countries with wide - spread covid - 19 must include other more common infections such as influenza and other respiratory tract diseases.\nfindings indicate that clinical symptoms alone would be insufficient to distinguish between coronavirus disease 2019 and other respiratory infections ( eg, influenza ) and / or to evaluate the effects of preventive interventions ( eg, vaccinations ).\nalthough covid - 19 has been extensively characterized clinically, the factors distinguishing sars - cov - 2 from other respiratory viruses are unknown.\nit is difficult to distinguish coronavirus disease - 2019 ( covid - 19 ) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.\n. here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish covid - 19 from other respiratory diseases, yet such essential information is largely unavailable.\nunfortunately, covid - 19 patients have symptoms similar to other common illnesses.\nin our retrospective cohort study comparing the clinical presentation of covid - 19 and other respiratory viral infections, we found that anosmia and dysgeusia were symptoms independently associated with covid - 19 and can be important differentiating"
        },
        {
          "qas": [
            {
              "id": "6428d7da690f196b51000050_001",
              "question": "Can untranslated regions (UTRs) regulate gene expression?"
            }
          ],
          "context": "untranslated regions ( utrs ) of eukaryotic mrnas play crucial roles in post - transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mrna transport, translation efficiency, subcellular localization, and message stability.\n3'untranslated regions ( utrs ) are known to play an important role in posttranscriptional regulation of gene expression.\nin higher eukaryotes, untranslated regions ( utrs ) of transcripts are one of the crucial regulators of gene expression ( influencing mrna stability and translation efficiency ).\nthe 5'and 3'untranslated regions of eukaryotic mrnas ( utrs ) play crucial roles in the post - transcriptional regulation of gene expression through the modulation of nucleo - cytoplasmic mrna transport, translation efficiency, subcellular localization,\nthe 3'untranslated region ( 3'utr ) can control gene expression by affecting the localization, stability and translation of mrnas.\nmany studies using reporter assays have demonstrated that 3'untranslated regions ( 3'- utrs ) regulate gene expression by controlling mrna stability and translation.\nuntranslated gene regions ( utrs ) play an important role in controlling gene expression.\nuntranslated regions ( utr ) play important roles in the posttranscriptional regulation of mrna processing.\nuntranslated regions ( utrs ) in eukaryotes play a significant role in the regulation of translation and mrna half - life, as well as interacting with specific rna - binding proteins.\nthe 5'and 3'untranslated regions ( utrs ) regulate crucial aspects of post - transcriptional gene regulation that are necessary for the maintece of cellular homeostasis"
        },
        {
          "qas": [
            {
              "id": "63f9cbb433942b094c00000c_001",
              "question": "Is alternative splicing associated with heart disease?"
            }
          ],
          "context": "we identified > 200 significant alternative splicing ( as ) events and distinct as profiles were observed in the right ( rv ) and left ( lv ) ventricles in pln - r14del compared to wt mouse hearts.\nepigenetic processes, defined as heritable changes in gene expression that occur without changes to the dna sequence, have emerged as a promising area of cardiovascular disease research.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nregulators in atherosclerotic cardiovascular disease, metabolic disease, and cancers ; 8 ) the potential mechanisms of several circrnas have been described in diseases, hinting at their potential applications as novel therapeutic targets.\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\naccumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\nfactors ; 4 ) circrnas regulate biological and pathological processes by sponging mirnas, binding to rna - binding protein ( rbp ), regulators of splicing and transcription, modifiers of parental gene expression, and regulators of protein translation or"
        },
        {
          "qas": [
            {
              "id": "61fa941ec9dfcb9c09000005_001",
              "question": "Should Intepirdine be used for Alzheimer's disease?"
            }
          ],
          "context": "expert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\ndiscussion : intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild - to - moderate ad dementia patients.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nverubecestat did not improve clinical ratings of dementia among patients with prodromal alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who\nconclusions : as compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy."
        },
        {
          "qas": [
            {
              "id": "61f7cb37882a024a10000029_001",
              "question": "Is rilonacept effective for pericarditis?"
            }
          ],
          "context": "objective : to review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis ( rp ).\nconcerning acute recurrent pericarditis ( rp ), an innovative interaction between cardiologists, internists and pediatric rheumatologists led to the intuition of a pivotal role of il - 1 in recurrent pericarditis characterized by an evident inflammatory\ncharacterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients.\ncurrently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials\n. currently, there are three available anti - il - 1 agents : anakinra ( recombit human il - 1ra ), rilonacept ( a soluble decoy receptor'trap ', binding both il - 1\u03b1 and il - 1\u03b2 ), and canakinumab ( human monoclonal anti - il - 1\u03b2 antibody ).\noverproduction of both il - 1\u03b1 ( released by inflamed / damaged pericardial cells ) and il - 1\u03b2 ( released by inflammatory cells ) is now a well - recognized therapeutic target in patients with recurrent idiopathic pericarditis\n. colchicine, an inhibitor of nlrp3 inflammasome formation, and il - 1 - targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab ( tcz ) is a humanized monoclonal antibody against il - 6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult ra populations\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis."
        },
        {
          "qas": [
            {
              "id": "64041f38201352f04a00001f_001",
              "question": "Is tebentafusp effective for uveal melanoma?"
            }
          ],
          "context": "this article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.\ntebentafusp was granted full approval on january 25th 2022 in the setting of hla - a * 02 : 01 - positive adult patients with unresectable or metastatic uveal melanoma.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc.\nexpert opinion : avelumab has shown clinical efficacy for metastatic and advanced uc in phase i studies after the failure of platinum - based therapy with a well - tolerated safety profile.\nnivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the fda for treatment of advanced - stage urothelial carcinoma.\nretation : avelumab showed antitumour activity in the treatment of patients with platinum - refractory metastatic urothelial carcinoma ; a manageable safety profile was reported in all avelumab - treated patients. these\nsions : mainte \" \" ce avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first - line chemotherapy\nfive new pd - 1 / pd - l1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma ( uc ) : pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab.\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\nand pembrolizumab ) and pd - l1 inhibitors ( atezolizumab, durvalumab, and avelumab ) in patients with nsclc."
        },
        {
          "qas": [
            {
              "id": "63f73f1b33942b094c000008_001",
              "question": "Is erenumab effective for trigeminal neuralgia?"
            }
          ],
          "context": "interpretation : erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and cgrp probably does not have an important role in paroxysmal pain.\nreceptor ( erenumab ) effectively prevent migraine attacks.\ncgrp receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against cgrp ( eptinezumab, fremanezumab and galcanezumab ) or the cgrp receptor ( erenumab ) effectively prevent migraine\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\ngalcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nfour monoclonal antibodies ( mabs ) targeting the cgrp pathway are currently under evaluation for the prevention of episodic and chronic migraine : eptinezumab ( ald403 ), fremanezumab ( tev - 48125 ), galcanezumab ( ly2951742 ), and erenumab ( amg334 ).\ngalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide, has demonstrated in previous phase 2 and phase 3 clinical studies ( \u22646 - month of treatment ) a reduction in the number of migraine headache\nthe efficacy and safety of calcitonin gene - related peptide monoclonal antibody for episodic migraine : a meta - analysis. based on the results of this meta - analysis, cgrp monoclonal antibodies significantly reduced the monthly migraine days and acute\neculizumab treatment improved symptoms compared with placebo in a phase ii study in patients with refractory gmg. d"
        },
        {
          "qas": [
            {
              "id": "643c88a257b1c7a315000030_001",
              "question": "Can other vaccines be given with COVID-19 vaccine?"
            }
          ],
          "context": ". the centers for disease control and prevention ( cdc ) has shifted their recommendations recently, allowing for the co - administration of the currently available covid - 19 vaccines with other vaccines\nit is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\n. this is based on the experience with non - covid - 19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone.\nconcomitant administration of covid - 19 and influenza vaccines could reduce burden on health - care systems. we aimed to assess the safety of concomitant administration of chadox1 or bnt162b2 plus an age - appropriate influenza vaccine.\n. concomitant vaccination with both covid - 19 and influenza vaccines over the next immunisation season should reduce the burden on health - care services for vaccine delivery, allowing for timely vaccine administration and protection from covid - 19 and\n. this may be of particular importance in the context of a worldwide vaccination campaign in response to the covid - 19 pandemic.\nassociation of receipt of the ad26. cov2. s covid - 19 vaccine with presumptive guillain - barre syndrome, february - july 2021.\ntherefore, many - but not all - of the antibody products with emergency use authorization should retain substantial efficacy against the prevailing variant strains of sars - cov - 2.\nour study supports the recommendation that patients with chronic pulmonary diseases, including asthma and copd who require treatment with either inhaled or systemic corticosteroids, should continue their use during the covid - 19 pandemic.\nunfortunately, covid - 19 patients have symptoms similar to other common illnesses."
        },
        {
          "qas": [
            {
              "id": "6441302d57b1c7a315000056_001",
              "question": "Is music therapy effective for pain management in neonates?"
            }
          ],
          "context": "breastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\nthis review supports the beneficial effects of music - based interventions on the health of preterm infants in a neonatal intensive care unit ; however, it also offers suggestions for future studies in order to increase the number of interventions with\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\nbf could significantly reduce pain response in healthy - term neonates during heel lance. mt did not enhance the effect of pain relief of bf.\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain.\nto increase the number of interventions with music therapists, since the results of music therapy approaches were more consistent for physiological and behavioural outcomes.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\n. these findings prompt to consider therapeutic instead of prophylactic treatment to ensure maximal vaccination efficacy and retain the possibility to treat pain and fever after vaccination.\nadvanced development phases while non - invasive neuromodulatory approaches were suggested to be potentially effective as non - pharmaceutical interventions for migraine.\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns."
        },
        {
          "qas": [
            {
              "id": "63f02b50f36125a426000014_001",
              "question": "Is there any association between Tripe palms and cancer?"
            }
          ],
          "context": "bladder cancer with an concomitant with tripe palms ( tp ) and / or mucosal involvement is relatively rare and, to our knowledge, only seven cases of an with bladder cancer have been reported in the english literature.\nbackground : tripe palms ( tp ) is one of the rare cutaneous paraneoplastic manifestations of various intra - abdominal malig \" \" cies.\nbackground : acanthosis nigricans ( an ), leser - trelat sign, and tripe palm are all skin diseases. to date, reports of these appearing as a paraneoplastic syndrome in a gastric cancer patient are quite rare.\n. special forms are florid cutaneous papillomatosis and tripe palms.\nrepens, hypertrichosis lanuginosa acquisita, papuloerythroderma of ofuji, tripe palms, and multicentric reticulohistiocytosis )\nacanthosis nigricans maligna : symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma\nfinally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically - diverse malig \" \" cies ( leser - trelat syndrome, trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita,\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\nmalig \" \" t mesothelioma is caused by exposure to asbestos, which is known to have carcinogenic effects.\nentrapment neuropathy of the palmar cutaneous branch of the median nerve concomitant with carpal tunnel syndrome : a case report."
        },
        {
          "qas": [
            {
              "id": "641c516d690f196b5100003f_001",
              "question": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?"
            }
          ],
          "context": "it has been reported that mutations in the superoxide dismutase ( sod ) 1 gene can lead to als.\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 ).\nthe sod1 gene encoding the superoxide dismutase 1 ( sod1 ) protein is mutated in approximately 15 % of familial amyotrophic lateral sclerosis ( als ) and 3 % of sporadic als.\nmutations in the cu / zn superoxide dismutase gene ( sod - 1 ) are reported in 20 % of familial amyotrophic lateral sclerosis ( als ) cases, but no definite report of a mutation in a \" truly \" sporadic case of als has been proved.\nthe superoxide dismutase - 1 ( sod1 ) gene is the first gene for familial amyotrophic lateral sclerosis ( als ) with autosomal domi \" \" t inheritance.\napproximately 2 % of amyotrophic lateral sclerosis ( als ) cases are caused by mutations in the super oxide dismutase 1 ( sod1 ) gene a\nmutations of the cu / zn superoxide dismutase ( sod - 1 ) gene were recently implicated in the pathogenesis of familial amyotrophic lateral sclerosis ( als ).\naccumulated evidence implies that mutations in the gene coding for cu / zn superoxide dismutase ( sod ) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis ( als ).\nabout 20 % of als families are associated with mutations in the gene for superoxide dismutase - 1 ( sod1 ) encoded on chromosome 21q22. 1.\ndomi \" \" t mutations in cu / zn - superoxide dismutase ( sod1 ) gene have been shown to cause a familial form of amyotrophic lateral sclerosis ( sod1 - als )."
        },
        {
          "qas": [
            {
              "id": "643c396457b1c7a31500002d_001",
              "question": "Are any medications available to prevent COVID-19 following exposure?"
            }
          ],
          "context": "early treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\nthe food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness.\nhydroxychloroquine ( hcq ) has been tried against covid - 19 owing to its in vitro virucidal action against sars - cov - 2, but the role of hcq as post - exposure prophylaxis ( pep ) remains inconclusive.\nin patients with non - severe covid - 19, casirivimab - imdevimab probably reduces hospitalisation ; bamlanivimab - etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. convalescen\ntecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\n. this study aimed to answer questions related to the use of hydroxychloroquine for pre - exposure or post - exposure prophylaxis of sars - cov - 2 infection and in the treatment of patients with mild covid - 19 in terms of hospitalization, adverse events, and\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\nto test hydroxychloroquine as postexposure prophylaxis for sars - cov - 2 infection."
        },
        {
          "qas": [
            {
              "id": "6440092d57b1c7a315000040_001",
              "question": "Has RTA 408 received FDA approval?"
            }
          ],
          "context": "in august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nno new drugs have been approved during the past 15 years ; and the available medications are not cost - effective.\n. there is still paucity of data regarding the use of canakinumab in the treatment of patients with rp.\ncurrent evidence does not support prophylactic use of clazosentan, magnesium, or simvastatin.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\nreceived marketing approval in the united states and japan for the treatment of ssc - ild.\ntaken together, our data do not support mother - to - infant transmission of sars - cov - 2 via milk.\nauthors'conclusions : there is currently no evidence that nicotine vaccines enhance long - term smoking cessation.\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nit is also reported that safety was tolerable within the limited study period. < br > < b > areas covered < / b > : we here review the recent progress in the development of baricitinib and its potential for the treatment of ra."
        },
        {
          "qas": [
            {
              "id": "643c446357b1c7a31500002f_001",
              "question": "Can reinfection occur after SARS-CoV-2 infection?"
            }
          ],
          "context": "sars - cov - 2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.\ncomparative genomic analysis demonstrates that true reinfection following sars - cov - 2 infection is possible.\nreinfection with sars - cov - 2 is a strong possibility. this case raises concerns that asymptomatic infections may not provide long - term protective immunity to all patients, which could make them susceptible to reinfection.\nsars - cov - 2 infection does not confer long immunity. however, studies suggest that prior infection is associated with lower risk of reinfection and milder outcomes of recurrent infections.\nour case supports the hypothesis that sars - cov - 2 reinfection may occur once antibody titers decrease or following the emergence of a new variant.\nit is currently unclear whether severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently\nprior to the emergence of antigenically distinct sars - cov - 2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses.\nthe rate of reinfection with sars - cov - 2 is relatively low. the protection against sars - cov - 2 after natural infection is comparable to that estimated for vaccine efficacy.\nreinfection by sars - cov - 2 under endemic conditions would likely occur between 3 months and 5 \u00b7 1 years after peak antibody response, with a median of 16 months.\nour findings indicate that reinfection results in restricted sars - cov - 2 replication despite substantial levels of humoral immunity, denoting the potential for transmission through reinfected asymptomatic individuals."
        },
        {
          "qas": [
            {
              "id": "63ee5eeaf36125a426000002_001",
              "question": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?"
            }
          ],
          "context": "pathogenic variants in dclre1c encoding artemis cause t - b - nk + severe combined immunodeficiency ( scid ), and patients with artemis - deficient scid ( art - scid ) require definitive therapy with allogeneic hematopoietic cell transplantation ( hct ).\nartemis deficiency disrupts development of adaptive immunity and leads to radiosensitive t - b - severe combined immunodeficiency ( rs - scid ).\nresults : seven infants were diagnosed with scid, yielding an incidence of 1 in 22, 819 live births. four of these infants had artemis - type scid.\nencouraging data for x - scid and preclinical work for artemis - scid and rag1 - scid are paving the way for the therapy to become a viable curative treatment option.\ntreatment for patients with ada - severe combined immunodeficiency ( ada - scid ) who lack a suitable matched related bone marrow donor.\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\ngermline mutations in cideb and protection against liver disease.\n. however, upon challenge with a combination of genotoxic ( aom ) and pro - inflammatory ( dss ) agents we found that the number of adenomas in the iec - cyld ( \u03b49 ) mice was dramatically increased compared to the control mice\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nmutations in the cu / zn superoxide dismutase 1 ( sod1 ) gene have been reported to cause adult - onset autosomal domi \" \" t amyotrophic lateral sclerosis ( fals )."
        },
        {
          "qas": [
            {
              "id": "640c821c201352f04a000023_001",
              "question": "Is Wilson's disease described as an iron storage disease?"
            }
          ],
          "context": "wilson's disease is an autosomal recessive inherited disease with congenital copper metabolism disorder, characterized by decreased ceruloplasmin and increased urine copper, which can involve multiple organs.\nwilson's disease is an autosomal recessive disorder in which the liver does not properly release copper into bile, resulting in prominent copper accumulation in various tissues.\nwilson's disease is rare autosomal - recessive disorder originated on the basis of metabolic copper over - storage.\nwilson's disease is an autosomal recessive disease of abnormal copper metabolism.\nwilson's disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.\nwilson's disease, a copper storage disorder, in which biliary copper excretion is reduced, is inherited as an autosomal recessive trait.\nhereditary deposition of iron ( primary haemochromatosis ) or copper ( wilson's disease ) are autosomal recessive metabolic disease characterized by progressive liver pathology and subsequent involvement of various other organs.\nwilson's disease represents a copper storage disease.\nwilson disease ( wd ) ( omim # 277900 ) is an autosomal recessive inherited disorder characterized by excess copper ( cu ) storage in different human tissues, such as the brain, liver, and the corneas of the eyes.\nwilson's disease is an autosomal recessive disease of copper metabolism which is widely recognized as a disease occurring clinically in children, adolescents, and young adults."
        },
        {
          "qas": [
            {
              "id": "6440084357b1c7a31500003e_001",
              "question": "Is omaveloxolone an activator of NFkB?"
            }
          ],
          "context": "the effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins.\npi3k - akt - nf - \u03bab signaling pathway, ii ) by exerting an efficient antioxidant effect, iii ) by inducing significant anti - inflammatory activity and iv ) by restoring brain - derived neurotrophic factor ( bdnf ) levels\nthalidomide is an immunomodulatory agent ; although its mechanisms of action are not fully understood, many authors have described its anti - inflammatory and immunosuppressive properties\ncombining in vivo and in vitro findings, we identified nine ahr agonists, six of which are marketed therapeutics and have been approved by the u. s. food and drug administration, including leflunomide, flutamide, and nimodipine.\nvesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\nozanimod : a first - in - class sphingosine 1 - phosphate receptor modulator for the treatment of ulcerative colitis.\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild."
        },
        {
          "qas": [
            {
              "id": "64040d73201352f04a000010_001",
              "question": "Can Efgartigimod be used for myasthenia gravis?"
            }
          ],
          "context": ". in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\ninterpretation : efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\nsafety and efficacy of eculizumab in anti - acetylcholine receptor antibody - positive refractory generalised myasthenia gravis ( regain ) : a phase 3, randomised, double - blind, placebo - controlled, multicentre study.\nrituximab seems to be particularly effective in musk myasthenia gravis, and eculizumab arises as an option in refractory achr myasthenia gravis.\nthe 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the us food and drug administration for myasthenia gravis.\na randomized, double - blind, placebo - controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\n< b > introduction < / b > : a phase 2 study of eculizumab for treating myasthenia gravis ( mg ) used the quantitative myasthenia gravis score ( qmg ) and myasthenia gravis activities of daily living profile ( mg - adl ) to evaluate baseline disease severity and\nefgartigimod is an fcrn inhibitor recently approved for mg treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development."
        },
        {
          "qas": [
            {
              "id": "6422e7ba690f196b51000044_001",
              "question": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier"
            }
          ],
          "context": "the present study aimed to investigate the potential protective effect of quercetin - biapigenin encapsulated into poly ( \u025b - polycaprolactone ) ( pcl ) \" \" oparticles against t - booh - induced oxidative stress in several brain cell lines, as well as evaluate the\nmicrobubbles in combination with focused ultrasound for the delivery of quercetin - modified sulfur oparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat alzheimer's disease.\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nthe next generation egfr tkis osimertinib and azd3759 have improved bbb penetration and the bloom study of osimertinib and azd3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\nwe report the discovery and early clinical development of azd3759, a selective egfr inhibitor that can fully penetrate the blood - brain barrier ( bbb ),\nemerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\nthe results showed the bbb penetration of azd3759 was decreased within 24 hr after radiation, however, the free concentration of azd3759 in brain kept at a high level in the context of radiation.\ncytoprotective effects of hesperetin and hesperidin against amyloid \u03b2 - induced impairment of glucose transport through downregulation of neuronal autophagy."
        },
        {
          "qas": [
            {
              "id": "6429eb8457b1c7a31500000a_001",
              "question": "Is adenosine methylation an epigenetic modification?"
            }
          ],
          "context": "methylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\nn6 - methyladenosine ( m6a ) is a dynamic reversible methylation modification of the adenosine n6 position and is the most common chemical epigenetic modification among mrna post - transcriptional modifications, including methylation, demethylation, and\nn6 - adenosine methylation ( m6a ) is one of the most common modifications on mrna.\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nthe accessibility of dna is regulated by epigenetic processes, including methylation of cytosine. in these circumstances the nucleic sequence of the dna does not change.\nepigenetics refers to heritable phenotypic alterations in the absence of dna sequence changes, and dna methylation is one of the extensively studied epigenetic alterations.\nn6 - methyladenosine ( m6a ) is methylation that occurs in the n6 - position of adenosine, which is the most prevalent internal modification on eukaryotic mrna.\nepigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in dna sequence.\nepigenetics refers to the heritable, but reversible, regulation of various biological functions mediated principally through changes in dna methylation and chromatin structure derived from histone modification.\nthe n6 - methyl adenosine ( m6a ) is an important epigenetic modification primarily present on mrna that controls the levels of transcripts and efficiency of translation in eukaryotes."
        },
        {
          "qas": [
            {
              "id": "64412c2757b1c7a315000055_001",
              "question": "Can breastfeeding be used to alleviate the procedural pain in neonates?"
            }
          ],
          "context": "breastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain.\nbf could significantly reduce pain response in healthy - term neonates during heel lance. mt did not enhance the effect of pain relief of bf.\nthe best non - pharmacological methods are breastfeeding followed by non - nutritive sucking coupled with sucrose sucking.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nin the neonate and infant, among other benefits, lactation confers protection from future both type 1 and type 2 diabetes.\nextracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\nbreast milk - fed neonates. key points : \u00b7 breast milk may rarely contain detectable sars - cov - 2 rna and was not detected in asymptomatic mothers.\nbased on the currently available limited evidence and recognizing the benefits of breastfeeding, it may be concluded that if the health of the mother and her newborn allows, direct breastfeeding or extracted breastmilk should be encouraged by the"
        },
        {
          "qas": [
            {
              "id": "64042000201352f04a000020_001",
              "question": "Can lenacapavir be used for HIV?"
            }
          ],
          "context": "in august 2022, lenacapavir received its first approval in the eu for use in combination with other antiretroviral ( s ) in adults with multi - drug resistant hiv infection, for whom it is otherwise not possible to construct a suppressive anti - viral\npurpose of review : this review summarizes available data for lenacapavir, an investigational first - in - class agent that disrupts functioning of hiv capsid protein across multiple steps in the viral life cycle.\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\ncabotegravir : its potential for antiretroviral therapy and preexposure prophylaxis.\nan evaluation of cabotegravir for hiv treatment and prevention.\ncabotegravir is a novel human immunodeficiency virus integrase enzyme inhibitor used for prevention and treatment of hiv infection.\nsummary : clinical trial results support the use of long - acting cab for hiv prep and long - acting cab and rpv as a switch strategy for adults with hiv - 1 who are first virologically suppressed with oral art.\nprofile of cabotegravir and its potential in the treatment and prevention of hiv - 1 infection : evidence to date.\ncabotegravir is an investigational integrase inhibitor in development for the treatment and pre - exposure prophylaxis of hiv - 1 infection.\nthe use of antiretrovirals as pre - exposure prophylaxis ( prep ) is highly efficacious in hiv prevention."
        },
        {
          "qas": [
            {
              "id": "6402c3fd201352f04a000009_001",
              "question": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?"
            }
          ],
          "context": "interpretation : prehospital treatment with transdermal gtn does not seem to improve functional outcome in patients with presumed stroke.\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nconclusions - prehospital treatment with gtn worsened outcomes in patients with intracerebral hemorrhage.\nthe primary outcome was not different between the two groups : 26 ( 52 % ) patients in the placebo group and 22 ( 44 % ) in the tranexamic acid group had intracerebral haemorrhage growth ( odds ratio [ or ] 0 \u00b7 72 [ 95 % ci 0 \u00b7 32 - 1 \u00b7 59 ], p = 0 \u00b7 41 )\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\ntreatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\ntirilazad did not significantly decrease unfavorable clinical outcome on the gos ( odds ratio [ or ] 1. 04, 95 % confidence interval [ ci ] 0. 89 - 1. 20 ) or cerebral infarction ( or 1. 04, 95 % ci 0. 89 - 1. 22 ).\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome."
        },
        {
          "qas": [
            {
              "id": "643ff48a57b1c7a31500003d_001",
              "question": "Is omaveloxolone a suppressor of Nrf2?"
            }
          ],
          "context": "the effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins.\ntranscriptome analysis of rate - limiting enzymes involved in hepatic gluconeogenesis revealed that moxifloxacin and gatifloxacin at a concentration of 1000 \u03bcm did not affect the expression of key gluconeogenic enzymes such as phosphoenolpyruvate\nsuper - enhancer that associates with the single active olfactory receptor gene\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\nour study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis.\ncombining in vivo and in vitro findings, we identified nine ahr agonists, six of which are marketed therapeutics and have been approved by the u. s. food and drug administration, including leflunomide, flutamide, and nimodipine.\nglutamate n - methyl - d - aspartate ( nmda ) receptor antagonists such as selfotel, aptiganel, gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects."
        },
        {
          "qas": [
            {
              "id": "64410f8057b1c7a315000054_001",
              "question": "Can salivary cortisol be used to evaluate pain in neonates?"
            }
          ],
          "context": "we observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nbf could significantly reduce pain response in healthy - term neonates during heel lance. mt did not enhance the effect of pain relief of bf.\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain.\nbackground : prior study demonstrated that baseline 22 - item sino - nasal outcome test ( snot - 22 ) aggregate scores accurately predict selection of surgical intervention in patients with chronic rhinosinus\nhowever, we recently found that cerebrospinal fluid ( csf ) concentration of the \" social \" neuropeptide arginine vasopressin ( avp ) is significantly lower in pediatric asd cases vs. controls.\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\n. responses from the sinonasal outcomes test - 22 ( snot - 22 ), a measure of patient hrqol, as well as the lund - kennedy and lund - mackay scores were recorded at enrollment\nthe sino - nasal outcome test - 22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis"
        },
        {
          "qas": [
            {
              "id": "6402c0d5201352f04a000008_001",
              "question": "Does nintedanib improve response rate in patients with bladder cancer?"
            }
          ],
          "context": "interpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n. nintedanib is a tyrosine - kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\n( us fda ) for the first - or second - line use in urothelial carcinoma, based on durable response and manageable safety profiles observed in relevant clinical trials.\npotential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.\nniraparib in ovarian cancer : results to date and clinical potential.\natezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising pd - 1 / pd - l1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.\nconclusion : nintedanib targets core features of ssc in fra2 - transgenic mice and ameliorates histological features of pulmonary arterial hypertension, destructive microangiopathy and pulmonary and dermal fibrosis"
        },
        {
          "qas": [
            {
              "id": "63f9ee5c33942b094c000014_001",
              "question": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?"
            }
          ],
          "context": "neuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n. knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\nwe show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\n. m6a regulates rna processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6a methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis."
        },
        {
          "qas": [
            {
              "id": "6431f71057b1c7a315000019_001",
              "question": "In twin-twin transfusion syndrome, are the twins identical?"
            }
          ],
          "context": "twin - twin transfusion syndrome ( ttts ) is a severe complication of monozygotic ( identical ) twin fetuses sharing one single ( monochorionic ) placenta.\ntwin - twin transfusion syndrome ( ttts ) is a severe complication of monozygotic ( identical ) twins, which share one single monochorionic placenta.\ntwin - twin transfusion syndrome ( ttts ) is an unusual and serious condition that occurs in twin preg \" \" cies when identical twins share a placenta but develop discordant amniotic fluid volumes.\ntwin - twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.\nobjective : twin - twin transfusion syndrome ( ttts ) is a severe preg \" \" cy complication of monochorionic ( identical ) twins that results in markedly discordant in utero environments for\nthe twin - twin transfusion syndrome is a rare but severe complication in monozygotic twins.\nn twin - to - twin transfusion syndrome ( ttts ), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor\nmonochorionic twins are at increased risk for unique complications including twin - twin transfusion syndrome ( ttts ), selective intrauterine growth restriction ( siugr ), and twin - reversed arterial perfusion ( trap ) sequence.\nhey are genetically identical and those with twin - twin transfusion syndrome ( ttts ) provide an ideal natural model in whom to study the influence of differing haemodynamic stresses on the developing vascular tre\nmost likely, the identical twin transfusion syndrome produces anoxia and brain damage during early prenatal development in the smaller identical twin."
        },
        {
          "qas": [
            {
              "id": "6415b7b8690f196b5100000c_001",
              "question": "Optogenetics refers to the study of gene expression optimization"
            }
          ],
          "context": "optogenetics refers to the ability to control cells that have been genetically modified to express light - sensitive ion channels.\noptogenetics refers to techniques that use light to control the cellular activity of targeted cells.\noptogenetics refers to the genetic modification of cells to express light - sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.\nthe recently introduced term'optogenetics'describes a variety of techniques for expressing genes in nerve cells that render them responsive to light.\noptogenetics refers to the control of biological processes with light.\noptogenetics is an innovative technique for optical control of cells.\noptogenetics is the genetic approach for controlling cellular processes with light.\noptogenetics is the use of genetically coded, light - gated ion channels or pumps ( opsins ) for millisecond resolution control of neural activity.\noptogenetics refers to a technique that uses light to modulate neuronal activity with a high spatiotemporal resolution, which enables the manipulation of learning and memory functions in the human brain.\noptogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits."
        },
        {
          "qas": [
            {
              "id": "63f03155f36125a426000019_001",
              "question": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?"
            }
          ],
          "context": "phase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\ndnx - 2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas : a case report.\nmethods : we conducted a single - center, dose - escalation study of dnx - 2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed dipg.\ndiffuse intrinsic pontine gliomas ( dipg ) are the most aggressive brain tumors in children with 5 - year survival rates of only 2 %\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\ndiagnoses included medulloblastoma, craniopharyngioma, ependymoma, glial tumors, germ cell tumors, and others.\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nsalvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\nxternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year."
        },
        {
          "qas": [
            {
              "id": "6436953757b1c7a315000028_001",
              "question": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?"
            }
          ],
          "context": "historically, functional neurological disorder ( fnd ) has been described in psychodynamic terms as the physical manifestation of psychological distress.\nfunctional neurological disorder ( fnd ) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs ( either motor or sensory ) that cannot be explained by any known medical or mental disease.\nfunctional neurological disorders ( fnds ), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options.\nfunctional neurological disorder ( fnd ) is characterized by neurological symptoms that cannot be explained by a structural neurological cause.\nfunctional neurological disorder ( fnd ) is a complex neuropsychiatric disorder characterized by abnormal or atypical sensorimotor, gait, dissociative, or special sensory symptoms in the absence of structural nervous system lesions to explain the\nfunctional neurological disorder ( fnd ) is a rare neuropsychiatric illness that commonly presents to the medical setting as opposed to the psychiatric setting.\nhe diagnosis of functional neurological disorder ( fnd ) requires differentiation from other neurologic diseases / syndromes, and from the comparatively rare diagnosis of feigning ( malingering and factitious disorder )\nfunctional neurological disorder ( fnd ) is a constellation of common neurological symptoms without exact organic pathophysiology.\nfunctional neurological disorder ( fnd ), otherwise known as conversion disorder, is characterized by abnormal sensory or motor symptoms that are determined to be \" incompatible \" with neurological disease.\nfunctional neurological disorder ( fnd ) is a common and highly disabling disorder, but its aetiology remains enigmatic."
        },
        {
          "qas": [
            {
              "id": "645004fa57b1c7a31500008b_001",
              "question": "Are accessible enhancers necessarily active?"
            }
          ],
          "context": "in this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers.\n. while the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\n. instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts : the closed silenced state and the accessible primed and repressed\n. our results indicate that tissue - specific chromatin conformation is not necessary for tissue - specific gene expression but rather acts as a scaffold facilitating gene expression when enhancers become active.\neuchromatin and heterochromatin have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. thus, dna accessibility is not likely to be the primary determi \" \" t of gene regulation.\nin conclusion, loci identified as active by starr - seq often overlap with those identified by chromatin accessibility and active epigenetic marking, yet a significant fraction is epigenetically repressed or display condition - specific enhancer\n. unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.\ncomputational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features.\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications."
        },
        {
          "qas": [
            {
              "id": "63eef9b6f36125a426000011_001",
              "question": "Is Prasinezumab effective for Parkinson\u2019s Disease?"
            }
          ],
          "context": "conclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\npimavanserin ( nuplazid\u2122 ) for the treatment of parkinson disease psychosis : a review of the literature. options for the treatment of parkinson disease psychosis are limited.\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\nthe development of pimavanserin as an antipsychotic opened a new therapeutic avenue in the treatment of pdp as well as targeting psychosis in other disorders such as alzheimer's disease.\ninterpretation pimavanserin may benefit patients with parkinson's disease psychosis for whom few other treatment options exist.\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\ninterpretation natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper - limb component."
        },
        {
          "qas": [
            {
              "id": "63f02e1bf36125a426000016_001",
              "question": "Was AAVS3 developed for hemophilia A?"
            }
          ],
          "context": "phase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\nlong - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\nerratum : safety and immunogenicity of modified vaccinia ankara - bavarian nordic smallpox vaccine in vaccinia - naive and experienced human immunodeficiency virus - infected individuals : an open - label, controlled clinical phase ii trial.\nthe advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\none of the most advanced and most promising vectors is the attenuated, non - replicating poxvirus mva ( modified vaccinia virus ankara ), a safer derivative of the uniquely successful smallpox vaccine\n. in contrast, c. 2403 g > a was less prevalent in male patients with chronic hcv - infection ( p < 0. 05 ). no association was observed for the third variant, c. 1 - 120t > g\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nstrimvelis ( autologous cd34 + cells transduced to express adenosine deaminase [ ada ] ) is the first ex vivo stem cell gene therapy approved by the european medicines agency ( ema ), indicated as a single treatment for patients with ada - severe combined"
        },
        {
          "qas": [
            {
              "id": "6419d79c690f196b5100003b_001",
              "question": "Does iron regulate oligodendrocyte maturation?"
            }
          ],
          "context": "these data indicate that iron delivered via transferrin and its receptor is intrinsically involved in oligodendrocyte maturation and thus plays a critical role in the onset of myelination.\nhere, using an in vitro cultured differentiation model of oligodendrocytes, we found that both transferrin receptor and ferritin - h are significantly upregulated during oligodendrocyte maturation, implying the essential role of iron in the development\niron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes.\nthe essential role of iron in the development of oligodendrocytes.\nfth iron storage is essential for early oligodendrocyte development as well as for opc maturation in the demyelinated adult brain.\nwhen disrupted, iron homeostasis negatively impacts oligodendrocyte ( olg ) differentiation and impairs myelination.\nh - ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.\ntotal iron content in unperfused brain is not significantly different between mcoln1 ( - / - ) and wild - type littermate mice, suggesting that the observed maturation delay or loss of oligodendrocytes might be caused by impaired iron handling, rather than\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\nthe current results provide further evidence of did impact on myelination, keeping ol away from the maturational path."
        },
        {
          "qas": [
            {
              "id": "644efd5157b1c7a315000086_001",
              "question": "Are epigenetic changes heritable?"
            }
          ],
          "context": "more interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nsome of these epigenetic changes appear to be heritable.\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in dna sequence.\nepigenetics refers to the heritable, but reversible, regulation of various biological functions mediated principally through changes in dna methylation and chromatin structure derived from histone modification.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\nepigenetic alterations are defined as heritable changes in gene expression mediated through mechanisms other than alterations in the dna sequence itself, including dna promoter methylation and various histone covalent modifications.\ntransient epigenetic changes across the entire genome can influence metabolic outcomes and might or might not be heritable.\nepigenetic modification refers to heritable changes in the genetic material without any changes in the nucleic acid sequence and results in heritable phenotypic changes.\nas a result, heritable epigenetic changes can include any that can alter a wave such as changes in form, midline, frequency, amplitude, or phase."
        },
        {
          "qas": [
            {
              "id": "644efd2c57b1c7a315000085_001",
              "question": "Do epigenetic changes change the DNA sequence?"
            }
          ],
          "context": "epigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\nthese modifications, also known as epigenetic code, do not change the dna sequence but alter the expression level of specific genes.\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic changes to the genome are biochemical alterations to the dna that do not change an individual's genome but do change and influence gene expression.\nepigenetic changes refer to heritable changes that may modulate gene expression without affecting dna sequence.\nepigenetic changes are reversible and do not affect the dna sequence itself but rather control levels of gene expression.\nepigenetic regulation refers to heritable changes in gene expression that do not involve any alteration of the dna sequence.\nepigenetic changes responding to the environmental and intercellular signals can turn on / off specific genes, but do not modify the dna sequence.\nepigenetics refers to structural modifications to genes that do not change the nucleotide sequence itself but instead control and regulate gene expression.\nepigenetic modifications are heritable changes in gene expression not encoded by the dna sequence."
        },
        {
          "qas": [
            {
              "id": "6414c5ba690f196b51000007_001",
              "question": "Can skin picking phenotype present following methylphenidate treatment?"
            }
          ],
          "context": "newly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\n. there is an excess of escaping genes associated with mental retardation, consistent with this being a common phenotype of polyx phenotypes.\n. the frequency of clinical features, objective software - based facial analysis metrics, and genome - wide peripheral blood dna methylation patterns in these patients were significantly different from that of ks1\nas atopic dermatitis ( ad ), psoriasis, vitiligo, and alopecia areata.\nhere, we conduct a meta - review to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response.\nrecapitulation and reversal of schizophrenia - related phenotypes in setd1a - deficient mice.\none possible but largely unexplored explanation is that exposure to sublethal doses of insecticides may alter epigenetic patterns that are heritable.\nother body - focused repetitive behaviors, such as trichotillomania.\nsome of these epigenetic changes appear to be heritable.\nconclusions \u2022 the review indicates that yoga, aerobic exercise, acupuncture, biofeedback, hypnosis, and inositol and n - acetylcysteine all show promise in the treatment of excoriation disorder and other body - focused repetitive behaviors, such as"
        },
        {
          "qas": [
            {
              "id": "644f0fd257b1c7a31500008a_001",
              "question": "Do enhancers have to be close to their gene targets?"
            }
          ],
          "context": "enhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nmany enhancers map quite far from their target genes, on the order of tens or even hundreds of kilobases.\n. unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.\nenhancers function independently of their distance and orientation to the promoters of target genes.\nin metazoans transcriptional enhancers and their more complex relatives, locus control regions, are often located at great linear distances from their target genes.\nuntil recently, identifying each gene's enhancers had been challenging because enhancers do not occupy prescribed locations relative to their target genes.\nepigenetic profiling of different tissues and cell - types has identified a large number of non - coding epigenetic regulatory elements ('enhancers') that can be located far away from coding genes.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\ncomputational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features."
        },
        {
          "qas": [
            {
              "id": "64463f9357b1c7a31500006a_001",
              "question": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?"
            }
          ],
          "context": "spinal muscular atrophy ( sma ) with respiratory distress type 1 ( smard1 ) is an exceptionally rare type of sma.\nthe total ache activity was either normal or decreased in the childhood sma ( type 1 ), the other sma groups and disease controls ( als, x - linked sma ).\neight of 38 patients ( 21 % ) with familial and 5 of 175 patients ( 3 % ) with sporadic amyotrophic lateral sclerosis ( als ) had missense mutations in the sod - 1 gene.\nfamilial amyotrophic lateral sclerosis ( fals ), a degenerative disorder of motor neurons, is associated with mutations in the cu / zn superoxide dismutase gene sod1 in some affected families.\nall mutations in the human gene for cuzn superoxide dismutase ( cuznsod ) reported to date are associated with the disease amyotrophic lateral sclerosis ( als ).\nover 30 different mutations of sod - 1 have now been identified in families with als.\nup to 20 % of als cases are inherited ( familial, fals ) and associated with mutations, usually of the superoxide dismutase type 1 ( sod - 1 ) gene.\nmutations in the cu / zn superoxide dismutase 1 ( sod1 ) gene have been reported to cause adult - onset autosomal domi \" \" t amyotrophic lateral sclerosis ( fals ).\napproximately 2 % of amyotrophic lateral sclerosis ( als ) cases are caused by mutations in the super oxide dismutase 1 ( sod1 ) gene a\nit has been reported that mutations in the superoxide dismutase ( sod ) 1 gene can lead to als."
        },
        {
          "qas": [
            {
              "id": "640418af201352f04a000018_001",
              "question": "Is Tilavonemab effective for progressive supranuclear palsy?"
            }
          ],
          "context": "using tau antibodies for progressive supranuclear palsy.\n. although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\ninterpretation : tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malig \" \" t mesothelioma.\nalthough treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma."
        },
        {
          "qas": [
            {
              "id": "641791ed690f196b51000032_001",
              "question": "Is SARS-CoV-2 transmitted through breast milk?"
            }
          ],
          "context": "whether sars - cov - 2 was transmitted through breast milk is unknown.\ncurrently, there is no evidence of sars - cov - 2 transmission through breast milk.\nno breast milk samples were positive for sars - cov - 2 and, to date, there is no evidence on the presence of sars - cov - 2 in breast milk of preg \" \" t women with covid - 19.\nhowever, there is limited published literature related to vertical transmission of any human coronaviruses ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nof sars - cov - 2 positive lactating mothers giving birth at our institution, most of their breast milk samples ( 95 % ) contained no detectable virus, and there was no evidence of covid - 19 infection in their breast milk - fed neonates. key points : \u00b7 breast\nhowever, there is limited published literature related to vertical transmission of any human coronavirus ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nbreast milk - fed neonates. key points : \u00b7 breast milk may rarely contain detectable sars - cov - 2 rna and was not detected in asymptomatic mothers.\nthe authors could not find evidence for transmission of sars - cov - 2 from mother to child through breastmilk in the population studied.\nno infectious sars - cov - 2 in breast milk from a cohort of 110 lactating women.\ntaken together, our data do not support mother - to - infant transmission of sars - cov - 2 via milk."
        },
        {
          "qas": [
            {
              "id": "644284a957b1c7a31500005c_001",
              "question": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?"
            }
          ],
          "context": "facioscapulohumeral muscular dystrophy ( fshd ) is a slowly progressive muscular dystrophy without approved therapies.\nthe treatment of fshd is currently supportive only.\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\nallow assessment of high - functioning boys with duchenne muscular dystrophy.\nagnosis and tracking of symptom progression of dmd usually relies on creatine kinase tests, evaluation of patient performance in various ambulatory assessments, and detection of dystrophin from muscle biopsies, which are invasive and painful for the\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nthe occurrence of functional neurological disorder ( fnd ) and somatic symptom disorder ( ssd ) in pd was not commonly accepted until recently, despite some evidence that emerged in the pre and early l - dopa era.\nfunctional neurological disorder ( fnd ), previously regarded as a diagnosis of exclusion, is now a rule - in diagnosis with available treatments.\nfunctional neurological symptom disorder ( fnd ) remains a clinical challenge. it is one of the many mimics of cerebrovascular accidents, spinal cord disorders, and lower motor neuron disease."
        },
        {
          "qas": [
            {
              "id": "644e642a57b1c7a315000075_001",
              "question": "Do all proteins start with methionine?"
            }
          ],
          "context": "protein synthesis is initiated universally with the amino acid methionine. in escherichia coli, studies with anticodon sequence mutants of the initiator methionine trna have shown that protein synthesis can be initiated with several other amino acids\nprotein synthesis generally starts with a methionine that is removed during translation.\nmethionine is the universal translation start but the first methionine is removed from most mature proteins.\nprotein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. n - terminal methionine can be co - translationally cleaved by the enzyme methionine aminopeptidase ( map ).\nthe removal of n - terminal translation initiator met by methionine aminopeptidase ( metap ) is often crucial for the function and stability of proteins.\n. translation initiation on such mrnas results in the synthesis of proteins harbouring different amino terminal domains potentially conferring on these isoforms distinct functions.\nmost mature proteins do not retain their initial n - terminal amino acid ( methionine in the cytosol and n - formyl methionine in the organelles ).\nsecondly, the degradation of some mrnas related to immune responses has been reported to be regulated by binding of rna - binding proteins to adenylate uridylate - rich elements ( au - rich elements, ares ) located in the 3'- untranslated region ( 3'- utr ).\nthe use of several translation initiation codons in a single mrna, by expressing several proteins from a single gene, contributes to the generation of protein diversity\nhu proteins are rna - binding proteins that are implicated in the control of stabilization, nuclear export, and / or translation of specific mrnas with au - rich elements ( ares ) in the 3'- untranslated region. th"
        },
        {
          "qas": [
            {
              "id": "5c58a74e86df2b917400000d_001",
              "question": "Is Baloxavir effective for influenza?"
            }
          ],
          "context": "background : baloxavir marboxil is a selective inhibitor of influenza cap - dependent endonuclease. it has shown therapeutic activity in preclinical models of influenza a and b virus infections, including strains resistant to current antiviral agents.\n. in february 2018, baloxavir received its first global approval in japan for the treatment of influenza a or b virus infections.\nbaloxavir marboxil ( xofluza\u2122 ; baloxavir ) is an oral cap - dependent endonuclease inhibitor that has been developed by roche and shionogi. the drug blocks influenza virus proliferation by inhibiting the initiation of mrna synthesis\njapan was the first country to approve baloxavir marboxil as a treatment for influenza.\ncharacterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\nconcomitant administration of covid - 19 and influenza vaccines could reduce burden on health - care systems. we aimed to assess the safety of concomitant administration of chadox1 or bnt162b2 plus an age - appropriate influenza vaccine.\nbrincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat ( the only oral smallpox antiviral currently in the us strategic\ncabotegravir : its potential for antiretroviral therapy and preexposure prophylaxis.\neffectiveness of rotavirus pentavalent vaccine"
        },
        {
          "qas": [
            {
              "id": "5be44bef133db5eb78000014_001",
              "question": "Are there microbes in human breast milk?"
            }
          ],
          "context": "the origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\nwe are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies.\nhowever, there is limited published literature related to vertical transmission of any human coronavirus ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nhowever, there is limited published literature related to vertical transmission of any human coronaviruses ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nextracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\nbreast milk - fed neonates. key points : \u00b7 breast milk may rarely contain detectable sars - cov - 2 rna and was not detected in asymptomatic mothers.\nof sars - cov - 2 positive lactating mothers giving birth at our institution, most of their breast milk samples ( 95 % ) contained no detectable virus, and there was no evidence of covid - 19 infection in their breast milk - fed neonates. key points : \u00b7 breast\nwhether sars - cov - 2 was transmitted through breast milk is unknown.\nbased on the currently available limited evidence and recognizing the benefits of breastfeeding, it may be concluded that if the health of the mother and her newborn allows, direct breastfeeding or extracted breastmilk should be encouraged by the\nalready without exogenous intervention, a multitude of phage - bacterial interactions occur within the human gut, some of which might play a direct role in disease progression"
        },
        {
          "qas": [
            {
              "id": "5c61bacae842deac67000001_001",
              "question": "Is cariprazine effective for treatment of bipolar disorder?"
            }
          ],
          "context": "clinically relevant response and remission outcomes in cariprazine - treated patients with bipolar i disorder.\nobjective : cariprazine, a dopamine d3 / d2 partial agonist atypical antipsychotic with preferential binding to d3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar i disorder.\nbackground : we evaluated the safety / tolerability of longer - term open - label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania.\n< b > background < / b > : cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the united states.\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\npimavanserin ( nuplazid\u2122 ) for the treatment of parkinson disease psychosis : a review of the literature. options for the treatment of parkinson disease psychosis are limited.\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,"
        },
        {
          "qas": [
            {
              "id": "5c55d75807647bbc4b000008_001",
              "question": "Is Bobble head doll syndrome associated with hydrocephalus?"
            }
          ],
          "context": "bobble - head doll syndrome is usually associated with dilation of the third ventricle, but is rarely associated with posterior fossa disease. patient : we describe an infant with fetal hydrocephalus and an arachnoid cyst of the posterior fossa.\nbrain magnetic reso \" \" ce imaging showed a large suprasellar arachnoid cyst extending into the third ventricle, with obstructive hydrocephalus, characteristic of bobble - head doll syndrome.\nsuprasellar arachnoid cysts can have varied presentations with signs and symptoms of obstructive hydrocephalus, visual impairment, endocrinal dysfunction, gait ataxia and rarely bobble - head doll movement.\nthe first is a 14 - year - old boy with bhds associated with aqueductal obstruction and triventricular hydrocephalus secondary to a tectal tumor.\nall the patients presented a psychomotor retardation due to an obstructive hydrocephalus.\nmri scan showed a large contrast - enhanced lesion in the region of the third ventricle along with gross hydrocephalus.\nhuntington's disease ( hd ) is a neurodegenerative disorder characterized by involuntary choreic movements, cognitive impairment, and behavioral changes, caused by the expansion of an unstable cag repeat in htt.\nmiller - dieker syndrome ( mds ), a disorder manifesting the severe brain malformation lissencephaly ( \" smooth brain \" ), is caused, in the majority of cases, by a chromosomal microdeletion of the distal short arm of chromosome 17.\nthe miller - dieker syndrome ( mds ), composed of characteristic facial abnormalities and a severe neuronal migration disorder affecting the cerebral cortex, is caused by visible or submicroscopic deletions of chromosome band 17p13.\nthe miller - dieker syndrome ( mds ), a syndrome with lissencephaly, distinctive craniofacial features, growth impairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13."
        },
        {
          "qas": [
            {
              "id": "5be44f50133db5eb78000017_001",
              "question": "Can breastfeeding confer protection from type I diabetes?"
            }
          ],
          "context": "in the neonate and infant, among other benefits, lactation confers protection from future both type 1 and type 2 diabetes.\nthe results from the tn - 10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a fcr non - binding monoclonal antibody to cd3 in people at high risk for disease.\n. a recent prevention trial using the anti - cd3 antibody teplizumab in individuals at a high risk of developing t1d has provided the first piece of evidence that a safe and transient intervention may be able to delay disease.\nclinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\ntreatment of type 1 diabetes with teplizumab : clinical and immunological follow - up after 7 years from diagnosis.\ntake home message in phase i / ii randomized control trials, in patients with new onset t1d, teplizumab slowed the rate of loss of beta - cell function over 2 years of follow - up.\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\nconclusion : in patients with t1d, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain."
        },
        {
          "qas": [
            {
              "id": "5be47bff133db5eb78000018_001",
              "question": "Can pets affect infant microbiomed?"
            }
          ],
          "context": "as a common effect in all birth scenarios, pre - and postnatal pet exposure enriched the abundance of oscillospira and / or ruminococcus ( p < 0. 05 ) with more than a twofold greater likelihood of high abundance\n. among vaginally born infants with maternal intrapartum antibiotic prophylaxis exposure, streptococcaceae were substantially and significantly reduced by pet exposure ( p < 0. 001, fdrp = 0. 03 ), reflecting an 80 % decreased likelihood of high abundance\nirradiation profoundly impacted gut microbiota profiles in both animals.\nspecific members of the gut microbiota are reliable biomarkers of irradiation intensity and lethality in large animal models of human health.\nthe origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\nan 80 % decreased likelihood of high abundance ( or 0. 20, 95 % ci, 0. 06 - 0. 70 ) for pet exposure during preg \" \" cy alone and a 69 % reduced likelihood ( or 0. 31, 95 % ci, 0. 16 - 0. 58 ) for exposure in the pre - and postnatal time periods.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nwe are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies.\nin addition, it has been demonstrated that immune disturbance may be responsible for some adverse preg \" \" cy outcomes such as preeclampsia ( pe ), recurrent spontaneous abortion ( rsa ) and intrauterine growth restriction ( iugr ).\nthe polymicrobial dysbiotic subgingival biofilm microbes associated with periodontal disease appear to contribute to developing pathologies in distal body sites, including the brain."
        },
        {
          "qas": [
            {
              "id": "5be48282133db5eb7800001b_001",
              "question": "Is there any association between the human gut microbiome and depression?"
            }
          ],
          "context": "bacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nmoreover, recent findings are suggestive of the possibility that dysregulation of the enteric microbiota ( i. e., dysbiosis ) and associated bacterial translocation across the intestinal epithelium may be involved in the pathophysiology of\nmay be involved in the pathophysiology of stress - related psychiatric disorders, particularly depression.\nspecific members of the gut microbiota are reliable biomarkers of irradiation intensity and lethality in large animal models of human health.\nbackground growing evidence documents the potential of machine learning for developing brain based diagnostic methods for major depressive disorder ( mdd ).\nirradiation profoundly impacted gut microbiota profiles in both animals.\nthe polymicrobial dysbiotic subgingival biofilm microbes associated with periodontal disease appear to contribute to developing pathologies in distal body sites, including the brain.\nalready without exogenous intervention, a multitude of phage - bacterial interactions occur within the human gut, some of which might play a direct role in disease progression\nour findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\nobesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition - related brain areas in patients with mdd."
        },
        {
          "qas": [
            {
              "id": "5c2f8127133db5eb78000032_001",
              "question": "Are whole-genome duplications more divergent than small-scale duplications in yeast?"
            }
          ],
          "context": "empirical data shows that whole - genome duplications ( wgds ) are more likely to be retained than small - scale duplications ( ssds ), though their relative contribution to the functional fate of duplicates remains unexplored.\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\nalso, we observe that transporter and glycolytic genes have a higher probability to be retained in duplicate after wgd and subsequent gene loss, both in the model as in s. cerevisiae, which leads to an increase in glycolytic flux after wgd\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\na recent study on circular dnas in yeast found that transposable element sequence residing in circular structures mostly corresponded to full - length transposable elements.\nfunctional and transcriptional divergence between the copies after gene duplication has been considered the main driver of innovations.\nalthough similar structures appear to be conserved in fission yeast, computational modeling and analysis of high - throughput chromosome conformation capture ( hi - c ) data have been used to argue that the small, highly constrained budding yeast\n. these patterns are strongly correlated with the functional dependencies and sequence divergence profiles of gene copies.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery"
        },
        {
          "qas": [
            {
              "id": "5c34794fda8336e21a000001_001",
              "question": "Do yeast LTR give rise to circular DNA?"
            }
          ],
          "context": "ty eccdna can arise from the circularization of extrachromosomal linear dna during the transpositional life cycle of retrotransposons, or from circularization of genomic ty dna\na recent study on circular dnas in yeast found that transposable element sequence residing in circular structures mostly corresponded to full - length transposable elements.\nsimilarly, circular dnas can be generated by recombination between ltrs residing at different genomic loci, in which case the circular dna will contain the intervening sequence.\ncircular retrotransposition products generated by a line retrotransposon\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\nthousands of eukaryotic protein - coding genes generate circular rnas that have covalently linked ends and are resistant to degradation by exonucleases.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nfor transcriptional elongation at some gc - rich cirna - producing loci.\nto explore the potential for using this methodology to express circular rna in vivo, circular forms of the hdv ribozyme and rnasep rna were produced in e. coli.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery"
        },
        {
          "qas": [
            {
              "id": "5c644c3de842deac67000018_001",
              "question": "Is cohesin linked to myeloid differentiation?"
            }
          ],
          "context": ". these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\n. emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. among these mechanisms is a role for cohesin in the control of inflammatory responses in hspcs and myeloid cells\nconsistent with a role for inflammatory signals in promoting myeloid differentiation of hematopoietic stem and progenitor cells ( hpscs ), cohesin mutations in hspcs led to reduced inflammatory gene expression and increased resistance to\n. inflammatory signals limit hspc self - renewal and drive hspc differentiation. consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for aml progression.\nthe conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, h3k27ac, h4k4me1, and enhancer transcription, but weakened interactions between enhancers.\nthis general architectural change correlates with enhanced binding of ctcf and cohesins and more pronounced insulation of contacts across chromatin boundaries in lineage - committed cells.\n. thus, gata - 1 deacetylation and its interaction with hdac1 modulates gata - 1 chromatin binding and transcriptional activity that control erythroid / megakaryocyte commitment and differentiation.\nspecific and robust interchromosomal contacts that increase with differentiation of the cells\nthese data indicate that the grb2 / mek pathway primarily mediates nanog gene repression upon es cell differentiation into primitive endoderm."
        },
        {
          "qas": [
            {
              "id": "5be49287133db5eb7800001e_001",
              "question": "Is pembrolizumab effective against Ewing's sarcoma?"
            }
          ],
          "context": "and pembrolizumab ) and pd - l1 inhibitors ( atezolizumab, durvalumab, and avelumab ) in patients with nsclc.\nby the emergence of modern immunotherapies with active agents like pd - 1 ( nivolumab, pembrolizumab ) and pd - l1 immune checkpoint blockers ( atezolizumab, avelumab, durvalumab ), new therapeutic options have become available for the treatment of patients\nmonoclonal antibodies that target programmed cell death protein 1 ( pd - 1 ), including nivolumab and pembrolizumab, and its ligand, pd - l1, including atezolizumab, durvalumab, avelumab, have all been investigated and approved in the setting of metastatic\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nin the phase iii pacific trial consolidation with durvalumab, an anti - pdl - 1 antibody, was associated with survival benefit in patients diagnosed with la - nsclc who responded to concurrent chemoradiotherapy.\ndifferent antagonistic antibodies targeting pd - 1 or pd - l1 ( atezolizumab, durvalumab, avelumab, nivolumab, and pembrolizumab ).\natezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising pd - 1 / pd - l1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.\nici, such as the pd - 1 inhibitors nivolumab and pembrolizumab and the pd - l1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced nsclc.\nacquisition : five antibodies including pembrolizumab ( pd - l1 antibody ), atezolizumab ( pd - 1 antibody ), nivolumab ( pd - 1 antibody ), avelumab and durvalumab ( pd - l1 antibodies ) have been approved in the treatment of advanced urothelial carcinoma in first -\nnone of the 13 patients with ewing's sarcoma had an objective response."
        },
        {
          "qas": [
            {
              "id": "5be94b87133db5eb78000020_001",
              "question": "Can gene therapy restore auditory function?"
            }
          ],
          "context": ". the data represent unprecedented recovery of inner ear function and suggest that biological therapies to treat deafness may be suitable for translation to humans with genetic inner ear disorders.\nwe demonstrate recovery of gene and protein expression, restoration of sensory cell function, rescue of complex auditory function and recovery of hearing and balance behavior to near wild - type levels\n. while non - aug initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized - - both for increased coding capacity and potentially also for novel regulatory mechanisms - - remains unclear.\na valuable approach to understand how individual and population genetic differences can predispose to disease is to assess the impact of genetic variants on cellular functions ( e. g., gene expression ) of cell and tissue types related to pathological\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nin this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nan understanding of the mechanism on the interaction of gm1 and a\u03b2s in ad may contribute to the development of new neuroregenerative therapies for this disorder.\noptogenetics refers to the ability to control cells that have been genetically modified to express light - sensitive ion channels.\noptogenetics refers to the genetic modification of cells to express light - sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.\nneeds further clarification to make greater use of its ability to treat brain diseases."
        },
        {
          "qas": [
            {
              "id": "5c58447f07647bbc4b000021_001",
              "question": "Is the PINES framework being used for the prediction of coding variants?"
            }
          ],
          "context": "here, we introduce the computational framework pines ( phenotype - informed noncoding element scoring ), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype - dependent manner\n. we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\n. pines enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest\nour results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\n. we also show how non - coding variants can help inform both the disease - causing mechanism underlying protein - coding variants and dosage tolerance of the gene.\n. our analyses show that non - coding variants upstream of genes within which coding variants are known to cause dd are an important cause of severe disease and demonstrate that analyzing 5'utrs can increase diagnostic yield\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes.\nand allowing for genotype - based prediction of risk of recurrence in some nonsyndromic families.\n. while non - aug initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized - - both for increased coding capacity and potentially also for novel regulatory mechanisms - - remains unclear."
        },
        {
          "qas": [
            {
              "id": "5c647c52e842deac6700001c_001",
              "question": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "erythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nesistance to erythropoietin therapy is a common complication of the modern management of anemia in chronic kidney disease\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\ninterpretation : erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis.\niron deficiency anemia is a common complication in end - stage renal disease ( esrd ) and impairs the therapeutic efficacy of recombi \" \" t erythropoietin.\nthis study was performed to validate the als - mitos as a 6 - month proxy of survival in 200 als patients followed up to 18 months. methods : analyses were performed on data from the recombi \" \" t human erythropoietin rct that failed to demonstrate"
        },
        {
          "qas": [
            {
              "id": "5c6638717c78d69471000012_001",
              "question": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "results celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\ninterpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\nneuroprotective agents are screened for use in patients with als.\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion."
        },
        {
          "qas": [
            {
              "id": "5c531e887e3cb0e231000018_001",
              "question": "Are ultraconserved enhancers important for normal development?"
            }
          ],
          "context": "ultraconserved enhancers are required for normal development.\nenhancer elements are essential for tissue - specific gene regulation during mammalian development\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\n. here we show that de novo mutations in highly evolutionarily conserved fetal brain - active elements are significantly and specifically enriched in neurodevelopmental disorders\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\nepigenetic profiling of different tissues and cell - types has identified a large number of non - coding epigenetic regulatory elements ('enhancers') that can be located far away from coding genes.\n. although highly conserved, the functional properties of promoters with different shapes and the genetic basis of their evolution remain unclear\nthe conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, h3k27ac, h4k4me1, and enhancer transcription, but weakened interactions between enhancers."
        },
        {
          "qas": [
            {
              "id": "5c5f12d91a4c55d80b000016_001",
              "question": "Is chlorotoxin a peptide?"
            }
          ],
          "context": "chlorotoxin ( ctx ) is a 36 - amino - acid disulfide - containing peptide derived from the venom of the scorpion leiurus quinquestriatus.\nchlorotoxin peptide\nchlorotoxin ( ctx ), a disulfide - rich peptide from the scorpion leiurus quinquestriatus,\nthe mature odontobuthus doriae chlorotoxin peptide has a 35 - amino - acid residue and four disulfide bounds.\nerabutoxin c, a minor neurotoxic component of the venom of a sea snake laticauda semifasciata, was isolated in pure form by repeated column chromatography on cm - cellulose columns.\nthe three - dimensional structure of erabutoxin b, a short - chain neurotoxic peptide purified from the venom of the sea snake laticauda semifasciata,\nthe study has established complete structural identity of the two sea - snake venom toxins, erabutoxin b and neurotoxin b, isolated from laticauda semifasciata snakes taken in different pacific ocean waters.\nthe three - dimensional structure of erabutoxin b, a neurotoxin in the venom of the sea snake laticauda semifasciata, has been determined from a 2. 75 a resolution electron density map.\nthe method was applied to a study of erabutoxin b molecule, a neurotoxic protein from a sea snake, to analyze the microenvironments of its single tryptophan and tyrosine residues.\nhere we examine the actions of six snake neurotoxins ( alpha - cobratoxin from naja naja siamensis, erabutoxin - a and b from laticauda semifasciata ; cm12 from n. haje annulifera, toxin iii 4 from notechis scutatus and a long toxin from n"
        },
        {
          "qas": [
            {
              "id": "5c00f38e133db5eb78000023_001",
              "question": "Does vesatolimod inhibit TLR7?"
            }
          ],
          "context": "vesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\ntory gene activation is inhibited in vitro by tocilizumab, a humanized antibody to il6 receptor ( il6r ). tocilizumab\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nhepatocyte - targeted delivery, and with the recent approvals of givlaari ( givosiran ) for the treatment of acute hepatic porphyria, oxlumo ( lumasiran ) for the treatment of primary hyperoxaluria, and leqvio ( inclisiran ) for the treatment of\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia."
        },
        {
          "qas": [
            {
              "id": "5c5f21a81a4c55d80b00001c_001",
              "question": "Is selenocysteine an aminoacid?"
            }
          ],
          "context": "selenocysteine ( sec ), a rare genetically encoded amino acid with unusual chemical properties, is of great interest for protein engineering.\nselenocysteine ( sec ) is a naturally available se - containing amino acid that displays splendid anticancer activities against several human tumors.\nprotein synthesis is initiated universally with the amino acid methionine. in escherichia coli, studies with anticodon sequence mutants of the initiator methionine trna have shown that protein synthesis can be initiated with several other amino acids\nprotein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. n - terminal methionine can be co - translationally cleaved by the enzyme methionine aminopeptidase ( map ).\nwe showed that 28 amino acids in the amino terminus of ppox contain an independently functioning signal for mitochondrial targeting.\nglutathione peroxidase ( gpx1 ) is the major selenoprotein in most tissues in animals.\nhave reported point mutations in the cytosolic cu / zn superoxide dismutase ( sod 1 ) gene in some families with familial amyotrophic lateral sclerosis ( als ).\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 ).\naccumulated evidence implies that mutations in the gene coding for cu / zn superoxide dismutase ( sod ) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis ( als ).\nmost mature proteins do not retain their initial n - terminal amino acid ( methionine in the cytosol and n - formyl methionine in the organelles )."
        },
        {
          "qas": [
            {
              "id": "5c58923c86df2b9174000005_001",
              "question": "Is Tecovirimat effective for smallpox?"
            }
          ],
          "context": "tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\ntreatment with the smallpox antiviral tecovirimat ( st - 246 ) alone or in combination with acam2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.\noral tecovirimat for the treatment of smallpox.\nfrom clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate.\nbrincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat ( the only oral smallpox antiviral currently in the us strategic\nmodified vaccinia ankara : potential as an alternative smallpox vaccine\nmodified vaccinia ankara was safe and immunogenic in subjects infected with hiv and represents a promising smallpox vaccine candidate for use in immunocompromised populations.\ntecovirimat : first global approval.\nimvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate."
        },
        {
          "qas": [
            {
              "id": "5c010e09133db5eb78000024_001",
              "question": "Can simvastatin alleviate depressive symptoms?"
            }
          ],
          "context": ". early improvement and response rates were significantly greater in the simvastatin group than the placebo group ( p = 0. 02 and p = 0. 01, respectively ) but remission rate was not significantly different between the two groups ( p = 0. 36 ).\nsimvastatin - treated patients experienced significantly more reductions in hdrs scores compared to the placebo group by the end of the trial ( p = 0. 02 )\nhigh - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nconclusions simvastatin showed no benefits in decreasing the incidence of vasospasm, dci, or all - cause mortality after aneurysmal sah. we conclude that patients with sah should not be treated routinely with simvastatin during the acute stage.\nconclusions compared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mrs\u22642, vasospasm, icu stay, hospital stay, and mortality in patients with acute\nrecently, acute simvastatin treatment was not shown to be beneficial in neurological outcome using modified rankin scale.\n. taken together, our results suggest that atorvastatin / metformin combination therapy may achieve additional anti - atherosclerotic benefits likely through increasing cholesterol efflux in macrophages.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\nor ssris without significant cyp2d6 inhibition ( citalopram / escitalopram / sertraline ), and the related prescribing of cyp2d6 - independent comparator drugs ( atenolol, rivastigmine, propoxyphene, anastrozole ).\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah )."
        },
        {
          "qas": [
            {
              "id": "5c5f2b771a4c55d80b000020_001",
              "question": "Is P. gingivalis bacteria found in brain?"
            }
          ],
          "context": "the polymicrobial dysbiotic subgingival biofilm microbes associated with periodontal disease appear to contribute to developing pathologies in distal body sites, including the brain.\nstudies using animal model of periodontitis and human post - mortem brain tissues from subjects with ad strongly suggest that a gram - negative periodontal pathogen, porphyromonas gingivalis ( pg ) and / or its product gingipain is / are translocated to the\nour findings provide new insight into the role of evs from gram - positive oral bacteria in periodontal diseases.\nits product gingipain is / are translocated to the brain.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nfusobacterium nucleatum is a gram - negative bacillius commonly found in oropharynx and is traditionally associated with lemierre syndrome, which is characterized by history of recent oropharyngeal infection, internal jugular vein thrombosis, and\nincreased diagnosis of lemierre syndrome and other fusobacterium necrophorum infections at a children's hospital.\nfusobacterium necrophorum is aaerobic gram - negative bacillus and is the most common organism reported to cause lemierre's syndrome which usually occurs one to three weeks post pharyngitis or oropharyngeal surgery.\nfusobacterium necrophorum, a well \u2010 known cause of lemierre's syndrome, was identified.\nfusobacterium species is known for being a causative agent for lemierre's syndrome, which is characterized by thrombophlebitis of the jugular vein."
        },
        {
          "qas": [
            {
              "id": "5c58ac2286df2b917400000f_001",
              "question": "Is ibudilast effective for multiple sclerosis?"
            }
          ],
          "context": "conclusions : in a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache,\nibudilast for the treatment of multiple sclerosis.\n. it summarizes prior and current clinical trials of ibudilast in ms as well as its pharmacology. expert opinion : although ibudilast has not been found to decrease the focal inflammatory activity in relapsing ms, it was shown to have an effect on\n. ibudilast may have a role in the treatment of progressive ms phenotypes.\nibudilast slowed brain atrophy in ppms and spms patients in a multicenter phase 2b study.\nconclusion : sprint - ms is designed to evaluate the safety and efficacy of ibudilast as a treatment for pms while simultaneously validating five different imaging biomarkers as outcome metrics for use in future phase ii proof - of - concept pms trials.\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nrelapsing ms, it was shown to have an effect on preserving brain volume and disability progression\ncurrent article provides an overview of the pharmacology of ibd with a focus on preclinical and clinical data supporting its potential neuroprotective benefits for neurological conditions, including multiple sclerosis, neuropathic pain, medication\nconclusions : among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide."
        },
        {
          "qas": [
            {
              "id": "5c0114ec133db5eb78000028_001",
              "question": "Does gepotidacin activate bacterial topoisomerase?"
            }
          ],
          "context": "gsk2140944 is a novel bacterial topoisomerase inhibitor in development for the treatment of bacterial infections.\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia.\n. previously, we reported that a variety of cardenolides impart anti - transmissible gastroenteritis coronavirus ( tgev ) activity in swine testicular ( st ) cells, through targeting of the cell membrane sodium / potassium pump, na + / k + - atpase.\ncardenolides have shown significant antitumor activity due to their ability to inhibit the na + k + atpase enzyme, and the expression of this enzyme is increased in tumor cells.\nactivity of a novel g - quadruplex - interactive telomerase inhibitor, telomestatin ( sot - 095 ),\na novel telomerase inhibitor, telomestatin, isolated from streptomyces anulatus is the most potent telomerase inhibitor so far.\nto sn - 38 ( topoisomerase i inhibitor ) through a proprietary hydrolyzable linker. methods : in this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single - agent chemotherapy of the physician's choice ( eribulin,\ntelomestatin, a strong telomerase inhibitor with g - quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers.\nwe demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation.\nasporin has been reported as a tumor suppressor in breast cancer, while asporin - activated invasion has been described in gastric cancer."
        },
        {
          "qas": [
            {
              "id": "5c5607aa07647bbc4b00000e_001",
              "question": "Is durvalumab used for lung cancer treatment?"
            }
          ],
          "context": "single - agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non - small - cell lung cancer, particularly the \u226525 % pd - l1 + population.\nnivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the fda for treatment of advanced - stage urothelial carcinoma.\nin the phase iii pacific trial consolidation with durvalumab, an anti - pdl - 1 antibody, was associated with survival benefit in patients diagnosed with la - nsclc who responded to concurrent chemoradiotherapy.\nand pembrolizumab ) and pd - l1 inhibitors ( atezolizumab, durvalumab, and avelumab ) in patients with nsclc.\nactivity of durvalumab plus olaparib in metastatic castration - resistant prostate cancer in men with and without dna damage repair mutations.\navelumab for the treatment of urothelial cancer.\natezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising pd - 1 / pd - l1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\nsix drugs including one ctla - 4 blocker ( ipilimumab ), two pd - 1 blockers ( nivolumab and pembrolizumab ) and three pd - l1 blockers ( atezolizumab, avelumab and durvalumab ) are approved for the treatment of different types of cancers including both solid\nince then, additional checkpoint inhibitors, including avelumab, durvalumab, and nivolumab, have gained approval."
        },
        {
          "qas": [
            {
              "id": "5c5f0c5a1a4c55d80b00000f_001",
              "question": "Is  LRP1 interacting with Urokinase receptor?"
            }
          ],
          "context": "interaction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\nupstream kinases, receptor interacting protein kinase ( ripk ) - 1 and ripk3, within a complex known as the necrosome\ndirect binding of domain 3 ( d3 ) of upar to lrp is required for clearance of upa - pai - 1 - occupied upar\nto activate nlrp3 inflammasome, a multiprotein complex that processes pro - interleukin - 1\u03b2 into its mature form.\nthe activation of mixed lineage kinase - like ( mlkl ) by receptor - interacting protein kinase - 3 ( ripk3 ) results in plasma membrane ( pm ) disruption and a form of regulated necrosis, called necroptosis.\n. currently, there are three available anti - il - 1 agents : anakinra ( recombit human il - 1ra ), rilonacept ( a soluble decoy receptor'trap ', binding both il - 1\u03b1 and il - 1\u03b2 ), and canakinumab ( human monoclonal anti - il - 1\u03b2 antibody ).\nthe auf1 ( hnrnpd ) and hur ( elav - like ) proteins, potential trans - acting factors for regulated mrna decay, bind in vitro to a + u - rich elements ( ares ) found in the 3'untranslated region ( 3'utr ) of many labile transcripts.\nwe reviewed the literature for prospective studies evaluating pd - 1 / pd - l1 inhibitors in refractory urothelial carcinoma patients, which formed the basis for us food and drug administration approval of 5 different antagonistic antibodies targeting pd - 1\nadditionally, we demonstrated that rnpc1 could bind to pr mrna via au - rich elements ( ares ) within pr 3'- untranslated region ( 3'- utr ) and then enhance pr mrna stability.\nalthough au - rich elements ( ares ) in the 3'utr of interleukin - 6 ( il - 6 ) mrna dictate mrna degradation, the role of ttp in the post - transcriptional regulation of il - 6 gene expression is unclear."
        },
        {
          "qas": [
            {
              "id": "5c0e838b133db5eb7800002e_001",
              "question": "Is obesity related to cognitive decline?"
            }
          ],
          "context": "obesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions.\nevidence for the increased prevalence of diabetes and obesity is reviewed as it relates to cognitive decline.\nobesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition - related brain areas in patients with mdd.\nthe data suggest that being overweight or obese in midlife may be more detrimental to subsequent age - related cognitive decline than being overweight or obese at later stages of the life span\nimpairments in cognitive function have been associated with obesity in both people and rodents.\nobesity in the pre - school years was associated with poorer outcomes for some cognitive measures in this study. stronger relationships between obesity and cognition or educational attainment may emerge later in childhood.\nthere is parallel evidence that people who are overweight or obese tend to perform worse on a variety of cognitive tasks\npoor cognitive performance was present in 37 % of the sample. general obesity ( bmi > or = 25 ) and poor cognition were strongly associated in the presence of abdominal obesity\noverweight and obesity are associated with an increased risk of subnormal intellectual performance in young adult males. subjects with low birth weight and adolescent overweight / obesity are at particular risk of subnormal performance.\nwhile research in this area is growing, our knowledge of obesity - related cognitive dysfunction and brain alterations has not yet been synthesized."
        },
        {
          "qas": [
            {
              "id": "5c589ddb86df2b917400000b_001",
              "question": "Is cabozantinib effective for hepatocellular carcinoma?"
            }
          ],
          "context": "conclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\ncabozantinib in the treatment of hepatocellular carcinoma.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\npositive results in recent phase iii clinical trials have confirmed the high value of anti - angiogenic therapies for hcc in both first ( sorafenib and lenvatinib ) and second line ( regorafenib and cabozantinib ) treatment modalities.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nrecently, a few systemic chemotherapies proved to be effective for advanced stage hcc in phase iii studies : lenvatinib as the first line of therapy, and regorafenib, cabozantinib, and ramucirumab as second - line therapy.\n. a randomized phase ii trial in second - line hcc showed improved overall survival ( hazard ratio : 0. 38 ; p = 0. 01 ) in patients with met - high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.\n. moreover, regorafenib and cabozantinib are useful second - line therapies after the failure of sorafenib.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib"
        },
        {
          "qas": [
            {
              "id": "5c56033607647bbc4b00000c_001",
              "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?"
            }
          ],
          "context": "tisagenlecleucel in children and young adults with b - cell lymphoblastic leukemia.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\nbackground : tisagenlecleucel is an anti - cd19 chimeric antigen receptor ( car19 ) t - cell therapy approved for the treatment of children and young adults with relapsed / refractory ( r / r ) b - cell acute lymphoblastic leukemia ( b - all ).\nor refractory diffuse large b - cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel.\nthe phase ii juliet trial suggests that the cd19 - targeting car t - cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large b - cell lymphoma.\nchimeric antigen receptor t cells demonstrate efficacy in b - cell malig \" \" cies, leading to us food and drug administration approval of axicabtagene ciloleucel ( october 2017 ) and tisagenlecleucel ( may 2018 ) for large b - cell lymphomas after 2 prior lines\nwithin the last one year, two anti - cd19 car t - cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the united states food and drug administration for the treatment of relapsed or refractory large b - cell lymphoma after\nengineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\n. food and drug administration ( fda ) approved novartis'tisagenlecleucel ( ctl - 019, kymriah ), which is a synthetic bioimmune product of anti - cd19 chimeric antigen receptor ( car ) t cells, for the treatment of relapsed / refractory b - cell acute"
        },
        {
          "qas": [
            {
              "id": "5c76cea17c78d694710000a7_001",
              "question": "Is ADP-ribosylation a PTM?"
            }
          ],
          "context": "adp - ribosylation is a post - translational modification ( ptm ) implicated in several crucial cellular processes, ranging from regulation of dna repair and chromatin structure to cell metabolism and stress responses.\nadp - ribosylation is a ptm, in which adp - ribosyltransferases use nicotinamide adenine dinucleotide ( nad + ) to modify target proteins with adp - ribose\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna\nmethylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\npost - transcriptional mrna regulation by rna binding proteins ( rbps ) associated with au - rich elements ( ares ) present in the 3'untranslated region ( 3'utr ) of specific mrnas modulates transcript stability and translation in eukaryotic cells.\nn6 - adenosine methylation ( m6a ) is one of the most common modifications on mrna.\nn6 - methyladenosine ( m6a ) is a dynamic reversible methylation modification of the adenosine n6 position and is the most common chemical epigenetic modification among mrna post - transcriptional modifications, including methylation, demethylation, and\nthe removal of n - terminal translation initiator met by methionine aminopeptidase ( metap ) is often crucial for the function and stability of proteins.\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\ny rna - binding proteins ( rbps ) have been shown to recognize and bind to mrnas that contains ares generally present in the 3'utr of mrnas. rbps"
        },
        {
          "qas": [
            {
              "id": "5c56fd7407647bbc4b000013_001",
              "question": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?"
            }
          ],
          "context": "conclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\nwe retrospectively analyzed 93 consecutive single - preg \" \" cy patients who underwent cesarean section with combined spinal - epidural anesthesia\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\n. 107 \u00b1 2 mmol / l, p = 0. 02 ). no differences were observed in the apgar score or other umbilical cord laboratory data at delivery ( na +, k +, ph, base excess )\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\nbf could significantly reduce pain response in healthy - term neonates during heel lance. mt did not enhance the effect of pain relief of bf.\n. some studies revealed changes in certain immune response parameters post - vaccination when analgesics / antipyretics were used either prophylactically or therapeutically. still, there is no evidence that these changes impact vaccine efficacy\n. the major outcome was umbilical cord chloride level at delivery. the volume infused from operating room admission until delivery was not significantly different between groups\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain."
        },
        {
          "qas": [
            {
              "id": "5c5f22951a4c55d80b00001d_001",
              "question": "Is phospholipid hydroperoxide glutathione peroxidase a selenoprotein?"
            }
          ],
          "context": "glutathione peroxidase ( gpx1 ) is the major selenoprotein in most tissues in animals.\nthe major selenoprotein expressed by germ cells in the testis, the phospholipid hydroperoxide glutathione peroxidase ( phgpx / gpx4 )\nthe selenoenzyme gpx4 is essential for early embryogenesis and cell viability for its unique function to prevent phospholipid oxidation.\nselenocysteine ( sec ), a rare genetically encoded amino acid with unusual chemical properties, is of great interest for protein engineering.\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\ncopper - zinc superoxide dismutase 1 ( sod1 ) is one of the most commonly mutated genes in als, and more than 160 mutations in sod1 have been reported.\nwe have previously identified a silencer ( negative enhancer ) in glutathione transferase p ( gst - p ) gene which is strongly and specifically induced during hepatocarcinogenesis of the rat.\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\nthe sod1 gene encoding the superoxide dismutase 1 ( sod1 ) protein is mutated in approximately 15 % of familial amyotrophic lateral sclerosis ( als ) and 3 % of sporadic als.\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 )."
        },
        {
          "qas": [
            {
              "id": "5c73aced7c78d69471000087_001",
              "question": "Is inositol effective for trichotillomania?"
            }
          ],
          "context": "future studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.\nother body - focused repetitive behaviors, such as trichotillomania.\nconclusions \u2022 the review indicates that yoga, aerobic exercise, acupuncture, biofeedback, hypnosis, and inositol and n - acetylcysteine all show promise in the treatment of excoriation disorder and other body - focused repetitive behaviors, such as\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nconclusions : in two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.\nadvanced development phases while non - invasive neuromodulatory approaches were suggested to be potentially effective as non - pharmaceutical interventions for migraine."
        },
        {
          "qas": [
            {
              "id": "5c640fa1e842deac67000011_001",
              "question": "Is TIAM1 favoring tumor progression in colorectal cancer (CRC)?"
            }
          ],
          "context": ". importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\ntogether, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity. < br >\n. nuclear tiam1 suppresses taz / yap interaction with teads, inhibiting expression of taz / yap target genes implicated in epithelial - mesenchymal transition, cell migration, and invasion, and consequently suppresses crc cell migration and invasion\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\nadamts18 is a novel tumor suppressor and is critical to the pathology of human colorectal cancer. however, the underlying mechanism is not clear\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\n. moreover, increased p38mapk and erk1 / 2 activities were detected in colon cancer cells from adamts18 - deficient mice"
        },
        {
          "qas": [
            {
              "id": "5c663afe7c78d69471000013_001",
              "question": "Is pacritinib effective for treatment of myelofibrosis?"
            }
          ],
          "context": "pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.\nexpert commentary : pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.\nconclusions and relevance : in patients with myelofibrosis and thrombocytopenia, including those with prior anti - jak therapy, pacritinib twice daily was more effective than bat, including ruxolitinib, for reducing splenomegaly and symptoms.\npacritinib is an active agent in patients with mf, offering a potential treatment option for patients with preexisting anemia and thrombocytopenia.\nthis article examines the role of jak2 and flt3 signaling in myelofibrosis and provides an overview of the clinical development of pacritinib as a new therapy for myelofibrosis.\npacritinib ( pac ), a multi - kinase inhibitor with specificity for jak2, flt3, and irak1 but sparing jak1, has demonstrated clinical activity in mf with minimal myelosuppression.\nother jakis, such as fedratinib and pacritinib, proved to be useful in mf.\npacritinib, a dual jak2 and flt3 inhibitor which also inhibits irak1, has demonstrated the ability to favorably impact mf - associated splenomegaly and symptom burden, while having limited myelosuppression with manageable gastrointestinal toxicity.\nwithout causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis.\ndevelopments of jak inhibitors, such as ruxolitinib, pacritinib, momelotinib, and febratinib enabled the effective management in mf patients."
        },
        {
          "qas": [
            {
              "id": "5c571f7607647bbc4b000017_001",
              "question": "Can exposure to heavy metals like lead(Pb) or cadmium(Cd) cause changes in DNA methylation patterns in Isoetes sinensis?"
            }
          ],
          "context": "hydrilla verticillata employs two different ways to affect dna methylation under excess copper stress. because of the accumulation of heavy metals, hydrilla verticillata ( l. f. ) royle, a rooted submerged perennial aquatic herb, is being developed as a\none possible but largely unexplored explanation is that exposure to sublethal doses of insecticides may alter epigenetic patterns that are heritable.\nhowever, full - methylation level of pb stress group ( 28. 34 % ) and cd stress group ( 20. 25 % ) was lower than control ( 33. 91 % ), in contrast, hemi - methylation level pb stress group ( 19. 89 % ) and cd stress group ( 27. 85 % ) were higher than control ( 13. 04 % ).\nfirst, stress - induced methylation changes are common and are mostly heritable.\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes.\nenvironmentally caused changes in chromosomes that do not alter the dna sequence but cause phenotypic changes by altering gene transcription are summarized as epigenetics.\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\ninduction and repair of dna damage as measured by the comet assay and the yield of somatic mutations in gamma - irradiated tobacco seedlings.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet"
        },
        {
          "qas": [
            {
              "id": "5c57031107647bbc4b000014_001",
              "question": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?"
            }
          ],
          "context": "moreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\n. several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),\ngapdh exhibits a high affinity for plasmin and a significantly lower affinity for plasminogen.\npurified gapdh was found to bind human plasminogen and fibrinogen in far - western blot and elisa - based assays.\nbinding of plasminogen ( plg ) to bacterial surfaces, as it has been shown that this interaction contributes to bacterial adhesion to host cells, invasion of host tissues, and evasion of the immune system\nstudies using animal model of periodontitis and human post - mortem brain tissues from subjects with ad strongly suggest that a gram - negative periodontal pathogen, porphyromonas gingivalis ( pg ) and / or its product gingipain is / are translocated to the\n. pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombit protein, patient - derived fibroblasts, plasma, and erythrocytes\ns viral glycoprotein cytoplasmic domains may play a role in this coordination, we have investigated the importance of the hemagglutinin - neuraminidase ( hn ) protein cytoplasmic domain in the assembly of the nonsegmented negative - strand rna\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\nthe gluconeogenesis key enzymes pepck ( phosphoenolpyruvate carboxykinase )"
        },
        {
          "qas": [
            {
              "id": "5c6549e1e842deac67000022_001",
              "question": "Can CPX-351 be used for the treatment of tuberculosis?"
            }
          ],
          "context": "cpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\ncpx - 351 ( united states : vyxeos\u00ae ; europe : vyxeos\u00ae liposomal ), a dual - drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1 : 5 molar ratio, is approved by the us fda and the ema for the treatment of adults with newly diagnosed\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\nfrequent dosing. this review focuses on the potential benefits and considerations for the study and use of 2 long - acting injectable agents, cabotegravir ( gsk1265744la, cab la ) and rilpivirine ( tmc278la, rpv la ), for use as chemoprophylaxis for hiv\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\nin prostate cancer, two parpi, rucaparib and olaparib, have been fda approved for the treatment of metastatic castration - resistant prostate cancer ( mcrpc ).\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia."
        },
        {
          "qas": [
            {
              "id": "5c654c14e842deac67000025_001",
              "question": "Does lucatumumab bind to CD140?"
            }
          ],
          "context": "in this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nsubsequent options include a tnf - alpha antagonist, followed by rituximab or possibly abatacept ; ( 2 ) tocilizumab, a monoclonal antibody, inhibits interleukin - 6 receptors.\nanother cd20 directed mab, ofatumumab, is in phase 3.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\n. here we describe a fully human bsab ( regn5458 ) that binds to b - cell maturation antigen ( bcma ) and cd3, and compare its antitumor activities vs those of anti - bcma car t cells to identify differences in efficacy and mechanism of action.\nbackground dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nin particular, depletion ( obinutuzumab, anti - cd20 monoclonal antibody ) or neutralization ( belimumab, anti - \" b - cell activating factor \" monoclonal antibody ) of b lymphocytes, and the use of a calcineurin inhibitor with a low profile of renal and\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy"
        },
        {
          "qas": [
            {
              "id": "5c73ad0b7c78d69471000093_001",
              "question": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?"
            }
          ],
          "context": "high - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nconclusions simvastatin showed no benefits in decreasing the incidence of vasospasm, dci, or all - cause mortality after aneurysmal sah. we conclude that patients with sah should not be treated routinely with simvastatin during the acute stage.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\nconclusions high - dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage.\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah ).\nsimvastatin - treated patients experienced significantly more reductions in hdrs scores compared to the placebo group by the end of the trial ( p = 0. 02 )\nconclusions compared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mrs\u22642, vasospasm, icu stay, hospital stay, and mortality in patients with acute\n. early improvement and response rates were significantly greater in the simvastatin group than the placebo group ( p = 0. 02 and p = 0. 01, respectively ) but remission rate was not significantly different between the two groups ( p = 0. 36 ).\nand mortality in patients with acute aneurysmal subarachnoid hemorrhage.\nrecently, acute simvastatin treatment was not shown to be beneficial in neurological outcome using modified rankin scale."
        },
        {
          "qas": [
            {
              "id": "5c72aaed7c78d6947100006f_001",
              "question": "Is pazopanib an effective treatment of glioblastoma?"
            }
          ],
          "context": ". pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n. we report the use of pazopanib in a patient with vhl disease for treatment of rcc who also harbored multiple cns hbs.\n. she was treated 24 months with pazopanib, a multityrosine kinase inhibitor ( tki ) targeting vegf and pdgf - \u03b2 pathways.\nvariable response of cns hemangioblastomas to pazopanib in a single patient with von hippel - lindau disease : case report.\nsingle - agent pazopanib did not prolong pfs in this patient population but showed in situ biological activity as demonstrated by radiographic responses.\nconclusion : the combination of inc280 / buparlisib resulted in no clear activity in patients with recurrent pten - deficient glioblastoma.\npazopanib therapy for cerebellar hemangioblastomas in von hippel - lindau disease : case report. von hippel - lindau ( vhl ) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system ( cns ).\nthe proteasome inhibitor bortezomib is effective for a variety of tumors, but not for gbm."
        },
        {
          "qas": [
            {
              "id": "5c643485e842deac67000015_001",
              "question": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?"
            }
          ],
          "context": "de novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. here we show that de novo mutations in highly evolutionarily conserved fetal brain - active elements are significantly and specifically enriched in neurodevelopmental disorders\n. we identified de novo mutations in three classes of putative regulatory elements in almost 8, 000 patients with developmental disorders\npossible mutations within highly conserved fetal brain - active elements cause neurodevelopmental disorders with a domi \" \" t mechanism.\n. we screened 9, 858 probands from the deciphering developmental disorders ( ddd ) study for de novo mutations in the 5'untranslated regions ( 5'utrs ) of genes within which variants have previously been shown to cause dd through a domit\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\n. we estimate that, genome - wide, 1 - 3 % of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain - active regulatory elements and that only 0. 15 % of all possible mutations within highly conserved fetal\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\n. the contribution of regulatory variation in non - coding regions to rare disease, including dd, remains very poorly understood\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases."
        },
        {
          "qas": [
            {
              "id": "5c7c0e2fd774d0424000000d_001",
              "question": "Are phagosomal proteins ubiquitinated?"
            }
          ],
          "context": "phagosomal proteins are ubiquitylated, and ubiquitylation was found to be required for formation of acidic multivesicular structures.\nmembranes of the bacterial phagosome are enriched with ubiquitinated proteins in a way that requires its dot / icm type iv secretion system, suggesting the involvement of effectors in the manipulation of the host ubiquitination machinery.\n, it is largely unknown how misfolded polypeptides form aggresomes and are eventually cleared by the aggresome - macroautophagy / autophagy pathway, so - called aggrephagy.\nautophagy is a cellular survival pathway that is necessary for the degradation of cellular constituents such as long - lived proteins and damaged organelles.\nautophagy is a homeostatic process involved in the turnover or elimination of cytoplasmic components, damaged organelles, and protein aggregates via a lysosomal degradation mechanism.\nthe selective branch of autophagy that deals with identification, capture and degradation of protein aggregates is called aggrephagy.\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nin this study, we demonstrate that autophagy is a critical mediator of the viral degradation pathway and that this pathway is not hiv - 1 specific.\nmechanistic insights into aggrephagy, a selective basal autophagy process to clear misfolded protein aggregates,"
        },
        {
          "qas": [
            {
              "id": "5c73ad327c78d69471000097_001",
              "question": "Does tremelimumab improve survival of mesothelioma patients?"
            }
          ],
          "context": "background : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\ninterpretation : tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malig \" \" t mesothelioma.\nthe first interim analysis of a randomized phase iii trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab ; these treatments currently apply to selected patients.\nsions : mainte \" \" ce avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first - line chemotherapy\nin the phase iii pacific trial consolidation with durvalumab, an anti - pdl - 1 antibody, was associated with survival benefit in patients diagnosed with la - nsclc who responded to concurrent chemoradiotherapy.\nprolonging the survival of small cell lung cancer patients.\nsingle - agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non - small - cell lung cancer, particularly the \u226525 % pd - l1 + population.\nramucirumab in second - line treatment due to their benefits in terms of overall survival.\n. a preliminary report of a randomized phase iii trial, the pacific trial, demonstrated an impressive increase in median progression - free survival with consolidative durvalumab, a pd - l1 inhibitor, compared with observation after ccrt.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc."
        },
        {
          "qas": [
            {
              "id": "5c6587d77c78d69471000005_001",
              "question": "Can enasidenib be used for the treatment of acute myeloid leukemia?"
            }
          ],
          "context": "in august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia.\nbackground : tisagenlecleucel is an anti - cd19 chimeric antigen receptor ( car19 ) t - cell therapy approved for the treatment of children and young adults with relapsed / refractory ( r / r ) b - cell acute lymphoblastic leukemia ( b - all ).\npacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.\ntisagenlecleucel in children and young adults with b - cell lymphoblastic leukemia.\nthe responses seen with venetoclax in rrmm with t ( 11 ; 14 ) ( high bcl - 2, low bcl - xl and mcl - 1 ) and selinexor in penta - refractory myeloma which fulfills the fda category of unmet need, opens up newer options for these patients.\nthe treatment of relapsed / refractory b - cell acute lymphoblastic leukemia ( b - all )."
        },
        {
          "qas": [
            {
              "id": "5c783236d774d04240000001_001",
              "question": "Is collagen the most abundant human protein?"
            }
          ],
          "context": "collagen is the most abundant protein family in mammals.\nas the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\ncollagen is a fibrillar protein that conforms the conjunctive and connective tissues in the human body, essentially skin, joints, and bones\n. this molecule is one of the most abundant in many of the living organisms due to its connective role in biological structures.\nin this study we quantify lysozyme, the most prevalent protein in tear fluid,\nthe collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\ntype ii collagen is a major component of articular cartilage and its breakdown is a key feature of osteoarthritis.\nthe human vitamin e - binding protein afamin\nthe human vitamin e - binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome"
        },
        {
          "qas": [
            {
              "id": "5c76be617c78d694710000a5_001",
              "question": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?"
            }
          ],
          "context": "a genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nbscr is also associated with endoplasmic reticulum aminopeptidase 2 ( erap2 ), an enzyme involved in processing hla class i ligands, thus implicating the a * 29 : 02 peptidome in this disease.\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\ncomprehensive circular rna profiling of proliferative vitreoretinopathy and its clinical significance\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate.\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nstaining for the transcription factors foxp2, satb1 and satb2 labeled most ganglion cells in the avian ganglion cell layer.\nthe restoration of epo production and epor mrna expression with asp treatment activated epor downstream jak2 / stat5 and pi3k / akt signaling, induced their target genes, such as bcl - xl, fam132b and tfrc, and increased bcl - 2 / bax ratio in bone"
        },
        {
          "qas": [
            {
              "id": "5c73ad377c78d6947100009a_001",
              "question": "Does Panitumumab prolong survival of biliary tract cancer patients?"
            }
          ],
          "context": "conclusions : panitumumab in combination with chemotherapy does not improve orr, pfs and os in patients with kras wild - type, advanced biliary cancer.\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nadding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract\nshown to be effective for advanced biliary tract cancer.\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\ninterpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.\ninterpretation : tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malig \" \" t mesothelioma.\nprolonging the survival of small cell lung cancer patients.\nconclusions : algenpantucel - l immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable pdac receiving soc neoadjuvant chemotherapy and chemoradiatio"
        },
        {
          "qas": [
            {
              "id": "5c6582207c78d69471000001_001",
              "question": "Is lucatumumab a polyclonal antibody?"
            }
          ],
          "context": "in this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nmonoclonal antibodies including nivolumab and pembrolizumab ; anti - pd - l1 antibodies including atezolizumab, avelumab, and durvalumab.\nbackground dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nsubsequent options include a tnf - alpha antagonist, followed by rituximab or possibly abatacept ; ( 2 ) tocilizumab, a monoclonal antibody, inhibits interleukin - 6 receptors.\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa.\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis."
        },
        {
          "qas": [
            {
              "id": "5c662c507c78d6947100000d_001",
              "question": "Is lithium effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "in a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nbackground lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nstudies in als showed consistently negative results and presented evidence against the use of lithium for the treatment of this disease.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\na comparison of the group of patients treated with lithium + riluzole and the control group treated with riluzole alone showed no statistically significant differences in rates of functional decline, deterioration of respiratory function, or survival\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results."
        },
        {
          "qas": [
            {
              "id": "5c73acea7c78d69471000085_001",
              "question": "Should dacomitinib be used for treatment of glioblastoma patients?"
            }
          ],
          "context": "conclusions : dacomitinib has a limited single - agent activity in recurrent gb with egfr amplification.\nexpert opinion : despite the poor global results of dacomitinib in recurrent gb shown in a phase ii trial, some patients had a significant benefit.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nconclusion : the combination of inc280 / buparlisib resulted in no clear activity in patients with recurrent pten - deficient glioblastoma.\nof glioblastoma or anaplastic astrocytoma, administration of toca 511 and toca fc, compared with soc, did not improve overall survival or other efficacy end points.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo."
        },
        {
          "qas": [
            {
              "id": "5c6d7bb57c78d6947100003b_001",
              "question": "Are there ultraconserved regions in the budding yeast (Saccharomyces cerevisiae)?"
            }
          ],
          "context": "the systematic analysis of ultraconserved genomic regions in the budding yeast.\nalthough similar structures appear to be conserved in fission yeast, computational modeling and analysis of high - throughput chromosome conformation capture ( hi - c ) data have been used to argue that the small, highly constrained budding yeast\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n. to facilitate the investigation of unique ucss, the ucsc genome browser was utilized to visualize the chromosomal position and related annotations of ucss in s. cerevisiae genome.\ngenomes contain many clusters of conserved noncoding elements\nthat the small, highly constrained budding yeast chromosomes could not have these structures\nchromatin is reconstituted in the fission yeast schizosaccharomyces pombefbp1 gene, which is robustly induced upon glucose starvation but tightly repressed under glucose - rich conditions.\n. in contrast, herein we analyze hi - c data for budding yeast and identify 200 - kb scale tads, whose boundaries are enriched for transcriptional activity\n. the close correspondence between extreme noncoding conservation and tads suggests that these tads are ancient, revealing a regulatory architecture conserved over hundreds of millions of years. metazoan genomes contain many clusters of conserved"
        },
        {
          "qas": [
            {
              "id": "5c640c2ee842deac67000010_001",
              "question": "Is there any role for HUWE1 in MYC signalling?"
            }
          ],
          "context": "huwe1 is a critical colonic tumour suppressor gene that prevents myc signalling, dna damage accumulation and tumour initiation.\n. taken together, these data identify huwe1 as a bona fide tumour suppressor gene in the intestinal epithelium and suggest a potential vulnerability of huwe1 - mutated tumours to dna - damaging agents and inhibitors of anti - apoptotic proteins.\nhe myc oncogene\n. genetic deletion of huwe1 rapidly accelerated tumourigenic in mice carrying loss of the intestinal tumour suppressor gene apc, with a dramatic increase in tumour initiation\ntcf3 - mediated repression to tcf1 / lef1 - mediated enhancement of wnt signaling, constituting a positive feedback loop that facilitates neuronal differentiation.\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces.\n. mechanistically, this phenotype was driven by increased myc and rapid dna damage accumulation leading to loss of the second copy of apc the increased levels of dna damage sensitised huwe1 - deficient tumours to dna - damaging agents and to deletion of\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\nhu proteins have been shown to bind to au - rich elements ( ares ) in the 3'- untranslated region of unstable mrnas.\nhic1 is a candidate tumor suppressor gene which is frequently hypermethylated in human tumors, and its location within the miller - dieker syndrome's critical deletion region at chromosome 17p13. 3 makes it a candidate gene for involvement in this gene"
        },
        {
          "qas": [
            {
              "id": "5c674aed7c78d69471000019_001",
              "question": "Do raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 Diabetes?"
            }
          ],
          "context": ". red raspberry ( rb ) contains high amounts of dietary fibers and polyphenolic compounds, which are known for their anti - oxidative and anti - inflammatory effects.\nmetformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti - inflammatory and anti - atherosclerotic properties.\nour studies establish that resistance training in older adults with type 2 diabetes results in muscle fiber hypertrophy, despite a greater accumulation of inflammatory cytokine transcripts in muscle.\nfive weeks of treatment with the glp - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.\ninflammation and insulin resistance by polarizing m2 macrophages and reducing metabolic endotoxemia\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\nthe monosaccharide analysis showed that rhamnose ( rha ) and glucose ( glu ) may play vital roles in maintaining the antioxidant and anti - aging activities.\nintroduction : for people with type 2 diabetes ( t2dm ) inadequately controlled with oral antidiabetic drugs ( oads ), evidence from both randomized controlled trials ( rcts ) and real - world studies has demonstrated that treatment intensification with\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\n. covid - 19 pandemic poses a pressing challenge for the diabetic population, since maintaining optimal blood glucose control is key to reduce morbidity and mortality rates."
        },
        {
          "qas": [
            {
              "id": "5c7836dad774d04240000002_001",
              "question": "Are Mesenchymal stem cells (MSC) multipotent cells?"
            }
          ],
          "context": "multipotent mesenchymal bone marrow - derived stem cells\nmultipotent hesc - derived mesenchymal cells ( mcs )\nanimal studies have shown that mesenchymal stromal cell ( msc ) infusions improve acute kidney injury ( aki ) outcomes when administered early after ischemic / reperfusion injury or within 24 hours after cisplatin administration.\nnanog safeguards pluripotency in mouse embryonic stem cells ( mescs ).\nmaintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\nadipose - derived stem cells ( hascs ) induced by nel - like 1 protein ( nell - 1 ).\ncurrent evidence suggests that es cells maintain their pluripotent state by expressing a battery of transcription factors including oct4 and nanog.\nneural stem cells induces neuronal and astrocyte differentiation, respectively.\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\ninterpretation administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke."
        },
        {
          "qas": [
            {
              "id": "5c6b198f7c78d69471000025_001",
              "question": "Is there a deep-learning algorithm for protein solubility prediction?"
            }
          ],
          "context": ". thus, it is imperative to develop novel, highly accurate in silico sequence - based protein solubility predictors. in this work we propose, deepsol, a novel deep learning - based protein solubility predictor\nprotein solubility plays a vital role in pharmaceutical research and production yield. for a given protein, the extent of its solubility can represent the quality of its function, and is ultimately defined by its sequence\nopal : prediction of morf regions in intrinsically disordered protein sequences.\n. in this study, we present a new morf predictor, opal, to identify morfs in disordered protein sequences. opal utilizes two independent sources of information computed using different component predictors\n. predicting these morfs in disordered protein sequences is a challenging task. method : in this study, we present morfpred - plus, an improved predictor over our previous proposed predictor to identify morfs in disordered protein sequences\nopal + : length - specific morf prediction in intrinsically disordered protein sequences.\nin this study, we introduce morfchibi, a new computational approach for fast and accurate prediction of morfs in protein sequences\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\ncan be improved by using machine learning methods.\nbackground : over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms"
        },
        {
          "qas": [
            {
              "id": "5c5215e67e3cb0e231000004_001",
              "question": "Have machine learning methods been used to predict the severity of major depressive disorder(MDD)?"
            }
          ],
          "context": "objective we aimed to integrate neural data and an advanced machine learning technique to predict individual major depressive disorder ( mdd ) patient severity.\nbackground growing evidence documents the potential of machine learning for developing brain based diagnostic methods for major depressive disorder ( mdd ).\n< b > background < / b > : although variation in the long - term course of major depressive disorder ( mdd ) is not strongly predicted by existing symptom subtype distinctions, recent research suggests that prediction can be improved by using machine learning\nthese results confirm that clinically useful mdd risk - stratification models can be generated from baseline patient self - reports and that ml methods improve on conventional methods in developing such models\nmachine learning framework involving eeg - based functional connectivity to diagnose major depressive disorder ( mdd ).\nhere, we conduct a meta - review to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response.\ncan be improved by using machine learning methods.\nsupport vector machine'weighting factors'( used for making predictions ) correlated strongly with subjective ratings of illness severity.\n. we extended the work in predictive modeling of treatment resistant depression ( trd ) via partition of the data from the sequenced treatment alternatives to relieve depression ( star * d ) cohort into a training and a testing dataset.\nidentification of risk factors of treatment resistance may be useful to guide treatment selection, avoid inefficient trial - and - error, and improve major depressive disorder ( mdd ) care"
        },
        {
          "qas": [
            {
              "id": "5c6583117c78d69471000002_001",
              "question": "Can midostaurin inhibit angiogenesis?"
            }
          ],
          "context": "midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor.\nits effectiveness in the clinic has been ascribed to wide - ranging properties, including anti - tnf - alpha, t - cell costimulatory and antiangiogenic activity.\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\nthalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malig \" \" cies\nin 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic and immunomodulatory activities, and its therapeutic effect on myeloma.\nthe anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nthe non - vascular, neural mechanism of action of lasmiditan may offer an alternative means to treat migraine especially in patients who have contra - indications for agents with vasoconstrictor activity.\npositive results in recent phase iii clinical trials have confirmed the high value of anti - angiogenic therapies for hcc in both first ( sorafenib and lenvatinib ) and second line ( regorafenib and cabozantinib ) treatment modalities.\n. research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors."
        },
        {
          "qas": [
            {
              "id": "5c629fffe842deac67000009_001",
              "question": "Does Groucho related gene 5 (GRG5) have a role only in late development?"
            }
          ],
          "context": "groucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\n. by both loss and gain of function approaches we demonstrate that ablation of grg5 deregulates the embryonic stem cell ( esc ) pluripotent state whereas its overexpression leads to enhanced self - renewal and acquisition of cancer cell - like properties\nmaintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\n. the malig \" \" t characteristics of teratomas generated by escs that overexpress grg5 reveal its pro - oncogenic potential.\nthe transcription factor grainyhead - like 2 ( grhl2 ) plays a crucial role in various developmental processes\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\nnotably, the expression of nanog, a key pluripotency regulator and repressor of extraembryonic endoderm specification in es cells, was significantly reduced in zic3 knockdown cells.\nthese data indicate that the grb2 / mek pathway primarily mediates nanog gene repression upon es cell differentiation into primitive endoderm.\nearly embryonic development, when downregulation of nanog plays a crucial role."
        },
        {
          "qas": [
            {
              "id": "5c6da11e7c78d69471000042_001",
              "question": "Are there tools for reviewing variant calls?"
            }
          ],
          "context": "variant review with the integrative genomics viewer.\n. we developed the variant inspector and expert rating tool ( viper ) to speed up this process by integrating the integrative genomics viewer into a web application\n. many tools have been developed to analyze genomic variation ranging from single nucleotide variants to whole chromosomal aberrations. as sequencing throughput increases, the number of variants called by such tools also grows\nviper : a web application for rapid expert review of variant calls.\n. to facilitate the investigation of unique ucss, the ucsc genome browser was utilized to visualize the chromosomal position and related annotations of ucss in s. cerevisiae genome.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\n. we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\n. analysts can then quickly iterate through variants, apply filters and make decisions based on the generated images and variant metadata\nthe whole exome sequencing, further verified with sanger sequencing and parental background.\n. new methods for analyzing the data and evaluating results are needed. results : we offer bagel ( bayesian analysis of gene essentiality ), a supervised learning method for analyzing gene knockout screens"
        },
        {
          "qas": [
            {
              "id": "5c65495be842deac67000021_001",
              "question": "Has ivosidenib been FDA approved for use against acute myeloid leukemia?"
            }
          ],
          "context": "the fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\nin august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia.\ntisagenlecleucel in children and young adults with b - cell lymphoblastic leukemia.\nexpert commentary : pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.\npacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\n. food and drug administration ( fda ) approved novartis'tisagenlecleucel ( ctl - 019, kymriah ), which is a synthetic bioimmune product of anti - cd19 chimeric antigen receptor ( car ) t cells, for the treatment of relapsed / refractory b - cell acute"
        },
        {
          "qas": [
            {
              "id": "5c51f44c07ef653866000004_001",
              "question": "Are Copy Number Variants (CNVs) depleted in regions of low mappability?"
            }
          ],
          "context": "human copy number variants are enriched in regions of low mappability.\n. in particular, we identify 347 genes with a novel exonic cnv in low - mappability regions, including 29 genes previously associated with disease.\n. in addition to known enrichments in segmental duplication and near centromeres and telomeres, we also report that cnvs are enriched in specific types of satellite and in some of the most recent families of transposable elements\n. finally, using this comprehensive approach, we identify 3455 regions with recurrent cnvs that were missing from existing catalogs\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\n. many tools have been developed to analyze genomic variation ranging from single nucleotide variants to whole chromosomal aberrations. as sequencing throughput increases, the number of variants called by such tools also grows\nmutational load considerations lead to the conclusion that the functional fraction within the human genome cannot exceed 25 %, and is probably considerably lower.\nin rsc - depleted cells, nfrs shrink such that the average positions of flanking nucleosomes move toward predicted sites.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\n. we estimate that, genome - wide, 1 - 3 % of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain - active regulatory elements and that only 0. 15 % of all possible mutations within highly conserved fetal"
        },
        {
          "qas": [
            {
              "id": "5c5b2f4b1a4c55d80b000001_001",
              "question": "Is Adar3 involved in learning and memory?"
            }
          ],
          "context": "adar3 is involved in learning and memory in mice.\n. meta - analysis of published data indicates that mouse adar3 expression is highest in the hippocampus, thalamus, amygdala, and olfactory region\n. we also show that adar3 transiently translocates from the cytoplasm to the nucleus upon kcl - mediated activation in sh - sy5y cells. these results indicate that adar3 contributes to cognitive processes in mammals.\n. consistent with this, we show that mice lacking exon 3 of adar3 ( which encodes two double stranded rna binding domains ) have increased levels of anxiety and deficits in hippocampus - dependent short - and long - term memory formation\n. rna sequencing revealed a dysregulation of genes involved in synaptic function in the hippocampi of adar3 - deficient mice\n. in vitro studies have suggested that adar3 acts as a negative regulator of a - i rna editing but the scope and underlying mechanisms are also unknown\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nprevious reports indicate that distinct rna sequence in the bdnf 3'utrs differentially regulates bdnf production in the brain to accommodate neuronal activity changes, conceivably through differential interactions with undefined trans - acting factors\n. notably, evolutionarily conserved setd1a targets are associated with neuropsychiatric genetic risk burden. reinstating setd1a expression in adulthood rescues cognitive deficits"
        },
        {
          "qas": [
            {
              "id": "5c5f2cef1a4c55d80b000022_001",
              "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?"
            }
          ],
          "context": "hiv pre - exposure prophylaxis ( prep ) is a new approach that involves the ongoing use of antiretroviral medications by hiv - negative individuals to reduce the risk of hiv infection.\npre - exposure prophylaxis ( prep ) is an experimental approach to hiv prevention and consists of antiretroviral drugs to be taken before potential hiv exposure in order to reduce the risk of hiv infection and continued during periods of risk.\ndaily oral pre - exposure prophylaxis ( prep ) is the use of antiretroviral drugs by hiv - negative people to prevent hiv infection.\nintroduction use of pre - exposure prophylaxis ( prep ) among people who inject drugs ( pwid ) has been shown to be effective in preventing hiv transmission.\nthe use of antiretrovirals as pre - exposure prophylaxis ( prep ) is highly efficacious in hiv prevention.\nprophylaxis ( prep ) to reduce the risk of hiv infection in high - risk populations.\nfollowing us food and drugs administration approval in july 2012 of daily oral tenofovir and emtricitabine for pre - exposure prophylaxis ( prep ) to prevent hiv infection in high - risk individuals in the usa, there has been much controversy about the\nthe antiviral agent tenofovir is highly effective for the treatment of hiv and hepatitis b virus infections, and the older prodrug tenofovir disoproxil fumarate ( tdf ) is also a component of daily preexposure prophylaxis ( prep ) to reduce the risk of\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\n. in addition, long - acting cab is a promising agent for hiv preexposure prophylaxis ( prep )."
        },
        {
          "qas": [
            {
              "id": "5c52cde87e3cb0e23100000e_001",
              "question": "Does allele phasing improve the phylogenetic utility of ultraconserved elements?"
            }
          ],
          "context": "allele phasing greatly improves the phylogenetic utility of ultraconserved elements.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\n. we find that the elevated nucleotide diversity of mae genes is also associated with greater allelic age : variants in these genes tend to be older and are enriched in polymorphisms shared by neanderthals and chimpanzees\n. both synonymous and nonsynonymous alleles of mae genes have elevated average population frequencies. we also observed strong enrichment of the mae signature among genes reported to evolve under balancing selection\ngenomes contain many clusters of conserved noncoding elements\n. we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\nhere, we introduce the computational framework pines ( phenotype - informed noncoding element scoring ), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype - dependent manner\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n. specifically, our results indicated that in primates up to 24 % of synonymous sites could be under purifying selection, while in rodents synonymous sites evolved neutrally.\n. pines enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest"
        },
        {
          "qas": [
            {
              "id": "5c5723a007647bbc4b000019_001",
              "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?"
            }
          ],
          "context": "yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\nhere we summarize the results of studies of prions of the yeast saccharomyces cerevisiae and of the use of yeast model for investigation of some human amyloidoses, such as prion diseases, alzheimer's, parkinson's, and huntington's diseases.\nyeast prions increasingly are serving as models for the understanding and treatment of many mammalian amyloidoses.\nyeast prions are models for both rare mammalian prion diseases and for several very common amyloidoses such as alzheimer's disease, type 2 diabetes, and parkinson's disease.\nyeast prions ( infectious proteins ) were discovered by their outre genetic properties and have become important models for an array of human prion and amyloid diseases.\nendogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions.\nyeast prions, based on self - seeded highly ordered fibrous aggregates ( amyloids ), serve as a model for human amyloid diseases.\nmechanism of amyloid formation is critical for a complete understanding of the yeast prion phenomenon and human amyloid - related diseases.\nthe yeast system has provided considerable insight into the biology of amyloid and prions.\nthese infectious yeast amyloidoses are outstanding models for the many common human amyloid - based diseases that are increasingly found to have some infectious characteristics. < br >"
        },
        {
          "qas": [
            {
              "id": "5c6b7bee7c78d6947100002a_001",
              "question": "Is dupilumab effective for treatment of asthma?"
            }
          ],
          "context": "dupilumab : a novel treatment for asthma.\nexpert opinion : supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.\nin addition, dupilumab is currently under phase iii development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients.\ndupilumab efficacy and safety in moderate - to - severe uncontrolled asthma.\nexpert opinion : patients with severe asthma who are not sufficiently controlled with standard - of - care represent the target asthma population for dupilumab.\ndupilumab inhibits interleukin - 4 ( il - 4 ) and interleukin - 13 ( il - 13 ) signaling and was previously found to be effective in asthma.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\nsimultaneous targeting of both il - 4 and il - 13 by blocking il - 4 receptor \u03b1 using dupilumab has yielded more consistent results in reducing asthma exacerbations and improving lung function, especially in patients with increased blood eosinophils.\nthe efficacy and safety profile of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and\nconclusions : dupilumab 300 mg q2w significantly improved ar - associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid par."
        },
        {
          "qas": [
            {
              "id": "5c6d441d7c78d69471000037_001",
              "question": "Does Eucommia ulmoides leaf extract ameliorates steatosis/fatty liver induced by high-fat diet?"
            }
          ],
          "context": "eucommia ulmoides oliver leaf extract ( ele ) has been shown to have anti - hypertensive and anti - obesity effects in rats that are fed a high - fat diet ( hfd ).\nboth forms of eucommia leaves minimised increases in body weight and visceral fat in a dose - dependent fashion.\nthe hepatic fatty acid synthase and hmg - coa reductase activities were significantly lowered by a du - zhong leaf extract supplement in high fat - fed hamsters.\ntogether, these results suggest that eue and its active components enhance lysosomal activity, resulting in decreased er stress and hepatic dyslipidemi\nthe human vitamin e - binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome\nepoxyeicosatrienoic acids ( eets ) are arachidonic acid metabolites produced by cytochrome p450 epoxygenases which are highly expressed in hepatocytes.\nnon - alcoholic fatty liver disease ( nafld ) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.\noleuropein, a phenolic secoiroid glycoside, is the main polyphenol in the olive oil\nepoxyeicosatrienoic acids ( eets ), lipid mediators synthesized from arachidonic acid by cytochrome p - 450 epoxygenases, are converted by soluble epoxide hydrolase ( seh ) to the corresponding dihydroxyeicosatrienoic acids ( dhets ).\nepoxyeicosatrienoic acids ( eets ) are potent lipid mediators formed by cytochrome p450 epoxygenases from arachidonic acid."
        },
        {
          "qas": [
            {
              "id": "5c6b82a17c78d6947100002f_001",
              "question": "Is verubecestat effective for Alzheimer\u2019s Disease?"
            }
          ],
          "context": "this reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\nverubecestat is an inhibitor of \u03b2 - site amyloid precursor protein cleaving enzyme 1 ( bace1 ) being evaluated in clinical trials for the treatment of alzheimer's disease.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nverubecestat did not improve clinical ratings of dementia among patients with prodromal alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who\nverubecestat, a bace1 inhibitor that reduces a\u03b2 levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial ( epoch ) of mild - to - moderate ad and was associated with adverse events.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nin apecs, verubecestat 40 mg worsened cognition and increased adverse effects. expert opinion : in recruiting subjects to clinical trials in alzheimer's disease, a clinical diagnosis involving the measurement of a\u03b2 should be undertaken for all\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nthese results support the continued global development of verubecestat as a potential disease - modifying agent for japanese and non - japanese subjects who are at - risk for developing ad."
        },
        {
          "qas": [
            {
              "id": "5c6f15577c78d69471000053_001",
              "question": "Is galcanezumab effective for treatment of migraine?"
            }
          ],
          "context": "galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.\nefficacy and safety of galcanezumab for the prevention of episodic migraine : results of the evolve - 2 phase 3 randomized controlled clinical trial.\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\ngalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide, has demonstrated in previous phase 2 and phase 3 clinical studies ( \u22646 - month of treatment ) a reduction in the number of migraine headache\nin september 2018, the us fda approved galcanezumab as a once - monthly subcutaneous injection for the preventive treatment of migraine in adults.\ncgrp receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against cgrp ( eptinezumab, fremanezumab and galcanezumab ) or the cgrp receptor ( erenumab ) effectively prevent migraine\nbackground safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene - related peptide, for prevention of migraine ( nct02163993 ) are reported here.\nthis interventional study provides class i evidence that galcanezumab is superior to placebo in the reduction of the number of monthly mhds. < br >\nfour monoclonal antibodies ( mabs ) targeting the cgrp pathway are currently under evaluation for the prevention of episodic and chronic migraine : eptinezumab ( ald403 ), fremanezumab ( tev - 48125 ), galcanezumab ( ly2951742 ), and erenumab ( amg334 ).\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention."
        },
        {
          "qas": [
            {
              "id": "5c52028807ef653866000009_001",
              "question": "Can mitochondria be inherited by both parents in humans?"
            }
          ],
          "context": "biparental inheritance of mitochondrial dna in humans.\nand mtdna are exclusively maternally inherited in humans\n. our results suggest that, although the central dogma of maternal inheritance of mtdna remains valid, there are some exceptional cases where paternal mtdna could be passed to the offspring.\ninterest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\nhowever, it is unclear whether the active changes mediated by variations in dna methyltransferase activity are heritable.\n. a comprehensive exploration of mtdna segregation in these families shows biparental mtdna transmission with an autosomal domi \" \" tlike inheritance mode\na combined genetic and biochemical approach revealed that human dnmt2 did not methylate dna but instead methylated a small rna ; mass spectrometry showed that this rna is aspartic acid transfer rna ( trna ( asp ) ) and that dnmt2 specifically methylated\nepigenetics is defined as the study of changes in gene function that are mitotically or meiotically heritable and do not lead to a change in dna sequence.\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\nepigenetic alterations, which, by definition, comprise mitotically and meiotically heritable changes in gene expression that are not caused by changes in the primary dna sequence, are increasingly being recognized for their roles in carcinogenesis."
        },
        {
          "qas": [
            {
              "id": "5c71648b7c78d69471000067_001",
              "question": "Can Diazepam be beneficial  in the treatment of  traumatic brain injury?"
            }
          ],
          "context": "he present experiment examined the effects of diazepam, a positive modulator at the gaba ( a ) receptor, on survival and cognitive performance in traumatically brain - injured animals. i\nhesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole - induced convulsions in mice : possible behavioral, biochemical and mitochondrial alterations. hesp possesses potent anticonvulsant activity which\ninterpretation : functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events.\n. none of the deaths was considered related to study medication. interpretation : our study does not provide evidence that tranexamic acid prevents intracerebral haemorrhage growth, although the treatment was safe with no increase in thromboembolic\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah ).\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nbased on existing evidence, it is still too early to recommend epo as the standard treatment for preterm brain injury.\ntranexamic acid did not increase the risk of post - intracerebral haemorrhage seizures in the first 90 days."
        },
        {
          "qas": [
            {
              "id": "5c57216e07647bbc4b000018_001",
              "question": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?"
            }
          ],
          "context": "however, although a number of clinical studies examining the efficacy of h3 receptor antagonists for a variety of cognitive disorders are currently underway, no clinical proof of concept for an h3 receptor antagonist has been reported to date.\ncep - 26401 is a novel orally active, brain - penetrant, high - affinity histamine h3 receptor ( h3r ) antagonist, with potential therapeutic utility in cognition enhancement\ncep - 26401 ( irdabisant ), a potent and selective histamine h\u2083 receptor antagonist / inverse agonist with cognition - enhancing and wake - promoting activities.\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nconclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nthe novel dehydroepiandrosterone ( dhea ) derivative bnn27 counteracts delay - dependent and scopolamine - induced recognition memory deficits in rats.\nneuroprotective effect of hesperetin and o - hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of alzheimer's disease\npotential neuroprotective effects of hesperidin on 3 - nitropropionic acid - induced neurotoxicity in rats."
        },
        {
          "qas": [
            {
              "id": "5c6f6d997c78d69471000055_001",
              "question": "Is pimavanserin effective for Parkinson's disease psychosis?"
            }
          ],
          "context": "pimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\npimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\ninterpretation pimavanserin may benefit patients with parkinson's disease psychosis for whom few other treatment options exist.\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\nthe development of pimavanserin as an antipsychotic opened a new therapeutic avenue in the treatment of pdp as well as targeting psychosis in other disorders such as alzheimer's disease.\nif this is granted, we believe the evidence of pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of parkinson's disease psychosis."
        },
        {
          "qas": [
            {
              "id": "5c5b52731a4c55d80b000003_001",
              "question": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?"
            }
          ],
          "context": "we aimed to evaluate the prognostic and predictive value of the nucleotide excision repair - related gene gtf2h5, which is localized at the 6q24. 2 - 26 deletion previously reported by our group to predict longer survival of high - grade serous ovarian\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\n. the prognostic value of this deletion was validated in two independent series, one consisting of 36 hgsocs analyzed by fluorescent in situ hybridization ( p = 0. 04 ) and another comprised of 411 hgsocs from the cancer genome atlas study ( tcga ) ( hr =\nwe found that loss at 6q24. 2 - 26 was significantly associated with the cluster of longer survival independently from other confounding factors ( hr = 0. 06, 95 % ci = 0. 01 - 0. 43, padj = 0. 005 )\nlonger survival of high - grade serous ovarian cancer patients.\nlonger survival of high - grade serous ovarian cancer patients.\n. in addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 hgsocs ( hr = 0. 74, 95 % ci = 0. 61 - 0. 90, log - rank p = 0. 002 ) and 675 high - figo stage hgsocs ( hr = 0. 76, 95 % ci = 0. 61 - 0. 96, log - rank p\ndeletions of chromosome 7q11. 23 ( williams syndrome ), 15q11 - q13 ( angelman syndrome, prader - willi syndrome ) and 22q11 ( di george syndrome )\nthe deletion of chromosome 22q11. 2 is involved in the majority of digeorge or velo - cardiofacial syndrome."
        },
        {
          "qas": [
            {
              "id": "5c65484ee842deac6700001f_001",
              "question": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?"
            }
          ],
          "context": "in the large international phase iii mavoric trial, patients with previously treated cutaneous t - cell lymphoma who received the anti - ccr4 monoclonal antibody mogamulizumab experienced significantly longer progression - free survival and higher response\nmacroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti - cd20 - based therapy.\ntocilizumab, an anti - il - 6 receptor antibody, and corticosteroids were initially used to treat the increase in acute inflammatory proteins and the anasarca, resulting in decreased cytokine levels.\nic agents, rituximab may be used for refractory lupus nephritis patients in combination with another dmard, and belimumab was recently approved by the us food and drug administration for csle treatment in children aged > 5 years\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nteplizumab ( anti - cd3 mab ) treatment preserves c - peptide responses in patients with new - onset type 1 diabetes in a randomized controlled trial : metabolic and immunologic features at baseline identify a subgroup of responders.\nozanimod interferes with migrations of activated t cells to the site of inflammation and is a promising drug for the uc treatment. key words : crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.\nconclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm.\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa."
        },
        {
          "qas": [
            {
              "id": "5c72ba807c78d69471000076_001",
              "question": "Is avelumab effective for bladder cancer?"
            }
          ],
          "context": "expert opinion : avelumab has shown clinical efficacy for metastatic and advanced uc in phase i studies after the failure of platinum - based therapy with a well - tolerated safety profile.\navelumab for the treatment of urothelial cancer.\nnivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the fda for treatment of advanced - stage urothelial carcinoma.\navelumab has been approved by the u. s. fda for the treatment of metastatic merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum - based regimen.\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\nretation : avelumab showed antitumour activity in the treatment of patients with platinum - refractory metastatic urothelial carcinoma ; a manageable safety profile was reported in all avelumab - treated patients. these\nsions : mainte \" \" ce avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first - line chemotherapy\n. areas covered : this article will review the pharmacological characteristics of avelumab, the efficacy studies which led to its approval, its safety profile, as well as its place within the management of urothelial carcinoma with immunotherapy.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc.\natezolizumab is the only member of this class currently approved for the treatment of bladder cancer, but nivolumab, pembrolizumab, durvalumab, and avelumab all have positive results for this indication, and approvals are anticipated in the near"
        },
        {
          "qas": [
            {
              "id": "5c6b7a9e7c78d69471000029_001",
              "question": "Is cabozantinib effective for Hepatocellular Carcinoma?"
            }
          ],
          "context": "conclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\ncabozantinib in the treatment of hepatocellular carcinoma.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\npositive results in recent phase iii clinical trials have confirmed the high value of anti - angiogenic therapies for hcc in both first ( sorafenib and lenvatinib ) and second line ( regorafenib and cabozantinib ) treatment modalities.\nrecently, a few systemic chemotherapies proved to be effective for advanced stage hcc in phase iii studies : lenvatinib as the first line of therapy, and regorafenib, cabozantinib, and ramucirumab as second - line therapy.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n. a randomized phase ii trial in second - line hcc showed improved overall survival ( hazard ratio : 0. 38 ; p = 0. 01 ) in patients with met - high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nshow a survival benefit in patients with advanced hepatocellular carcinoma.\n. moreover, regorafenib and cabozantinib are useful second - line therapies after the failure of sorafenib."
        },
        {
          "qas": [
            {
              "id": "5c5839e707647bbc4b00001f_001",
              "question": "Is there a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay?"
            }
          ],
          "context": ". taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\nconsistent with the findings described in bcl11b - deficient mice\nimpairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13.\n. six frameshift mutations, two nonsense mutations, one missense mutation, and two chromosomal rearrangements resulting in diminished bcl11b expression, arose de novo. a further frameshift mutation was transmitted from a similarly affected mother\nusing massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in bcl11b\nsyndrome exhibit a microdeletion within chromosome 22q11.\nconstitutional 11q interstitial deletion syndrome presents with congenital anomalies including microcephaly with craniostenosis, minor dysmorphic features, vitreoretinopathy, and renal anomalies.\n. concerning the role of bcl11b in the immune system, extensive immune phenotyping of our patients revealed alterations in the t cell compartment and lack of peripheral type 2 innate lymphoid cells ( ilc2s ), consistent with the findings described in\na 15 - month - old girl with miller - dieker syndrome, a contiguous gene deletion syndrome involving chromosome 17p13. 3 and resulting in lissencephaly, was diagnosed with precursor b - cell acute lymphoblastic leukemia.\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function."
        },
        {
          "qas": [
            {
              "id": "5c6f6ae37c78d69471000054_001",
              "question": "Is Lasmiditan effective for migraine?"
            }
          ],
          "context": "classification of evidence this study provides class i evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.\nlasmiditan for the treatment of acute migraine : a review and potential role in clinical practice.\ninterpretation oral lasmiditan seems to be safe and effective in the acute treatment of migraine.\nfor the understanding of migraine pathophysiology, it is very important to note that a selective 5 - ht ( 1f ) receptor agonist like lasmiditan is effective in the acute treatment of migraine.\nalthough ongoing phase iii clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk.\n. research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.\n. furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg ( 40. 7 % vs 29. 5 % ; or 1. 6, 95 % ci 1. 3 - 2. 1, p < 0. 001 ) and lasmiditan 100 mg ( 40. 9 % ; or 1. 7, 95 % ci, 1. 3 - 2. 2, p < 0. 001 ) were free of their mbs at 2 hours\nthe 5 - ht1f receptor agonist lasmiditan, a drug acting through non - vasoconstrictive mechanisms, represents a promising safe, effective and tolerated acute migraine therapy also for patients at cardiovascular risk.\nlasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders.\nlasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine management."
        },
        {
          "qas": [
            {
              "id": "5c6d97497c78d69471000040_001",
              "question": "Are there graph kernel libraries available implemented in JAVA?"
            }
          ],
          "context": ". the core of all graph kernels is implemented in c + + for efficiency. using the kernel matrices computed by the package, we can easily perform tasks such as classification, regression and clustering on graph - structured samples.\n. graph kernels have been proposed as a powerful and efficient approach to this problem of graph comparison\n. here we provide graphkernels, the first r and python graph kernel libraries including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and the state - of - the - art weisfeiler - lehman graph\nand the state - of - the - art weisfeiler - lehman graph kernel\nmeasuring the similarity of graphs is a fundamental step in the analysis of graph - structured data, which is omnipresent in computational biology\n. the scripts are compatible with linux, mac os and the ms windows 10 subsystem for linux and are available as a graphical user interface, a web service at http : / / \" \" oplot. bioinf. be and command line tools.\n. the flexibility and power of spiralize are demonstrated by five examples from real - world datasets.\nthe library of integrated network - based cellular signatures ( lincs ) l1000 big data provide gene expression profiles induced by over 10 000 compounds, shrnas, and kinase inhibitors using the l1000 platform.\nrecently, resources such as the library of integrated network - based cellular signatures ( lincs ) l1000 database provide gene expression profiles induced by various chemical and genetic perturbations\nbackground : over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms"
        },
        {
          "qas": [
            {
              "id": "5c6df86b7c78d69471000045_001",
              "question": "Is baricitinib effective for rheumatoid arthritis?"
            }
          ],
          "context": "< b > objective < / b > : baricitinib is an orally administered inhibitor of jak1 and jak2 that has been shown to be effective in treating rheumatoid arthritis ( ra ).\nobjective baricitinib is an oral, once - daily selective janus kinase ( jak1 / jak2 ) inhibitor for adults with moderately to severely active rheumatoid arthritis ( ra ).\ntwo different janus kinase ( jak ) inhibitors - baricitinib and tofacitinib - are effective and licensed in active rheumatoid arthritis ( ra ).\nin february 2017, baricitinib was approved in the eu, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant\nin patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.\nexpert opinion jak inhibitors are effective in the treatment of rheumatoid arthritis as evidenced by several inhibitors enabling the majority of treated patients to achieve acr20 responses, with baricitinib and incb - 039110 both effective when\nthus, once - daily baricitinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated emerging treatment for patients with moderate to severe active ra who have responded inadequately to or are intolerant of\nconclusions : the efficacy and safety profile of baricitinib was maintained during long - term treatment of japanese patients with ra and background methotrexate therapy.\nbaricitinib is effective in treatment of ra, and did not appear to have significant safety concerns during the first 6 months of treatment.\nobjectives oral targeted synthetic disease - modifying anti - rheumatic drugs ( dmards ), including the janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis ( ra )."
        },
        {
          "qas": [
            {
              "id": "5c73acf27c78d6947100008a_001",
              "question": "Is Semagacestat effective for treatment of Alzheimer's disease?"
            }
          ],
          "context": "objective : semagacestat, a \u03b3 - secretase inhibitor, demonstrated an unfavorable risk - benefit profile in a phase 3 study of patients with alzheimer's disease ( identity trials ), and clinical development was halted.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nthe recent failure of semagacestat in two large phase iii studies questions the value of \u03b3 - secretase inhibitors in treating alzheimer's disease.\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nchanges in neuropsychiatric inventory associated with semagacestat treatment of alzheimer's disease. in participants with mild to moderate ad, high dose semagacestat treatment was associated with greater severity and faster worsening of nps in a\nconclusions : as compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.\na clinical trial with the wide - spectrum \u03b3 - secretase inhibitor semagacestat has, however, demonstrated that global inhibition of all \u03b3 - secretases causes serious toxicity.\nhowever, the preliminary equivocal cognitive results obtained with bapineuzumab as well as the detrimental cognitive effects observed with semagacestat, a potent \u03b3 - secretase inhibitor, raise the possibility that targeting a\u03b2 may not be clinically"
        },
        {
          "qas": [
            {
              "id": "5c840daf617e120c34000007_001",
              "question": "Does Rhamnose have any effect on aging?"
            }
          ],
          "context": "some of these mechanisms will be reviewed as well as the capacity of fucose - and rhamnose - rich oligo - and polysaccharides ( frop and rrop ) to counteract several of the mechanisms involved in skin aging.\nthe monosaccharide analysis showed that rhamnose ( rha ) and glucose ( glu ) may play vital roles in maintaining the antioxidant and anti - aging activities.\nas the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\n. reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\nwhich is consistent with an antifibrinolytic effect.\nand accumulation of undegraded glycosaminoglycans ( gags ), heparan sulfate, and dermatan sulfate\ncollagen is a fibrillar protein that conforms the conjunctive and connective tissues in the human body, essentially skin, joints, and bones\nit is also the most studied bee product, aimed at unravelling its bioactivities, such as antimicrobial, antioxidant, anti - aging, immunomodulatory, and general tonic action against laboratory animals, microbial organisms, farm animals, and clinical\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\npotential anti - inflammatory effects of hesperidin from the genus citrus."
        },
        {
          "qas": [
            {
              "id": "5c7d6b3e45e140a523000001_001",
              "question": "Is there any approved treatment for NAFLD?"
            }
          ],
          "context": "nonalcoholic fatty liver disease ( nafld ) has an increasing prevalence worldwide. at present, no specific pharmacotherapy is approved for nafld.\nnonalcoholic fatty liver disease ( nafld ) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy.\nnon - alcoholic fatty liver disease ( nafld ) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.\n. those with the progressive variant of nafld, non - alcoholic steatohepatitis ( nash ), are at significantly increased risk of multisystem morbidity and mortality. however, there are currently no approved pharmacologic therapies for nash.\nalthough much progress has been made in enhancing our understanding of nafld pathogenesis, development of pharmacologic treatments has been hindered by challenges in clinical trial enrollment and complexities in clinical trial design.\nrecently, a few systemic chemotherapies proved to be effective for advanced stage hcc in phase iii studies : lenvatinib as the first line of therapy, and regorafenib, cabozantinib, and ramucirumab as second - line therapy.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nresults : currently, the fda has approved several molecules for the treatment of obesity, both in monotherapy and in combination\npositive results in recent phase iii clinical trials have confirmed the high value of anti - angiogenic therapies for hcc in both first ( sorafenib and lenvatinib ) and second line ( regorafenib and cabozantinib ) treatment modalities.\nexpert opinion : based on favorable phase iii clinical trial data, sorafenib and lenvatinib are considered promising agents for hcc as first - line systemic chemotherapy"
        },
        {
          "qas": [
            {
              "id": "5c72bd047c78d69471000077_001",
              "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?"
            }
          ],
          "context": ". pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\npazopanib therapy for cerebellar hemangioblastomas in von hippel - lindau disease : case report. von hippel - lindau ( vhl ) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system ( cns ).\nvariable response of cns hemangioblastomas to pazopanib in a single patient with von hippel - lindau disease : case report.\n. we report the use of pazopanib in a patient with vhl disease for treatment of rcc who also harbored multiple cns hbs.\n. she was treated 24 months with pazopanib, a multityrosine kinase inhibitor ( tki ) targeting vegf and pdgf - \u03b2 pathways.\nrecurrent multiple cns hemangioblastomas with vhl disease treated with pazopanib : a case report and literature review. hemangioblastoma is a rare benign neoplasm, accounting for less than 2 % of all primitive brain tumors.\ncabozantinib in the treatment of hepatocellular carcinoma.\nsingle - agent pazopanib did not prolong pfs in this patient population but showed in situ biological activity as demonstrated by radiographic responses.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo."
        },
        {
          "qas": [
            {
              "id": "5c89461675a4a5d219000013_001",
              "question": "Is Netrin-1 a secreted protein?"
            }
          ],
          "context": "netrin - 1, a multifunctional secreted protein, is up - regulated in cancer and inflammation.\nnetrin - 1, a laminin - related secreted protein, displays proto - oncogenic activity in cancers.\nnetrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nthe axon guidance cues netrin - 1 is a secreted protein overexpressed in many different cancer tissues\nnetrins are a family of secreted protein related to laminin and act as tropic cues directing axon growth and cell migration during neural development.\netrin - 1 is a laminin - related secreted protein, is highly induced after tissue injury, and may serve as a marker of injury.\nhydin was recently identified as an axonemal protein ; however, its function is as yet unknown.\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\nwe show that menin physically interacts with proteins involved in the canonical wnt signaling pathway, including beta - catenin, tcf3 ( tcfl1 ), and weakly with tcf4 ( tcfl2 ).\nprecise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility."
        },
        {
          "qas": [
            {
              "id": "5c62a529e842deac6700000b_001",
              "question": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?"
            }
          ],
          "context": ". around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n. here, we show that clusters of cnes strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains ( tads ) in human and drosophila\nalthough similar structures appear to be conserved in fission yeast, computational modeling and analysis of high - throughput chromosome conformation capture ( hi - c ) data have been used to argue that the small, highly constrained budding yeast\nthat the small, highly constrained budding yeast chromosomes could not have these structures\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\n. in contrast, herein we analyze hi - c data for budding yeast and identify 200 - kb scale tads, whose boundaries are enriched for transcriptional activity\n. thus, our work defines spatial organization within the budding yeast nucleus, demonstrates the conserved role of genome architecture in regulating dna replication, and identifies a molecular mechanism specifically regulating interactions between"
        },
        {
          "qas": [
            {
              "id": "5c72a5ca7c78d6947100006d_001",
              "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?"
            }
          ],
          "context": "continuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\nan understanding of the mechanism on the interaction of gm1 and a\u03b2s in ad may contribute to the development of new neuroregenerative therapies for this disorder.\nrecently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\nits product gingipain is / are translocated to the brain.\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects."
        },
        {
          "qas": [
            {
              "id": "5c72f8557c78d69471000080_001",
              "question": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?"
            }
          ],
          "context": "miller - dieker syndrome ( mds, chromosome 17p13. 3 microdeletion ).\nmiller - dieker syndrome with der ( 17 ) t ( 12 ; 17 ) ( q24. 33 ; p13. 3 ) pat presenting with a potential risk of mis - identification as a de novo submicroscopic deletion of 17p13. 3.\nthe miller - dieker syndrome, a disorder of neuronal migration, is caused by deletions of chromosome 17p13. 3.\nand thus combines abnormalities of chromosome 15 associated with the prader - willi syndrome and of chromosome 17 associated with the miller - dieker syndrome.\nthe miller - dieker syndrome ( type i lissencephaly ) is a neuronal migration disorder which is associated with microdeletions in the short arm of chromosome 17.\nmiller - dieker syndrome and trisomy 5p in a child carrying a derivative chromosome with a microdeletion in 17p13. 3 telomeric to the lis1 and the d17s379 loci.\nfamilial miller - dieker syndrome associated with pericentric inversion of chromosome 17.\nthus, we propose that monosomy of distal 17p may be the cause of miller - dieker syndrome in some patients.\nmiller - dieker syndrome ( mds ) is caused by a heterozygous deletion of chromosome 17p13. 3 involving the genes lis1 and ywhae ( coding for 14. 3. 3\u03b5 ) and leads to malformations during cortical development.\nthe miller - dieker syndrome ( mds ), composed of characteristic facial abnormalities and a severe neuronal migration disorder affecting the cerebral cortex, is caused by visible or submicroscopic deletions of chromosome band 17p13."
        },
        {
          "qas": [
            {
              "id": "5c93e6a1ecadf2e73f00001b_001",
              "question": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?"
            }
          ],
          "context": "interplay between rnaseh2 and mov10 controls line - 1 retrotransposition.\ncircular retrotransposition products generated by a line retrotransposon\npausing, with ldb1 regulating recruitment of metastasis - associated 1 family, member 2, a component of the nucleosome remodeling deacetylase complex, on these negative enhancers, required for the repressive enhancer function.\nwe propose that such an r - loop dependent cirna degradation likely represents a mechanism that on one hand limits cirna accumulation by recruiting rnase h1 and on the other hand resolves r - loops for transcriptional elongation at some gc - rich\nsatb1 binds to the ase and rag promoters, facilitating inclusion of rag2 in the chromatin hub and the loading of rna polymerase ii to both the rag1 and rag2 promoters.\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\neffect on the stability and translational rate of mrnas.\nof posttranscriptional tpr gene silencing by rna interference ( rnai ).\nthis study aimed to explore the regulatory mechanism of methyltransferase3 ( mettl3 ) - mediated long non - coding rna ( lncrna ) n6 - methyladenosine ( m6a ) modification in the osteogenic differentiation of human adipose - derived stem cells ( hascs ) induced by\n. here, we demonstrate that standard protocols involving rnase r can fail to digest > 20 % of all highly expressed linear rnas, but these shortcomings can largely be overcome."
        },
        {
          "qas": [
            {
              "id": "5c8cfca70101eac870000005_001",
              "question": "Has the protein SIRT2 been associated to cervical cancer?"
            }
          ],
          "context": "a progressive increase in the expression of both sirt2 and sirt7 was noted during cancer progression in the following order : normal < preneoplasia < cancer.\nwe demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation.\npecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\nasporin has been reported as a tumor suppressor in breast cancer, while asporin - activated invasion has been described in gastric cancer.\nthe special at - rich sequence binding protein 1 ( satb1 ) and its role in solid tumors.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\nthe pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\nselenocysteine ( sec ) is a naturally available se - containing amino acid that displays splendid anticancer activities against several human tumors."
        },
        {
          "qas": [
            {
              "id": "5c6438a5e842deac67000016_001",
              "question": "Are recessive coding variants responsible for the majority of undiagnosed nonconsanguineous individuals?"
            }
          ],
          "context": "our results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\nclinical genetic testing of protein - coding regions identifies a likely causative variant in only around half of developmental disorder ( dd ) cases\n. our analyses show that non - coding variants upstream of genes within which coding variants are known to cause dd are an important cause of severe disease and demonstrate that analyzing 5'utrs can increase diagnostic yield\n. we also show how non - coding variants can help inform both the disease - causing mechanism underlying protein - coding variants and dosage tolerance of the gene.\n. the contribution of regulatory variation in non - coding regions to rare disease, including dd, remains very poorly understood\n. we estimate that, genome - wide, 1 - 3 % of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain - active regulatory elements and that only 0. 15 % of all possible mutations within highly conserved fetal\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\ngenome - wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or dna mutations, only explained a minority of the expected heritable fraction\nand allowing for genotype - based prediction of risk of recurrence in some nonsyndromic families."
        },
        {
          "qas": [
            {
              "id": "5c6445f0e842deac67000017_001",
              "question": "Is the NLM medical text indexer (MTI) still useful and relevant?"
            }
          ],
          "context": ". the nlm medical text indexer ( mti ) is the main product of this project and has been providing automated indexing recommendations since 2002\n. the role of mti at nlm is also expanding into new areas, further reinforcing the idea that mti is increasingly useful and relevant.\n. after all of this time, the questions arise whether mti is still useful and relevant. methods : to answer the question about mti usefulness, we track a wide variety of statistics related to how frequently medline indexers refer to mti\nrecommendations over the years from 15. 75 % of the articles they index in 2002 to 62. 44 % in 2014 showing that the indexers find mti to be increasingly useful\nto how frequently medline indexers refer to mti recommendations, how well mti performs against human indexing, and how often mti is used\nbased on our findings, yes, mti is still relevant and useful, and needs to be improved and expanded.\n. mti performed well in both of the bioasq challenges ranking within the top tier teams. conclusions : based on our findings, yes, mti is still relevant and useful, and needs to be improved and expanded\n. this cross - library team's mission is to explore indexing methodologies for ensuring quality and currency of nlm document collections\n. the mti performance statistics show significant improvement in precision ( + 0. 2992 ) and f1 ( + 0. 1997 ) with modest gains in recall ( + 0. 0454 ) over the years. mti consistency is comparable to the available indexer consistency studies\n. the bioasq challenge results have shown that we need to incorporate more machine learning into mti while still retaining the indexing rules that have earned mti the indexers'trust over the years"
        },
        {
          "qas": [
            {
              "id": "5c8972d4d558e5f232000006_001",
              "question": "Has strimvelis been approved by the European Medicines Agency?"
            }
          ],
          "context": "strimvelis ( autologous cd34 + cells transduced to express adenosine deaminase [ ada ] ) is the first ex vivo stem cell gene therapy approved by the european medicines agency ( ema ), indicated as a single treatment for patients with ada - severe combined\nreceived marketing approval in the united states and japan for the treatment of ssc - ild.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\nin august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\ntreatment for patients with ada - severe combined immunodeficiency ( ada - scid ) who lack a suitable matched related bone marrow donor.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis."
        },
        {
          "qas": [
            {
              "id": "5c83f858617e120c34000003_001",
              "question": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?"
            }
          ],
          "context": "bacillus calmette - guerin immunotherapy for bladder cancer. bacillus calmette - guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer.\nintravesical bacillus calmette - guerin is used to treat patients with superficial bladder cancer.\nbacillus of calmette - guerin ( bcg ) therapy for high risk non muscle invasive bladder cancer treatment in older patients.\nintravesical administration of bacillus calmette - guerin has been shown to be highly effective treatment of superficial bladder cancer.\nbcg ( bacillus of calmette guerin ) therapy of high - risk superficial bladder cancer.\npurpose bacillus calmette - guerin is the most effective therapy for nonmuscle invasive bladder cancer.\nintravesical bacillus calmette - guerin therapy for superficial bladder cancer : effect of bacillus calmette - guerin viability on treatment results. we treated 40 patients with superficial bladder cancer via intravesical bacillus calmette - guerin for 1 )\nintravesical bacillus calmette - guerin is a viable therapeutic option in patients with high risk superficial bladder cancer and concomitant lymphoma or chronic lymphocytic leukemia, treatment with low dose oral steroids or treatment with inhaled\nwe review how the bacillus calmette - guerin vaccine evolved to become standard therapy for superficial bladder cancer.\na randomized controlled prospective evaluation of intravesical and percutaneous bacillus calmette - guerin immunotherapy was done in 57 patients with transitional cell carcinoma of the bladder."
        },
        {
          "qas": [
            {
              "id": "5c73acf17c78d69471000089_001",
              "question": "Is eculizumab used for treatment of myasthenia gravis?"
            }
          ],
          "context": "eculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\nthe 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the us food and drug administration for myasthenia gravis.\nsafety and efficacy of eculizumab in anti - acetylcholine receptor antibody - positive refractory generalised myasthenia gravis ( regain ) : a phase 3, randomised, double - blind, placebo - controlled, multicentre study.\nrituximab seems to be particularly effective in musk myasthenia gravis, and eculizumab arises as an option in refractory achr myasthenia gravis.\na randomized, double - blind, placebo - controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\n< b > introduction < / b > : a phase 2 study of eculizumab for treating myasthenia gravis ( mg ) used the quantitative myasthenia gravis score ( qmg ) and myasthenia gravis activities of daily living profile ( mg - adl ) to evaluate baseline disease severity and\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\neculizumab treatment improved symptoms compared with placebo in a phase ii study in patients with refractory gmg. d\ninterpretation : efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis."
        },
        {
          "qas": [
            {
              "id": "5c928afeecadf2e73f000018_001",
              "question": "Can cardiospheres be produced from skin fibroblasts?"
            }
          ],
          "context": "here we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\nmultipotent mesenchymal bone marrow - derived stem cells\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\nadipose - derived stem cells ( hascs ) induced by nel - like 1 protein ( nell - 1 ).\nmultipotent hesc - derived mesenchymal cells ( mcs )\nhere, we comprehensively characterize mouse cardiac progenitor cells ( cpcs ) marked by nkx2 - 5 and isl1 expression from e7. 5 to e9. 5 using single - cell rna sequencing and transposase - accessible chromatin profiling ( atac - seq ).\nall three fibroblast populations were pdgfr\u03b1 + / cd34 + but were distinct in their expression of ngfr / spon2 / angptl7 ( f1 ), cxcl14 / smoc2 / rgs2 ( f2 ), and clec3b / col14a1 / mmp3 ( f3 ), with potential functions in the regulation of immune responses, response to\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\ncurrent evidence suggests that es cells maintain their pluripotent state by expressing a battery of transcription factors including oct4 and nanog.\nvariants with gene expression from these cultured cells"
        },
        {
          "qas": [
            {
              "id": "5c73ad347c78d69471000098_001",
              "question": "Does Axitinib prolong survival of Pancreatic Cancer patients?"
            }
          ],
          "context": "interpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.\nhowever, as with other tyrosine kinase inhibitors of the same class, axitinib does not prolong overall survival ; therefore, selection of second - line tyrosine kinase inhibitor therapy, including axitinib, must be carefully considered to maximize\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nresults : among japanese patients, median overall survival was not estimable ( 95 % confidence interval, 7. 4 months - not estimable ) with axitinib / gemcitabine ( n = 58 ) and 9. 9 months ( 95 % confidence interval, 7. 4 - 10. 5 ) with placebo / gemcitabine ( n = 56 )\n. median overall survival was 8 \u00b7 5 months ( 95 % ci 6 \u00b7 9 - 9 \u00b7 5 ) for gemcitabine plus axitinib ( n = 314, data missing for two patients ) and 8 \u00b7 3 months ( 6 \u00b7 9 - 10 \u00b7 3 ) for gemcitabine plus placebo ( n = 316 ; hazard ratio 1 \u00b7 014, 95 % ci 0 \u00b7 786 - 1 \u00b7 309 ; one - sided p = 0 \u00b7 5436 ).\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\n. 5. 4 months ( 1. 8 - 10. 5 ) with placebo / gemcitabine. similarly, no difference was detected in overall survival between axitinib / gemcitabine and placebo / gemcitabine in patients from north america or the european union.\nprolonging the survival of small cell lung cancer patients.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy."
        },
        {
          "qas": [
            {
              "id": "5c5217fd7e3cb0e231000005_001",
              "question": "Is there any association between suicide and autism in adolescents, yes or no?"
            }
          ],
          "context": "of subjects supported for suicidal thoughts or attempted suicide exhibited an autism spectrum disorder ( 62 out of 806 subjects ), all ages combined.\nof subjects supported for suicidal thoughts or attempted suicide exhibited an autism spectrum disorder ( 62 out of 806 subjects ), all ages combined.\nrisk of suicide attempts among adolescents and young adults with autism spectrum disorder : a nationwide longitudinal follow - up study.\ndetection of suicidality in adolescents with autism spectrum disorders\nalthough the suicide risk of autism spectrum disorder ( asd ) has been suggested to be higher than previously recognized, there are few case reports focusing on the process for preventing suicide reattempts.\nsuicide is a major problem in western society. however we have very little understanding of suicidal behaviour among individuals with autism spectrum disorders.\n: in all subjects from our research on pubmed, 21. 3 % of subjects with autism spectrum disorder reported suicidal ideation, have attempted suicide or died by suicide ( 115 out of 539 subjects ) and 7. 7 % of subjects supported for suicidal thoughts or\nthe suicidal behaviors are frequently observed in the adolescents and adults with an asd without intellectual deficience.\nthe emerging studies indicate that the increased risk of self - injurious behavior in younger and less cognitively able children with asd3, 4 is matched by an increased risk of suicidality in those at a more advanced developmental level.\nconsistent with the previous findings, rate of suicidality is higher in individuals with asd"
        },
        {
          "qas": [
            {
              "id": "5c8c05c70101eac870000001_001",
              "question": "Is lactotransferrin a tumour suppressor?"
            }
          ],
          "context": "lactotransferrin ( ltf ) has been confirmed to act as a tumor suppressor in multiple cancers\nthe tumor suppressor function of lactotransferrin ( ltf ) has been reported in a variety of tumors, including gc, nasopharyngeal carcinoma ( npc ) and prostate cancer.\nlactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing akt through multiple mechanisms.\nltf is likely to be a candidate tumor suppressor and downregulates the development of npc by inhibiting npc proliferation through induction of cell cycle arrest and modulation of the mapk signaling pathway.\nwe previously reported that ltf is significantly down - regulated in nasopharyngeal carcinoma ( npc ) and acts as a tumor suppressor by suppressing akt signaling.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\npten is a potent tumour suppressor\nwe have previously identified a silencer ( negative enhancer ) in glutathione transferase p ( gst - p ) gene which is strongly and specifically induced during hepatocarcinogenesis of the rat.\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity"
        },
        {
          "qas": [
            {
              "id": "5c6ad3be7c78d69471000021_001",
              "question": "Are there tools for visualizing and processing long-read sequencing data?"
            }
          ],
          "context": "variant review with the integrative genomics viewer.\nhere we describe nanopack, a set of tools developed for visualization and processing of long - read sequencing data from oxford nanopore technologies and pacific biosciences. availability and implementation : the nanopack tools are written in python3 and\n. we developed the variant inspector and expert rating tool ( viper ) to speed up this process by integrating the integrative genomics viewer into a web application\n. many tools have been developed to analyze genomic variation ranging from single nucleotide variants to whole chromosomal aberrations. as sequencing throughput increases, the number of variants called by such tools also grows\n. to facilitate the investigation of unique ucss, the ucsc genome browser was utilized to visualize the chromosomal position and related annotations of ucss in s. cerevisiae genome.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\nthods : we present genome - wide single - cell chromatin accessibility profiles in > 1, 600 cells derived from a human pancreatic islet sample using single - cell combinatorial indexing atac - seq ( sci - atac - seq ). w\nthis paper presents scasat ( single - cell atac - seq analysis tool ), a complete pipeline to process scatac - seq data with simple steps.\n. new methods for analyzing the data and evaluating results are needed. results : we offer bagel ( bayesian analysis of gene essentiality ), a supervised learning method for analyzing gene knockout screens\nsingle - cell sequencing assay for transposase - accessible chromatin ( scatac - seq ) is the state - of - the - art technology for analyzing genome - wide regulatory landscapes in single cells."
        },
        {
          "qas": [
            {
              "id": "5c674eac7c78d6947100001b_001",
              "question": "Has Hesperidin any role as a Neuroprotective Agent?"
            }
          ],
          "context": "emerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\nhesperidin, a flavanoglycone abundantly present in citrus fruits, is reported to have antioxidant, anti - inflammatory, and neuroprotective properties.\nneuroprotective effects of hesperidin on cerebral vasospasm\nhesperidin inhibits glutamate release and exerts neuroprotection against excitotoxicity induced by kainic acid in the hippocampus of rats.\nneuroprotective effect of hesperetin and o - hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of alzheimer's disease\nthe neuroprotective effect of hesperidin in nmda - induced retinal injury acts by suppressing oxidative stress and excessive calpain activation.\npotential neuroprotective effects of hesperidin on 3 - nitropropionic acid - induced neurotoxicity in rats.\nantioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. the present study evaluated antioxidant and neuroprotective activities of hesperidin, a flavanone mainly isolated from citrus fruits, and its aglycone hesperetin using\nhesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole - induced convulsions in mice : possible behavioral, biochemical and mitochondrial alterations. hesp possesses potent anticonvulsant activity which\ncytoprotective effects of hesperetin and hesperidin against amyloid \u03b2 - induced impairment of glucose transport through downregulation of neuronal autophagy."
        },
        {
          "qas": [
            {
              "id": "5c8857e975a4a5d219000009_001",
              "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?"
            }
          ],
          "context": "the apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\ntreatment with memantine, a noncompetitive nmda receptor antagonist which is an approved drug for treatment of alzheimer's disease, rescued protein phosphatase - 2a activity by decreasing its demethylation at leu309 selectively and attenuated\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\naccumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\nl - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nverubecestat is an inhibitor of \u03b2 - site amyloid precursor protein cleaving enzyme 1 ( bace1 ) being evaluated in clinical trials for the treatment of alzheimer's disease."
        },
        {
          "qas": [
            {
              "id": "5c6d9a157c78d69471000041_001",
              "question": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?"
            }
          ],
          "context": ". these intrinsically disordered regions ( idrs ) participate in binding events through regions called molecular recognition features ( morfs ). computational prediction of morfs helps identify the potentially functional regions in idrs\n. key to their biological function are the molecular recognition features ( morfs ) located within long disordered regions. computationally identifying these morfs from disordered protein sequences is a challenging task\n. these idps expose short binding regions called molecular recognition features ( morfs ) that permit interaction with structured protein regions\n. molecular recognition features ( morfs ) are segments of intrinsically disordered regions that bind to partner proteins, where binding is concomitant with a transition to a structured conformation\n. predicting these morfs in disordered protein sequences is a challenging task. method : in this study, we present morfpred - plus, an improved predictor over our previous proposed predictor to identify morfs in disordered protein sequences\nopal : prediction of morf regions in intrinsically disordered protein sequences.\nmorfpred - plus : computational identification of morfs in protein sequences using physicochemical properties and hmm profiles.\nintrinsically disordered proteins and regions are involved in a wide range of cellular functions, and they often facilitate protein - protein interactions\n. in this study, we present a new morf predictor, opal, to identify morfs in disordered protein sequences. opal utilizes two independent sources of information computed using different component predictors\n. morfs facilitate translation, transport, signaling, and regulatory processes and are found across all domains of life. a popular computational tool, morfpred, accurately predicts morfs in protein sequences"
        },
        {
          "qas": [
            {
              "id": "5c97a08becadf2e73f000029_001",
              "question": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?"
            }
          ],
          "context": "submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and di george syndrome.\nthe deletion of chromosome 22q11. 2 is involved in the majority of digeorge or velo - cardiofacial syndrome.\n< b > unlabelled < / b > : most of the children with di george syndrome and 60 % of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.\n22q11. 2ds has several presentations including di george's syndrome, velo - cardio - facial syndrome or shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population ( prevalence estimated at 1 / 4000 births, de novo :\nthe 22q11. 2 deletion syndrome ( di george syndrome ) is one of the most prevalent genetic disorders.\nthe miller - dieker syndrome ( mds ), composed of characteristic facial abnormalities and a severe neuronal migration disorder affecting the cerebral cortex, is caused by visible or submicroscopic deletions of chromosome band 17p13.\ndi george syndrome due to mutation on 22q or 10q ) and can also result from microdeletion or point mutation ( in the shprintzen syndrome 70 % represent microdeletion and 30 % point mutation at 22q11, in rubinstein - taybi syndrome 10 % cases result from\ndeletions of chromosome 7q11. 23 ( williams syndrome ), 15q11 - q13 ( angelman syndrome, prader - willi syndrome ) and 22q11 ( di george syndrome )\nthe miller - dieker syndrome, a disorder of neuronal migration, is caused by deletions of chromosome 17p13. 3.\nsyndrome exhibit a microdeletion within chromosome 22q11."
        },
        {
          "qas": [
            {
              "id": "5c8ab614d558e5f23200000d_001",
              "question": "Is the protein Asporin related to disease?"
            }
          ],
          "context": "asporin has been reported as a tumor suppressor in breast cancer, while asporin - activated invasion has been described in gastric cancer.\naccumulating evidence demonstrates the involvement of asporin in oa pathogenesis.\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nour results suggest that aspn is a stromally expressed biomarker that correlates with disease progression, and is observed in reactive stroma.\neach of these species was present at very low copy numbers in primary and cultured cells ; however, only the expression of anril isoforms containing exons proximal to the ink4 / arf locus correlated with the asvd risk alleles.\nexpression of \u03b1 - taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.\nnetrin - 1, a multifunctional secreted protein, is up - regulated in cancer and inflammation.\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\nthe sod1 gene encoding the superoxide dismutase 1 ( sod1 ) protein is mutated in approximately 15 % of familial amyotrophic lateral sclerosis ( als ) and 3 % of sporadic als.\nnetrin - 1, a laminin - related secreted protein, displays proto - oncogenic activity in cancers."
        },
        {
          "qas": [
            {
              "id": "5ca61176ecadf2e73f00004e_001",
              "question": "Can TAD disruption lead to disease?"
            }
          ],
          "context": "recent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\nwe demonstrate that disruption of tads can rewire long - range regulatory architecture and result in pathogenic phenotypes.\nrecent studies have shown that tad disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.\ntad boundaries are insulators of genomic neighborhoods. in this issue, sun et al. show that disease - associated tandem repeats are located to tad boundaries and affect their insulation.\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n. here, we show that clusters of cnes strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains ( tads ) in human and drosophila\nits perturbation will lead to human disease, highlighting the accumulating evidence that links the diverse 3d genome architecture components to a multitude of human diseases and the emerging mechanisms by which 3d genome derangement causes disease\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\ndisruption of a tad boundary causes ectopic chromosomal contacts and long - range transcriptional misregulation.\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture."
        },
        {
          "qas": [
            {
              "id": "5c8908a475a4a5d21900000c_001",
              "question": "Is L-4F an apoE mimetic peptide?"
            }
          ],
          "context": "l - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nthe transmembrane lipoprotein phospholemman ( fxyd1 )\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\nthe main ligand binding site of lfa - 1 is the i - domain, which recognizes intercellular adhesion molecules ( icams ), members of the immunoglobulin superfamily.\ndemonstrating antiatherothrombotic properties of dipeptidyl peptidase - 4 inhibitors on proven markers is of substantial clinical significance"
        },
        {
          "qas": [
            {
              "id": "5c890c3375a4a5d21900000e_001",
              "question": "Can oleuropein aglycone interfere with amyloid aggregation?"
            }
          ],
          "context": ". it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\noleuropein, a phenolic secoiroid glycoside, is the main polyphenol in the olive oil\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\n. reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\ncytoprotective effects of hesperetin and hesperidin against amyloid \u03b2 - induced impairment of glucose transport through downregulation of neuronal autophagy.\n. we have combined available genomics data with a comprehensive proteomics approach to get the annotated olive tree ( olea europaea l. ) pollen proteome and define its complex allergenome.\n. these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\naccumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\ntogether, these results suggest that eue and its active components enhance lysosomal activity, resulting in decreased er stress and hepatic dyslipidemi\nmoreover, we observed an in vitro - inhibition of human neutrophil elastase, a protease involved in the inflammatory process, by extracts and fractions from yarrow, which suggests additional mechanisms of antiphlogistic action."
        },
        {
          "qas": [
            {
              "id": "5caa0806ecadf2e73f000057_001",
              "question": "Is Apelin usually decreased in diabetes?"
            }
          ],
          "context": ". moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.\napelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\n. 5. 1 % / year, p < 0. 001 ). < br > < b > conclusions < / b > : plasma apelin is a novel biomarker for predicting type 2 diabetes in men. < br >\nin men at risk for diabetes ( hba1c 5. 7 - 6. 4 %, fpg 100 - 125mg / dl, or ogtt - 2h - pg 140 - 199mg / dl ), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations ( 10. 6 % / year\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\nrare variants in pparg with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\nc - peptide ) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.\nc - peptide ) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children."
        },
        {
          "qas": [
            {
              "id": "5ca0fdb0ecadf2e73f000049_001",
              "question": "Is actin present in the nucleus?"
            }
          ],
          "context": "while it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.\nthe revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin.\nthe discovery of nuclear actin opened new perspective on the field, suggesting that the nuclear activities of actin reflect the functions of primordial actin - like proteins.\nour findings establish that nuclear actin - based mobility shapes chromatin organization by generating repair domains that are essential for homology - directed repair in eukaryotic cells.\nthe dna - organizing mechanism of condensin depends on the energy of atp hydrolysis but how this activity specifically promotes proper compaction and segregation of chromosomes during mitosis remains poorly understood.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\n. functional studies using fibroblast cells from two affected individuals with the c. 1516c > t mutation showed a truncated wasf1 and a defect in actin remodeling\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\n. in eukaryotic systems, however, a yeast initiator trna aminoacylated with isoleucine was found to be inactive in initiation in mammalian cell extracts."
        },
        {
          "qas": [
            {
              "id": "5c8fea130101eac87000000d_001",
              "question": "Can miR-122 target RUNX2?"
            }
          ],
          "context": "mir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nour study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis.\nmesenchymal - epithelial transition in sarcomas is controlled by the combinatorial expression of microrna 200s and grhl2.\nwe found that : i ) the circrna expression profile revealed 1, 285 significant differences in circrna expression, with circrna expression downregulated in 594 samples and upregulated in 691 samples via interactions with mirnas.\nube4b might act as an oncogene in regulating rcc development. therefore it could be served as an effective indicator to predict os and a potential biomarker for targeted therapy of rcc patients.\nhowever, other genes such as the proto - oncogene c - myc are promising targets for anticancer therapy\nlb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition"
        },
        {
          "qas": [
            {
              "id": "5c960d88ecadf2e73f00001f_001",
              "question": "Tocilizumab is an anti-TNF antibody, yes or no?"
            }
          ],
          "context": "tocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\ntocilizumab ( tcz ; roactemra\u00ae or actemra\u00ae ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin 6 ( il - 6 ) receptor antagonist.\ntocilizumab ( tcz ), is a recombi \" \" t humanized anti - interleukin - 6 receptor ( il - 6r ) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis ( sjia ) and polyarticular juvenile idiopathic\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\ntocilizumab ( roactemra or actemra ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin ( il ) - 6 receptor antagonist.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab ( tcz ) is a humanized monoclonal antibody against il - 6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult ra populations\ntocilizumab ( roactemra ( \u00ae ) ; actemra ( \u00ae ) ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin - 6 receptor antagonist.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6."
        },
        {
          "qas": [
            {
              "id": "5c9e6ab9ecadf2e73f000035_001",
              "question": "Is it possible to analyze exosomes with FACS?"
            }
          ],
          "context": "we used a novel strategy for generating metabolically - labeled fluorescent exosomes that can be counted by flow cytometry assay ( facs ) and characterized.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwhose presence was validated by a bead - exosome facs assay.\n. cell apoptosis was tested by caspase - 3 / - 9 activity assay, histone dna elisa assay, annexin v facs assay and tunel staining assay. cell cycle progression was tested by propidium iodide ( pi ) facs assay. signaling was tested by western blotting assay\nsingle - cell sequencing assay for transposase - accessible chromatin ( scatac - seq ) is the state - of - the - art technology for analyzing genome - wide regulatory landscapes in single cells.\nsingle - cell atac - seq ( scatac - seq ) technology has also been developed to study cell type - specific chromatin accessibility in tissue samples containing a heterogeneous cellular population.\nthe results demonstrated these exosomes all expressed cd9, cd63, cd81, alix\nhere we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta\nexpressed exosomal marker tumor susceptibility gene ( tsg ) 101 and flotillin ( flot ) 1."
        },
        {
          "qas": [
            {
              "id": "5c915e51ecadf2e73f00000c_001",
              "question": "Can prevnar 13 be used in children?"
            }
          ],
          "context": "based on published immunogenicity and safety data, as well as the recent recommendations by the acip for routine use in infants and indications for high - risk pediatric patients, pcv13 is a revised formulation of pneumococcal vaccine that should be\npasteur ), became available in the us during the 2011 - 2012 influenza season for adults 18 - 64 years of age\nin this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of dtap ( 5 ) coadministered with ipv and hib vaccines or 1 lot of dtap ( 5 ) - ipv - hib combination vaccine.\nten pneumococcal vaccine serotypes, protein d, antipolyribosyl - ribitol phosphate, antidiphtheria, antitetanus, and antipertactin.\nand toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth ( preschool ) dtap ( 5 ) dose.\nof pneumococcal vaccine that should be included on pharmacy formularies.\nrotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\nwith the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine - preventable disease among children in the eu\nconclusions norway achieved a high national coverage and excellent adherence with the strict age limits for rotavirus vaccine administration during the first year of introduction, indicating robustness of the national immunisation programme.\ntetanus, 5 - component acellular pertussis vaccine [ dtap ( 5 ) ; daptacel ], inactivated poliovirus vaccine [ ipv ; ipol ], and haemophilus influenzae type b [ hib ] vaccine [ acthib ] ), when administered to infants and toddlers concomitantly with other routinely"
        },
        {
          "qas": [
            {
              "id": "5c9160bcecadf2e73f00000d_001",
              "question": "Was stelara developed by Amgen?"
            }
          ],
          "context": "nice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\ntocilizumab ( actemra ; genentech, inc ) is the first biologic therapy targeting the cytokine interleukin 6 ( il - 6 ).\n. food and drug administration ( fda ) approved novartis'tisagenlecleucel ( ctl - 019, kymriah ), which is a synthetic bioimmune product of anti - cd19 chimeric antigen receptor ( car ) t cells, for the treatment of relapsed / refractory b - cell acute\n. clinical development is underway in the usa, europe and japan for autoimmune disorders, chronic lymphocytic leukaemia, b cell lymphoma, sjogren's syndrome, pemphigus and rheumatoid arthritis\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\nst implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with sle, specifically lupus nephritis. by targ\nthis article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\nintroduction : deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a phase 2 clinical trial of adults with moderate to severe plaque psoriasis."
        },
        {
          "qas": [
            {
              "id": "5c9e766becadf2e73f000038_001",
              "question": "Can mitochondria pass through membrane nanotubes?"
            }
          ],
          "context": ". our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\ninterest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\nmembrane \" \" otubes ( mnts ) act as \" highways \" between cells to facilitate the transfer of multiple signals and play an important role in many diseases\nmembrane \" \" otubes play important functional roles in numerous cell activities such as cellular transport and communication.\nwe show evidence that mitochondria transfer from jurkat cells to mscs, which is mediated by cell adhesion\nthus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\ncardenolides have shown significant antitumor activity due to their ability to inhibit the na + k + atpase enzyme, and the expression of this enzyme is increased in tumor cells.\nthese findings are valuable to the design and rationale behind the possible targeted drug delivery to specific cellular organelles using gros.\natp - binding cassette ( abc ) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs."
        },
        {
          "qas": [
            {
              "id": "5c9f1b0cecadf2e73f00003c_001",
              "question": "Are protamines ubiquitously expressed?"
            }
          ],
          "context": "protamines are nuclear proteins which are specifically expressed in haploid male germ cells.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nhu proteins are rna - binding proteins that are implicated in the control of stabilization, nuclear export, and / or translation of specific mrnas with au - rich elements ( ares ) in the 3'- untranslated region. th\nwhile it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.\nin many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by pr domain - containing protein 9 ( prdm9 ).\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\nhu proteins have been shown to bind to au - rich elements ( ares ) in the 3'- untranslated region of unstable mrnas.\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\nthe auf1 ( hnrnpd ) and hur ( elav - like ) proteins, potential trans - acting factors for regulated mrna decay, bind in vitro to a + u - rich elements ( ares ) found in the 3'untranslated region ( 3'utr ) of many labile transcripts.\nmost mature proteins do not retain their initial n - terminal amino acid ( methionine in the cytosol and n - formyl methionine in the organelles )."
        },
        {
          "qas": [
            {
              "id": "5c891d5075a4a5d219000011_001",
              "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?"
            }
          ],
          "context": ". reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\n. the aim of this study was to in vitro and in vivo investigate the mechanism ( s ) by which crocus sativus exerts its positive effect against ad.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\nemerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nneuroprotective effect of hesperetin and o - hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of alzheimer's disease\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\ndiseases avoiding the growth of toxic oligomers and displaying protection against cognitive deterioration."
        },
        {
          "qas": [
            {
              "id": "5ca0848aecadf2e73f000044_001",
              "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?"
            }
          ],
          "context": ". new fda - approved therapies for ad are crisaborole and dupilumab.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\ndupilumab is the first biological treatment approved for moderate - to - severe atopic dermatitis ( ad ).\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\ntreatment with memantine, a noncompetitive nmda receptor antagonist which is an approved drug for treatment of alzheimer's disease, rescued protein phosphatase - 2a activity by decreasing its demethylation at leu309 selectively and attenuated\nin march of 2017, the united states food and drug administration ( fda ) approved dupilumab for the treatment of moderate - to - severe atopic dermatitis in adults that is uncontrolled with topical medications, becoming the first biologic agent approved to"
        },
        {
          "qas": [
            {
              "id": "5c891e5575a4a5d219000012_001",
              "question": "Do Crocus sativus extracts loosen the blood-brain barrier?"
            }
          ],
          "context": "crocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n. reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\n. the aim of this study was to in vitro and in vivo investigate the mechanism ( s ) by which crocus sativus exerts its positive effect against ad.\npotential anti - inflammatory effects of hesperidin from the genus citrus.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nemerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\nconclusion : cerebrolysin injection during the acute period of sah appeared to reduce the mortality rate, especially in poor - grade patients. this study suggests the potential of cerebrolysin for treating aneurysmal sah\nmicrobubbles in combination with focused ultrasound for the delivery of quercetin - modified sulfur oparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat alzheimer's disease.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >"
        },
        {
          "qas": [
            {
              "id": "5ca0fa96ecadf2e73f000048_001",
              "question": "Are artificial blood cells available?"
            }
          ],
          "context": "the critical point for the break through for artificial blood products did not come yet but could be ahead -\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nwe suggest a novel method that uses artificial blood cells ( hemoglobin vesicles, hb - vs ) as photosensitizers in dye laser treatment ( at 595 - nm wavelength ) for port - wine stains ( i. e., capillary malformations presenting as red birthmarks ) based on the\nengineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nbased on existing evidence, it is still too early to recommend epo as the standard treatment for preterm brain injury.\n. as on previous occasions, the results obtained in the laboratory are not reproduced in clinical practice.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\nret - he was the only red cell marker affected prior to the onset of brain id. the clinical practice of using anemia as the preferred biomarker for diagnosis of iron deficiency may need reconsidering.\ncurrent evidence does not support prophylactic use of clazosentan, magnesium, or simvastatin.\nno new drugs have been approved during the past 15 years ; and the available medications are not cost - effective."
        },
        {
          "qas": [
            {
              "id": "5c895cf0f9c2ba6b28000001_001",
              "question": "Have apolipoprotein mimetics been used in clinical trials?"
            }
          ],
          "context": "the apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nl - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\n. to date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns\nof a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development.\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\ncurrently, new therapies are emerging that promise more convenience and an improved safety profile ( ofatumumab ) or remyelinating potential with clinical improvement ( opicinumab ).\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nmodified vaccinia ankara ( mva ) poxvirus has been assessed for cardiac safety in a large placebo - controlled clinical trial."
        },
        {
          "qas": [
            {
              "id": "5ca10fefecadf2e73f00004a_001",
              "question": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?"
            }
          ],
          "context": "the philadelphia chromosome, t ( 9 ; 22 ) ( q34 ; q11 ), is present in 95 % of cml patients, resulting in constitutive tyrosine kinase activity ; however, ~ 5 % of cml patients possess a philadelphia variant.\nchronic myeloid leukemia is a stem cell disease with the presence of philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22.\nchronic myeloid leukemia ( cml ) is myeloproliferative neoplasm characterized by philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90 % of cases.\nand thus combines abnormalities of chromosome 15 associated with the prader - willi syndrome and of chromosome 17 associated with the miller - dieker syndrome.\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\nthe girl was diagnosed by subtelomeric fish and array - cgh, showing a 4. 43 - mb heterozygous deletion on chromosome 10p that involved 14 genes and a 3. 22 - mb single - copy gain on chromosome 17p, which includes the critical region of the miller - dieker\nsyndrome exhibit a microdeletion within chromosome 22q11.\nan additional inv dup chromosome, miller - dieker syndrome due to deletion of the 17p13. 3 segment including the lissencephaly1 gene, ring chromosome 20, and wolf - hirschhorn syndrome due to deletion of at least the 4p16. 3 segment.\nb - cell precursor acute lymphoblastic leukemia ( bcp - all ) with tcf3 - pbx1 fusion gene expression has constitutively elevated levels of wnt16b and ror1 ( receptor tyrosine kinase - like orphan receptor ), a ligand and a receptor from the wnt signaling\na 15 - month - old girl with miller - dieker syndrome, a contiguous gene deletion syndrome involving chromosome 17p13. 3 and resulting in lissencephaly, was diagnosed with precursor b - cell acute lymphoblastic leukemia."
        },
        {
          "qas": [
            {
              "id": "5c9f7bb6ecadf2e73f00003e_001",
              "question": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?"
            }
          ],
          "context": ". although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro - intestinal immune - suppression of the infant.\nhowever, on serial measurements in breast milk after an infusion, drug levels did not surpass 480 ng / ml, which was roughly 1 / 100 of the comparable serum levels.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab is expected to ameliorate the autoimmune inflammatory diseases with il - 6 overproduction and has been clinically developed as a therapeutic agent for ra, systemic - onset and articular types of jia, crohn's disease, etc.\ntocilizumab, a monoclonal antibody against the il - 6 receptor, was initiated at a dose of 8 mg / kg every 4 weeks.\nextracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\ntocilizumab, an anti - il - 6 receptor antibody, and corticosteroids were initially used to treat the increase in acute inflammatory proteins and the anasarca, resulting in decreased cytokine levels.\nthe humanized anti - human il - 6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bdmards to treat moderate to severe active ra in patients\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6."
        },
        {
          "qas": [
            {
              "id": "5c8fe71b0101eac87000000b_001",
              "question": "Does RUNX2 inhibit astrocyte differentiation?"
            }
          ],
          "context": "the method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\nneural stem cells induces neuronal and astrocyte differentiation, respectively.\niron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes.\nregulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.\n. we then focus on one of these, silc1, and show that it regulates neuroregeneration in cultured cells and in vivo, through cis - acting activation of the transcription factor sox11.\nwhich wnt signaling inhibits neuro - ectodermal lineage differentiation in mouse embryonic stem cells.\nmir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\n. thus, gata - 1 deacetylation and its interaction with hdac1 modulates gata - 1 chromatin binding and transcriptional activity that control erythroid / megakaryocyte commitment and differentiation.\nh - ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.\n. the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells."
        },
        {
          "qas": [
            {
              "id": "5c9906dcecadf2e73f00002f_001",
              "question": "Are cardenolides inhibitors of Na+/K+ ATPase?"
            }
          ],
          "context": "cardenolides have shown significant antitumor activity due to their ability to inhibit the na + k + atpase enzyme, and the expression of this enzyme is increased in tumor cells.\n: we found evidence for low cardenolides by hplc, but substantial toxicity when extracts were assayed on na + / k + - atpases.\n. previously, we reported that a variety of cardenolides impart anti - transmissible gastroenteritis coronavirus ( tgev ) activity in swine testicular ( st ) cells, through targeting of the cell membrane sodium / potassium pump, na + / k + - atpase.\namiloride regulates iks and aps with transmural differences and reduces arrhythmogenicity through the modulation of kcnq1 splicing. we suggested that the modulation of kcnq1 splicing may help prevent arrhythmia.\nmetoprolol and carvedilol are metabolised by cyp2d6.\nthese findings suggest that greater exposure to isradipine might slow disease progression.\nmoreover, inhibition of atm kinase or deficiency in nuclear actin polymerization causes carcinogenic ret / ptc chromosome rearrangements after dsbs induction in human cells.\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\npirfenidone and nintedanib are emerging agents that exert pleiotropic effects, reflective of the multiple mechanistic pathways of ipf.\nmoreover, we observed an in vitro - inhibition of human neutrophil elastase, a protease involved in the inflammatory process, by extracts and fractions from yarrow, which suggests additional mechanisms of antiphlogistic action."
        },
        {
          "qas": [
            {
              "id": "5c900779ecadf2e73f000001_001",
              "question": "Can antisense threapy be used for Huntington's disease?"
            }
          ],
          "context": "in this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nin huntington's disease ( hd ), expansion of cag codons in the huntingtin gene ( htt ) leads to the aberrant formation of protein aggregates and the differential degeneration of striatal medium spiny neurons ( msns ).\nhuntington disease ( hd ) is a progressive autosomal domi \" \" t neurodegenerative disorder, characterized by abnormal movements, cognitive decline, and psychiatric symptoms, caused by a cag repeat expansion in the huntingtin ( htt ) gene on chromosome 4p.\nhuntington's disease ( hd ) is an autosomal domit neurodegenerative disease caused by the expansion of a cag trinucleotide repeat in exon 1 of the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is an autosomal progressive neurodegenerative disorder caused by the expansion of cag repeats in the htt gene.\nhuntington's disease ( hd ) is a progressive neurodegenerative disorder caused by a cag trinucleotide repeat expansion in the huntingtin ( htt ) gene, which encodes a polyglutamine tract in the htt protein.\nhuntington's disease ( hd ) is an autosomal domitly inherited disorder caused by the expansion of cag repeats in the huntingtin ( htt ) gene.\nimportance huntington disease ( hd ), a prototypic monogenic disease, is caused by an expanded cag repeat in the htt gene exceeding 35 units.\nhuntington's disease ( hd ), a domitly inherited neurodegenerative disease, is defined by its genetic cause, a cag - repeat expansion in the htt gene, its motor and psychiatric symptomology and primary loss of striatal medium spiny neurons ( msns )"
        },
        {
          "qas": [
            {
              "id": "5ca5127eecadf2e73f00004c_001",
              "question": "Is collagen matrix of human articular cartilage changing with disease?"
            }
          ],
          "context": "the collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.\ntype ii collagen is a major component of articular cartilage and its breakdown is a key feature of osteoarthritis.\nthe chondrocytes in ageing articular cartilage have limited capacity to turnover the interterritorial matrix.\ncollagen is a fibrillar protein that conforms the conjunctive and connective tissues in the human body, essentially skin, joints, and bones\nas the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\nits perturbation will lead to human disease, highlighting the accumulating evidence that links the diverse 3d genome architecture components to a multitude of human diseases and the emerging mechanisms by which 3d genome derangement causes disease\ncollagen is the most abundant protein family in mammals.\nand accumulation of undegraded glycosaminoglycans ( gags ), heparan sulfate, and dermatan sulfate\ncells and chondrocytes, it is believed that radiation - associated damage to dna does not play a major role in the mechanism of cell death in low - let radiosensitive tumors / normal tissues such as malig \" \" t lymphoma cells and lymphocytes\nmatrix molecules in human renal proximal tubular cells ( hkcs ) induced by high glucose, to provide help for renal tubulointerstitial fibrosis therapy."
        },
        {
          "qas": [
            {
              "id": "5c9162b5ecadf2e73f00000e_001",
              "question": "Is ustekinumab a polyclonal antibody?"
            }
          ],
          "context": "ustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\nbackground dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\ninhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast.\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nsubsequent options include a tnf - alpha antagonist, followed by rituximab or possibly abatacept ; ( 2 ) tocilizumab, a monoclonal antibody, inhibits interleukin - 6 receptors.\nconclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm."
        },
        {
          "qas": [
            {
              "id": "5cb37f76ecadf2e73f00005c_001",
              "question": "Is Pim-1 a protein phosphatase?"
            }
          ],
          "context": "the pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\npim - 1 proto - oncogene, serine / threonine kinase ( pim - 1 ) phosphorylates a series of substrates to exert its oncogenic function in numerous malig \" \" cies.\nrecent crystallographic studies of pim - 1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates.\nphospholemman ( fxyd1 ) is a single - transmembrane protein regulator of na, k - atpase, expressed strongly in heart, skeletal muscle, and brain and phosphorylated by protein kinases a and c at ser - 68 and ser - 63, respectively.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nof the mixed lineage kinase domain - like protein ( mlkl ) upon its phosphorylation.\nrankl promotes paxillin serine and tyrosine phosphorylation,\nhere, we describe the crystal structure of pim1 in complex with a newly developed pyrido [ 4, 3 - d ] pyrimidine - derivative inhibitor ( ski - o - 068 ).\nthe crystal structure of this compound with pim1 confirmed the predicted binding mode and protein - ligand interactions except those in the acidic ribose pocket.\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces."
        },
        {
          "qas": [
            {
              "id": "5cb38a56ecadf2e73f00005e_001",
              "question": "Is myc a tumour suppressor gene?"
            }
          ],
          "context": "he myc oncogene\noncogenic myc, a master transcription factor that turns on anabolic metabolism to promote cell growth in many cancers.\nhowever, other genes such as the proto - oncogene c - myc are promising targets for anticancer therapy\nthe proto - oncogene protein c - myc\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\nhuwe1 is a critical colonic tumour suppressor gene that prevents myc signalling, dna damage accumulation and tumour initiation.\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes.\npten is a potent tumour suppressor\n. conversely, mettl1 overexpression induces oncogenic cell transformation and cancer."
        },
        {
          "qas": [
            {
              "id": "5cb3a2dd99d1e53537000001_001",
              "question": "Is CD63 an exosomal marker?"
            }
          ],
          "context": "f exosome marker proteins ( e. g., cd63, alix )\nthe results demonstrated these exosomes all expressed cd9, cd63, cd81, alix\ncd63 levels and acetylcholinesterase ( ache ) activity were used as markers of exosome,\nexpressed exosomal marker tumor susceptibility gene ( tsg ) 101 and flotillin ( flot ) 1.\nflotillin 1 and tumor susceptibility gene 101 ( tsg101 ), two exosomal marker proteins,\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwhose presence was validated by a bead - exosome facs assay.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\nwe used a novel strategy for generating metabolically - labeled fluorescent exosomes that can be counted by flow cytometry assay ( facs ) and characterized.\nhere we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta"
        },
        {
          "qas": [
            {
              "id": "5ca0c81eecadf2e73f000047_001",
              "question": "Is subdural empyema a complication of sinusitis?"
            }
          ],
          "context": "subdural empyema is an uncommon but serious complication of sinusitis.\nsubdural empyema is a rare complication of sinusitis although very severe.\nsubdural empyema is a rare complication of sinusitis in children.\nsubdural empyema is a rare but serious complication of paranasal sinusitis which may result in death or permanent disability in a significant proportion of cases.\nintracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures.\nsubdural empyema is a rare but potentially life - threatening complication following paranasal sinusitis and should be considered as a neurological emergency.\nsubdural empyema as a complication of sinusitis in the pediatric population.\nwolf in sheep's clothing subdural empyema : a rare complication of acute sinusitis.\nwe present a patient with subdural empyema in whom the diagnosis was delayed, followed by a discussion of suppurative complications of sinusitis.\nthe symptoms of subdural empyema may be mild and may be the same as those associated with sinusitis, or the infection may result in alteration of the level of consciousness and focal neurologic deficits."
        },
        {
          "qas": [
            {
              "id": "5c98ac7fecadf2e73f00002b_001",
              "question": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no"
            }
          ],
          "context": "the genus anaplasma belonging to the anaplasmataceae family ( order rickettsiales ) comprises obligate intracellular gram - negative bacteria of veterinary and public health importance\nhuman granulocytic anaplasmosis ( hga ), an increasingly recognized febrile tick - borne illness, is caused by a gram - negative obligate intracellular bacterium anaplasma phagocytophilum\n. six species and five types of strains genetically related are currently assigned to the genus anaplasma including anaplasma marginale, a. centrale, a. bovis, a. phagocytophilum, a. ovis and a. platys as classified species, and \" a. capra \", a\nclostridium is a large genus of obligate anaerobes belonging to the firmicutes phylum of bacteria, most of which have a gram - positive cell wall structure.\ngram - negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via toll - like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor - \u03b1 and to activate nlrp3 inflammasome, a multiprotein\nfusobacterium necrophorum is a gram - negative anaerobic bacterium that is the causative agent of the invasive disease lemierre's syndrome.\nstudies using animal model of periodontitis and human post - mortem brain tissues from subjects with ad strongly suggest that a gram - negative periodontal pathogen, porphyromonas gingivalis ( pg ) and / or its product gingipain is / are translocated to the\nsuch bacteria are either obligate anaerobic bacteria like clostridium or bifidobacterium or facultative anaerobic like escherichia coli or salmonella.\nclostridia belong to those bacteria which are considered as obligate anaerobe, e. g. oxygen is harmful or lethal to these bacteria.\n. several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),"
        },
        {
          "qas": [
            {
              "id": "5cb380b8ecadf2e73f00005d_001",
              "question": "Is the crystal structure of Pim-1 available?"
            }
          ],
          "context": "the crystal structures of pim1 in apo form and bound with amppnp have been solved\nhere, we describe the crystal structure of pim1 in complex with a newly developed pyrido [ 4, 3 - d ] pyrimidine - derivative inhibitor ( ski - o - 068 ).\nusing the determined x - ray crystal structure of pim1 complexed to the compound 1 - r as a control, we discuss the importance of including the protein flexibility inherent in the ensemble docking protocol, for the accuracy of the structure prediction of\nthe crystal structure of this compound with pim1 confirmed the predicted binding mode and protein - ligand interactions except those in the acidic ribose pocket.\nrecent crystallographic studies of pim - 1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates.\na co - crystal structure of lead molecule ( hs38 ) in complex with dapk3, a dual pim / dapk3 inhibitor ( hs56 )\ncrystallographic and docking data analyses have been undertaken using inhibitor complexes\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\nthe pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\nwithin sgs, single - molecule localization microscopy revealed distributed hotspots of immobilized g3bp1 and imp1 that reflect the presence of relatively immobile \" \" ometer - sized \" \" ocores."
        },
        {
          "qas": [
            {
              "id": "5c92159becadf2e73f000012_001",
              "question": "Do tumour-associated macrophages have a prognostic role in gliomas?"
            }
          ],
          "context": "accumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\n. tp53 mutations are frequent in low - grade gliomas and secondary glioblastomas derived therefrom.\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nexpression of \u03b1 - taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.\npathologic diagnoses were one glioblastoma, two cases of anaplastic astrocytoma, one medulloblastoma, one low - grade glioma, one high - grade glial tumor, and one atypical meningioma.\ndata presented here expand the importance of fsps as shared and general tumour - specific antigens.\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\ntumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\ngram - negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via toll - like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor - \u03b1 and to activate nlrp3 inflammasome, a multiprotein"
        },
        {
          "qas": [
            {
              "id": "5c9f0dabecadf2e73f00003b_001",
              "question": "Is TNF-\u03b1 an activator of pancreatic stellate cells?"
            }
          ],
          "context": "tnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\nactivated pscs expressed il - 33 in the nucleus, and the expression was increased by il - 1\u03b2, tnf - \u03b1, pdgf - bb, and ifn - \u03b3, but not tgf - \u03b21.\npi3k - akt - nf - \u03bab signaling pathway, ii ) by exerting an efficient antioxidant effect, iii ) by inducing significant anti - inflammatory activity and iv ) by restoring brain - derived neurotrophic factor ( bdnf ) levels\nexpression of \u03b1 - taxilin in hepatocellular carcinoma correlates with growth activity and malig \" \" t potential of the tumor.\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\nits effectiveness in the clinic has been ascribed to wide - ranging properties, including anti - tnf - alpha, t - cell costimulatory and antiangiogenic activity.\ntranscriptionally activated by glucose starvation through the activation of a mitogen - activated protein kinase ( mapk ).\nwestern blotting assays presented upregulated expressions of tnf receptor - activating factor 6 ( traf6 ) and integrin \u03b23 induced by gingipains and rankl compared to rankl alone\nwe found immune activation coexistent with elevation of multiple targetable immune checkpoint molecules, including pd - l1, pd - l2, pd - 1, tim - 3, b7 - h3, btla, and ctla - 4, along with increases in tumor infiltration by cd4 ( + ) foxp3 ( + ) regulatory t cells in\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling."
        },
        {
          "qas": [
            {
              "id": "5c9e738decadf2e73f000037_001",
              "question": "Can mitochondria transfer from cell to cell?"
            }
          ],
          "context": "interest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\nwe show evidence that mitochondria transfer from jurkat cells to mscs, which is mediated by cell adhesion\nmitochondrial number and capillary density of muscle, and possible changes in energy sources\nbiparental inheritance of mitochondrial dna in humans.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\n. our results suggest that, although the central dogma of maternal inheritance of mtdna remains valid, there are some exceptional cases where paternal mtdna could be passed to the offspring.\nthus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\nmembrane \" \" otubes ( mnts ) act as \" highways \" between cells to facilitate the transfer of multiple signals and play an important role in many diseases\nthe revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin."
        },
        {
          "qas": [
            {
              "id": "5e48e0e0f8b2df0d49000001_001",
              "question": "Are gut microbiota profiles altered by irradiation?"
            }
          ],
          "context": "irradiation profoundly impacted gut microbiota profiles in both animals.\nspecific members of the gut microbiota are reliable biomarkers of irradiation intensity and lethality in large animal models of human health.\nour findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\nwhereas most endogenous and exogenous dna damaging agents typically generate lesions that are relatively isolated and can be repaired easily, ionizing radiation ( ir ) also induces clustered lesions causing dna double strand breaks ( dsbs )\ngamma - ray irradiation introduces single and / or double strand breaks into the dna molecule of the cells.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\nsurvivors of childhood all treated with high - dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation - induced meningioma\ninduction ( 2 and 5 gy ) of gamma - ray - induced dna damage and its repair ( during 60 min after irradiation ) was measured with the alkaline and neutral comet assay.\nthere is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma."
        },
        {
          "qas": [
            {
              "id": "5c7a4c35d774d04240000007_001",
              "question": "Is TIM-3 a target for cancer immunotherapy in NSCLC?"
            }
          ],
          "context": ". furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nthe abnormal expression of tim - 3 on mdsc might be involved in the pathogenesis of pe, and could be a marker to evaluate the immune function in pe.\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit.\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\nphase iii trials of the anti - insulin - like growth factor type 1 receptor ( igf - ir ) antibody figitumumab ( f ) in unselected non - small - cell lung cancer ( nsclc ) patients were recently discontinued owing to futility.\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement."
        },
        {
          "qas": [
            {
              "id": "5c7019557c78d6947100005f_001",
              "question": "Does an interferon (IFN) signature exist for SLE patients?"
            }
          ],
          "context": "in sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\nthe ifn - i score ( positive or negative ), as a measure of ifn - i activation, was assessed using real - time quantitative pcr ( rt - pcr ) expression values of ifn - i signature genes ( ifi44, ifi44l, ifit1, ly6e, mxa, ifitm1 ) in cd14 + monocytes of csle patients\njak inhibitor has the amelioration effect in lupus - prone mice : the involvement of ifn signature gene downregulation.\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\nin response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\nwe found that cdcs from prediseased tcsle male mice express the ifn signature as female tcsle cdcs do. estrogens are necessary but not sufficient to express this ifn signature, but high doses of e2 can compensate for other steroidal components.\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\nepilepsy is characterized by a relevant epidemiological and clinical burden. in the extant literature, an increased risk of seizures has been described in several inflammatory / autoimmune disorders, including systemic lupus erythematosus ( sle ).\nof a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development.\ncent findings : recently, the belimumab in subjects with systemic lupus erythematosus - lupus nephritis trial tested belimumab, an inhibitor of b - cell activating factor, as an add - on therapy to steroids and either mycophenolate mofetil ( mmf ) or"
        },
        {
          "qas": [
            {
              "id": "5e36d924b5b409ea5300000b_001",
              "question": "Is AND-1/Ctf4 essential for proliferation?"
            }
          ],
          "context": ". thus, our findings uncover a fork protection function of and - 1 / ctf4 manifested via the wd40 domain that is essential for proliferation and averts genome instability.\nin hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition.\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\ntcf3, is recruited to a palindromic motif enriched in the promoter of cell cycle repressor genes, such as p15ink4b, p16ink4a and p19arf, which mediate the wnt - dependent anti - proliferative effect in mescs. consistently, abl\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces.\ntcf3 - mediated repression to tcf1 / lef1 - mediated enhancement of wnt signaling, constituting a positive feedback loop that facilitates neuronal differentiation.\nand - 1 / ctf4 bridges the cmg helicase and dna polymerase alpha, facilitating replication\nthe transcription factor t - cell factor 3 ( tcf3 ), one component of the wnt pathway, is known as a cell - intrinsic inhibitor of many pluripotency genes in embryonic stem cells ( escs ) that influences the balance between pluripotency and differentiation.\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. our data indicate that tet proteins regulate inkt cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the t cell antigen receptor ( tcr )."
        },
        {
          "qas": [
            {
              "id": "5e4adcbe6d0a277941000017_001",
              "question": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?"
            }
          ],
          "context": "the results indicate that braf ( v600e ) mutation is correlated with a lower expression of nis in ptcs without ht, suggesting the radioiodine - refractory effects during ria therapy in these patients.\nthe status of braf mutation may not affect the clinical response to rai therapy for patients with ptmc with intermediate - risk to high - risk features. more trials examining the role of braf mutation in guiding postoperative rai therapy are needed.\nour results suggest that the combination of brafv600e + ve mutation and mibi - ve scintigraphy may be considered a negative prognostic clue, which predicts the absence of radioiodine uptake at pt - wbs in dtc patients with incomplete bio - chemical response\nresults : a more aggressive course of breast cancer is observed in patients exposed to radiation from the chernobyl accident under the age of 30 years ( p <. 01 ).\nirradiation, however, acts as an oncogenic factor as a delayed effect and it is rare that glioblastoma multiforme develops during the remission period of all.\nradiation - induced sarcomas are recognized complications of radiation therapy and are associated with poor prognosis.\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\nfoxa1 expression can independently predict chemosensitivity of er - positive breast cancer patients.\ncranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims )."
        },
        {
          "qas": [
            {
              "id": "5e30b56efbd6abf43b000037_001",
              "question": "Is the BAGEL algorithm used for arrayed CRISPR screens?"
            }
          ],
          "context": "bagel : a computational framework for identifying essential genes from pooled library screens\n. coupled with gold - standard reference sets of essential and nonessential genes, bagel offers significantly greater sensitivity than current methods, while computational optimizations reduce runtime by an order of magnitude. conclusions : using bagel,\n. new methods for analyzing the data and evaluating results are needed. results : we offer bagel ( bayesian analysis of gene essentiality ), a supervised learning method for analyzing gene knockout screens\nan order of magnitude. conclusions : using bagel, we identify ~ 2000 fitness genes in pooled library knockout screens in human cell lines at 5 % fdr, a major advance over competing platforms\n. bagel shows high sensitivity and specificity even across screens performed by different labs using different libraries and reagents.\n. to identify additional therapeutic targets in aml, we optimize a genome - wide clustered regularly interspaced short palindromic repeats ( crispr ) screening platform and use it to identify genetic vulnerabilities in aml cells\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\npredictions based on single - cell rna - seq ( scrna - seq ) can more accurately reconstruct bulk chromatin accessibility than using scatac - seq.\n. we examine patterns of genetic diversity within and between populations and explore alternative colonization scenarios using approximate bayesian computation"
        },
        {
          "qas": [
            {
              "id": "5e2b253ffbd6abf43b000006_001",
              "question": "Is AZD5153 active in prostate cancer?"
            }
          ],
          "context": ". azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay\n. azd5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. azd5153 was non - cytotoxic to the prostate epithelial cells\n. its anti - tumor activity was further enhanced with co - treatment of the akt specific inhibitor mk - 2206. conclusion : together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\n. signaling was tested by western blotting assay. the nude mice pc - 3 xenograft model was applied to test azd5153's activity in vivo. results : azd5153 inhibited proliferation and survival of established and primary prostate cancer cells\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\n. azd5153 downregulated brd4 targets ( cyclin d1, myc, bcl - 2, fosl1 and cdk4 ) in pc - 3 and primary prostate cancer cells. further studies show that akt could be the primary resistance factor of azd5153\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n. pharmacological inhibition or genetic depletion of akt induced brd4 downregulation, sensitizing azd5153 - induced cytotoxicity in pc - 3 cells. in vivo, azd5153 oral administration inhibited pc - 3 xenograft tumor growth in nude mice\nof this aggressive form of prostate cancer offers potential for improved outcomes with early introduction of parp inhibitor - based therapy.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases."
        },
        {
          "qas": [
            {
              "id": "5e2b3784fbd6abf43b000009_001",
              "question": "Is GRG5 involved only in late embryonic mouse development?"
            }
          ],
          "context": ". here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\ngroucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n. by both loss and gain of function approaches we demonstrate that ablation of grg5 deregulates the embryonic stem cell ( esc ) pluripotent state whereas its overexpression leads to enhanced self - renewal and acquisition of cancer cell - like properties\nthe transcription factor grainyhead - like 2 ( grhl2 ) plays a crucial role in various developmental processes\nearly embryonic development, when downregulation of nanog plays a crucial role.\ngrhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\nthese data indicate that the grb2 / mek pathway primarily mediates nanog gene repression upon es cell differentiation into primitive endoderm.\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\nfrom mouse embryonic day 11. 5 primordial germ cells.\n. the malig \" \" t characteristics of teratomas generated by escs that overexpress grg5 reveal its pro - oncogenic potential."
        },
        {
          "qas": [
            {
              "id": "5e480909d14c9f295d000003_001",
              "question": "Are astronauts in higher risk for developing cancer?"
            }
          ],
          "context": "despite years of research, understanding of the space radiation environment and the risk it poses to long - duration astronauts remains limited. there is a disparity between research results and observed empirical effects seen in human astronaut crews\nrisks of lung, breast, and gastrointestinal ( gi ) cancers increase with higher radiation dose.\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\nfurthermore, the upward trends of increases in a variety of other tumors including breast cancer, cancers of central nervous system and renal cancer have been reported in the persons exposed to chornobyl fallout.\ncervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites ( colon, rectum / anus, urinary bladder, ovary, and genital sites )\nradiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\nradiation therapy for prostate cancer is associated with an increased risk of bladder cancer.\nresults : a more aggressive course of breast cancer is observed in patients exposed to radiation from the chernobyl accident under the age of 30 years ( p <. 01 ).\n. the risk of colon and rectum cancer over 20 years of follow - up after radiation remained the same across three eras ( 1973 - 1980, 1981 - 1990, and 1991 - 2000 )\nafter 8 years, the hazard ratio for developing colon cancer was 2. 00 ( 95 % ci 1. 43 - 2. 80 ) for women with radiation versus those without radiation treatment."
        },
        {
          "qas": [
            {
              "id": "5e2906948b3851296d00000a_001",
              "question": "Is Niraparib effective for ovarian cancer?"
            }
          ],
          "context": "niraparib for the treatment of ovarian cancer.\nniraparib slows ovarian cancer progression.\npurpose : niraparib is a highly selective inhibitor of parp - 1 and parp - 2 approved in the united states for mainte \" \" ce treatment of adult patients with recurrent ovarian cancer in complete or partial response to platinum - based chemotherapy.\ncurrent evidence suggests that niraparib is an effective new option with a manageable tolerability profile for the mainte \" \" ce treatment of recurrent, platinum - sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults, with\nniraparib in ovarian cancer : results to date and clinical potential.\nniraparib is a poly adenosine diphosphate ribose polymerase inhibitor that has shown to be clinically effective as mainte \" \" ce therapy in patients with platinum sensitive, recurrent ovarian cancer.\nniraparib and olaparib have been approved by the us fda for mainte \" \" ce therapy after partial or complete remission in recurrent ovarian cancer.\nindeed, three parp1 inhibitors ( olaparib, rucaparib, and niraparib ) have recently been approved by the food and drug administration for the treatment of ovarian cancer.\noral niraparib, a highly - selective, potent poly ( adp - ribose ) polymerase ( parp ) - 1 and parp - 2 inhibitor, is approved in the usa for the mainte \" \" ce treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer\nniraparib, an orally available selective inhibitor of poly ( adenosine diphosphate - ribose ) polymerase ( parp ), is the first parp inhibitor approved for use in patients with ovarian cancer who do not harbor a germ - line or somatic mutation in the breast"
        },
        {
          "qas": [
            {
              "id": "5c72768a7c78d6947100006c_001",
              "question": "Are genes that escape X-chromosome inactivation related to mental impairment?"
            }
          ],
          "context": "genes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\n. there is an excess of escaping genes associated with mental retardation, consistent with this being a common phenotype of polyx phenotypes.\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation.\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\nconsistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.\nthe normal x chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the hunter gene.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nfrom skewed x inactivation of the paternal nonmutant x chromosome.\nfamilial x - chromosome inactivation ( xci ) skewing was investigated in a family in which a female mucopolysaccharidosis type ii ( mps ii ) ( hunter syndrome, an x - linked genetic disease ) occurred. among e"
        },
        {
          "qas": [
            {
              "id": "5e29fe76aa19d74431000007_001",
              "question": "Has LB-100 been tested in clinical trials?"
            }
          ],
          "context": "based on positive results from a phase i / ii clinical trial\nto determine the mtd and to assess the safety, tolerability, and potential activity of lb - 100, a first - in - class small - molecule inhibitor of protein phosphatase 2a ( pp2a ) in adult patients with progressive solid tumors.\nand open - label extension studies are needed to determine the long - term safety and efficacy of this promising therapy.\npositive phase iii - study data have been published for lenvatinib as first - line and cabozantinib as second - line therapy.\n. to date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns\nten classes of neuroprotective agents have reached phase iii efficacy trials but have shown mixed results\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\nthis system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\nhere, we provide a comprehensive review of the preclinical and clinical activity of tirabrutinib, a drug approved in japan for relapsed or refractory primary central nervous system lymphoma and all lines of waldenstrom"
        },
        {
          "qas": [
            {
              "id": "5e290a268b3851296d00000d_001",
              "question": "Is palbociclib effective for glioblastoma?"
            }
          ],
          "context": "conclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\nthe proteasome inhibitor bortezomib is effective for a variety of tumors, but not for gbm.\nconclusion : the combination of inc280 / buparlisib resulted in no clear activity in patients with recurrent pten - deficient glioblastoma.\nof glioblastoma or anaplastic astrocytoma, administration of toca 511 and toca fc, compared with soc, did not improve overall survival or other efficacy end points.\na phase iii study failed for carboplatin, paclitaxel, with or without figitumumab in first - line treating metastatic non - small cell lung cancer ( nsclc ).\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful."
        },
        {
          "qas": [
            {
              "id": "5e36d807b5b409ea5300000a_001",
              "question": "Does the Mcm2-Ctf4-Pol\u03b1 axis play a role in transfer of histones to leading strand DNA at the replication forks?"
            }
          ],
          "context": "the mcm2 - ctf4 - pol\u03b1 axis facilitates parental histone h3 - h4 transfer to lagging strands.\n. here, we show that the mcm2 - ctf4 - pol\u03b1 axis facilitates the transfer of parental ( h3 - h4 ) 2 tetramers to lagging - strand dna at replication forks\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\n. mutating the conserved histone - binding domain of the mcm2 subunit of the cmg ( cdc45 - mcm - gins ) dna helicase, which translocates along the leading - strand template, results in a marked enrichment of parental ( h3 - h4 ) 2 on leading strand, due to the\n. similar effects are observed in ctf4 and pol\u03b1 primase mutants that disrupt the connection of the cmg helicase to pol\u03b1 that resides on lagging - strand template\nand - 1 / ctf4 bridges the cmg helicase and dna polymerase alpha, facilitating replication\nparental ( h3 - h4 ) 2 on leading strand, due to the impairment of the transfer of parental ( h3 - h4 ) 2 to lagging strands\n. in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\nwe suggest that loading and translocation are mediated by conformational changes in cohesin's hinge driven by cycles of atp hydrolysis.\nour findings establish that nuclear actin - based mobility shapes chromatin organization by generating repair domains that are essential for homology - directed repair in eukaryotic cells."
        },
        {
          "qas": [
            {
              "id": "5e2b0d71fbd6abf43b000001_001",
              "question": "Can discharge destinations be accurately predicted using the Risk Assessment and Prediction Tool (RAPT)?"
            }
          ],
          "context": "background : the risk assessment and prediction tool ( rapt ) is used to predict patient discharge disposition after total joint arthroplasty.\nconclusions : the rapt accurately predicted discharge disposition for high - and low - risk patients in our cohort.\nconclusion : our analysis identified age, lower lumbar / lumbosacral surgery, and rapt walk score as independent predictors of discharge to snf, and demonstrated superior predictive power compared with the total rapt score when combined in a novel\npurpose : the aim of this study was to evaluate the value of conventional factors, the risk assessment and predictor tool ( rapt ) and performance - based functional tests as predictors of delayed recovery after total hip arthroplasty ( tha ).\nobjective : to assess the relevance of the rapt ( risk assessment and prediction tool ), among a cohort of patients undergoing total hip arthroplasty ( tha ).\n. additionally, it identifies intermediate - risk patients and could be used to implement targeted interventions to facilitate discharge home in this group of patients.\n. the model had high sensitivity and accuracy in predicting the 1 - year overall survival rate ( area under the curve = 0. 717 ). the prediction model risk score was an independent predictor of crc.\nthese results confirm that clinically useful mdd risk - stratification models can be generated from baseline patient self - reports and that ml methods improve on conventional methods in developing such models\nconclusions : the results of this meta - analysis suggest that cfrt and hfrt provide similar survival outcomes for patients with dipg.\nin terms of hospitalization, adverse events, and mortality."
        },
        {
          "qas": [
            {
              "id": "5e2db15cfbd6abf43b000014_001",
              "question": "Has amantadine ER been approved by the FDA?"
            }
          ],
          "context": "extended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\nads - 5102 ( amantadine ) extended - release ( er ) capsules ( gocovritm ) is a recent us fda - approved treatment for dyskinesia in pd patients.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\n. it was approved by the food and drug administration ( fda ) in march 2017 for using in adults with relapsing - remitting multiple sclerosis ( rrms ) and primary progressive multiple sclerosis ( ppms ).\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nthe food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness."
        },
        {
          "qas": [
            {
              "id": "5e2a0eb1aa19d7443100000c_001",
              "question": "Can PRL3-zumab inhibit PRL3+ cancer cells in vitro and in vivo?"
            }
          ],
          "context": "here we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\n. signaling was tested by western blotting assay. the nude mice pc - 3 xenograft model was applied to test azd5153's activity in vivo. results : azd5153 inhibited proliferation and survival of established and primary prostate cancer cells\nlines dose - dependently inhibits proliferation in vitro and in a mouse xenograft model\nbackground : anti - programmed cell death ligand 1 ( pd - l1 ) / programmed cell death 1 antibodies have shown clinical activity in platinum - treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nwe reviewed the literature for prospective studies evaluating pd - 1 / pd - l1 inhibitors in refractory urothelial carcinoma patients, which formed the basis for us food and drug administration approval of 5 different antagonistic antibodies targeting pd - 1\nover, our findings showed that combination of tocilizumab ( actemra ; roche ), an anti - il - 6r monoclonal antibody, with carboplatin synergistically inhibited growth and proliferation of the eoc cells and the most direct axis for il - 6 gene expression was\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\n. azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay"
        },
        {
          "qas": [
            {
              "id": "5ca61b14ecadf2e73f00004f_001",
              "question": "Does Estrogen lead to forkhead FoxA1 activation?"
            }
          ],
          "context": "furthermore, knockdown of foxa1 expression blocks the association of er with chromatin and estrogen - induced gene expression demonstrating the necessity of foxa1 in mediating an estrogen response in breast cancer cells.\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\nfoxa1 is a key determi \" \" t of estrogen receptor function and endocrine response.\nfoxa1 determines estrogen receptor action in breast cancer progression\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nwe showed that ctcf acts upstream of the \" pioneer \" factor foxa1 in determining the genomic response to estrogen.\nfoxa1 expression could be a prognostic marker in er - positive breast cancer.\nfoxa1 expression can independently predict chemosensitivity of er - positive breast cancer patients.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway."
        },
        {
          "qas": [
            {
              "id": "5cc011e2a49efeb44c000001_001",
              "question": "Does association with the nuclear pore promote gene silencing?"
            }
          ],
          "context": "silencing nuclear pore protein tpr elicits a senescent - like phenotype in cancer cells.\nnanog, oct4 and repressor proteins co - occupy nanog - target genes in mouse es cells, suggesting that nanog and oct4 together may communicate with distinct repression complexes to control gene transcription.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nof posttranscriptional tpr gene silencing by rna interference ( rnai ).\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\n. nup358 localizes to the nuclear pore complex and to the cytoplasmic annulate lamellae ( al ), and these structures dynamically associate with two mrnp granules : processing bodies ( p bodies ) and stress granules ( sgs ).\niation to proliferation control. our results revealed a chromatin looping mechanism of long - range control and argue against models involving homogeneous spreading of pcg silencers\npcg proteins, dna methylation, and gene repression by chromatin looping.\nconsistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.\n. a likely explanation for the reduction of or transcription is the striking reorganization of nuclear architecture observed in the osn lineage, which disrupts multi - chromosomal compartments regulating or expression in humans and hamsters"
        },
        {
          "qas": [
            {
              "id": "5e29f959aa19d74431000004_001",
              "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?"
            }
          ],
          "context": "lb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\nbackground : anti - programmed cell death ligand 1 ( pd - l1 ) / programmed cell death 1 antibodies have shown clinical activity in platinum - treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab\nin a phase ii study, researchers found that the parp inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in brca1 or brca2.\nto determine the mtd and to assess the safety, tolerability, and potential activity of lb - 100, a first - in - class small - molecule inhibitor of protein phosphatase 2a ( pp2a ) in adult patients with progressive solid tumors.\nolaparib targets some advanced prostate cancers.\nrecent findings : the approval of several parpi ( olaparib, rucaparib, and niraparib ) has driven the focus of anticancer treatment on synthetic lethality in prostate cancer too.\nniraparib in ovarian cancer : results to date and clinical potential.\nrecent clinical studies show favorable results for the parp inhibitor olaparib used as single agent for treatment of metastatic castration - resistant pca.\nlines dose - dependently inhibits proliferation in vitro and in a mouse xenograft model"
        },
        {
          "qas": [
            {
              "id": "5e2dac4efbd6abf43b00000f_001",
              "question": "Has istadefylline been considered as a treatment for Parkinson's disease?"
            }
          ],
          "context": ". it is an adenosine receptor a2a antagonists that will represent an important option for patients with advanced pd where it has been demonstrated efficacy in decreasing daily off time and is well tolerated.\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\npimavanserin, a serotonin ( 2a ) receptor inverse agonist, for the treatment of parkinson's disease psychosis.\nif this is granted, we believe the evidence of pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of parkinson's disease psychosis.\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\nthe development of pimavanserin as an antipsychotic opened a new therapeutic avenue in the treatment of pdp as well as targeting psychosis in other disorders such as alzheimer's disease.\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ]."
        },
        {
          "qas": [
            {
              "id": "5e2dad57fbd6abf43b000010_001",
              "question": "Is amantadine ER the first approved treatment for akinesia?"
            }
          ],
          "context": "extended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\nads - 5102 ( amantadine ) extended - release ( er ) capsules ( gocovritm ) is a recent us fda - approved treatment for dyskinesia in pd patients.\npimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\nif this is granted, we believe the evidence of pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of parkinson's disease psychosis.\nobjective : pimavanserin is the first united states food and drug administration ( fda ) - approved treatment for parkinson's disease psychosis ( pdp ).\nis the only fda - approved treatment for the hallucinations and delusions seen in patients with psychosis of parkinson's disease.\nreceptor inverse agonist pimavanserin was recently approved by the us fda for the treatment of pdp and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\nthe development of pimavanserin as an antipsychotic opened a new therapeutic avenue in the treatment of pdp as well as targeting psychosis in other disorders such as alzheimer's disease.\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ]."
        },
        {
          "qas": [
            {
              "id": "5e480ccfd14c9f295d000005_001",
              "question": "Is g-H2AX a marker for double strand breaks?"
            }
          ],
          "context": "the specific phosphorylation of histone h2ax on serine residue 139, described as \u03b3 - h2ax, is an excellent indicator or marker of dna double - strand breaks ( dsbs ).\nexpression of the dna double - strand break marker gamma - h2ax ( \u03b3h2ax )\nph2ax, a marker of the dna double - strand break ( dsb )\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet\nof histone h2ax ( gamma - h2ax ) and alkaline comet assays.\ngle cell gel electrophoresis ( e. g., comet assay ) and immunofluoresence microscopy to detect the presence of gamma - h2ax foci, we find that cr [ vi ] induces dna double - strand breaks similar to ionizing radiation ( ir ). we also demo\ngamma - ray irradiation introduces single and / or double strand breaks into the dna molecule of the cells.\ndna double - strand breaks ( dsbs ) are major dna lesions that are constantly formed during physiological processes such as dna replication, transcription, and recombination, or as a result of exogenous agents such as ionizing radiation, radiomimetic\ninfluence of chromatin structure on the induction of dna double strand breaks by ionizing radiation.\nevaluation of primary dna - damage is one way to identify potential genotoxic agents and for this purpose the comet assay has, for the last decades, been used to monitor dna single strand and double strand breaks in individual cells"
        },
        {
          "qas": [
            {
              "id": "5c7f806d617e120c34000001_001",
              "question": "Are tumour specific antigens originating from known protein coding genes?"
            }
          ],
          "context": "tumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\nit is well established that mhc class i molecules present peptides from endogenous proteins, such as virus or tumour antigens, to cd8 + t lymphocytes.\nthese ctls recognize short peptides derived from tumour - associated antigens in conjunction with class i molecules expressed on tumour cells.\ndata presented here expand the importance of fsps as shared and general tumour - specific antigens.\nthe focus on cellular immune responses, combined with rapid biotechnological advances, resulted in the identification of tumour specific antigens, such as mart - 1 and gp100, that could be recognised by autologous til\nthe pioneering studies of srivastava and colleagues led to the proposal that heat - shock proteins ( hsps ) function as ubiquitous tumour - specific antigens, with the specificity residing in a population of bound peptides that identify the tissue of\nhowever, other genes such as the proto - oncogene c - myc are promising targets for anticancer therapy\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\nof bound peptides that identify the tissue of origin of the hsp.\ntherefore, we propose that cd4 ( + ) t cells that recognize secreted tsa may be superior for immunotherapy by t cell transfer, because the local extracellular antigen concentration will be higher for secreted tsa."
        },
        {
          "qas": [
            {
              "id": "5e2a04feaa19d74431000009_001",
              "question": "Can LB-100 downregulate miR-33?"
            }
          ],
          "context": "lb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\n. mir - 130b was predicted to have binding sites within the uc. 63 + sequence. the expression of mir - 130b was significantly disturbed by the overexpression or knockdown of uc. 63 +\nwe found that : i ) the circrna expression profile revealed 1, 285 significant differences in circrna expression, with circrna expression downregulated in 594 samples and upregulated in 691 samples via interactions with mirnas.\n. we also showed that uc. 63 + regulated the expression of mmp2 via mir - 130b regulation. furthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\n. in vitro studies have suggested that adar3 acts as a negative regulator of a - i rna editing but the scope and underlying mechanisms are also unknown\noverexpression of tcf3 attenuated the effect of mir - 17 on modulating canonical wnt signaling.\n. because of the absence of treatment effect, we could not identify a gene signature predictive of clinical benefit to mage - a3 immunotherapeutic.\n. mir - 181b - 1 ectopic overexpression further diminishes bcl - 2 expression leading to suppression of saml cell growth, and enhancement of dnr cytotoxicity.\nour results suggest that the combination of brafv600e + ve mutation and mibi - ve scintigraphy may be considered a negative prognostic clue, which predicts the absence of radioiodine uptake at pt - wbs in dtc patients with incomplete bio - chemical response\nthe library of integrated network - based cellular signatures ( lincs ) l1000 big data provide gene expression profiles induced by over 10 000 compounds, shrnas, and kinase inhibitors using the l1000 platform."
        },
        {
          "qas": [
            {
              "id": "5e30f638fbd6abf43b000045_001",
              "question": "Does teplizumab hold promise for diabetes prevention?"
            }
          ],
          "context": "conclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm.\n. a recent prevention trial using the anti - cd3 antibody teplizumab in individuals at a high risk of developing t1d has provided the first piece of evidence that a safe and transient intervention may be able to delay disease.\nteplizumab ( anti - cd3 mab ) treatment preserves c - peptide responses in patients with new - onset type 1 diabetes in a randomized controlled trial : metabolic and immunologic features at baseline identify a subgroup of responders.\nthe results from the tn - 10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a fcr non - binding monoclonal antibody to cd3 in people at high risk for disease.\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\ntake home message in phase i / ii randomized control trials, in patients with new onset t1d, teplizumab slowed the rate of loss of beta - cell function over 2 years of follow - up.\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\nclinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\nanti - cd3 teplizumab and anti - cd3 otelixizumab have been shown to provide c - peptide preservation.\ntreatment of type 1 diabetes with teplizumab : clinical and immunological follow - up after 7 years from diagnosis."
        },
        {
          "qas": [
            {
              "id": "5e2dfab2fbd6abf43b00001d_001",
              "question": "Does ProSavin use an adenoviral vector?"
            }
          ],
          "context": "prosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\nlong - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\none of the most advanced and most promising vectors is the attenuated, non - replicating poxvirus mva ( modified vaccinia virus ankara ), a safer derivative of the uniquely successful smallpox vaccine\nthe advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\npossible to construct a suppressive anti - viral regimen.\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nin this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\nmodified vaccinia virus ankara ( mva ) is a replication - deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombi \" \" t viral vector to produce vaccines against infectious diseases and cancer.\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy."
        },
        {
          "qas": [
            {
              "id": "5e3238bcfbd6abf43b000056_001",
              "question": "Does radiation for tinea capitis increases brain tumor risk?"
            }
          ],
          "context": "there is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma.\nit is well known that radiation can induce meningiomas. these tumors usually arise in patients with a history of low - dose radiation to the scalp for treatment of tinea capitis or high - dose radiation for a previous brain tumor.\nlong - term follow - up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.\nin addition to high dose radiation - induced meningiomas, intracranial meningiomas were observed in patients who underwent low - dose radiation for tinea capitis in childhood, applied en mass to immigrants coming to israel from the north africa and the\nalthough meningiomas are known to be induced by low doses of cranial irradiation, such as those given to treat tinea capitis, little experience has been reported on the induction of meningiomas by high - dose cranial irradiation.\na benign disease ( especially tinea capitis ), as well as after irradiation at higher doses of a few tens of grays for the treatment of cancer ( in particular cerebral irradiation in acute lymphoblastic leukaemia ).\nemphasis is placed on meningiomas resulting from childhood treatment for primary brain tumor or tinea capitis, exposure to dental x - rays, and exposure to atomic explosions in hiroshima and nagasaki.\nparadoxically, radiation is also a risk factor for gbm development, raising the possibility that radiotherapy of brain tumors could promote tumor recurrence or trigger secondary gliomas.\nsurvivors of childhood all treated with high - dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation - induced meningioma\na 39 - year - old male developed primary brain lymphoma 33 years after receiving scalp irradiation for tinea capitis."
        },
        {
          "qas": [
            {
              "id": "5e2dbd0afbd6abf43b000017_001",
              "question": "Is pimavanserin a typical antipsychotic?"
            }
          ],
          "context": "pimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nreceptor inverse agonist pimavanserin was recently approved by the us fda for the treatment of pdp and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.\npimavanserin, a selective 5 - ht2a inverse agonist / antagonist, was approved in the u. s. for treating hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\npimavanserin, a serotonin ( 2a ) receptor inverse agonist, for the treatment of parkinson's disease psychosis.\nbackground pimavanserin is a selective 5 - ht2a receptor inverse agonist and antagonist approved in the usa for the treatment of hallucinations and delusions associated with parkinson's disease psychosis.\nobjective : our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5 - ht2a receptor inverse agonist / antagonist indicated for the treatment of hallucinations and delusions associated with parkinson's disease\npimavanserin ( acp - 103 ) is a selective inverse agonist of the 5 - hydroxytryptamine 2a ( 5 - ht2a ) receptor intended to treat patients with parkinson's disease psychosis ( pdp ).\npimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp )."
        },
        {
          "qas": [
            {
              "id": "5e5b93a2752ebcdc7a000003_001",
              "question": "Can Flotillin be used as exosomal marker?"
            }
          ],
          "context": "expressed exosomal marker tumor susceptibility gene ( tsg ) 101 and flotillin ( flot ) 1.\nflotillin 1 and tumor susceptibility gene 101 ( tsg101 ), two exosomal marker proteins,\nwe used a novel strategy for generating metabolically - labeled fluorescent exosomes that can be counted by flow cytometry assay ( facs ) and characterized.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\nf exosome marker proteins ( e. g., cd63, alix )\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwhose presence was validated by a bead - exosome facs assay.\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\netrin - 1 is a laminin - related secreted protein, is highly induced after tissue injury, and may serve as a marker of injury."
        },
        {
          "qas": [
            {
              "id": "5e30f417fbd6abf43b000043_001",
              "question": "Is Apremilast effective for Beh\u00e7et\u2019s Syndrome?"
            }
          ],
          "context": "conclusions apremilast was effective in treating oral ulcers, which are the cardinal manifestation of behcet's syndrome.\napremilast is now approved for the treatment of oral ulcer of behcet syndrome in the united states.\nin patients with oral ulcers associated with behcet's syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (\nibudilast for the treatment of multiple sclerosis.\nconclusion : deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.\npoetyk pso - 1 and pso - 2 involved 1688 patients with moderate - to - severe psoriasis. after 16 weeks, in both studies, over 50 % of patients treated with deucravacitinib reached pasi75, which was significantly superior to placebo and apremilast\ninhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast.\nof rare oral lesions and management of patients'systemic disease.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\ndupilumab inhibits interleukin - 4 ( il - 4 ) and interleukin - 13 ( il - 13 ) signaling and was previously found to be effective in asthma."
        },
        {
          "qas": [
            {
              "id": "5e46ece93f5415952900000e_001",
              "question": "Is Rad4/XPC a DNA damage sensing protein?"
            }
          ],
          "context": "kinetic gating mechanism of dna damage recognition by rad4 / xpc.\ntwist - open mechanism of dna damage recognition by the rad4 / xpc nucleotide excision repair complex.\nthis paper attempts a correlation between the induction and repair of dna damage measured in the comet assay and the clinical observed reaction in order to evaluate the suitability of the comet assay for prediction of radiation sensitivity.\nthe comet assay is recognized as a rapid and sensitive method in quantifying radiation induced dna damage.\nthese findings indicate that the lesions recognized by rad4 / xpc thermodynamically destabilize the watson - crick double helix in a manner that facilitates the flipping - out of two base pairs.\nthe relationship between cellular radiosensitivity and radiation - induced dna damage measured by the comet assay.\nthe comet assay is frequently used to measure dna damage in individual cells.\nspecial at - rich sequence - binding protein 1 ( satb1 ) functions as an accessory factor in base excision repair.\nreliable comet assay measurements for detecting dna damage induced by ionising radiation and chemicals.\nthe au / u - rich element - binding protein hur has been shown to bind to p53 mrna 3'utr and enhance translation in response to dna - damaging uvc radiation."
        },
        {
          "qas": [
            {
              "id": "5e5b60adb761aafe0900000b_001",
              "question": "Is the protein ABCG2 transmembrane?"
            }
          ],
          "context": "the transmembrane atp - binding cassette transporter g2\nthe atp - binding cassette ( abc ) transporter family is a large class of atp energy - dependent transmembrane proteins\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\nthe transmembrane lipoprotein phospholemman ( fxyd1 )\nace2 is a type 1 integral membrane protein and contains a catalytically active ectodomain that can be shed from the cell surface into the extracellular space,\natp - binding cassette ( abc ) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs.\ne - cadherin, a central component of the adherens junction ( aj ), is a single - pass transmembrane protein\nve - cadherin protein levels were also increased in the plasma membrane fraction.\nthe plasma membrane - bound e - cadherin protein\nusing super - resolution and expansion microscopy, we find that the sg component ubap2l [ 11, 12 ] and the core protein g3bp1 [ 5, 11 - 13 ] occupy different domains inside sgs."
        },
        {
          "qas": [
            {
              "id": "5e3247f1fbd6abf43b00005b_001",
              "question": "Can radiotherapy cause radiation induced osteosarcoma?"
            }
          ],
          "context": "radiation - induced osteosarcoma is a well - known but rare complication of radiotherapy for brain neoplasms with a poor prognosis\nradiation - induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma.\nalthough a rare complication of ionizing radiation, radiation - induced osteosarcoma is now more frequently recognized as radiation therapy has become common and cancer survival has increased\nradiation - induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma : a case report and review of the literature.\nas the prognosis of radiation - induced osteosarcoma is poorer than that of primary osteo - sarcoma, careful attention is required for consideration of the long - term survival of patients with glioma.\nosteosarcoma after radiotherapy for prostate cancer.\nradiation - induced fibrosarcoma after radiotherapy for osteosarcoma in the mandibular condyle.\nextraskeletal osteosarcoma occurring following radiotherapy for thyroid cancer, and the only case reported in the soft tissue of the head and neck region.\nin this case, osteosarcoma was possibly a radiation - induced osteosarcoma with a short latency period of 3 years.\nosteosarcoma following radiotherapy : a case report."
        },
        {
          "qas": [
            {
              "id": "5cf4dec0a49efeb44c00000c_001",
              "question": "Are lamina-associated domains (LADs) associated with transcriptional activation?"
            }
          ],
          "context": "such lamina - associated domains ( lads ) are thought to help organize chromosomes inside the nucleus and have been associated with gene repression.\npausing, with ldb1 regulating recruitment of metastasis - associated 1 family, member 2, a component of the nucleosome remodeling deacetylase complex, on these negative enhancers, required for the repressive enhancer function.\nwe found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\nzld facilitates binding of dl to regulatory dna, and that this is associated with increased chromatin accessibility.\ntad boundaries are insulators of genomic neighborhoods. in this issue, sun et al. show that disease - associated tandem repeats are located to tad boundaries and affect their insulation.\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\nalthough ldb1 - dependent activated genes are regulated at the level of transcriptional initiation, the ldb1 - dependent repressed transcription units appear to be regulated primarily at the level of promoter pausing, with ldb1 regulating recruitment of\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing."
        },
        {
          "qas": [
            {
              "id": "5e31cc22fbd6abf43b000050_001",
              "question": "Is Hemochromatosis type 4 is caused by a mutation in a recessive gene?"
            }
          ],
          "context": "hemochromatosis type 4 is a rare form of primary iron overload transmitted as an autosomal domi \" \" t trait caused by mutations in the gene encoding the iron transport protein ferroportin 1 ( slc40a1 ).\nhemochromatosis type 4, also known as ferroportin disease, is an autosomal domi \" \" t genetic disorder caused by pathogenic mutations in the slc40a1 gene, which encodes ferroportin 1 ( fpn1 ).\ntype 4 hemochromatosis follows an autosomal domi \" \" t trait ; the corresponding mutation affects the basolateral iron carrier ferroportin 1.\nhemochromatosis is caused by mutations in hfe, a protein that competes with transferrin ( tf ) for binding to transferrin receptor 1 ( tfr1 ).\nseverely affect iron homeostasis causing type 4 hereditary hemochromatosis, an autosomal domi \" \" t iron overload condition with variable phenotypic manifestations\nhereditary deposition of iron ( primary haemochromatosis ) or copper ( wilson's disease ) are autosomal recessive metabolic disease characterized by progressive liver pathology and subsequent involvement of various other organs.\nhereditary hemochromatosis and wilson disease are autosomal recessive storage disorders of iron and copper overload, respectively.\nmutations in the cu / zn superoxide dismutase 1 ( sod1 ) gene have been reported to cause adult - onset autosomal domi \" \" t amyotrophic lateral sclerosis ( fals ).\nhemochromatosis and wilson's disease are known as iron and copper accumulation disorders, respectively.\nthese studies describe how point mutations of the transferrin receptor can cause a microcytic anemia that does not respond to iron therapy and would not be detected by routine iron studies, such as serum ferritin."
        },
        {
          "qas": [
            {
              "id": "5e371a1db5b409ea53000015_001",
              "question": "Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?"
            }
          ],
          "context": "patient - derived xenografts ( pdx ) and patient - derived organoids ( pdo ) serve as promising tools to identify new drugs with therapeutic potential in pdac.\n. we compared responses to anticancer agents ex vivo in organoids and pdo - based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials\nour data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs\n. molecular profiling of tumor organoids was matched to drug - screening results, suggesting that pdos could complement existing approaches in defining cancer vulnerabilities and improving treatment responses\n. our data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.\n. phenotypic and genotypic profiling of pdos showed a high degree of similarity to the original patient tumors\n. we report on a living biobank of pdos from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1 / 2 clinical trials\n. laboratory studies were carried out in human mcrpc organoid cultures, prostate cancer ( pca ) cell lines, and mouse xenograft models\n. importantly, parp inhibitors attenuate cell growth in human mcrpc - derived organoids and human crpc cells harboring single - copy loss of both genes. conclusions : our findings suggest that early identification of this aggressive form of prostate cancer\n. here we expose human intestinal organoids to genotoxic pks + e. coli by repeated luminal injection over five months"
        },
        {
          "qas": [
            {
              "id": "5e49c5336d0a277941000011_001",
              "question": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?"
            }
          ],
          "context": ". immunohistochemical staining using 406 nsclc and 265 escc specimens confirmed that ly6k overexpression was associated with poor prognosis for patients with nsclc ( p = 0. 0003 ), as well as escc ( p = 0. 0278 ), and multivariate analysis confirmed its\ngene expression profile analyses of non - small cell lung carcinomas ( nsclc ) and esophageal squamous cell carcinomas ( escc ) revealed that lymphocyte antigen 6 complex locus k ( ly6k ) was specifically expressed in testis and transactivated in a majority\n0. 0278 ), and multivariate analysis confirmed its independent prognostic value for nsclc ( p = 0. 0035 ).\n. in addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 hgsocs ( hr = 0. 74, 95 % ci = 0. 61 - 0. 90, log - rank p = 0. 002 ) and 675 high - figo stage hgsocs ( hr = 0. 76, 95 % ci = 0. 61 - 0. 96, log - rank p\n. moreover, kaplan - meier analysis showed that the high expression of serum uc. 63 + correlated with a worse prognosis ( p = 0. 020 )\nwe found that loss at 6q24. 2 - 26 was significantly associated with the cluster of longer survival independently from other confounding factors ( hr = 0. 06, 95 % ci = 0. 01 - 0. 43, padj = 0. 005 )\npurpose : hodgkin lymphoma ( hl ) survivors face an increased risk of treatment - related lung cancer.\n. in this series, lc patients with early stages had a shorter elapsed time from hl diagnosis and longer os, therefore the role of lc screening in hl survivors should be prospectively evaluated and smoking cessation counseling ought to be a key aspect\nprolonging the survival of small cell lung cancer patients.\nbackground : patients treated for hodgkin's lymphoma ( hl ) have a higher risk of developing second lung cancer ( slc ) compared with the general population."
        },
        {
          "qas": [
            {
              "id": "5d31daacb3a6380763000003_001",
              "question": "Are the members of the KRAB-ZNF  gene family promoting gene repression?"
            }
          ],
          "context": "because kap1 is recruited to the dna via interaction with krab - znf proteins, we suggest that expression of krab - znf genes may be controlled via an auto - regulatory mechanism involving kap1.\nthe stem cell zinc finger 1 ( szf1 ) / znf589 protein belongs to the large family of kruppel - associated box domain - zinc finger ( krab - znf ) transcription factors, which are present only in higher vertebrates and epigenetically repress transcription by\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nhere, using a reporter system, we show that trim28 / krab - znfs alter dna methylation patterns in addition to h3k9me3 to cause stable gene repression during reprogramming\n. using several expression datasets, we identified krab - znfs ( znf114, znf483, znf589 ) in the human genome that maintain pluripotency.\npcg proteins, dna methylation, and gene repression by chromatin looping.\nfurther analyses of our data sets link gabpa to cognitive disorders, diabetes, krab zinc finger ( krab - znf ), and human - specific genes.\nrepressive loops within polycomb domains are formed after the midblastula transition between polycomb response elements by the action of gaga factor and polycomb proteins.\nnanog, oct4 and repressor proteins co - occupy nanog - target genes in mouse es cells, suggesting that nanog and oct4 together may communicate with distinct repression complexes to control gene transcription.\nfor repression by grhl2, suggesting that the emt transcription factors grhl2 and zeb1 form a double negative regulatory feedback loop in breast cancer cells"
        },
        {
          "qas": [
            {
              "id": "5e5b5c6fb761aafe0900000a_001",
              "question": "Is the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excreting uric acid?"
            }
          ],
          "context": "tp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\natp - binding cassette ( abc ) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs.\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\nthe transmembrane atp - binding cassette transporter g2\nthe atp - binding cassette ( abc ) transporter family is a large class of atp energy - dependent transmembrane proteins\nras gtpase - activating protein - binding protein ( g3bp1 ) is an rna - binding protein that is essential for assembling stress granules.\n. the protein encoded by cadm2 is involved in glutamate signaling ( p - value = 7. 22 \u00d7 10 ( - 15 ) ), gamma - aminobutyric acid ( gaba ) transport ( p - value = 1. 36 \u00d7 10 ( - 11 ) ) and neuron cell - cell adhesion ( p - value = 1. 48 \u00d7 10 ( - 13 ) )\nbscr is also associated with endoplasmic reticulum aminopeptidase 2 ( erap2 ), an enzyme involved in processing hla class i ligands, thus implicating the a * 29 : 02 peptidome in this disease.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nmber of the elav family of rna - binding proteins, has been implicated in this pathway through its binding to adenine and uridine ( au ) - rich stability elements ( are ) located in the 3'untranslated regions ( 3'- utrs ) of the mrna. whereas three"
        },
        {
          "qas": [
            {
              "id": "5e30f23cfbd6abf43b000042_001",
              "question": "Is modified vaccinia Ankara effective for smallpox?"
            }
          ],
          "context": "modified vaccinia ankara : potential as an alternative smallpox vaccine\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\nmodified vaccinia ankara was safe and immunogenic in subjects infected with hiv and represents a promising smallpox vaccine candidate for use in immunocompromised populations.\nimvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\nwhile modified vaccinia virus ankara ( mva ) is currently in clinical development as a safe vaccine against smallpox and heterologous infectious diseases, its immunogenicity is likely limited due to the inability of the virus to replicate\nmodified vaccinia virus ankara ( mva ) is a highly attenuated vaccinia virus that is under consideration as an alternative to the conventional smallpox vaccine dryvax\nmodified vaccinia virus ankara ( mva ) is a replication - deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombi \" \" t viral vector to produce vaccines against infectious diseases and cancer.\none of the most advanced and most promising vectors is the attenuated, non - replicating poxvirus mva ( modified vaccinia virus ankara ), a safer derivative of the uniquely successful smallpox vaccine\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\nmodified vaccinia virus ankara ( mva ) is an attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombi \" \" t viral vector to produce vaccines against infectious diseases and cancer"
        },
        {
          "qas": [
            {
              "id": "5e30f76afbd6abf43b000046_001",
              "question": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?"
            }
          ],
          "context": "nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\npotential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.\nin the senscis\u00ae trial, nintedanib reduced the rate of ild progression in patients with systemic sclerosis - associated ild\nobjectives nintedanib is approved for the treatment of idiopathic pulmonary fibrosis ( ipf ) and was demonstrated to slow disease progression in patients with ipf by reducing decline in forced vital capacity by 50 %.\ndesign of a randomised, placebo - controlled clinical trial of nintedanib in patients with systemic sclerosis - associated interstitial lung disease ( senscis\u2122 ).\n. these data might have direct implications for the ongoing phase iii clinical trial with nintedanib in ssc - associated interstitial lung disease.\nconclusion : nintedanib targets core features of ssc in fra2 - transgenic mice and ameliorates histological features of pulmonary arterial hypertension, destructive microangiopathy and pulmonary and dermal fibrosis\n. it is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis - associated lung fibrosis.\nnewer agents with anti - fibrotic properties, such as pirfenidone or nintedanib, might hold promise also for the pulmonary fibrosis seen in sarcoidosis.\nnintedanib ( ofev\u2122 ), an oral triple kinase inhibitor targeting pro - fibrotic pathways, has been used for treatment of idiopathic pulmonary fibrosis ( ipf )."
        },
        {
          "qas": [
            {
              "id": "5e49a1196d0a27794100000d_001",
              "question": "Is PF-05190457 an inverse agonist of the ghrelin receptor?"
            }
          ],
          "context": "pf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nreceptor inverse agonist pimavanserin was recently approved by the us fda for the treatment of pdp and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\nobjective : our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5 - ht2a receptor inverse agonist / antagonist indicated for the treatment of hallucinations and delusions associated with parkinson's disease\npimavanserin, a serotonin ( 2a ) receptor inverse agonist, for the treatment of parkinson's disease psychosis.\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nantagonist fosphenytoin, magnesium, glycine site antagonist gv150526 and piracetam.\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\npimavanserin, a selective 5 - ht2a inverse agonist / antagonist, was approved in the u. s. for treating hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia."
        },
        {
          "qas": [
            {
              "id": "5e30e9e3fbd6abf43b00003c_001",
              "question": "Is Ubrogepant effective for migraine?"
            }
          ],
          "context": "ubrogepant for the treatment of migraine.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\nthe cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\ncgrp receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against cgrp ( eptinezumab, fremanezumab and galcanezumab ) or the cgrp receptor ( erenumab ) effectively prevent migraine\nubrogepant ( mk - 1602 ) is a novel, oral, calcitonin gene - related peptide receptor antagonist in clinical development with positive phase iii outcomes for acute treatment of migraine.\nrecently, orally administered next - generation small molecule cgrp - ras have been shown to have safety and efficacy in acute treatment ( ubrogepant and rimegepant ) and prevention ( atogepant ) of migraine, giving additional cgrp - based therapeutic options\narea covered : this review reports on compounds currently under development for the oral treatment of acute migraine attacks, focusing on calcitonin - gene - related - peptide receptor antagonists, specifically ubrogepant and rimegepant.\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the fda for this indication.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine."
        },
        {
          "qas": [
            {
              "id": "5e30f494fbd6abf43b000044_001",
              "question": "Is Selinexor effective for multiple myeloma?"
            }
          ],
          "context": "conclusions selinexor - dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.\nconclusion the combination of selinexor and dexamethasone has an orr of 21 % in patients with heavily pretreated, refractory myeloma with limited therapeutic options.\nselinexor ( in combination with dexamethasone ) received accelerated approval in the usa in july 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma ( rrmm ).\nthe fda granted accelerated approval to selinexor plus low - dose dexamethasone for triple - class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data.\nobjective : to review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma ( mm ).\nselinexor plus low - dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins.\nsafety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia.\n. the combination of selinexor and dexamethasone has demonstrated activity in \" penta - refractory \" mm, ( ie, mm refractory to the 5 most active anti - mm agents currently used in treatment ).\nselinexor, an exportin - 1 inhibitor, yielded promising results in quad - or penta - refractory mm including patients resistant to daratumumab."
        },
        {
          "qas": [
            {
              "id": "5e447f2448dab47f26000013_001",
              "question": "Are there lncRNAs that control the extent of neuronal outgrowth?"
            }
          ],
          "context": ". we show that two of these lncrnas regulate the extent of neuronal outgrowth\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\nit is now evident that noncoding rnas play key roles in regulatory networks determining cell fate and behavior, in a myriad of different conditions, and across all species\nhere, we profiled gene expression following sciatic nerve crush in mice and identified long noncoding rnas ( lncrnas ) that act in the regenerating neurons and which are typically not expressed in other contexts\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nprevious reports indicate that distinct rna sequence in the bdnf 3'utrs differentially regulates bdnf production in the brain to accommodate neuronal activity changes, conceivably through differential interactions with undefined trans - acting factors\nrecent evidence has demonstrated that circular rnas ( circrnas ) played crucial roles in fine - tuning the levels of gene expression by sequestering the corresponding microrna ( mirnas )."
        },
        {
          "qas": [
            {
              "id": "5e4af1d86d0a277941000018_001",
              "question": "Does metformin has as an antitumor effect?"
            }
          ],
          "context": "the anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\nmetformin, an antidiabetic drug, inhibits the endometrial cancer cell growth in vivo by improving the insulin resistance ;\nthere is no evidence of antitumor effect of metformin. a possible decrease only for breast, liver and prostate cancer, is compatible with random fluctuations.\nan association between metformin and tumorigenesis\nmetformin abated the progression of diabetes - accelerated atherosclerosis by inhibiting mitochondrial fission in endothelial cells.\npleiotropic benefits of metformin in attenuation of atherosclerosis.\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.\nmetformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti - inflammatory and anti - atherosclerotic properties.\ncardenolides have shown significant antitumor activity due to their ability to inhibit the na + k + atpase enzyme, and the expression of this enzyme is increased in tumor cells.\nmetformin's effects on lipids and atherosclerotic vascular disease and / or provide insights into the drug's mechanisms of action on the heart and vasculature."
        },
        {
          "qas": [
            {
              "id": "5e3234e0fbd6abf43b000054_001",
              "question": "Can radiation induced meningiomas be treated with radiosurgery?"
            }
          ],
          "context": "conclusions gamma knife radiosurgery is both a safe and effective treatment for radiation - induced meningiomas.\nstereotactic radiosurgery ( srs ) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation - induced tumors is unclear.\nit is well known that radiation can induce meningiomas. these tumors usually arise in patients with a history of low - dose radiation to the scalp for treatment of tinea capitis or high - dose radiation for a previous brain tumor.\nalthough meningiomas are known to be induced by low doses of cranial irradiation, such as those given to treat tinea capitis, little experience has been reported on the induction of meningiomas by high - dose cranial irradiation.\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\n. we encountered a patient who developed multiple intracranial radiation - induced meningiomas ( rims ) 25 years after prophylactic cranial irradiation for the treatment of acute leukemia in childhood.\ncranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims ).\nradiation - induced world health organization grade ii meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. three case reports.\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection."
        },
        {
          "qas": [
            {
              "id": "5e3709a4b5b409ea53000012_001",
              "question": "Is there a BRCA mutation analysis in the Greek population?"
            }
          ],
          "context": "comprehensive brca mutation analysis in the greek population. experience from a single clinical diagnostic center.\n. our results indicate that different types of mutational events in the brca1 and brca2 genes are responsible for the hereditary component of breast / ovarian cancer in the greek population\n. we performed molecular analysis of the brca1 and brca2 genes in 898 greek families, using sanger sequencing or next generation sequencing for the detection of small insertion / deletion frameshift, nonsynonymous, truncating and splice - site\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes.\n. in total, a pathogenic mutation was identified in 12. 9 % of 898 families analyzed. of the 116 mutations identified in total 9 % were novel and 14. 7 % were large genomic rearrangements\n. sensitive and accurate detection of brca1 and brca2 mutations is crucial for personalized clinical management of individuals affected by breast or ovarian cancer, and for the identification of at - risk healthy relatives\na germ - line or somatic mutation in the breast cancer gene ( brca ).\na germ - line or somatic mutation in the breast cancer gene ( brca ).\nusing massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in bcl11b\n. the same mutational signature was detected in a subset of 5, 876 human cancer genomes from two independent cohorts, predomi \" \" tly in colorectal cancer"
        },
        {
          "qas": [
            {
              "id": "5e2dbf48fbd6abf43b00001a_001",
              "question": "Has ProSavin undergone phase IV clinical trials by 2018?"
            }
          ],
          "context": "long - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nbased on positive results from a phase i / ii clinical trial\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\nobjective to review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of pimavanserin for the treatment of hallucinations and delusions of parkinson's disease psychosis ( pdp ).\nten classes of neuroprotective agents have reached phase iii efficacy trials but have shown mixed results"
        },
        {
          "qas": [
            {
              "id": "5d35b9ecb3a6380763000004_001",
              "question": "Does deletion of cohesin change gene expression?"
            }
          ],
          "context": "these structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\nin support of this model, single - molecule imaging experiments indicate that saccharomyces cerevisiae condensin complexes can extrude dna loops in an atp - hydrolysis - dependent manner in vitro.\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\ndna compaction by cohesin requires adenosine triphosphate ( atp ) hydrolysis and is force sensitive.\nthe conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, h3k27ac, h4k4me1, and enhancer transcription, but weakened interactions between enhancers.\n. in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\nwe suggest that loading and translocation are mediated by conformational changes in cohesin's hinge driven by cycles of atp hydrolysis.\nwe observed that a single condensin complex is able to extrude tens of kilobase pairs of dna at a force - dependent speed of up to 1500 base pairs per second, using the energy of adenosine triphosphate hydrolysis\nthe dna - organizing mechanism of condensin depends on the energy of atp hydrolysis but how this activity specifically promotes proper compaction and segregation of chromosomes during mitosis remains poorly understood.\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )"
        },
        {
          "qas": [
            {
              "id": "5e2e1d6afbd6abf43b000026_001",
              "question": "Do MAIT cells have a role in multiple myeloma?"
            }
          ],
          "context": "here we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\nwe describe recent observations with regard to functional exhaustion of inkt and mait cells in mm pathology and discuss the potential application of checkpoint inhibition as an attractive target for prolonged activation of these immunomodulatory t\nprolonged activation of these immunomodulatory t cells in the treatment of mm.\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\nt regulatory cells ( tregs ) have a role in immunosuppression and control of autoimmunity, and are currently an important topic in the study of immune response to tumor cells.\nmxa, ifitm1 ) in cd14 + monocytes of csle patients and healthy controls ( hcs )\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nmaternal immune tolerance is important for maintaining preg \" \" cy, and researchers have increasingly focused on the critical roles of cytokines in the pathogenesis of pe in recent years."
        },
        {
          "qas": [
            {
              "id": "5e3e843748dab47f26000007_001",
              "question": "Are stretch enhancers transcribed more than super-enhancers?"
            }
          ],
          "context": "super - enhancers are transcriptionally more active and cell type - specific than stretch enhancers.\n. these results suggest that super - enhancers are transcriptionally more active and cell type - specific than stretch enhancers, and importantly, most of the stretch enhancers that are distinct from super - enhancers do not show an association with cell\n. importantly, a vast majority of super - enhancers ( 85 % ) overlap with only a small subset of stretch enhancers ( 13 % ), which are enriched for cell type - specific biological functions, and control cell identity genes\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\nsuper - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\nmany enhancers map quite far from their target genes, on the order of tens or even hundreds of kilobases.\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\nin metazoans transcriptional enhancers and their more complex relatives, locus control regions, are often located at great linear distances from their target genes.\nthe term'super - enhancer'has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of mediator binding, as measured by chromatin immunoprecipitation and sequencing ( chip - seq )."
        },
        {
          "qas": [
            {
              "id": "5e31c4adfbd6abf43b00004d_001",
              "question": "Is mesothelioma caused by asbestos exposure?"
            }
          ],
          "context": "malig \" \" t mesothelioma is caused by exposure to asbestos, which is known to have carcinogenic effects.\nmesothelioma, a rare tumor, is highly correlated with asbestos exposure.\nmalig \" \" t mesothelioma and lung cancer are caused by all major types of asbestos.\noccupational asbestos exposure occurs in many workplaces and is a well - known cause of mesothelioma and lung cancer.\nbackground malig \" \" t mesothelioma caused by asbestos exposure has a long latency period.\nmalig \" \" t mesothelioma is a rare and aggressive pleural or peritoneal tumour almost always caused by exposure to asbestos fibres.\nasbestos exposure causes asbestosis and malig \" \" t mesothelioma, disorders which remain difficult to cure.\noccupational exposure to asbestos occurs in many workplaces and is well known to cause asbestosis, lung cancer, and mesothelioma.\nmost mpem is caused by asbestos exposure\nobjective malig \" \" t pleural mesothelioma in rural turkey frequently results from environmental exposure to tremolite asbestos or fibrous zeolite ( erionite )."
        },
        {
          "qas": [
            {
              "id": "5e46fda33f54159529000012_001",
              "question": "Are there interactions between short and long noncoding RNAs?"
            }
          ],
          "context": ". other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\n. among these noncoding rnas are short rnas, such as micrornas, snornas, and piwi - interacting rnas, and the functions of those are relatively well understood\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\n. here, i review the known types of interactions between small and long rnas, discuss their outcomes, and bring representative examples from studies in mammals.\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\nit is now evident that noncoding rnas play key roles in regulatory networks determining cell fate and behavior, in a myriad of different conditions, and across all species\nrecent evidence has demonstrated that circular rnas ( circrnas ) played crucial roles in fine - tuning the levels of gene expression by sequestering the corresponding microrna ( mirnas ).\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats"
        },
        {
          "qas": [
            {
              "id": "5e5b90b3752ebcdc7a000002_001",
              "question": "Can brain derived exosomes carry APP molecules?"
            }
          ],
          "context": "accumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\nthese exosomes contained app and were capable of efficiently transferring app to normal primary neurons.\nhere we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta\nhere, we show that small lipid vesicles called exosomes, secreted in the extracellular milieu by cortical neurons, carry endogenous app\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nbacteria derived - extracellular vesicles\n. reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\nand regulators of protein translation or being translated into peptides in various diseases ; 5 ) circrnas have been identified for their enrichment and stability in exosomes and detected in body fluids such as human blood, saliva, and cerebrospinal\nsuch as human blood, saliva, and cerebrospinal fluids, suggesting that these exo - circrnas have potential applications as disease biomarkers and novel therapeutic targets ; 6 ) several circrnas are regulated by oxidative stress and mediate reactive"
        },
        {
          "qas": [
            {
              "id": "5d38826ea1e1595105000016_001",
              "question": "Is SATB1 positioned close to AT-rich sequences?"
            }
          ],
          "context": "satb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\nspecial at - rich sequence binding protein - 1 ( satb1 ) is localized to the nucleus and remodels chromatin structure in t cells\nspecial at - rich sequence - binding protein 1 ( satb1 ), a dna - binding protein expressed predomitly in thymocytes, recognizes an atc sequence context that consists of a cluster of sequence stretches with well - mixed a's, t's, and c's without g's on one\nsatb1 ( special at - rich binding protein 1 ) is a global chromatin organizer regulating the expression of a large number of genes\nspecial at - rich sequence - binding protein 1 ( satb1 ) is a cell type - specific matrix attachment region binding protein, functioning as a global genome organizer.\nchromatin organizers satb2 and satb1\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\npecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling."
        },
        {
          "qas": [
            {
              "id": "5d38462b7bc3fee31f000012_001",
              "question": "Does metformin alleviate atherosclerosis?"
            }
          ],
          "context": "pleiotropic benefits of metformin in attenuation of atherosclerosis.\nmetformin's effects on lipids and atherosclerotic vascular disease and / or provide insights into the drug's mechanisms of action on the heart and vasculature.\nmetformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses\nmetformin abated the progression of diabetes - accelerated atherosclerosis by inhibiting mitochondrial fission in endothelial cells.\nmetformin inhibits monocyte - to - macrophage differentiation via ampk - mediated inhibition of stat3 activation : potential role in atherosclerosis.\n. taken together, our results suggest that atorvastatin / metformin combination therapy may achieve additional anti - atherosclerotic benefits likely through increasing cholesterol efflux in macrophages.\nmetformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti - inflammatory and anti - atherosclerotic properties.\nmetformin treatment prevents srebp2 - mediated cholesterol uptake and improves lipid homeostasis during oxidative stress - induced atherosclerosis\ncombined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high - cholesterol diet.\nthe anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac"
        },
        {
          "qas": [
            {
              "id": "5e2e1017fbd6abf43b000020_001",
              "question": "Are CD8+ (cytotoxic) T cells and  CD4+ Helper T cells generated in the thyroid and express the T-cell receptor?"
            }
          ],
          "context": "in the mammalian thymus, cd4 helper t cells and cd8 cytotoxic t cells arise from a common precursor that expresses both cd4 and cd8.\ncytotoxic t lymphocytes and the cd4 + 8 - tcr + t helper cells.\n. the cd4 ( + ) helper versus cd8 ( + ) cytotoxic t - cell fate decision serves as an excellent model to study binary fate decision processes. these two cell types are derived from common precursors in the thymus.\nin the thymus, immature cd8 ( - 4 ) - tcr - cells differentiate, possibly via a short stage of cd8 + 4 - thymocytes, into cd8 + 4 + tcr + t cells and mature further into the main t cell populations, the cd8 + 4 - tcr + cytotoxic t lymphocytes and the cd4 + 8 - tcr + t\nin the thymus, mature cd4 + cd8 - and cd4 - cd8 + t cells expressing alpha beta t - cell antigen receptors ( tcr ) develop from immature thymocytes through cd4 + cd8 + alpha beta tcr + intermediates.\nsignals elicited by binding of the t - cell antigen receptor and the cd4 / cd8 co - receptor to major histocompatibility complex ( mhc ) molecules control the generation of cd4 + ( helper ) or cd8 + ( cytotoxic ) t cells from thymic precursors that initially\ncd4 + cd8 + progenitor thymocytes undergo selection following interaction with mhc class i and class ii molecules bearing peptide self - antigens, giving rise to cd8 + cytotoxic and cd4 + helper or regulatory t cell lineages, respectively.\na fundamental question in developmental immunology is how bipotential thymocyte precursors generate both cd4 + helper and cd8 + cytotoxic t cell lineages.\ndevelopment, differentiation, and function of thymocytes and cd4 ( + ) and cd8 ( + ) t cells are controlled by a multitude of secreted and intracellular factors\namongst these, naturally occurring cd4 ( + ) cd25 ( + ) treg cells ( ntreg ) represent a major lymphocyte population engaged in the domi \" \" t control of self - reactive t responses and maintaining tolerance in several models of autoimmunity."
        },
        {
          "qas": [
            {
              "id": "5e31d181fbd6abf43b000053_001",
              "question": "Is Huntington's disease is caused by expansion of a CTG repeat in the HTT gene on Chromosome 4?"
            }
          ],
          "context": "background huntington's disease is caused by a cag repeat expansion in the huntingtin gene, htt.\nhuntington's disease ( hd ) is a neurodegenerative disorder caused by a cag trinucleotide repeat expansion in the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is a progressive neurodegenerative disorder caused by a cag trinucleotide repeat expansion in the huntingtin ( htt ) gene, which encodes a polyglutamine tract in the htt protein.\nhuntington's disease ( hd ) is an autosomal disease caused by a cag repeat expansion in the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is a neurodegenerative disease caused by the expansion of a cag trinucleotide repeat in exon 1 of the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is an autosomal domit disorder caused by an expansion in the trinucleotide cag repeat in exon - 1 in the huntingtin gene, located on chromosome 4.\nhuntington's disease ( hd ), caused by a cag repeat expansion in the huntingtin ( htt ) gene, is characterized by abnormal protein aggregates and motor and cognitive dysfunction.\nhuntington's disease ( hd ) is an inherited neurodegenerative disease caused by an expanded cag repeat in the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is an autosomal domit neurodegenerative disease caused by the expansion of a cag trinucleotide repeat in exon 1 of the huntingtin ( htt ) gene.\nhuntington's disease ( hd ) is caused by a cag repeat expansion that encodes a polyglutamine ( polyq ) expansion in the hd disease protein, huntingtin ( htt )."
        },
        {
          "qas": [
            {
              "id": "5e323780fbd6abf43b000055_001",
              "question": "Is there an increased risk of meningiomas in atomic bomb survivors?"
            }
          ],
          "context": ". the present findings strongly suggest that meningioma is one of the tumors induced by atomic bombing in hiroshima.\nhigh incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.\nthe radiation - induced occurrence of meningiomas and other brain tumours most probably contributes to the continuously increasing incidence of these diseases which is observed in several industrial nations, as well as the exposure of the bone marrow\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\nemphasis is placed on meningiomas resulting from childhood treatment for primary brain tumor or tinea capitis, exposure to dental x - rays, and exposure to atomic explosions in hiroshima and nagasaki.\nit is well known that radiation can induce meningiomas. these tumors usually arise in patients with a history of low - dose radiation to the scalp for treatment of tinea capitis or high - dose radiation for a previous brain tumor.\nthe incidences of meningioma among the survivors of hiroshima in 5 - year intervals since 1975 were 5. 3, 7. 4, 10. 1, and 14. 9, respectively.\nsurvivors of childhood all treated with high - dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation - induced meningioma\n. the incidence among nagasaki atomic - bomb survivors over 40 years of age, especially in those proximally exposed, appears to be increasing, in inverse proportion to the exposure distance, since 1981, 36 years after the explosion of the atomic bomb.\nradiation - induced world health organization grade ii meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. three case reports."
        },
        {
          "qas": [
            {
              "id": "5e41620648dab47f2600000e_001",
              "question": "Is poliosis circumscripta another term for a white or unpigmented patch of hair or skin?"
            }
          ],
          "context": "although traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\nacanthosis nigricans maligna : symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma\nas atopic dermatitis ( ad ), psoriasis, vitiligo, and alopecia areata.\nfinally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically - diverse malig \" \" cies ( leser - trelat syndrome, trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita,\nrepens, hypertrichosis lanuginosa acquisita, papuloerythroderma of ofuji, tripe palms, and multicentric reticulohistiocytosis )\noccasionally, alien species of ticks transferred to the territory of poland are recorded : amblyomma sphenodonti, amblyomma exornatum, amblyomma flavomaculatum, amblyomma latum, amblyomma nuttalli, amblyomma quadricavum, amblyomma transversale,\n. oral lesions of pv are distinct and present as multiple white or yellow pustules with an erythematous base that coalesce and undergo necrosis to form a typical \" snail tracks \" appearance\npresenting as red birthmarks ) based on the results of animal experiments.\nxerosis was present in two cases, and paronychia, pyogenic granuloma, trichomegaly, and madarosis were observed in one patient each.\nthe disease affects mainly female patients, who often deny the habit, and it usually presents with a bizarre pattern nonscarring patchy alopecia with short hair and a negative pull test."
        },
        {
          "qas": [
            {
              "id": "5e44bdba48dab47f2600001c_001",
              "question": "Is Selumetinib effective for low-grade glioma?"
            }
          ],
          "context": "3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\ninterpretation : selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common braf aberrations and nf1 - associated paediatric low - grade glioma.\nconclusion selumetinib has promising antitumor activity in children with lgg.\nthe next generation egfr tkis osimertinib and azd3759 have improved bbb penetration and the bloom study of osimertinib and azd3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\nselinexor, an exportin - 1 inhibitor, yielded promising results in quad - or penta - refractory mm including patients resistant to daratumumab.\nthe phase ii juliet trial suggests that the cd19 - targeting car t - cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large b - cell lymphoma.\nthis article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma."
        },
        {
          "qas": [
            {
              "id": "5d35c227b3a6380763000007_001",
              "question": "Is SATB1 expressed in thymocytes?"
            }
          ],
          "context": "satb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nhigh level expression of the xlr nuclear protein in immature thymocytes and colocalization with the matrix - associated region - binding satb1 protein\nthe transcription factor satb1 that regulates the t - cell maturation\nspecial at - rich sequence - binding protein 1 ( satb1 ), a dna - binding protein expressed predomitly in thymocytes, recognizes an atc sequence context that consists of a cluster of sequence stretches with well - mixed a's, t's, and c's without g's on one\nspecial at - rich sequence binding protein - 1 ( satb1 ) is localized to the nucleus and remodels chromatin structure in t cells\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\nchromatin organizers satb2 and satb1"
        },
        {
          "qas": [
            {
              "id": "5e44c18648dab47f2600001f_001",
              "question": "Does gavestinel improve outcomes of stroke patients?"
            }
          ],
          "context": "the wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\ntreatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.\nin this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.\nconclusion : consistent with the clinical outcomes in the gain trials, no effects of gavestinel on ischemic infarction was observed.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\nmethods : we studied all patients of the glycine antagonist ( gavestinel ) in neuroprotection ( gain ) international trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke - related causes\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\ninterpretation : prehospital treatment with transdermal gtn does not seem to improve functional outcome in patients with presumed stroke."
        },
        {
          "qas": [
            {
              "id": "5e4c06d96d0a27794100002e_001",
              "question": "Can Systemic Lupus Erythematosus cause seizures?"
            }
          ],
          "context": "seizures are one of the most serious neuropsychiatric manifestations of systemic lupus erythematous ( sle ).\nepilepsy is characterized by a relevant epidemiological and clinical burden. in the extant literature, an increased risk of seizures has been described in several inflammatory / autoimmune disorders, including systemic lupus erythematosus ( sle ).\nepileptic seizures and eeg features in juvenile systemic lupus erythematosus.\nconclusions seizures tend to occur early in the course of systemic lupus erythematosus, and contribute to damage accrual.\nobjective to evaluate the frequency and risk factors of epileptic seizures in a large cohort of patients with systemic lupus erythematosus ( sle ).\nto determine the factors associated with seizures in systemic lupus erythematosus ( sle ).\nthe aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus ( sle\nthe mean \u00b1 sd age at sle diagnosis and at onset of pres was 25. 02 \u00b1 13. 78 and 28. 31 \u00b1 12. 61 years, respectively. seizure was the most common presenting symptom, as seen in 28 episodes, followed by acute severe headache in 17,\nintellectual disability with autistic features and seizures\nstructural nervous system lesions to explain the symptoms."
        },
        {
          "qas": [
            {
              "id": "5e4fd4d56d0a277941000034_001",
              "question": "Is Impetigo a viral infection that affects the skin?"
            }
          ],
          "context": "impetigo contagiosa is a common, superficial, bacterial infection of the skin characterised by an inflamed and infected epidermis caused by staphylococcus aureus, streptococcus pyogenes or both.\nimpetigo is a common, superficial, bacterial infection of the skin characterized by an inflamed and infected epidermis.\nimpetigo, a bacterial skin infection that involves the superficial layers of the skin, is one of the most common skin infections in children ages 2 to 5 but can occur in individuals across the lifespan.\nimpetigo is a superficial, but contagious, bacterial infection of the skin that predomi \" \" tly affects children and is common in primary care.\nimpetigo is a superficial bacterial infection that most commonly affects the face and extremities of children.\nof impetigo, a highly contagious bacterial skin infection\nimpetigo, cellulitis, and abscess comprise the majority of childhood bacterial skin infections and are treated with topical or systemic antibiotics that cover group a streptococcus and staphylococcus aureus.\nimpetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children\nbackground impetigo can result from staphylococcus aureus ( s. aureus ).\nimpetigo is the most common bacterial skin infection of children."
        },
        {
          "qas": [
            {
              "id": "5e44caaf48dab47f26000024_001",
              "question": "Should Lubeluzole be used for treatment of ischemic stroke?"
            }
          ],
          "context": "treatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\nconclusions : in patients with acute ischemic stroke, the dosage regimen of 7. 5 mg over 1 hour followed by 10 mg / d of intravenous lubeluzole is safe and statistically significantly reduced mortality.\nconclusions : this study failed to show an efficacy of lubeluzole in the treatment of acute stroke.\nconclusions : lubeluzole, given in the acute phase of ischaemic stroke, is not associated with a significant reduction of death or dependency at the end of scheduled follow - up period but seems to be associated with a significant increase of\n. lubeluzole treatment similarly resulted in significantly greater improvements in functional status ( barthel index ) ( p =. 038 ) and overall disability ( rankin scale ) ( p =. 034 ) after 12 weeks\n. controlling for relevant covariates, the degree of neurological recovery ( nihss ) at week 12 significantly favored lubeluzole over placebo ( p =. 033 )\n. a global test statistic confirmed that lubeluzole - treated patients had a more favorable clinical outcome at 12 weeks ( p =. 041 ).\nhowever, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long qt syndrome and ventricular arrhythmias."
        },
        {
          "qas": [
            {
              "id": "5e36994092b3349b55000002_001",
              "question": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?"
            }
          ],
          "context": ". our data indicate that tet proteins regulate inkt cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the t cell antigen receptor ( tcr ).\nwe found that simultaneous deletion of tet2 and tet3 in mouse cd4 + cd8 + double - positive thymocytes resulted in dysregulated development and proliferation of invariant natural killer t cells ( inkt cells )\n. tet2 - tet3 double - knockout ( dko ) inkt cells displayed pronounced skewing toward the nkt17 lineage, with increased dna methylation and impaired expression of genes encoding the key lineage - specifying factors t - bet and thpok\n. transfer of purified tet2 - tet3 dko inkt cells into immunocompetent recipient mice resulted in an uncontrolled expansion that was dependent on the nonclassical major histocompatibility complex ( mhc ) protein cd1d, which presents lipid antigens to\nthe transcription factor t - cell factor 3 ( tcf3 ), one component of the wnt pathway, is known as a cell - intrinsic inhibitor of many pluripotency genes in embryonic stem cells ( escs ) that influences the balance between pluripotency and differentiation.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\nmaintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\nfurthermore, our data show that the mechanism by which pten null eccs emerge in vitro and cause tumors in vivo is through increased survival and self - renewal, due to failed repression of the transcription factor nanog.\ntfii - i is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. tfii - i has been implicated in neuronal and immunologic diseases as well as in thymic epithelial cancer"
        },
        {
          "qas": [
            {
              "id": "5e3c80abb5b409ea53000024_001",
              "question": "Thymoquinone is ineffective against radiation induced enteritis, yes or no?"
            }
          ],
          "context": "tq might be used for radiation enteritis treatment.\nsuggesting that these pathways do not predispose cyld - deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and / or pro - inflammatory stress. conclusions : our findings underscore a critical tumor - suppressing role\n. although the protective effect of ivermectin was shown in the overall and pre - exposure populations, the results were unreliable owing to poor - quality evidence.\nour findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\nconclusion : treatment with marimastat after induction therapy for sclc did not result in improved survival and had a negative impact on quality of life.\nno significant associations between space radiation dose and mortality were found using logistic regression with an internal reference group, adjusting for medical radiation.\nalthough thalidomide was withdrawn in the 1960s after its teratogenic property was recognized, it was subsequently found that this drug possesses immunomodulatory and anti - inflammatory effects.\nthere was no apparent difference between bovine and rhesus - based rotavirus vaccines in the protective efficacy against severe rotavirus gastroenteritis.\nthalidomide and its immunomodulatory analogues have numerous effects on the body's immune system, including potential anti - cancer and anti - inflammatory activities."
        },
        {
          "qas": [
            {
              "id": "5e5d27531af46fc130000007_001",
              "question": "Has the Spanich flu virus been reconstructed?"
            }
          ],
          "context": "reconstruction of the 1918 influenza virus has facilitated considerable advancements in our understanding of this extraordinary pandemic virus.\nreconstruction of the 1918 virus and studies elucidating the exceptional virulence and transmissibility of the virus are providing exciting new insights into this devastating pandemic strain.\nthese viral rna sequences eventually permitted reconstruction of the complete 1918 virus, which has yielded, almost a century after the deaths of its victims, novel insights into influenza virus biology and pathogenesis and has provided important\nand pathogenesis and has provided important information about how to prevent and control future pandemics.\nwe report a 12 - year - old girl infected with influenza a h1n1 whose clinical course was complicated by rapid progressive neurologic deterioration and striking ct and mri findings consistent with acute necrotizing encephalopathy ( ane ).\nwe show that although covid - 19 and influenza are different in many ways, there are numerous similarities ; thus, in addition to using nucleic acid - based polymerase chain reaction ( pcr ) and antibody - based approaches, clinicians and epidemiologists\nan intradermal version of fluzone\u00ae split - virion inactivated trivalent influenza vaccine, containing 9 \u00b5g hemagglutinin per strain of a / h1n1, a / h3n2, and one b lineage virus ( fluzone intradermal, sanofi pasteur ), became available in the us during the\npasteur ), became available in the us during the 2011 - 2012 influenza season for adults 18 - 64 years of age\nprior to the emergence of antigenically distinct sars - cov - 2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses.\ncharacterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil."
        },
        {
          "qas": [
            {
              "id": "5e3a6c49b5b409ea53000017_001",
              "question": "Is Verubecestat effective for Alzheimer's Disease?"
            }
          ],
          "context": "this reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\nverubecestat is an inhibitor of \u03b2 - site amyloid precursor protein cleaving enzyme 1 ( bace1 ) being evaluated in clinical trials for the treatment of alzheimer's disease.\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nverubecestat, a bace1 inhibitor that reduces a\u03b2 levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial ( epoch ) of mild - to - moderate ad and was associated with adverse events.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\nverubecestat did not improve clinical ratings of dementia among patients with prodromal alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nin apecs, verubecestat 40 mg worsened cognition and increased adverse effects. expert opinion : in recruiting subjects to clinical trials in alzheimer's disease, a clinical diagnosis involving the measurement of a\u03b2 should be undertaken for all\nthese results support the continued global development of verubecestat as a potential disease - modifying agent for japanese and non - japanese subjects who are at - risk for developing ad."
        },
        {
          "qas": [
            {
              "id": "5e44c76f48dab47f26000022_001",
              "question": "Is Aptiganel effective for treatment of stroke?"
            }
          ],
          "context": "conclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\n. the larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nno improvement in clinical outcome of stroke has been seen with competitive nmda antagonists ( selfotel ) and non - competitive nmda antagonists ( dextrorphan, gv150526, aptiganel and eliprodil\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\nglutamate n - methyl - d - aspartate ( nmda ) receptor antagonists such as selfotel, aptiganel, gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.\n. aptiganel was also associated with a trend towards worse functional outcome ( or 1. 20 [ 0. 88 - 1. 65 ] ) although this was not the case for either of the other two compounds.\nconclusions : this study failed to show an efficacy of lubeluzole in the treatment of acute stroke.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\n. the mortality rate at 120 days in patients treated with high - dose aptiganel was higher than that in patients who received placebo ( 26. 3 % vs 19. 2 % ; p =. 06 )."
        },
        {
          "qas": [
            {
              "id": "5e47656935b8f0833c000004_001",
              "question": "Is indinavir effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "group differences in the rate of decline were not significant between the groups for the als functional rating scale ( p = 0. 36 ) or for the secondary variables. the toxicity and negative efficacy trends discourage further indinavir trials in als.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nneuroprotective agents are screened for use in patients with als.\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nbictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of the latest class of antiretrovirals available to treat human immunodeficiency virus ( hiv ) infection, the integrase strand transfer inhibitors.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported."
        },
        {
          "qas": [
            {
              "id": "5e324167fbd6abf43b00005a_001",
              "question": "Is there an increased risk for meningiomas in childhood leukemia survivors?"
            }
          ],
          "context": "high incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\ncranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims ).\n. we encountered a patient who developed multiple intracranial radiation - induced meningiomas ( rims ) 25 years after prophylactic cranial irradiation for the treatment of acute leukemia in childhood.\nsurvivors of childhood all treated with high - dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation - induced meningioma\nintraventricular meningioma after cranial irradiation for childhood leukemia.\nradiation - induced world health organization grade ii meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. three case reports.\nfocal cranial hyperostosis from meningioma : a complication from previous radiation treatment for childhood t - cell acute lymphoblastic leukemia.\nradiation - induced meningiomas : a shadow in the success story of childhood leukemia"
        },
        {
          "qas": [
            {
              "id": "5e540ed36d0a277941000054_001",
              "question": "Does saracatinib promote oncogenesis?"
            }
          ],
          "context": ". saracatinib blocked the src / fak, her family, and oncogenic signaling pathways, and it induced g ( 1 ) arrest and apoptosis in snu216 and nci - n87 cells.\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\na phase ii study of saracatinib ( azd0530 ), a src inhibitor, administered orally daily to patients with advanced thymic malig \" \" cies.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nexpert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\nwe demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation."
        },
        {
          "qas": [
            {
              "id": "5e2e0fa2fbd6abf43b00001f_001",
              "question": "Is BCL11B involved in schizophrenia?"
            }
          ],
          "context": "interacting partners bcl11b and gatad2a are also schizophrenia risk genes indicating that other genes interacting with or are regulated by satb2 are making a contribution to schizophrenia and cognition.\nconsistent with the findings described in bcl11b - deficient mice\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\n. six frameshift mutations, two nonsense mutations, one missense mutation, and two chromosomal rearrangements resulting in diminished bcl11b expression, arose de novo. a further frameshift mutation was transmitted from a similarly affected mother\n. our findings advance understanding of how setd1a mutations predispose to schizophrenia ( scz ) and point to novel therapeutic interventions.\nusing massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in bcl11b\nit a candidate gene for involvement in this gene deletion syndrome.\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\n. interestingly, the most severely affected patient harbours a missense mutation within a zinc - finger domain of bcl11b, probably affecting the dna - binding structural interface, similar to the recently published patient\nrecapitulation and reversal of schizophrenia - related phenotypes in setd1a - deficient mice."
        },
        {
          "qas": [
            {
              "id": "5e338cf5fbd6abf43b00005d_001",
              "question": "Are Chernobyl survivors at increased risk for breast cancer?"
            }
          ],
          "context": "historically, data from the chernobyl reactor accident 27 years ago demonstrated a strong correlation with thyroid cancer, but data on the radiation effects of chernobyl on breast cancer incidence have remained inconclusive.\nan increase in breast cancer incidence has been reported in areas of belarus and ukraine contaminated by the chernobyl accident and has become an issue of public concern.\nin contrast, millions of people were exposed to radioactive isotopes in the fallout from the chernobyl accident, within the first 20 years there was a large increase in thyroid carcinoma incidence and a possible radiation - related increase in breast\nresults : a more aggressive course of breast cancer is observed in patients exposed to radiation from the chernobyl accident under the age of 30 years ( p <. 01 ).\nfor breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the chernobyl accident.\nfurthermore, the upward trends of increases in a variety of other tumors including breast cancer, cancers of central nervous system and renal cancer have been reported in the persons exposed to chornobyl fallout.\nepidemiological cohort studies found increased incidence ( 1990 - 2012 gg. ) of thyroid cancer in victims of chernobyl accident ( liquidators - in 4. 6 times, evacuated - in 4. 0 times, residents of contaminated areas - in 1. 3 times ) and increased incidence\n. the incidence among nagasaki atomic - bomb survivors over 40 years of age, especially in those proximally exposed, appears to be increasing, in inverse proportion to the exposure distance, since 1981, 36 years after the explosion of the atomic bomb.\nrisks of lung, breast, and gastrointestinal ( gi ) cancers increase with higher radiation dose.\na possible radiation - related increase in breast cancer, but as yet there is no general increase in malig \" \" cies."
        },
        {
          "qas": [
            {
              "id": "5d36b4817bc3fee31f000007_001",
              "question": "Is SATB1 necessary for T-cell maturation?"
            }
          ],
          "context": "satb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nthe transcription factor satb1 that regulates the t - cell maturation\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\nchromatin organizers satb2 and satb1\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\nspecial at - rich sequence binding protein - 1 ( satb1 ) is localized to the nucleus and remodels chromatin structure in t cells\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\nsatb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\nhigh level expression of the xlr nuclear protein in immature thymocytes and colocalization with the matrix - associated region - binding satb1 protein"
        },
        {
          "qas": [
            {
              "id": "5e46bf743f54159529000008_001",
              "question": "Have toll-like receptor 2 activators been found in food?"
            }
          ],
          "context": ". tlr2 activators are found in many common foods,\ntlr2 activators are found in many common foods, but the role of tlr2 in oral tolerance and allergic sensitization to foods is not well understood.\ntoll - like receptor 9 ( tlr9 ) activation is attributed to delivery of bacterial dna\nthe c - type lectin receptor clec4e and toll - like receptor tlr4 expressed by host cells are among the first line of defense in encountering pathogens.\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\nwe found immune activation coexistent with elevation of multiple targetable immune checkpoint molecules, including pd - l1, pd - l2, pd - 1, tim - 3, b7 - h3, btla, and ctla - 4, along with increases in tumor infiltration by cd4 ( + ) foxp3 ( + ) regulatory t cells in\ngram - negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via toll - like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor - \u03b1 and to activate nlrp3 inflammasome, a multiprotein\nlactotransferrin ( ltf ) has been confirmed to act as a tumor suppressor in multiple cancers\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\nparalleled by significant reductions in t - helper 2 - associated inflammatory biomarkers."
        },
        {
          "qas": [
            {
              "id": "5e33904afbd6abf43b00005f_001",
              "question": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?"
            }
          ],
          "context": "it is recognized that survivors of hodgkin's disease are at a substantially increased risk of lung cancer.\npurpose this study was undertaken to investigate the effects of radiation dose, chemotherapy, and smoking on the risk of lung cancer following treatment of hodgkin's disease.\npurpose : hodgkin lymphoma ( hl ) survivors face an increased risk of treatment - related lung cancer.\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\nincreased risk of lung cancer, non - hodgkin's lymphoma, and leukemia following hodgkin's disease.\nbackground : patients treated for hodgkin's lymphoma ( hl ) have a higher risk of developing second lung cancer ( slc ) compared with the general population.\nbackground lung cancer is a frequent cause of death in patients cured of hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described.\nbackground : long - term hodgkin lymphoma ( hl ) survivors have an increased risk of late cardiac morbidity and secondary lung cancer after chemotherapy and mediastinal radiotherapy.\nrisks of lung, breast, and gastrointestinal ( gi ) cancers increase with higher radiation dose.\npurpose : hodgkin lymphoma ( hl ) survivors have an increased risk of cardiovascular disease ( cd ), lung cancer, and breast cancer."
        },
        {
          "qas": [
            {
              "id": "5e33916afbd6abf43b000061_001",
              "question": "Does radiotherapy for prostate cancer increase bladder cancer risk?"
            }
          ],
          "context": "radiation therapy for prostate cancer is associated with an increased risk of bladder cancer.\nradiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\nradiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer ( bc ).\nresults : during the median follow - up period of 4. 3 and 3. 1 years, secondary bladder cancer occurred in 11 ( 3. 4 % ) and 5 ( 1. 1 % ) of patients with prostate cancer treated with external beam radiotherapy and radical prostatectomy, respectively.\n. following brachytherapy only an increased for the development of bladder cancer ( hr : 2. 14, 95 % ci 1. 03 - 3. 94 ) has been observed.\ncervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites ( colon, rectum / anus, urinary bladder, ovary, and genital sites )\nbased on the data in the literature, there is a consistently increased risk of bladder cancer ( hr : 1. 67, 95 % ci 1. 55 - 1. 80 ), rectal cancer ( hr : 1. 79, 95 % ci 1. 34 - 2. 38 ), and colorectal cancer ( hr : 1. 79, 95 % ci 1. 34 - 23. 8 ) following percutaneous\nthe data suggested that high - dose pelvic irradiation was associated with increase in cancers of the bladder, kidneys, rectum, ovaries, corpus uteri, and non - hodgkin's lymphoma but, apparently, not leukemia, hodgkin's disease, breast cancer, or colon\nconclusions : the increased risk of blca after prostate radiation occurs predomi \" \" tly after 10 years, regardless of ethnicity"
        },
        {
          "qas": [
            {
              "id": "5e51a2d76d0a27794100003a_001",
              "question": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?"
            }
          ],
          "context": "an unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\ngenome - wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or dna mutations, only explained a minority of the expected heritable fraction\n. we find that the elevated nucleotide diversity of mae genes is also associated with greater allelic age : variants in these genes tend to be older and are enriched in polymorphisms shared by neanderthals and chimpanzees\ngenes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\nour results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\na valuable approach to understand how individual and population genetic differences can predispose to disease is to assess the impact of genetic variants on cellular functions ( e. g., gene expression ) of cell and tissue types related to pathological\n. both synonymous and nonsynonymous alleles of mae genes have elevated average population frequencies. we also observed strong enrichment of the mae signature among genes reported to evolve under balancing selection\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\n. single - cell measurements demonstrate that variants modulating promoter shape often increase expression noise, whereas heteroallelic interactions with other promoter variants alleviate these effects"
        },
        {
          "qas": [
            {
              "id": "5e5437ffb761aafe09000002_001",
              "question": "Has MLE4901 been tested in phase III clinical trials?"
            }
          ],
          "context": "based on positive results from a phase i / ii clinical trial\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\nten classes of neuroprotective agents have reached phase iii efficacy trials but have shown mixed results\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\npositive phase iii - study data have been published for lenvatinib as first - line and cabozantinib as second - line therapy.\nthis system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nthe study was a 4 - week phase ib multiple ascending dose, randomized, double - blind, placebo - controlled trial of azd0530 in ad patients with mini - mental state examination ( mmse ) scores ranging from 16 to 26.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\nalthough ongoing phase iii clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk."
        },
        {
          "qas": [
            {
              "id": "5e5508e2b761aafe09000006_001",
              "question": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?"
            }
          ],
          "context": "oral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\nneurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes : a phase 2, randomised, double - blind, placebo - controlled trial.\nthe novel dehydroepiandrosterone ( dhea ) derivative bnn27 counteracts delay - dependent and scopolamine - induced recognition memory deficits in rats.\nhere, we determined that liraglutide does not activate glp - 1 - producing neurons in the hindbrain, and liraglutide - dependent body weight reduction in rats was independent of glp - 1 receptors ( glp - 1rs ) in the vagus nerve, area postrema, and\nhowever, although a number of clinical studies examining the efficacy of h3 receptor antagonists for a variety of cognitive disorders are currently underway, no clinical proof of concept for an h3 receptor antagonist has been reported to date.\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing."
        },
        {
          "qas": [
            {
              "id": "5e763645c6a8763d2300000d_001",
              "question": "Has ORMD-0801 been tested in patients?"
            }
          ],
          "context": "in efforts to provide patients with a more compliable treatment method, oramed pharmaceuticals tested the capacity of its oral insulin capsule ( ormd - 0801, 8 mg insulin ) in addressing this resistant clinical state.\nbased on positive results from a phase i / ii clinical trial\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nthis system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\na phase ii study of saracatinib ( azd0530 ), a src inhibitor, administered orally daily to patients with advanced thymic malig \" \" cies.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\nmetastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study.\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nthe study was a 4 - week phase ib multiple ascending dose, randomized, double - blind, placebo - controlled trial of azd0530 in ad patients with mini - mental state examination ( mmse ) scores ranging from 16 to 26."
        },
        {
          "qas": [
            {
              "id": "5e763c3fc6a8763d23000010_001",
              "question": "Was vivotif licensed in Europe and the US at the same time?"
            }
          ],
          "context": ". the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.\nvivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella ( ty21a ) and reproduces the natural infection\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nusa, there has been much controversy about the implementation of this prep regimen in other countries throughout the world, and in europe in particular.\nrotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\npasteur ), became available in the us during the 2011 - 2012 influenza season for adults 18 - 64 years of age\n. 5. 4 months ( 1. 8 - 10. 5 ) with placebo / gemcitabine. similarly, no difference was detected in overall survival between axitinib / gemcitabine and placebo / gemcitabine in patients from north america or the european union.\n. median overall survival was 10. 3 ( 95 % confidence interval : 8. 1 - 11. 6 ) and 8. 5 ( 6. 2 - 11. 4 ) mo in the tivantinib and placebo group, respectively ( hazard ratio = 0. 82, 95 % confidence interval : 0. 58 - 1. 15 ).\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy."
        },
        {
          "qas": [
            {
              "id": "5e43090d48dab47f26000011_001",
              "question": "Are stem cell transplants used to treat acute kidney injury?"
            }
          ],
          "context": "animal studies have shown that mesenchymal stromal cell ( msc ) infusions improve acute kidney injury ( aki ) outcomes when administered early after ischemic / reperfusion injury or within 24 hours after cisplatin administration.\nrisk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on acute kidney injury network criteria.\nearly diagnostic markers for detection of acute kidney injury in allogeneic hematopoietic stem cell transplant recipients.\nintravenous iron therapy is increasingly being used worldwide to treat anemia in chronic kidney disease and more recently iron deficiency in heart failure.\npresenting clinical and preclinical evidence for rituximab, tocilizumab, pirfenidone, and nintedanib, as well as hematopoietic stem cell transplantation and lung transplantation.\ne treatment of anemia in chronic kidney disease.\ninterpretation administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke.\ntreatment of anemia in patients with chronic kidney disease\nmatrix molecules in human renal proximal tubular cells ( hkcs ) induced by high glucose, to provide help for renal tubulointerstitial fibrosis therapy.\nuse of epogen for treatment of anemia associated with chronic renal failure."
        },
        {
          "qas": [
            {
              "id": "5e51dab06d0a27794100003d_001",
              "question": "Is deletion at 6q24.2-26 associated with shorter survival for ovarian cancer patients?"
            }
          ],
          "context": "we found that loss at 6q24. 2 - 26 was significantly associated with the cluster of longer survival independently from other confounding factors ( hr = 0. 06, 95 % ci = 0. 01 - 0. 43, padj = 0. 005 )\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\nwe aimed to evaluate the prognostic and predictive value of the nucleotide excision repair - related gene gtf2h5, which is localized at the 6q24. 2 - 26 deletion previously reported by our group to predict longer survival of high - grade serous ovarian\n. the prognostic value of this deletion was validated in two independent series, one consisting of 36 hgsocs analyzed by fluorescent in situ hybridization ( p = 0. 04 ) and another comprised of 411 hgsocs from the cancer genome atlas study ( tcga ) ( hr =\ndeletions of chromosome 7q11. 23 ( williams syndrome ), 15q11 - q13 ( angelman syndrome, prader - willi syndrome ) and 22q11 ( di george syndrome )\nlonger survival of high - grade serous ovarian cancer patients.\nlonger survival of high - grade serous ovarian cancer patients.\nthe deletion of chromosome 22q11. 2 is involved in the majority of digeorge or velo - cardiofacial syndrome.\nsyndrome exhibit a microdeletion within chromosome 22q11."
        },
        {
          "qas": [
            {
              "id": "5d35eb01b3a638076300000f_001",
              "question": "Are there negative enhancers?"
            }
          ],
          "context": "enhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\nenhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\nthe term'super - enhancer'has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of mediator binding, as measured by chromatin immunoprecipitation and sequencing ( chip - seq ).\nenhancers are cis - regulatory elements in the genome that cooperate with promoters to control target gene transcription\n. instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts : the closed silenced state and the accessible primed and repressed\nin this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers.\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\nepigenetic profiling of different tissues and cell - types has identified a large number of non - coding epigenetic regulatory elements ('enhancers') that can be located far away from coding genes."
        },
        {
          "qas": [
            {
              "id": "5e540db06d0a277941000053_001",
              "question": "Has saracatinib been tested in clinical trials?"
            }
          ],
          "context": "saracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\na phase ii study of saracatinib ( azd0530 ), a src inhibitor, administered orally daily to patients with advanced thymic malig \" \" cies.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\n. saracatinib blocked the src / fak, her family, and oncogenic signaling pathways, and it induced g ( 1 ) arrest and apoptosis in snu216 and nci - n87 cells.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\nthere were no significant differences in survival in a non - small cell lung cancer prinomastat study, and in a small cell lung cancer marimastat trial.\nniraparib in ovarian cancer : results to date and clinical potential."
        },
        {
          "qas": [
            {
              "id": "5e500d8c6d0a277941000035_001",
              "question": "Is \u03b1CGRP a member of the CGRP family?"
            }
          ],
          "context": ". these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\ngiving additional cgrp - based therapeutic options for migraine patients.\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention.\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\nrecently, orally administered next - generation small molecule cgrp - ras have been shown to have safety and efficacy in acute treatment ( ubrogepant and rimegepant ) and prevention ( atogepant ) of migraine, giving additional cgrp - based therapeutic options\ncalcitonin gene - related peptide ( cgrp ) receptor antagonists ( gepants - rimegepant and ubrogepant ) and serotonin 5 - ht _ _ sub _ _ 1f _ _ end _ sub _ _ receptor agonists ( ditans - lasmiditan ) have completed phase 3 clinical trials and will soon offer novel,"
        },
        {
          "qas": [
            {
              "id": "5e44c33a48dab47f26000020_001",
              "question": "Can Enlimomab improve stroke outcomes?"
            }
          ],
          "context": "treatment with a murine anti - icam - 1 antibody ( enlimomab ) has been investigated in patients with acute ischemic stroke in the enlimomab acute stroke trial ( east )\nconclusions doses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 + / - 10 days.\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nthese observations provide several possible mechanisms for central nervous system - related clinical deterioration that occurred when enlimomab was given in acute ischemic stroke.\n. the negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment ( p = 0. 005 ). there were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nresults at day 90, the modified rankin scale score was worse in patients treated with enlimomab than with placebo ( p = 0. 004 ).\n. unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy"
        },
        {
          "qas": [
            {
              "id": "5d384ce87bc3fee31f000013_001",
              "question": "Does GRHL2 over-expression lead to EMT?"
            }
          ],
          "context": "grhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\ninterestingly, we could further demonstrate that expression of grhl2 is directly suppressed by the transcription factor zinc finger enhancer - binding protein 1 ( zeb1 ), which in turn is a direct target for repression by grhl2, suggesting that the emt\nmesenchymal - epithelial transition in sarcomas is controlled by the combinatorial expression of microrna 200s and grhl2.\ngrainyhead - like 2 ( grhl2 ), a transcription factor, has been reported to be associated with several tumor processes including emt.\nfor repression by grhl2, suggesting that the emt transcription factors grhl2 and zeb1 form a double negative regulatory feedback loop in breast cancer cells\ntranscription factor - - grainyhead - like 2 ( grhl2 ) maintains the epithelial phenotype\n. furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\n. conversely, mettl1 overexpression induces oncogenic cell transformation and cancer.\nwe explored the role of grainyhead - like 2 ( grhl2 ), a suppressor of emt, in the progression of pdac\nin hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition."
        },
        {
          "qas": [
            {
              "id": "5e7f5cc5835f4e4777000015_001",
              "question": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?"
            }
          ],
          "context": ". in advance of the 2015 - 2016 season, fluzone intradermal was replaced with fluzone intradermal quadrivalent vaccine, which contains 9 \u00b5g hemagglutinin per strain of the two a - strain viruses and both b - strain lineage viruses ( victoria and yamagata ).\nan intradermal version of fluzone\u00ae split - virion inactivated trivalent influenza vaccine, containing 9 \u00b5g hemagglutinin per strain of a / h1n1, a / h3n2, and one b lineage virus ( fluzone intradermal, sanofi pasteur ), became available in the us during the\n. this is based on the experience with non - covid - 19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone.\nthe advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\nimvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy.\ne vaccine and placebo groups\nbalb / c mice immunized with subcutaneous injections of the recombi \" \" t protein with or without liposome / saponin ( lip / sap ) as an adjuvant.\ndespite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\npasteur ), became available in the us during the 2011 - 2012 influenza season for adults 18 - 64 years of age"
        },
        {
          "qas": [
            {
              "id": "5e821ac5835f4e4777000031_001",
              "question": "Is endotrophin derived from collagen?"
            }
          ],
          "context": "endotrophin production from type iv collagen\nhigh levels of col6a3 and its cleaved product, endotrophin ( etp )\nendotrophin is released from col vi\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate.\netrin - 1 is a laminin - related secreted protein, is highly induced after tissue injury, and may serve as a marker of injury.\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\nbiologically active epoxyeicosatrienoic acid ( eet ) regioisomers are synthesized from arachidonic acid by cytochrome p450 epoxygenases of endothelial, myocardial, and renal tubular cells.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\nas the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\nepoxyeicosatrienoic acids ( eets ) are synthesized from arachidonic acid by cytochrome p450 epoxygenases in endothelial cells."
        },
        {
          "qas": [
            {
              "id": "5e7f6090835f4e477700001a_001",
              "question": "Can Daptacel be used instead of IPOL?"
            }
          ],
          "context": "tetanus, 5 - component acellular pertussis vaccine [ dtap ( 5 ) ; daptacel ], inactivated poliovirus vaccine [ ipv ; ipol ], and haemophilus influenzae type b [ hib ] vaccine [ acthib ] ), when administered to infants and toddlers concomitantly with other routinely\nin this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of dtap ( 5 ) coadministered with ipv and hib vaccines or 1 lot of dtap ( 5 ) - ipv - hib combination vaccine.\nten pneumococcal vaccine serotypes, protein d, antipolyribosyl - ribitol phosphate, antidiphtheria, antitetanus, and antipertactin.\nbased on published immunogenicity and safety data, as well as the recent recommendations by the acip for routine use in infants and indications for high - risk pediatric patients, pcv13 is a revised formulation of pneumococcal vaccine that should be\nand toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth ( preschool ) dtap ( 5 ) dose.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy.\nrotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\nbalb / c mice immunized with subcutaneous injections of the recombi \" \" t protein with or without liposome / saponin ( lip / sap ) as an adjuvant.\nvivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella ( ty21a ) and reproduces the natural infection\nfrequent dosing. this review focuses on the potential benefits and considerations for the study and use of 2 long - acting injectable agents, cabotegravir ( gsk1265744la, cab la ) and rilpivirine ( tmc278la, rpv la ), for use as chemoprophylaxis for hiv"
        },
        {
          "qas": [
            {
              "id": "5e806ff7835f4e4777000027_001",
              "question": "Is ACE2 expressed on cell surfaces?"
            }
          ],
          "context": "ace2 is a type 1 integral membrane protein and contains a catalytically active ectodomain that can be shed from the cell surface into the extracellular space,\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\nangiotensin - converting enzyme 2 ( ace2 ), a relatively new member of the ras, has drawn extensive attention since 2003, because of the findings that ace2 is the receptor for sars corona virus and that mainte \" \" ce of normal ace2 levels in the lung is\nthe infection of target cells by the sars cov is mediated through the interaction of the viral spike ( s ) protein ( 1255 amino acids ) and its cellular receptor, angiotensin - converting enzyme 2 ( ace2 ).\nthe viral spike glycoprotein ( s ) utilizes angiotensin - converting enzyme 2 ( ace2 ) as a host protein receptor and mediates fusion of the viral and host membranes, making s essential to viral entry into host cells and host species tropism.\ncell entry studies demonstrated that three newly identified sarsr - covs with different s protein sequences are all able to use human ace2 as the receptor\nthe trimeric sars coronavirus ( sars - cov ) surface spike ( s ) glycoprotein consisting of three s1 - s2 heterodimers binds the cellular receptor angiotensin - converting enzyme 2 ( ace2 ) and mediates fusion of the viral and cellular membranes through a pre -\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate.\nepoxyeicosatrienoic acids ( eets ) are synthesized from arachidonic acid by cytochrome p450 epoxygenases in endothelial cells.\nbiologically active epoxyeicosatrienoic acid ( eet ) regioisomers are synthesized from arachidonic acid by cytochrome p450 epoxygenases of endothelial, myocardial, and renal tubular cells."
        },
        {
          "qas": [
            {
              "id": "5e7744c3835f4e4777000005_001",
              "question": "Can leuprorelin acetate be used as androgen deprivation therapy?"
            }
          ],
          "context": "long - term adt with lam is a well - accepted, tolerated, effective, and low - burden treatment option for patients with advanced, hormone - sensitive pca.\nthe profound phase iii trial, comparing olaparib with enzalutamide / abiraterone therapy, revealed increased radiological progression - free survival ( rpfs ) and overall survival ( os ) among patients with metastatic castration - resistant prostate cancer\nof this aggressive form of prostate cancer offers potential for improved outcomes with early introduction of parp inhibitor - based therapy.\nconclusion. the use of hd thiotepa and asct is feasible in patients with relapsed osteosarcoma. a randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.\ncastration - resistant prostate cancer in clinical practice.\ncastration - resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next - generation hormonal agent.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\nthe safety and efficacy of the use of methotrexate in long - term therapy for rheumatoid arthritis.\nand daprodustat may become an effective alternative for treatment of anemia with ckd.\nin the phase iii pacific trial consolidation with durvalumab, an anti - pdl - 1 antibody, was associated with survival benefit in patients diagnosed with la - nsclc who responded to concurrent chemoradiotherapy."
        },
        {
          "qas": [
            {
              "id": "5e6e35b07fc1ee872b000004_001",
              "question": "Are astrocytes part of the blood brain barrier?"
            }
          ],
          "context": "the blood - brain barrier ( bbb ) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.\nthe blood - brain barrier ( bbb ) consists of endothelial cells, astrocytes, and pericytes embedded in basal lamina ( bl ).\nseveral brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro bbb model.\nh - ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\nneural stem cells induces neuronal and astrocyte differentiation, respectively.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\nsuch as human blood, saliva, and cerebrospinal fluids, suggesting that these exo - circrnas have potential applications as disease biomarkers and novel therapeutic targets ; 6 ) several circrnas are regulated by oxidative stress and mediate reactive"
        },
        {
          "qas": [
            {
              "id": "5e639a8b1af46fc130000011_001",
              "question": "Is Li\u2013Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?"
            }
          ],
          "context": "li - fraumeni syndrome is a rare autosomal domi \" \" t cancer predisposition syndrome.\nli - fraumeni syndrome ( lfs ) is a rare, autosomal domi \" \" t, hereditary cancer predisposition disorder.\nli - fraumeni syndrome ( lfs ) is a rare hereditary autosomal domi \" \" t cancer disorder.\nli - fraumeni syndrome ( lfs ) is an autosomal domi \" \" t hereditary cancer disorder.\nli - fraumeni syndrome ( lfs ) is a rare hereditary cancer syndrome associated with an autosomal domi \" \" t mutation inheritance in the tp53 tumor suppressor gene and a wide spectrum of cancer diagnoses.\nli - fraumeni syndrome ( lfs ) is an autosomal domi \" \" t disorder occurring at a young age that predisposes individuals to multiple forms of cancer and to a heterogeneous spectrum of malig \" \" cies.\nli - fraumeni syndrome ( lfs ) is a rare cancer predisposition syndrome inherited in an autosomal domi \" \" t fashion that involves a germline mutation of tumor protein 53 ( tp53 ).\nthe li - fraumeni syndrome ( lfs ) is an autosomal domi \" \" t hereditary disorder associated with different tumor types in childhood and young adults.\nli - fraumeni syndrome ( lfs ) is an inherited, autosomal - domi \" \" t condition that predisposes individuals to a wide - spectrum of tumors at an early age.\nli - fraumeni syndrome is an autosomal domi \" \" t disorder that is characterized by various types of cancer in childhood and adult cases."
        },
        {
          "qas": [
            {
              "id": "5e776c72835f4e477700000e_001",
              "question": "Has the drug Afrezza been approved by the FDA?"
            }
          ],
          "context": ". afrezza has been marketed since february, 2015 by sanofi after getting fda approval in june 2014.\ndespite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nresults : currently, the fda has approved several molecules for the treatment of obesity, both in monotherapy and in combination\ncompounds including most of the fda - approved drugs.\n. new fda - approved therapies for ad are crisaborole and dupilumab.\napremilast is now approved for the treatment of oral ulcer of behcet syndrome in the united states.\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\nin august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\nin contrary, mannkind corporation started developing its ultra - rapid - acting insulin afrezza in a bold bid, probably by managing the issues in which exubera was not successful"
        },
        {
          "qas": [
            {
              "id": "5e8220e6835f4e4777000032_001",
              "question": "Is Protoporphyrinogen oxidase localized to the mitochondrium?"
            }
          ],
          "context": "based on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\nwe showed that 28 amino acids in the amino terminus of ppox contain an independently functioning signal for mitochondrial targeting.\nglutathione peroxidase ( gpx1 ) is the major selenoprotein in most tissues in animals.\nthe major selenoprotein expressed by germ cells in the testis, the phospholipid hydroperoxide glutathione peroxidase ( phgpx / gpx4 )\nthe oxidoreductase mical\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\nepoxygenases metabolize arachidonic acid to four regioisomeric epoxyeicosatrienoic acids ( eets ) and selected monohydroxyeicosatetraenoic acids ( hetes ).\nthe selenoenzyme gpx4 is essential for early embryogenesis and cell viability for its unique function to prevent phospholipid oxidation.\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate."
        },
        {
          "qas": [
            {
              "id": "5e36d498b5b409ea53000008_001",
              "question": "Do de novo truncating mutations in WASF1 cause cancer?"
            }
          ],
          "context": "de novo truncating mutations in wasf1 cause intellectual disability with seizures.\n. this study provides evidence that de novo heterozygous mutations in wasf1 cause a rare form of intellectual disability.\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. functional studies using fibroblast cells from two affected individuals with the c. 1516c > t mutation showed a truncated wasf1 and a defect in actin remodeling\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\namong them, the most studied is werner's syndrome, \" adult progeria \", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in dna repair.\nmutations in the cu / zn superoxide dismutase 1 ( sod1 ) gene have been reported to cause adult - onset autosomal domi \" \" t amyotrophic lateral sclerosis ( fals ).\nintroduction : werner syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the werner syndrome gene belonging to the family of recq helicase.\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 ).\nmissense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy."
        },
        {
          "qas": [
            {
              "id": "5e64ed381af46fc130000015_001",
              "question": "Are ICAMS, Intracellular Adhesion Molecules, part of the immunoglobulin superfamily?"
            }
          ],
          "context": "intercellular adhesion molecules ( icams ) belong to the immunoglobulin superfamily and participate in diverse cellular processes including host - pathogen interactions.\nthe intercellular adhesion molecules ( icams ) are members of the immunoglobulin superfamily and have been identified to play major roles in inflammation and immune responses.\nintercellular adhesion molecules ( icams ) are structurally related members of the immunoglobulin supergene family and are ligands for the beta2 integrin molecules present on leukocytes.\nintracellular adhesion molecule 1 ( icam - 1 ) is an adhesion - related molecule belonging to the immunoglobulin superfamily.\nintercellular adhesion molecule - 1 ( icam - 1 ), vascular cell adhesion molecule - 1 ( vcam - 1 ) and platelet - endothelial cell adhesion molecule - 1 ( pecam - 1 ) are members of the immunoglobulin super - family which are present on the surface of endothelial cells.\nimmunologically important integrin ligands are the intercellular adhesion molecules ( icams ), immunoglobulin superfamily members present on inflamed endothelium and antigen - presenting cells.\nmembers of the immunoglobulin superfamily of endothelial adhesion molecules, vascular cell adhesion molecule ( vcam - 1 ) and intercellular cell adhesion molecule ( icam - 1 ), participate in leukocyte adhesion to the endothelium and play an important role\nit has now been shown that adhesion molecules, particularly those of the immunoglobulin super family ( e. g. icam - 1, vcam - 1 and pecam - 1 ),\nicam - 1 is a member of immunoglobulin - like superfamily of adhesion molecules that binds lfa - 1 to mediate leukocytes adhesion and migration.\nmembers of the immunoglobulin superfamily of endothelial adhesion molecules, vascular cell adhesion molecule ( vcam - 1 ) and intercellular cell adhesion molecule ( icam - 1 ), strongly participate in leukocyte adhesion to the endothelium and play an"
        },
        {
          "qas": [
            {
              "id": "5e57fa23b761aafe09000008_001",
              "question": "Is traditional Chinese medicine associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment?"
            }
          ],
          "context": "using tcm significantly decreased the incidence of chf in patients with breast cancer who received conventional chemotherapy with or without radiotherapy.\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\nboth acupotomy and acupuncture have been widely used clinically to treat csr in china with satisfied efficacy.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nbackground : long - term hodgkin lymphoma ( hl ) survivors have an increased risk of late cardiac morbidity and secondary lung cancer after chemotherapy and mediastinal radiotherapy.\nresults : a more aggressive course of breast cancer is observed in patients exposed to radiation from the chernobyl accident under the age of 30 years ( p <. 01 ).\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers."
        },
        {
          "qas": [
            {
              "id": "5e6df5b51af46fc130000025_001",
              "question": "Is PTEN a tumour suppressor?"
            }
          ],
          "context": "pten is a potent tumour suppressor\ngenomic aberrations of the pten tumour suppressor gene are among the most common in prostate cancer.\nfurthermore, our data show that the mechanism by which pten null eccs emerge in vitro and cause tumors in vivo is through increased survival and self - renewal, due to failed repression of the transcription factor nanog.\n. genetic deletion of huwe1 rapidly accelerated tumourigenic in mice carrying loss of the intestinal tumour suppressor gene apc, with a dramatic increase in tumour initiation\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies.\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\n. taken together, these data identify huwe1 as a bona fide tumour suppressor gene in the intestinal epithelium and suggest a potential vulnerability of huwe1 - mutated tumours to dna - damaging agents and inhibitors of anti - apoptotic proteins.\nadamts18 is a novel tumor suppressor and is critical to the pathology of human colorectal cancer. however, the underlying mechanism is not clear\ntumours to dna - damaging agents and to deletion of the anti - apoptotic protein mcl1"
        },
        {
          "qas": [
            {
              "id": "5d387098a1e1595105000006_001",
              "question": "Is the tyrosine kinase BTK implicated in autoimmunity?"
            }
          ],
          "context": "btk function in b cells in the context of host defense and autoimmunity.\nautoimmunity, hypersensitivity to b cell receptor ( bcr ) cross - linking, and splenomegaly caused by myeloerythroid hyperplasia were alleviated by btk deficiency in lyn - / - mice.\nautoimmunity was fully dependent on btk kinase activity, because btk inhibitor treatment ( pci - 32765 ) could normalize b - cell activation and differentiation, and because autoantibodies were absent in btk transgenic mice overexpressing a kinase inactive\nbruton's tyrosine kinase ( btk ) is a proximal transducer of the bcr signal that allows for b - cell activation and differentiation\naugmented tlr9 - induced btk activation in pir - b - deficient b - 1 cells provokes excessive autoantibody production and autoimmunity.\ninhibitors of btk and itk : state of the new drugs for cancer, autoimmunity and inflammatory diseases.\ngiven the phenotype of affected patients, namely lack of b - lymphocytes and plasma cells with the ensuing inability to mount humoral immune responses, btk inhibitors were anticipated to have beneficial effects on antibody - mediated pathologies, such as\n. recently, selective inhibition of btk by pci - 32765 has shown promise in limiting activity of multiple cells types in various models of cancer and autoimmunity.\neffects on antibody - mediated pathologies, such as autoimmunity\n. clinical development is underway in the usa, europe and japan for autoimmune disorders, chronic lymphocytic leukaemia, b cell lymphoma, sjogren's syndrome, pemphigus and rheumatoid arthritis"
        },
        {
          "qas": [
            {
              "id": "5d387721a1e159510500000c_001",
              "question": "Is induction of interferon by TLR7 higher in males?"
            }
          ],
          "context": ". haplotype analysis confirmed the differential distribution of tlr7 variants between the groups. within the group of female patients with chronic hcv - infection, c. 32t was predictive of an unfavourable outcome of interferon - alpha therapy ( p < 0. 05 )\nwe found that cdcs from prediseased tcsle male mice express the ifn signature as female tcsle cdcs do. estrogens are necessary but not sufficient to express this ifn signature, but high doses of e2 can compensate for other steroidal components.\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\nin response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\ntoll - like receptor 9 ( tlr9 ) activation is attributed to delivery of bacterial dna\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\nthe c - type lectin receptor clec4e and toll - like receptor tlr4 expressed by host cells are among the first line of defense in encountering pathogens.\nthe tryptophan - degrading activity of ido1 was not induced significantly by chlamydia infection alone, but the addition of ifng greatly increased its activity."
        },
        {
          "qas": [
            {
              "id": "5e64f1921af46fc130000018_001",
              "question": "Is there a vaccine for rotavirus?"
            }
          ],
          "context": "rotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\nurgency of introducing a vaccine to help control rotavirus disease\nis there evidence that rotavirus vaccines are effective in preventing acute gastroenteritis complications such as dehydration and hospitalization\nimpact of rotavirus vaccines on rotavirus disease\nrotavirus vaccine rix4414 ( rotarix\u2122 ) : a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.\nwith the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine - preventable disease among children in the eu\nwith safe and efficacious rotavirus vaccines now on the verge of widespread adoption, researchers can be vital advocates for their uptake into routine immunization programs\na live attenuated monovalent rotavirus vaccine ( rotarix ) containing human rotavirus strain rix4414 of g1p1a p [ 8 ] specificity is being developed to meet the global need.\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nclinical and immunological studies of rotavirus vaccines."
        },
        {
          "qas": [
            {
              "id": "5e2d7ceefbd6abf43b00000b_001",
              "question": "Is BNN20 involved in Parkinson's disease?"
            }
          ],
          "context": ". these results could be of clinical relevance, as they suggest bnn - 20 as an important neuroprotective agent acting through the trkb neurotrophin receptor pathway, mimicking the action of the endogenous neurotrophin bdnf\n. thus bnn - 20 could be proposed for treatment of pd.\n. this indicates that bnn - 20 exerts its beneficial action ( at least in part ) through the trkb - pi3k - akt - nf - \u03bab signaling pathway\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\n. using the \" weaver \" mouse, a genetic model of pd, which exhibits progressive dopaminergic neurodegeneration in the substantia nigra ( sn ), we have shown that long - term administration ( p1 - p21 ) of bnn - 20 almost fully protected the dopaminergic neurons\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\nalmost fully protected the dopaminergic neurons and their terminals, via i ) a strong anti - apoptotic effect, probably mediated through the tropomyosin receptor kinase b ( trkb ) neurotrophin receptor's pi3k - akt - nf - \u03bab signaling pathway, ii ) by exerting\n. acute bnn - 20 administration to weaver / ngl mice induced a strong nf - \u03bab - dependent transcriptional response in the brain as detected by bioluminescence imaging, which was abolished by co - administration of the trkb inhibitor ana - 12\n. herein, we propose as a therapeutic for pd the small molecule 17 - beta - spiro - [ 5 - androsten - 17, 2'- oxiran ] - 3beta - ol ( bnn - 20 ), a synthetic analogue of dhea, which crosses the bbb and is deprived of endocrine side - effects\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period."
        },
        {
          "qas": [
            {
              "id": "5e35d3c6158f994d3a000003_001",
              "question": "Is there a role for MRPL53 in cancer?"
            }
          ],
          "context": ". mrpl53 ( 2p13. 1 ) encodes a 39s protein subunit of mitochondrial ribosomes and interacts with myc, a transcription factor required for normal facial morphogenesis.\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n. m6a regulates rna processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6a methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis.\n. this resulted in the discovery of a novel susceptibility locus for nscl / p, rs1063588, the best eqtl for the mrpl53 gene, where evidence for association was mostly driven by the native american ancestry component of our brazilian sample\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n. we also showed that uc. 63 + regulated the expression of mmp2 via mir - 130b regulation. furthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells."
        },
        {
          "qas": [
            {
              "id": "5e36a4b7b5b409ea53000003_001",
              "question": "Does Uc.63+ promote sensitivity to treatment in prostate cancer?"
            }
          ],
          "context": "furthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\n. we also showed that uc. 63 + regulated the expression of mmp2 via mir - 130b regulation. furthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\n. in patients treated with docetaxel, the expression of serum uc. 63 + in the docetaxel - resistant patients was higher than that in the docetaxel - sensitive patients ( p = 0. 011 )\n. these results substantially support the important role that uc. 63 + plays in pc progression by interacting with mir - 130b and indicate that uc. 63 + could potentially be a promising serum marker for deciding the best treatment for patients with crpc.\n. quantitative real - time polymerase chain reaction analysis revealed that the expression of t - ucr uc. 63 + was increased in pc tissues. mtt assay and wound healing assay revealed that uc. 63 + was involved in cell growth and cell migration\nthe au / u - rich element - binding protein hur has been shown to bind to p53 mrna 3'utr and enhance translation in response to dna - damaging uvc radiation.\nwe demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation.\n. signaling was tested by western blotting assay. the nude mice pc - 3 xenograft model was applied to test azd5153's activity in vivo. results : azd5153 inhibited proliferation and survival of established and primary prostate cancer cells\n. azd5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. azd5153 was non - cytotoxic to the prostate epithelial cells\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells."
        },
        {
          "qas": [
            {
              "id": "5e2b3d97fbd6abf43b00000a_001",
              "question": "Does BNN27 promote memory loss?"
            }
          ],
          "context": "the novel dehydroepiandrosterone ( dhea ) derivative bnn27 counteracts delay - dependent and scopolamine - induced recognition memory deficits in rats.\n. intraperitoneal ( i. p. ) administration of bnn27 ( 3 and 10mg / kg ) antagonized delay - dependent deficits in the not in the normal rat, suggesting that this dhea derivative affected acquisition, storage and retrieval of information\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\n. the present study was designed to investigate the effects of bnn27 on recognition memory in rats\n. these results could be of clinical relevance, as they suggest bnn - 20 as an important neuroprotective agent acting through the trkb neurotrophin receptor pathway, mimicking the action of the endogenous neurotrophin bdnf\n. in addition, bnn27 ( 3 and 10mg / kg, i. p. ) counteracted the scopolamine [ 0. 2mg / kg, subcutaneously ( s. c. ) ] - induced non - spatial and spatial recognition memory deficits\nneuroprotective effect of hesperetin and o - hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of alzheimer's disease\n. herein, we propose as a therapeutic for pd the small molecule 17 - beta - spiro - [ 5 - androsten - 17, 2'- oxiran ] - 3beta - ol ( bnn - 20 ), a synthetic analogue of dhea, which crosses the bbb and is deprived of endocrine side - effects\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury"
        },
        {
          "qas": [
            {
              "id": "5e4946bf6d0a277941000005_001",
              "question": "Are genomic regulatory blocks (GRBs) any different than TADs?"
            }
          ],
          "context": "clusters of cnes define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks ( grbs )\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n. the close correspondence between extreme noncoding conservation and tads suggests that these tads are ancient, revealing a regulatory architecture conserved over hundreds of millions of years. metazoan genomes contain many clusters of conserved\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\ntad boundaries are insulators of genomic neighborhoods. in this issue, sun et al. show that disease - associated tandem repeats are located to tad boundaries and affect their insulation.\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n. in contrast, herein we analyze hi - c data for budding yeast and identify 200 - kb scale tads, whose boundaries are enriched for transcriptional activity\n. the set of tads that are associated with high levels of noncoding conservation exhibit distinct properties compared to tads devoid of extreme noncoding conservation\nbrd4 and mediator were found to co - occupy thousands of enhancers associated with active genes."
        },
        {
          "qas": [
            {
              "id": "5e67bc121af46fc13000001c_001",
              "question": "Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients?"
            }
          ],
          "context": "spinal intradural primary malig \" \" t peripheral nerve sheath tumors ( mpnst ) are rare in patients without neurofibromatosis.\nprimary malig \" \" t peripheral nerve sheath tumors ( mpnsts ) are extremely rare in patients without a history of neurofibromatosis ; only 18 cases have been reported in the english - language literature to this point.\nan smn may have a benign course, as in meningioma, or be a dilemma for the patient, as in glioblastoma.\ntwo rare cases of intractable epilepsy caused by dysembryoplastic neuroepithelial tumours ( dnet ) are reported and their different management discussed\nthe predomi \" \" ce of meningiomas over neuroepithelial tumors in the japanese population was noteworthy and warrants further investigation.\nthe entrapment syndromes discussed are suprascapular nerve entrapment, carpal tunnel syndrome, cubital tunnel syndrome, meralgia paraesthetica, thoracic outlet syndrome and anterior interosseous nerve syndrome.\nsecondary brain tumors rarely arise after cranial irradiation ; among them, meningiomas and glioblastomas are the most common and secondary oligodendroglial tumors the most rare.\nmalig \" \" t neoplasms ( excluding nonmelanoma skin cancer ), 9. 1 % ( 95 % ci = 8. 1 % to 10. 1 % ) for nonmelanoma skin cancer, and 3. 1 % ( 95 % ci = 2. 5 % to 3. 8 % ) for meningioma.\ncarpal tunnel syndrome, an entrapment neuropathy of the median nerve, is rarely seen in childhood.\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery."
        },
        {
          "qas": [
            {
              "id": "5e776541835f4e4777000009_001",
              "question": "Can MVA85A confer immunity against smallpox?"
            }
          ],
          "context": "we assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus ankara expressing antigen 85a ( mva85a ), in adults infected with hiv - 1.\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\nwhile modified vaccinia virus ankara ( mva ) is currently in clinical development as a safe vaccine against smallpox and heterologous infectious diseases, its immunogenicity is likely limited due to the inability of the virus to replicate\nmodified vaccinia virus ankara ( mva ) is a replication - deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombi \" \" t viral vector to produce vaccines against infectious diseases and cancer.\nmodified vaccinia virus ankara ( mva ) is an attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombi \" \" t viral vector to produce vaccines against infectious diseases and cancer\na randomized, double - blind, placebo - controlled phase ii trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine ( mva - bn\u00ae ) in 56 - 80 - year - old subjects.\nimvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\nmodified vaccinia virus ankara ( mva ) is a highly attenuated vaccinia virus that is under consideration as an alternative to the conventional smallpox vaccine dryvax\nintroduction : to guide the use of modified vaccinia ankara ( mva ) vaccine in response to a release of smallpox virus, the immunogenicity and safety of shorter vaccination intervals, and administration by jet injector ( ji ), were compared to the\nbackground : modified vaccinia ankara ( mva ) is being developed as a safer smallpox vaccine and is being placed in the us strategic national stockpile ( sns ) as a liquid formulation for subcutaneous ( sc ) administration at a dose of 1\u00d710 ( 8 ) tcid50 in a"
        },
        {
          "qas": [
            {
              "id": "5e6e2c1e7fc1ee872b000002_001",
              "question": "Is MLL3 part of the ASCOM complex?"
            }
          ],
          "context": "mll3 as part of activating signal cointegrator - 2 - containing complex ( ascom )\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\ntranscription factor complexes. these myb complexes assemble aberrantly with lyl1, e2a, c / ebp family members, lmo2, and satb1.\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\ntlk1 substrates were identified as the histone h3 and asf1 ( a histone h3 / h4 chaperone )\nwell - known oncohistones, with mutations on both h3. 1 and h3. 3, include h3k36m in chondroblastoma, h3k27m in glioma\nchromosome microdeletions within 17p13. 3 can result in either isolated lissencephaly sequence ( ils ) or miller - dieker syndrome ( mds ).\nreconstituted transcription reactions established that the brahma ( brm ) chromatin - remodeling complex is essential for zeste - directed activation on nucleosomal templates.\nof the mixed lineage kinase domain - like protein ( mlkl ) upon its phosphorylation.\nthe methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation."
        },
        {
          "qas": [
            {
              "id": "5e476da1d14c9f295d000002_001",
              "question": "Is marimastat effective for small-cell lung cancer?"
            }
          ],
          "context": "the phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\nthere were no significant differences in survival in a non - small cell lung cancer prinomastat study, and in a small cell lung cancer marimastat trial.\nconclusion : treatment with marimastat after induction therapy for sclc did not result in improved survival and had a negative impact on quality of life.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\na phase iii study failed for carboplatin, paclitaxel, with or without figitumumab in first - line treating metastatic non - small cell lung cancer ( nsclc ).\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\nconclusion : adding figitumumab to standard chemotherapy failed to increase os in patients with advanced nonadenocarcinoma nsclc.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study."
        },
        {
          "qas": [
            {
              "id": "5e4b64126d0a277941000028_001",
              "question": "Is Figitumumab effective for non-small cell lung cancer?"
            }
          ],
          "context": "one recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit.\nphase iii trials of the anti - insulin - like growth factor type 1 receptor ( igf - ir ) antibody figitumumab ( f ) in unselected non - small - cell lung cancer ( nsclc ) patients were recently discontinued owing to futility.\nconclusion : adding figitumumab to standard chemotherapy failed to increase os in patients with advanced nonadenocarcinoma nsclc.\na phase iii study failed for carboplatin, paclitaxel, with or without figitumumab in first - line treating metastatic non - small cell lung cancer ( nsclc ).\nthe insulin - like growth factor receptor ( igf - 1r ) monoclonal antibody figitumumab, while initially promising, appears to increase toxicity and death in combination with chemotherapy in the treatment of patients with nsclc of squamous histology ;\ntwo phase iii trials of the anti - igf - 1r monoclonal antibody, figitumumab ( cp - 751, 871 ), were discontinued in 2010 as it was considered unlikely either trial would meet their primary endpoints.\n. in light of disappointing clinical data with figitumumab and other targeted agents, it is likely that the use of molecular markers will become important in predicting response to treatment.\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\nsingle - agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non - small - cell lung cancer, particularly the \u226525 % pd - l1 + population."
        },
        {
          "qas": [
            {
              "id": "5e3ab58db5b409ea5300001c_001",
              "question": "The LINCS L1000 data set contains gene expression data for drug treated human cells, yes or no?"
            }
          ],
          "context": "the lincs l1000 data repository contains almost two million gene expression profiles for thousands of small molecules and drugs.\nthe library of integrated network - based cellular signatures ( lincs ) l1000 data set currently comprises of over a million gene expression profiles of chemically perturbed human cell lines.\nthe library of integrated network - based cellular signatures ( lincs ) l1000 big data provide gene expression profiles induced by over 10 000 compounds, shrnas, and kinase inhibitors using the l1000 platform.\nthe ge data is from the library of integrated network - based cellular signatures ( lincs ) l1000 dataset that measured changes in ge before and after treatment of human cells with over 20 000 small - molecule compounds including most of the fda - approved\nrecently, resources such as the library of integrated network - based cellular signatures ( lincs ) l1000 database provide gene expression profiles induced by various chemical and genetic perturbations\nthe library of integrated cellular signatures ( lincs ) project provides comprehensive transcriptome profiling of human cell lines before and after chemical and genetic perturbations.\nvariants with gene expression from these cultured cells\n. single cell rna - seq analysis of lin - ckit + ( lk ) cells further reveal a profound change in cell subpopulations and signature gene expression patterns in hsc, myeloid progenitors, and erythroid / megakaryocyte clusters in ki mice\n. we identify 492 aml - specific cell - essential genes, including several established therapeutic targets such as dot1l, bcl2, and men1, and many other genes including clinically actionable candidates\n. using several expression datasets, we identified krab - znfs ( znf114, znf483, znf589 ) in the human genome that maintain pluripotency."
        },
        {
          "qas": [
            {
              "id": "5e46bdcd3f54159529000007_001",
              "question": "Is there a vaccine for peanut allergy?"
            }
          ],
          "context": "recent advances in immunotherapy and vaccine development for peanut allergy.\nimmunotherapy, immunotherapy with modified food antigens, and immunotherapy with a recombi \" \" t peanut vaccine ).\ncurrently, two forms of peanut immunotherapy, oral immunotherapy ( oit ) and epicutaneous immunotherapy ( epit ), are in phase iii clinical trials and have shown promise to induce desensitization in many subjects\n. japonicum infection ( allergen sensitization before infection ) on asthma were rarely investigated.\n. anaphylaxis may be triggered by a variety of antigens including insect and reptile venom, a variety of drugs, vaccines, and food\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy.\nthis article presents an overview of potential treatments of food allergy, with an emphasis on various forms of immunotherapy ( including oral immunotherapy, sublingual immunotherapy, epicutaneous immunotherapy, immunotherapy with modified food\nit is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\ntlr2 activators are found in many common foods, but the role of tlr2 in oral tolerance and allergic sensitization to foods is not well understood."
        },
        {
          "qas": [
            {
              "id": "5e476b99d14c9f295d000001_001",
              "question": "Is golimumab effective for sarcoidosis?"
            }
          ],
          "context": "although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa.\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nadditionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe covid - 19, but there is no evidence guiding the use of biologic therapy.\ngolodirsen is a provisionally approved pmo - based drug for approx. 8 % of all dmd patients amenable to exon 53 skipping.\nindeed, worldwide clinical trials of tnf inhibiting biologic disease modifying antirheumatic drugs ( bdmards ) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti - human il - 6 receptor antibody,\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit."
        },
        {
          "qas": [
            {
              "id": "5e80675d835f4e4777000026_001",
              "question": "Is SARS virus interacting with ACE2 encoded protein?"
            }
          ],
          "context": "the infection of target cells by the sars cov is mediated through the interaction of the viral spike ( s ) protein ( 1255 amino acids ) and its cellular receptor, angiotensin - converting enzyme 2 ( ace2 ).\nthe trimeric sars coronavirus ( sars - cov ) surface spike ( s ) glycoprotein consisting of three s1 - s2 heterodimers binds the cellular receptor angiotensin - converting enzyme 2 ( ace2 ) and mediates fusion of the viral and cellular membranes through a pre -\nangiotensin - converting enzyme 2 ( ace2 ), a relatively new member of the ras, has drawn extensive attention since 2003, because of the findings that ace2 is the receptor for sars corona virus and that mainte \" \" ce of normal ace2 levels in the lung is\nthe viral spike glycoprotein ( s ) utilizes angiotensin - converting enzyme 2 ( ace2 ) as a host protein receptor and mediates fusion of the viral and host membranes, making s essential to viral entry into host cells and host species tropism.\ncell entry studies demonstrated that three newly identified sarsr - covs with different s protein sequences are all able to use human ace2 as the receptor\nthere has been a lot of speculation that patients with coronavirus disease 2019 ( covid - 19 ) who are receiving angiotensin - converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) may be at increased risk for adverse outcomes.\nthere are theoretical concerns that angiotensin - converting enzyme inhibitors ( aceis ) and angiotensin receptor blockers ( arbs ) could increase the risk of severe covid - 19.\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\nis a monoclonal antibody that works directly against the spike protein of sars - cov - 2 to block its attachment and entry into a human cell.\nsome studies of hospitalized patients suggested that the risk of death and / or severe illness due to covid - 19 is not associated with the use of angiotensin - converting enzyme inhibitors ( aceis ) and / or angiotensin ii receptor type 1 blockers ( arbs )"
        },
        {
          "qas": [
            {
              "id": "5e3ebaa348dab47f2600000a_001",
              "question": "Is the FIP virus thought to be a mutated strain for the Feline enteric Coronavirus?"
            }
          ],
          "context": "it is caused by fip virus ( fipv ), a virulent mutant strain of feline enteric coronavirus ( fecv ).\nfeline infectious peritonitis ( fip ) results from mutations in the viral genome during a common feline enteric coronavirus ( fecv ) infection.\nfeline enteric coronavirus ( fecv ) causes inapparent or mild enteritis in cats, but a highly fatal disease, called feline infectious peritonitis ( fip ), can arise through mutation of fecv to fip virus ( fipv ).\nfeline infectious peritonitis virus ( fipv ) was presumed to arise from mutations in the 3c of a ubiquitous and largely nonpathogenic feline enteric coronavirus ( fecv ).\nbackground feline infectious peritonitis ( fip ) is a lethal systemic disease, caused by the fip virus ( fipv ) ; a virulent mutant of feline enteric coronavirus ( fecv ).\nfeline infectious peritonitis ( fip ) is an almost invariably fatal feline coronavirus ( fcov ) - induced disease thought to arise from a combination of viral mutations and an overexuberant immune response.\nthis coronavirus is a virulent mutant of the harmless, ubiquitous feline enteric coronavirus ( fecv ).\nwhilst intact in all fecvs, the 3c gene was mutated in the majority ( 71. 4 % ) of fipvs, but not in all, implying that mutation in 3c is not the ( single ) cause of fip.\nmembers of the paramyxoviridae such as measles, mumps, and parainfluenza viruses have pleomorphic, enveloped virions that contain negative - sense unsegmented rna genomes.\nthe avian paramyxovirus type 1 ( apmv - 1 ), or newcastle disease virus ( ndv ), comprise a diverse group of viruses with a single - stranded, negative - sense rna genome."
        },
        {
          "qas": [
            {
              "id": "5d36bb777bc3fee31f00000a_001",
              "question": "Does SATB1 regulate the RAG1 and RAG2 genes?"
            }
          ],
          "context": "special at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\nsatb1 binds to the ase and rag promoters, facilitating inclusion of rag2 in the chromatin hub and the loading of rna polymerase ii to both the rag1 and rag2 promoters.\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nthe transcription factor satb1 that regulates the t - cell maturation\nspecial at - rich binding protein 1 ( satb1 ) nuclear protein, expressed predomi \" \" tly in t cells, regulates genes through targeting chromatin remodeling during t - cell maturation.\nsatb1 ( special at - rich binding protein 1 ) is a global chromatin organizer regulating the expression of a large number of genes\nchromatin organizers satb2 and satb1\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\nsatb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars )."
        },
        {
          "qas": [
            {
              "id": "5d371ec97bc3fee31f00000c_001",
              "question": "Is CTCF bound at nucleosome free regions?"
            }
          ],
          "context": "nucleosome occupancy at nucleosome - free regions ( nfrs ), many of which are located at sites occupied by the multivalent factors ctcf and cohesin.\nnucleosome depletion at 5'- hs4 was dependent on interaction of the insulator protein ccctc - binding factor ( ctcf ) and was required for enhancer blocking.\nhese differences extend to histone variants ( h2a. z ) and marks ( h3k4 methylation ), as well as insulator binding ( such as ctcf ), independent of the expression levels of affected genes.\nrobust inter - nucleosomal interactions exist around transcription start site ( tss ), transcription termination sites ( tts ) or around ctcf binding sites\n. in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\nthis general architectural change correlates with enhanced binding of ctcf and cohesins and more pronounced insulation of contacts across chromatin boundaries in lineage - committed cells.\nin contrast, the upstream nucleosome which covers the tata box under repressed conditions is shifted approximately 50 bp further upstream by the atp - dependent chromatin remodeler rsc upon activation\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\nh2a. z probably helps rsc in keeping the gene nucleosome - fre"
        },
        {
          "qas": [
            {
              "id": "5e3c6850b5b409ea5300001f_001",
              "question": "Is bortezomib a Proteasome inhibitor?"
            }
          ],
          "context": "the proteasome - inhibitor bortezomib\nproteasome inhibitor bortezomib\nthe proteasome inhibitor bortezomib is emerging as a potent anti - cancer agent.\nthe proteasome inhibitor bortezomib is used to treat multiple myeloma ( mm ).\nbortezomib as the first proteasome inhibitor anticancer drug : current status and future perspectives.\nthe proteasome inhibitor bortezomib ( also known as velcade and ps - 341 ) is a clinically effective antineoplastic drug that is fda approved for treatment of hematologic malig \" \" cies such as multiple myeloma and mantle cell lymphoma.\nbortezomib ( velcade\u2122 ) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma ( mm ).\nregulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.\nthe proteasome inhibitor bortezomib, registered for multiple myeloma treatment, is currently explored for activity in solid tumors including non - small cell lung cancer ( nsclc ).\nthe proteasome inhibitor bortezomib is effective for a variety of tumors, but not for gbm."
        },
        {
          "qas": [
            {
              "id": "5d3856ca7bc3fee31f000016_001",
              "question": "Is PRDM9 essential for meiosis?"
            }
          ],
          "context": "prdm9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis.\nprdm9 ( pr domain - containing protein 9 ) is a meiosis - specific protein that trimethylates h3k4 and controls the activation of recombination hot spots. it is an essential enzyme in the progression of early meiotic prophase.\nprdm9 methyltransferase activity is essential for meiotic dna double - strand break formation at its binding sites.\nin many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by pr domain - containing protein 9 ( prdm9 ).\nour findings do not identify the nature of the underlying dna sequences, but argue against the proposed role of prdm9 as an essential transcription factor in mouse meiosis\nwe found that although the post - set zinc finger and the krab domains are not essential for the methyltransferase activity of prdm9 in cell culture, the krab domain mutant mice show only residual prdm9 methyltransferase activity and undergo meiotic\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\nand pten mediated repression is important for the insulation of male germ cells from pluripotency.\n. in aggregate, our data indicate that domains typically involved in regulation of gene expression do not serve that role in prdm9, but are likely involved in setting the proper chromatin environment for initiation and completion of homologous\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells."
        },
        {
          "qas": [
            {
              "id": "5e4b5f9a6d0a277941000021_001",
              "question": "Should Pentoxifylline be used for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "conclusions : pentoxifylline is not beneficial in als and should be avoided in patients treated with riluzole.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nneuroprotective agents are screened for use in patients with als.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\ninterpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis"
        },
        {
          "qas": [
            {
              "id": "5e52bc986d0a277941000049_001",
              "question": "Is the CADM2 gene associated with differences in information processing speed?"
            }
          ],
          "context": ". our findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\nour findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\nthe cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\n. the variant is associated with expression of cadm2 in the cingulate cortex ( p - value = 4 \u00d7 10 ( - 4 ) )\n( p - value = 3. 28 \u00d7 10 ( - 9 ) after adjustment for age, gender and education ) in an intron of the gene cell adhesion molecule 2 ( cadm2 ) for performance on the ldst / dsst\n. the protein encoded by cadm2 is involved in glutamate signaling ( p - value = 7. 22 \u00d7 10 ( - 15 ) ), gamma - aminobutyric acid ( gaba ) transport ( p - value = 1. 36 \u00d7 10 ( - 11 ) ) and neuron cell - cell adhesion ( p - value = 1. 48 \u00d7 10 ( - 13 ) )\ninteracting partners bcl11b and gatad2a are also schizophrenia risk genes indicating that other genes interacting with or are regulated by satb2 are making a contribution to schizophrenia and cognition.\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\nfurther analyses of our data sets link gabpa to cognitive disorders, diabetes, krab zinc finger ( krab - znf ), and human - specific genes.\n. rs17518584 is located about 170 kb upstream of the transcription start site of the major transcript for the cadm2 gene, but is within an intron of a variant transcript that includes an alternative first exon"
        },
        {
          "qas": [
            {
              "id": "5e494cf96d0a277941000008_001",
              "question": "Is Nivolumab (Opdivo) a PD-L1 inhibitor?"
            }
          ],
          "context": "nivolumab ( opdivo ( \u00ae ) ; nivolumab bms\u2122 ) was the first programmed death ( pd ) - 1 immune checkpoint inhibitor to be approved for use in advanced, squamous non - small cell lung cancer ( nsclc ) following prior chemotherapy.\nan improvement in the understanding of the role of the immune system in tumor immunosurveillance has led to the development of the programmed death - 1 ( pd - 1 ) immune checkpoint inhibitor nivolumab ( opdivo ).\nici, such as the pd - 1 inhibitors nivolumab and pembrolizumab and the pd - l1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced nsclc.\nmonoclonal antibodies including nivolumab and pembrolizumab ; anti - pd - l1 antibodies including atezolizumab, avelumab, and durvalumab.\nmonoclonal antibodies that target programmed cell death protein 1 ( pd - 1 ), including nivolumab and pembrolizumab, and its ligand, pd - l1, including atezolizumab, durvalumab, avelumab, have all been investigated and approved in the setting of metastatic\nprogrammed cell death protein 1 ( pd - 1 ) - blocking antibodies nivolumab or pembrolizumab\nnowadays, five immune checkpoint inhibitors blocking pd - 1 ( pembrolizumab, nivolumab ) or pd - l1 ( atezolizumab, durvalumab, and avelumab ) have been approved by the united states food and drug administration ( us fda ) for the first - or second - line use in\nand pembrolizumab ) and pd - l1 inhibitors ( atezolizumab, durvalumab, and avelumab ) in patients with nsclc.\nby the emergence of modern immunotherapies with active agents like pd - 1 ( nivolumab, pembrolizumab ) and pd - l1 immune checkpoint blockers ( atezolizumab, avelumab, durvalumab ), new therapeutic options have become available for the treatment of patients\ndifferent antagonistic antibodies targeting pd - 1 or pd - l1 ( atezolizumab, durvalumab, avelumab, nivolumab, and pembrolizumab )."
        },
        {
          "qas": [
            {
              "id": "5e4b5fd86d0a277941000022_001",
              "question": "Does clinical trial data support the use of minocycline for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\na recent publication of the results of a clinical trial of minocycline in 412 als patient has aroused considerable controversy in the als scientific community.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nconclusions and relevance : minocycline did not delay the progress of cognitive or functional impairment in people with mild ad during a 2 - year period.\nthis pilot study shows that minocycline and riluzole can be taken safely together. further trials are needed to assess efficacy of such treatment.\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion.\nneuroprotective agents are screened for use in patients with als."
        },
        {
          "qas": [
            {
              "id": "5e776a10835f4e477700000c_001",
              "question": "Is the drug Exubera currently (March 2020) available?"
            }
          ],
          "context": "despite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\nin contrary, mannkind corporation started developing its ultra - rapid - acting insulin afrezza in a bold bid, probably by managing the issues in which exubera was not successful\n. afrezza has been marketed since february, 2015 by sanofi after getting fda approval in june 2014.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy.\nno new drugs have been approved during the past 15 years ; and the available medications are not cost - effective.\nby the japanese ministry of health and welfare in march 2020 and has recently become available for clinical practice\ncabotegravir : its potential for antiretroviral therapy and preexposure prophylaxis.\nin march 2020, oral tirabrutinib was approved in japan for the treatment of recurrent or refractory primary central nervous system lymphoma.\nhowever, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long qt syndrome and ventricular arrhythmias.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive."
        },
        {
          "qas": [
            {
              "id": "5e3c6e15b5b409ea53000023_001",
              "question": "Are breaks in double stranded DNA associated with ionizing radiation?"
            }
          ],
          "context": "exposure of cells to ionizing radiation induces dna double - strand breaks.\ndna double - strand breaks are considered to be the most deleterious lesion induced by ionizing radiation.\ndouble - stranded breaks ( dsbs ) are the most injurious type of dna damage, being induced by ionizing radiation ( ir ) and cytotoxic agents used in cancer treatment\nionizing radiation and radiomimetic drugs such as bleomycin, calichieamycin, neocarzinostatin chromophore, and other synthetic agents can produce both single and double strand breaks in dna.\nwhereas most endogenous and exogenous dna damaging agents typically generate lesions that are relatively isolated and can be repaired easily, ionizing radiation ( ir ) also induces clustered lesions causing dna double strand breaks ( dsbs )\ninfluence of chromatin structure on the induction of dna double strand breaks by ionizing radiation.\ndouble - stranded breaks ( dsbs ) are cytotoxic dna lesions caused by oxygen radicals, ionizing radiation, and radiomimetic chemicals\ndna double - strand breaks ( dsbs ) are major dna lesions that are constantly formed during physiological processes such as dna replication, transcription, and recombination, or as a result of exogenous agents such as ionizing radiation, radiomimetic\ngamma - ray irradiation introduces single and / or double strand breaks into the dna molecule of the cells.\nthe induction of dna interstrand cross - links by ionizing radiation has been largely ignored in favour of studies on double - strand break formation and repair."
        },
        {
          "qas": [
            {
              "id": "5e52c0c76d0a27794100004b_001",
              "question": "Is KAT2A involved in Acute myeloid leukemia (AML)?"
            }
          ],
          "context": ". our results propose that kat2a inhibition should be investigated as a therapeutic strategy in aml and provide a large number of genetic vulnerabilities of this leukemia that can be pursued in downstream studies.\nkat2a inhibition demonstrated anti - aml activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human amls of diverse genotypes while sparing normal hemopoietic stem - progenitor cells.\n. kat2a inhibition demonstrated anti - aml activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human amls of diverse genotypes while sparing normal hemopoietic stem - progenitor cells\nchronic myeloid leukemia is a stem cell disease with the presence of philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22.\nmediator kinase inhibition further activates super - enhancer - associated genes in aml.\ndkk1 has been implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic breast cancer, and osteoblastic metastases of prostate cancer.\nchronic myeloid leukemia ( cml ) is myeloproliferative neoplasm characterized by philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90 % of cases.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\n. we validate selected genes using genetic and pharmacological inhibition, and chose kat2a as a candidate for downstream study\nthis article examines the role of jak2 and flt3 signaling in myelofibrosis and provides an overview of the clinical development of pacritinib as a new therapy for myelofibrosis."
        },
        {
          "qas": [
            {
              "id": "5e4b639c6d0a277941000027_001",
              "question": "Is NicVAX vaccine effective for smoking cessation?"
            }
          ],
          "context": "conclusion the nicotine vaccine, nicvax, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.\nrecently, the most advanced candidate vaccine, nicvax, failed to meet the primary endpoint in two large phase iii studies, although the correlation of higher abstinence rates in subjects with higher immunity to nicotine was observed.\nauthors'conclusions : there is currently no evidence that nicotine vaccines enhance long - term smoking cessation.\nunfortunately, the only vaccine tested in two large, randomized phase iii trials, 3'- amino - methyl - nicotine r - exoprotein a conjugate vaccine ( nicvax ( \u00ae ), nabi biopharmaceuticals, md, usa ), did not demonstrate efficacy.\nthere was no difference in abstinence rates between nicvax and placebo from weeks 9 to 52 [ 27. 7 versus 30. 0 %, odds ratio ( or ) = 0. 89, 95 % confidence interval ( ci ) = 0. 62 - 1. 29 ] or weeks 37 to 52 ( 33. 8 versus 33. 2 %, or = 1. 03, 95 % ci = 0. 73 - 1. 46 ).\n. two phase iii nicvax trials, for which full results were not available, reported similar quit rates of approximately 11 % in both groups.\n. the top 30 % antibody responders, compared to the placebo group, showed a non - significant tendency towards higher abstinence rates from weeks 37 to 52 ( 42. 2 versus 33. 2 %, or = 1. 47, 95 % ci = 0. 89 - 2. 42 )\nthis study did not meet the primary efficacy endpoint of post - exposure prevention of symptomatic covid - 19 with azd7442 versus placebo.\nhealth benefits versus risks to assess whether to continue vaccination\n. some studies revealed changes in certain immune response parameters post - vaccination when analgesics / antipyretics were used either prophylactically or therapeutically. still, there is no evidence that these changes impact vaccine efficacy"
        },
        {
          "qas": [
            {
              "id": "5e48b1ddd14c9f295d000012_001",
              "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?"
            }
          ],
          "context": "interpretation natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper - limb component.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\nin this review, we summarize the pathophysiological mechanisms involved in the development of spms and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of ms, to exert beneficial\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\nconclusions : in a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache,\n. ibudilast may have a role in the treatment of progressive ms phenotypes.\nwhen using the anti - cd20 monoclonal antibodies ocrelizumab and ofatumumab in the treatment of ms, it is not necessary to test for nabs as these occur very infrequently.\n. however, the neutral results of this trial suggest that it does not improve the six - month global functional performance of patients.\nof relapsing forms of ms, to exert beneficial effects in reducing disease progression unrelated to relapses in spms."
        },
        {
          "qas": [
            {
              "id": "5e52c9266d0a27794100004e_001",
              "question": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?"
            }
          ],
          "context": "however, recent discoveries of new ahr ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy\ncombining in vivo and in vitro findings, we identified nine ahr agonists, six of which are marketed therapeutics and have been approved by the u. s. food and drug administration, including leflunomide, flutamide, and nimodipine.\nthus representing a notable drug target to explore.\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nthalidomide is attracting growing interest because of its reported immunomodulatory and anti - inflammatory properties.\nthe auf1 ( hnrnpd ) and hur ( elav - like ) proteins, potential trans - acting factors for regulated mrna decay, bind in vitro to a + u - rich elements ( ares ) found in the 3'untranslated region ( 3'utr ) of many labile transcripts.\nrecent studies show that mouse epidermis expresses cyp2b19, a keratinocyte - specific epoxygenase that generates 11, 12 - and 14, 15 - epoxyeicosatrienoic ( eet ) acids from arachidonate.\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response."
        },
        {
          "qas": [
            {
              "id": "5d385f717bc3fee31f00001a_001",
              "question": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?"
            }
          ],
          "context": "in contrast, the upstream nucleosome which covers the tata box under repressed conditions is shifted approximately 50 bp further upstream by the atp - dependent chromatin remodeler rsc upon activation\nsuch as h3k9me, h3k27me, h2aub, or active marks such as h3k4me, h3k36me, h3ac ), and chromatin remodeling ( nucleosome composition, occupancy, and location ).\nreconstituted transcription reactions established that the brahma ( brm ) chromatin - remodeling complex is essential for zeste - directed activation on nucleosomal templates.\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\naccordingly, the absence of swr - c or histone h2a. z results in compromised chromatin remodeling and impaired gene expression in the absence of rsc and h3k4 methylation.\nwe postulate that zrf1 operates in conjunction with cellular remodeling machines and suggest that on - site remodeling might be a hallmark of many chromatin - associated signaling pathways.\nh2a. z probably helps rsc in keeping the gene nucleosome - fre\ntranscription factors and chromatin - remodeling complexes are key determi \" \" ts of embryonic stem cell ( esc ) identity.\nin rsc - depleted cells, nfrs shrink such that the average positions of flanking nucleosomes move toward predicted sites.\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location."
        },
        {
          "qas": [
            {
              "id": "5e7f69d2835f4e4777000021_001",
              "question": "Has ZP-PTH been tested in a phase II clinical trial?"
            }
          ],
          "context": "this system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\nbased on positive results from a phase i / ii clinical trial\nresults : the six - month progression - free survival ( pfs ) rates in phase ii ( n = 41 ) were 0 % and 15 % in the pten / egfrviii - positive and pten / egfrviii - negative cohorts, respectively, leading to early termination.\nit has been demonstrated to be efficacious, well tolerated and safe for the treatment of pdp.\na phase ii study of saracatinib ( azd0530 ), a src inhibitor, administered orally daily to patients with advanced thymic malig \" \" cies.\npositive phase iii - study data have been published for lenvatinib as first - line and cabozantinib as second - line therapy.\nto determine the mtd and to assess the safety, tolerability, and potential activity of lb - 100, a first - in - class small - molecule inhibitor of protein phosphatase 2a ( pp2a ) in adult patients with progressive solid tumors.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\nin phase ii clinical trials, including patients with advanced castration - resistant pc, olaparib seems to be efficacious and well tolerated.\ncalcitonin gene - related peptide ( cgrp ) receptor antagonists ( gepants - rimegepant and ubrogepant ) and serotonin 5 - ht _ _ sub _ _ 1f _ _ end _ sub _ _ receptor agonists ( ditans - lasmiditan ) have completed phase 3 clinical trials and will soon offer novel,"
        },
        {
          "qas": [
            {
              "id": "5e48b9abd14c9f295d000015_001",
              "question": "Are multipotent adult progenitor cells effective for treatment of stroke?"
            }
          ],
          "context": "interpretation administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke.\n. although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke ( < 36\nmultipotent mesenchymal bone marrow - derived stem cells\nanimal studies have shown that mesenchymal stromal cell ( msc ) infusions improve acute kidney injury ( aki ) outcomes when administered early after ischemic / reperfusion injury or within 24 hours after cisplatin administration.\nmany researchers have recognized the positive effects of fty720 and launched basic and clinical experiments to test the use of this agent against stroke\nmultipotent hesc - derived mesenchymal cells ( mcs )\ncurrently, new therapies are emerging that promise more convenience and an improved safety profile ( ofatumumab ) or remyelinating potential with clinical improvement ( opicinumab ).\ntreatment with a murine anti - icam - 1 antibody ( enlimomab ) has been investigated in patients with acute ischemic stroke in the enlimomab acute stroke trial ( east )\nhere we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\n. in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment."
        },
        {
          "qas": [
            {
              "id": "5e3d8edf48dab47f26000003_001",
              "question": "Autophagy is the process where a virus obtains nutrients from it's host, yes or no?"
            }
          ],
          "context": "autophagy is a lysosome - associated, degradative process that catabolizes cytosolic components to recycle nutrients for further use and maintain cell homeostasis.\nautophagy is an evolutionarily conserved cellular process in which intracellular components are eliminated via lysosomal degradation to supply nutrients for organelle biogenesis and metabolic homeostasis.\nautophagy is a homeostatic process involved in the turnover or elimination of cytoplasmic components, damaged organelles, and protein aggregates via a lysosomal degradation mechanism.\nautophagy is known as a catabolic process for the recycling of the cytoplasmic macromolecules.\nautophagy is a self - eating process, in which the damaged or excessed cell organelles and misfolded protein aggregates are removed from the cellular microenvironment.\nautophagy is a cellular survival pathway that is necessary for the degradation of cellular constituents such as long - lived proteins and damaged organelles.\nin this study, we demonstrate that autophagy is a critical mediator of the viral degradation pathway and that this pathway is not hiv - 1 specific.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\nthe selective branch of autophagy that deals with identification, capture and degradation of protein aggregates is called aggrephagy.\nmechanistic insights into aggrephagy, a selective basal autophagy process to clear misfolded protein aggregates,"
        },
        {
          "qas": [
            {
              "id": "5d387a51a1e159510500000e_001",
              "question": "Does CXorf21 escape X chromosome inactivation?"
            }
          ],
          "context": "genes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\nfrom skewed x inactivation of the paternal nonmutant x chromosome.\nfamilial x - chromosome inactivation ( xci ) skewing was investigated in a family in which a female mucopolysaccharidosis type ii ( mps ii ) ( hunter syndrome, an x - linked genetic disease ) occurred. among e\nchromatin conformation capture using in situ hi - c on fluorescence - activated cell - sorted olfactory sensory neurons and their progenitors shows that olfactory receptor gene clusters from 18 chromosomes make specific and robust interchromosomal contacts\nthe normal x chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the hunter gene.\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\nzelda binds cis - regulatory elements ( tagteam heptamers ), making chromatin accessible for gene transcription.\ncrossing villin - cre transgenic mice to previously generated mice carrying a loxp - flanked cyld exon 9 ( cyld ( flx9 ) mice ). results : we found that iec - cyld ( \u03b49 ) mice did not present spontaneous intestinal abnormalities up to one year of age\n. in drosophila, the dna - binding protein zelda ( also known as vielfaltig ) is required for this transition and for transcriptional activation of the zygotic genome.\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation."
        },
        {
          "qas": [
            {
              "id": "5e52ab626d0a277941000046_001",
              "question": "Does promoter shape vary across populations?"
            }
          ],
          "context": ". our results identify promoter shape as a molecular trait that can evolve independently of promoter strength. broad promoters typically harbor shape - associated variants, with signatures of adaptive selection\nanimal promoters initiate transcription either at precise positions ( narrow promoters ) or dispersed regions ( broad promoters ), a distinction referred to as promoter shape\n. although highly conserved, the functional properties of promoters with different shapes and the genetic basis of their evolution remain unclear\n. single - cell measurements demonstrate that variants modulating promoter shape often increase expression noise, whereas heteroallelic interactions with other promoter variants alleviate these effects\n. these results uncover new functional properties of natural promoters and suggest the minimization of expression noise as an important factor in promoter evolution.\nlevels ( strength ) or the distribution of tsss within a promoter ( shape )\n. dispersed promoters display higher associations with well - positioned nucleosomes downstream of the tss and a more clearly defined nucleosome free region upstream, while focused promoters have a less organized nucleosome structure, yet higher\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\nenhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\n. here we used natural genetic variation across a panel of 81 drosophila lines to measure changes in transcriptional start site ( tss ) usage, identifying thousands of genetic variants affecting transcript levels ( strength ) or the distribution of tsss"
        },
        {
          "qas": [
            {
              "id": "5e4b5ef36d0a27794100001f_001",
              "question": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "an effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\nthe six months intent - to - treat analysis showed no statistically significant effect but a trend in favour of 2 mg xaliproden compared to placebo for reduction in the rate of deterioration of fvc, limbs functional score, and manual muscle testing score\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n. in all 20 studies no favourable effect for the treatment of cramps in als / mnd could be demonstrated, but many studies were underpowered to draw a definite conclusion.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival."
        },
        {
          "qas": [
            {
              "id": "5e8101e3835f4e477700002e_001",
              "question": "Is cathepsin L active in endosomes?"
            }
          ],
          "context": "cathepsin l in the late endosome / lysosome\nendosomal cathepsin l\ncleavage by the endosomal / lysosomal protease cathepsin l\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nthe acidic environment of the endosome ( ph 6. 0 ) while maintaining its binding affinity to il - 6r in plasma ( ph 7. 4 )\nphagosomal proteins are ubiquitylated, and ubiquitylation was found to be required for formation of acidic multivesicular structures.\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\ntear lysozyme\nace2 is a type 1 integral membrane protein and contains a catalytically active ectodomain that can be shed from the cell surface into the extracellular space,\nautophagy is a lysosome - associated, degradative process that catabolizes cytosolic components to recycle nutrients for further use and maintain cell homeostasis."
        },
        {
          "qas": [
            {
              "id": "5e4b5f566d0a277941000020_001",
              "question": "Is celecoxib effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\nin conclusion, the celecoxib - creatine combination was selected as preferable to the minocycline - creatine combination for further evaluation.\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\na recent publication of the results of a clinical trial of minocycline in 412 als patient has aroused considerable controversy in the als scientific community.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nneuroprotective agents are screened for use in patients with als.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment."
        },
        {
          "qas": [
            {
              "id": "5e6e8600c6a8763d23000002_001",
              "question": "Is the protein MCL-1 anti-apoptotic?"
            }
          ],
          "context": "anti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\nanti - apoptotic bcl - 2 family members, such as bcl - 2, bcl - xl or mcl - 1\nincreased expression of anti - apoptotic proteins ( bcl - xl, mcl - 1 and xiap )\nrepression of anti - apoptotic proteins ( mcl - 1, bcl - xl and xiap )\ntumours to dna - damaging agents and to deletion of the anti - apoptotic protein mcl1\nextensively established key effectors of such apoptotic bypass mechanisms, the antiapoptotic bcl - 2 ( apoptosis regulator bcl - 2 ) proteins, determine the response of cancer cells to chemotherapeutics\nlike many cancers, tnbc cells often deregulate programmed cell death by upregulating anti - apoptotic proteins of the b - cell cll / lymphoma 2 ( bcl - 2 ) family.\ndecreasing the expression of anti - apoptotic factors, including apoptosis regulator bcl - 2 and bcl - 2 - like protein 1 in fadu cells\nchanisms by which the essential, and possibly terminal, necroptotic effector, mlkl, triggers the disruption of cellular membranes to cause cell lysis.\nthe activation of mixed lineage kinase - like ( mlkl ) by receptor - interacting protein kinase - 3 ( ripk3 ) results in plasma membrane ( pm ) disruption and a form of regulated necrosis, called necroptosis."
        },
        {
          "qas": [
            {
              "id": "5e48bd2ed14c9f295d000017_001",
              "question": "Is ozanezumab effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "despite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\ninterpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n. additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\nconclusions : this study failed to show an efficacy of lubeluzole in the treatment of acute stroke.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als."
        },
        {
          "qas": [
            {
              "id": "5e4b62946d0a277941000024_001",
              "question": "Is Dexmecamylamine effective for depression?"
            }
          ],
          "context": "tc - 5214 ( dexmecamylamine ) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder ( mdd ) and is currently being evaluated by targacept as a treatment for overactive bladder.\nno notable differences were observed between dexmecamylamine and placebo for any secondary end point.\nin these 2 flexibly - dosed studies, no specific therapeutic effects were observed for tc - 5214 ( 1 - 4 mg bid ) adjunct to antidepressant in the primary endpoint or any secondary endpoint ; however, tc - 5214 was generally well tolerated.\nconclusions selinexor - dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.\n. the combination of selinexor and dexamethasone has demonstrated activity in \" penta - refractory \" mm, ( ie, mm refractory to the 5 most active anti - mm agents currently used in treatment ).\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nselinexor, an exportin - 1 inhibitor, yielded promising results in quad - or penta - refractory mm including patients resistant to daratumumab.\nthe novel dehydroepiandrosterone ( dhea ) derivative bnn27 counteracts delay - dependent and scopolamine - induced recognition memory deficits in rats.\nand daprodustat may become an effective alternative for treatment of anemia with ckd.\nconclusion the combination of selinexor and dexamethasone has an orr of 21 % in patients with heavily pretreated, refractory myeloma with limited therapeutic options."
        },
        {
          "qas": [
            {
              "id": "5e7f64a5835f4e477700001e_001",
              "question": "Can CMB305 be used against sarcomas?"
            }
          ],
          "context": "the potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\nrhabdomyosarcoma and other soft tissue sarcomas, ewing's sarcoma and other bone sarcomas.\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\n. here we describe a fully human bsab ( regn5458 ) that binds to b - cell maturation antigen ( bcma ) and cd3, and compare its antitumor activities vs those of anti - bcma car t cells to identify differences in efficacy and mechanism of action.\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\nexpert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\ncd3 - engaging bispecific antibodies ( bsabs ) and chimeric antigen receptor ( car ) t cells are potent therapeutic approaches for redirecting patient t cells to recognize and kill tumors\nresults from a phase i / ii trial suggest that an antibody - drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple - negative breast cancer. a"
        },
        {
          "qas": [
            {
              "id": "60258ebe1cb411341a0000a8_001",
              "question": "Has tocilizumab been assessed against Covid-19?"
            }
          ],
          "context": "preliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\ntocilizumab, an anti - il - 6 receptor antibody, and corticosteroids were initially used to treat the increase in acute inflammatory proteins and the anasarca, resulting in decreased cytokine levels.\nthe food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness.\ntocilizumab ( tcz ) is a humanized monoclonal antibody against il - 6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult ra populations\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\ntocilizumab is expected to ameliorate the autoimmune inflammatory diseases with il - 6 overproduction and has been clinically developed as a therapeutic agent for ra, systemic - onset and articular types of jia, crohn's disease, etc."
        },
        {
          "qas": [
            {
              "id": "5fdb2e60a43ad3127800000c_001",
              "question": "Is the TFR1 gene dispensable for erythropoiesis?"
            }
          ],
          "context": "these findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\nthe signaling functions of both tfr1 and tfr2 in erythroid cells were unexpected and these recent findings open a new field of research regarding the last steps of erythroid differentiation and their regulation.\nin humans, hematopoietic erythroid precursor cells express high levels of tfr1 and specifically take up the fth homopolymer ( h - ferritin ).\naken together, decreasing tfr1 expression during \u03b2 - thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate\n. the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\nwe found decreased expression of hepcidin and tfr2 and increased expression of tfr1 and ngal in the beta - thalassemia mouse models, compared with the control mice.\nprovides an endogenous mechanism to upregulate hepcidin, leading to sustained iron - restricted erythropoiesis and preventing systemic iron overload in \u03b2 - thalassemic mice.\nsoluble transferrin receptor - 1 ( stfr1 ) concentrations are increased in the plasma under two conditions that are associated with increased iron absorption, i. e. iron deficiency and increased erythropoiesis.\nhemochromatosis is caused by mutations in hfe, a protein that competes with transferrin ( tf ) for binding to transferrin receptor 1 ( tfr1 ).\nthese studies describe how point mutations of the transferrin receptor can cause a microcytic anemia that does not respond to iron therapy and would not be detected by routine iron studies, such as serum ferritin."
        },
        {
          "qas": [
            {
              "id": "5e94aadf0d431b5f73000002_001",
              "question": "Is Bcl-2-like protein 1 an pro apoptotic protein?"
            }
          ],
          "context": "anti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\nanti - apoptotic bcl - 2 family members, such as bcl - 2, bcl - xl or mcl - 1\nincreased expression of anti - apoptotic proteins ( bcl - xl, mcl - 1 and xiap )\nrepression of anti - apoptotic proteins ( mcl - 1, bcl - xl and xiap )\nlike many cancers, tnbc cells often deregulate programmed cell death by upregulating anti - apoptotic proteins of the b - cell cll / lymphoma 2 ( bcl - 2 ) family.\nextensively established key effectors of such apoptotic bypass mechanisms, the antiapoptotic bcl - 2 ( apoptosis regulator bcl - 2 ) proteins, determine the response of cancer cells to chemotherapeutics\ndecreasing the expression of anti - apoptotic factors, including apoptosis regulator bcl - 2 and bcl - 2 - like protein 1 in fadu cells\ntumours to dna - damaging agents and to deletion of the anti - apoptotic protein mcl1\n. taken together, these data identify huwe1 as a bona fide tumour suppressor gene in the intestinal epithelium and suggest a potential vulnerability of huwe1 - mutated tumours to dna - damaging agents and inhibitors of anti - apoptotic proteins.\nbackground : anti - programmed cell death ligand 1 ( pd - l1 ) / programmed cell death 1 antibodies have shown clinical activity in platinum - treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab"
        },
        {
          "qas": [
            {
              "id": "5e52c96b6d0a27794100004f_001",
              "question": "Glucoraphanin from broccoli can help reduce obesity , yes or no?"
            }
          ],
          "context": "glucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\ndata from most recent meta - analyses showed that the overall placebo - subtracted weight reduction ( % ) with the use of anti - obesity drugs for at least 12 months ranges from 2. 9 % to 6. 8 % ; phentermine / topiramate ( - 6. 8 % ) liraglutide ( - 5. 4 % ),\nconclusions : low - dose liraglutide still has high efficacy in weight reduction in taiwanese people, especially for those of younger age.\nconclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\nconclusion : liraglutide ( monotherapy or added to metformin ) significantly reduced fat mass and fat percentage vs. glimepiride in patients with t2d.\nconclusions : in adolescents with obesity, the use of liraglutide ( 3. 0 mg ) plus lifestyle therapy led to a significantly greater reduction in the bmi standard - deviation score than placebo plus lifestyle therapy.\nfive weeks of treatment with the glp - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.\nresults : currently, the fda has approved several molecules for the treatment of obesity, both in monotherapy and in combination\nthis meta - analysis finds a significant reduction in body weight with orlistat ( n = 10, 435 ; \u2206 - 3. 07 kg, 95 % ci, - 3. 76 to - 2. 37 ), phentermine plus topiramate ( n = 2985 ; \u2206 - 9. 77 kg ; 95 % ci, - 11. 73 to - 7. 81 ), lorcaserin ( n = 16, 856 ; \u2206 - 3. 08 kg ; 95 % ci,\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice."
        },
        {
          "qas": [
            {
              "id": "5e6f774ec6a8763d23000009_001",
              "question": "Are bacteria in the genus Clostridium facultative anaerobes?"
            }
          ],
          "context": "clostridia belong to those bacteria which are considered as obligate anaerobe, e. g. oxygen is harmful or lethal to these bacteria.\nclostridium is a large genus of obligate anaerobes belonging to the firmicutes phylum of bacteria, most of which have a gram - positive cell wall structure.\nsuch bacteria are either obligate anaerobic bacteria like clostridium or bifidobacterium or facultative anaerobic like escherichia coli or salmonella.\nantimicrobial production by strictly anaerobic clostridium spp.\nwe report here the closed genome of clostridium pasteurianum atcc 6013, a saccharolytic, nitrogen - fixing, and spore - forming gram - positive obligate anaerobe\nclostridium pasteurianum bb, a saccharolytic and spore - forming obligate anaerobe\nclostridium difficile is a spore - forming obligate anaerobe that is a leading cause of healthcare - associated infections\nfusobacterium necrophorum is a gram - negative anaerobic bacterium that is the causative agent of the invasive disease lemierre's syndrome.\nf. necrophorum is unique among non - spore - forming anaerobes, first for its virulence and association with lemierre's syndrome as a monomicrobial infection and second because it seems probable that it is an exogenously acquired infection.\nthe genus anaplasma belonging to the anaplasmataceae family ( order rickettsiales ) comprises obligate intracellular gram - negative bacteria of veterinary and public health importance"
        },
        {
          "qas": [
            {
              "id": "5fdb4253a43ad31278000022_001",
              "question": "Do nematodes contain architectural proteins like CTCF?"
            }
          ],
          "context": "our findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\nof ctcf from several nematodes is paralleled by a loss of two of its interactors, the polycomb repressive complex subunit suz12 and the multifunctional transcription factor tyy1. in contrast to earlier st\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces.\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\nhe most highly enriched motif ( lm1 ) corresponds to the x - box motif known from yeast and nematode\nso far poorly characterised mode present in more derived nematodes\nwe show that menin physically interacts with proteins involved in the canonical wnt signaling pathway, including beta - catenin, tcf3 ( tcfl1 ), and weakly with tcf4 ( tcfl2 ).\nthis general architectural change correlates with enhanced binding of ctcf and cohesins and more pronounced insulation of contacts across chromatin boundaries in lineage - committed cells.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,"
        },
        {
          "qas": [
            {
              "id": "6025912a1cb411341a0000aa_001",
              "question": "Is tocilizumab a tumor necrosis factor inhibitor?"
            }
          ],
          "context": "tocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\nsubsequent options include a tnf - alpha antagonist, followed by rituximab or possibly abatacept ; ( 2 ) tocilizumab, a monoclonal antibody, inhibits interleukin - 6 receptors.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\ntocilizumab ( tcz ; roactemra\u00ae or actemra\u00ae ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin 6 ( il - 6 ) receptor antagonist.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab ( tcz ), is a recombi \" \" t humanized anti - interleukin - 6 receptor ( il - 6r ) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis ( sjia ) and polyarticular juvenile idiopathic\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\ntocilizumab ( roactemra or actemra ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin ( il ) - 6 receptor antagonist.\ntocilizumab ( tcz ) is a compound that inhibits the il - 6 receptor."
        },
        {
          "qas": [
            {
              "id": "5e43ee1f48dab47f26000012_001",
              "question": "Do circular exons increase gene expression?"
            }
          ],
          "context": "circular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\n. while non - aug initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized - - both for increased coding capacity and potentially also for novel regulatory mechanisms - - remains unclear.\nexonic circrna, circular intronic rna, and exon - intron circular rna.\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\nour objective was to characterize non - canonical circrnas, namely not originating from back splicing and circrna produced by non - coding genes.\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\nhuman transcriptome contains a large number of circular rnas ( circrnas ) that are mainly produced by back splicing of pre - mrna.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\nrecent evidence has demonstrated that circular rnas ( circrnas ) played crucial roles in fine - tuning the levels of gene expression by sequestering the corresponding microrna ( mirnas )."
        },
        {
          "qas": [
            {
              "id": "5e4d6e446d0a27794100002f_001",
              "question": "Is MAGE-A3 immunotherapeutic effective for non-small-cell lung cancer?"
            }
          ],
          "context": "uvant treatment with the mage - a3 immunotherapeutic did not increase disease - free survival compared with placebo in patients with mage - a3 - positive surgically resected nsclc. ba\n. because of the absence of treatment effect, we could not identify a gene signature predictive of clinical benefit to mage - a3 immunotherapeutic.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit.\nphase iii trials of the anti - insulin - like growth factor type 1 receptor ( igf - ir ) antibody figitumumab ( f ) in unselected non - small - cell lung cancer ( nsclc ) patients were recently discontinued owing to futility.\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\npurpose of review : the therapeutic armamentarium for advanced non - small - cell lung cancer has evolved considerably over the past years\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer."
        },
        {
          "qas": [
            {
              "id": "5e94a8250d431b5f73000001_001",
              "question": "Does protein ALEX1 contain armadillo repeats?"
            }
          ],
          "context": "alex1 ( arm protein lost in epithelial cancers, on chromosome x ), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.\narm protein lost in epithelial cancers, on chromosome x 1 ( alex1 ) is a novel member of the armadillo family which has two armadillo repeats as opposed to more than six repeats in the classical armadillo family members.\nwe cloned the full - length cdna of rabbit rgs4, which contains a long 3'- untranslated region ( utr ) with several au - rich elements ( ares ).\neach of these species was present at very low copy numbers in primary and cultured cells ; however, only the expression of anril isoforms containing exons proximal to the ink4 / arf locus correlated with the asvd risk alleles.\nwe showed that 28 amino acids in the amino terminus of ppox contain an independently functioning signal for mitochondrial targeting.\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\ntryptic cleavage and peptide sequence analysis demonstrated that the 98 - kd protein is identical to a recently cloned protein, special a - t - rich binding protein 1 ( satb1 )\nand ulnar neuropathy at the elbow, constitute a significant part of the daily work in edx laboratories.\nhere, we find that cxcr4 harbors au - rich elements ( ares ) in the 3'- untranslated region ( 3'- utr ) that bind and respond to the rna - binding proteins, tristetraprolin ( ttp / zfp36 ) and hur ( elavl1 )."
        },
        {
          "qas": [
            {
              "id": "5e3390fafbd6abf43b000060_001",
              "question": "Does radiotherapy for cervical cancer increases risk of colon cancer?"
            }
          ],
          "context": "cervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites ( colon, rectum / anus, urinary bladder, ovary, and genital sites )\n. radiation - induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.\nafter 8 years, the hazard ratio for developing colon cancer was 2. 00 ( 95 % ci 1. 43 - 2. 80 ) for women with radiation versus those without radiation treatment.\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\nradiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\n. the risk of colon and rectum cancer over 20 years of follow - up after radiation remained the same across three eras ( 1973 - 1980, 1981 - 1990, and 1991 - 2000 )\nrisks of lung, breast, and gastrointestinal ( gi ) cancers increase with higher radiation dose.\nthe data suggested that high - dose pelvic irradiation was associated with increase in cancers of the bladder, kidneys, rectum, ovaries, corpus uteri, and non - hodgkin's lymphoma but, apparently, not leukemia, hodgkin's disease, breast cancer, or colon\nradiation therapy for prostate cancer is associated with an increased risk of bladder cancer.\nradiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer ( bc )."
        },
        {
          "qas": [
            {
              "id": "5fe31321a43ad3127800004b_001",
              "question": "Is yeast fbp1 affected by glucose starvation stress?"
            }
          ],
          "context": "the fission yeast fbp1 gene, whose transcription is massively induced upon glucose starvation.\nfission yeast, glucose starvation triggers lncrna transcription across promoter regions of stress - responsive genes including fbp1 ( fructose - 1, 6 - bisphosphatase1 ). at\nthe schizosaccharomyces pombe fbp1 gene, which encodes fructose - 1, 6 - bis - phosphatase, is transcriptionally repressed by glucose through the activation of the camp - dependent protein kinase a ( pka ) and transcriptionally activated by glucose starvation\nantisense transcripts from the fission yeast fbp1 locus ( fbp1 - as ) are expressed in glucose - rich conditions and anticorrelated with transcription of metabolic stress - induced lncrna ( mlonrna ) and mrna on the sense strand during glucose starvation.\nchromatin is reconstituted in the fission yeast schizosaccharomyces pombefbp1 gene, which is robustly induced upon glucose starvation but tightly repressed under glucose - rich conditions.\ncation stress and glucose starvation selectively caused chromatin structure alteration around cre - like sequences in cta3 ( + ) and fbp1 ( + ) promoters, respectively, in correlation with transcriptional activation.\n. the stress - activated protein kinase ( sapk ) pathway and its effectors, sty1 mapk and transcription factor atf1, play a critical role in the adaptation of fission yeast to grow on alternative non - fermentable carbon sources by inducing the expression\ncarbon sources by inducing the expression of fbp1 + gene, coding for the gluconeogenic enzyme fructose - 1, 6 - bis\ntranscriptionally activated by glucose starvation through the activation of a mitogen - activated protein kinase ( mapk ).\nwe herein show that the chromatin configuration is altered into an accessible state within 290 bp downstream from the initiation site of metabolic - stress - induced lncrnas ( mlonrnas ) in the promoter of the fission yeast fbp1 gene, whose transcription"
        },
        {
          "qas": [
            {
              "id": "5e4b64516d0a277941000029_001",
              "question": "Is Semagacestat effective for Alzheimer's Disease?"
            }
          ],
          "context": "recently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nobjective : semagacestat, a \u03b3 - secretase inhibitor, demonstrated an unfavorable risk - benefit profile in a phase 3 study of patients with alzheimer's disease ( identity trials ), and clinical development was halted.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\nconclusions : as compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.\nthe recent failure of semagacestat in two large phase iii studies questions the value of \u03b3 - secretase inhibitors in treating alzheimer's disease.\n. patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events ( p < 0. 001 for all comparisons with placebo ).\n. semagacestat was associated with more adverse events, including skin cancers and infections.\nts from phase iii studies showed that semagacestat failed to slow disease progression, and it was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. furthermore, sem\nchanges in neuropsychiatric inventory associated with semagacestat treatment of alzheimer's disease. in participants with mild to moderate ad, high dose semagacestat treatment was associated with greater severity and faster worsening of nps in a"
        },
        {
          "qas": [
            {
              "id": "5e9eba150d431b5f73000005_001",
              "question": "Do nematodes contain a CTCF gene?"
            }
          ],
          "context": "our findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\nso far poorly characterised mode present in more derived nematodes\nof ctcf from several nematodes is paralleled by a loss of two of its interactors, the polycomb repressive complex subunit suz12 and the multifunctional transcription factor tyy1. in contrast to earlier st\nwhilst intact in all fecvs, the 3c gene was mutated in the majority ( 71. 4 % ) of fipvs, but not in all, implying that mutation in 3c is not the ( single ) cause of fip.\nin addition, we reveal that tcf3 is essential within the neural ectoderm to maintain anterior character and that its interaction with hesx1 ensures the repression of wnt targets in the developing forebrain.\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces.\nstrikingly, without atp, we observe the emergence of hundreds of ctcf - independent loops that link regulatory dna.\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\nhe most highly enriched motif ( lm1 ) corresponds to the x - box motif known from yeast and nematode\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,"
        },
        {
          "qas": [
            {
              "id": "60259fe91cb411341a0000b3_001",
              "question": "Is tocilizumab a csDMARD?"
            }
          ],
          "context": "biological ( b ) dmards ( tumour necrosis factor inhibitors ( adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ), abatacept, rituximab, tocilizumab, sarilumab and biosimilar ( bs ) dmards ) and targeted synthetic ( ts ) dmards ( the janus\nrecently, an anti - il - 6 receptor monoclonal antibody, tocilizumab, has been licensed for the treatment as monotherapy or in combination with methotrexate of moderate to severe ra, when disease modifying anti - rheumatic drugs or anti - tumour necrosis\nobjectives oral targeted synthetic disease - modifying anti - rheumatic drugs ( dmards ), including the janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis ( ra ).\nthe task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic ( cs ) dmards ( methotrexate ( mtx ), leflunomide, sulfasalazine ) ; glucocorticoids ( gcs ) ; biological ( b ) dmards ( tumour necrosis factor\ntocilizumab ( tcz ), is a recombi \" \" t humanized anti - interleukin - 6 receptor ( il - 6r ) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis ( sjia ) and polyarticular juvenile idiopathic\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\nindeed, worldwide clinical trials of tnf inhibiting biologic disease modifying antirheumatic drugs ( bdmards ) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti - human il - 6 receptor antibody,\nthe humanized anti - human il - 6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bdmards to treat moderate to severe active ra in patients\ntocilizumab is expected to ameliorate the autoimmune inflammatory diseases with il - 6 overproduction and has been clinically developed as a therapeutic agent for ra, systemic - onset and articular types of jia, crohn's disease, etc."
        },
        {
          "qas": [
            {
              "id": "601c1a271cb411341a000011_001",
              "question": "Can SMAD6 variants cause craniosynostosis?"
            }
          ],
          "context": "enrichment of heterozygous missense and truncating smad6 variants was previously reported in nonsyndromic sagittal and metopic synostosis, and interaction of smad6 variants with a common polymorphism nearbmp2 ( rs1884302 ) was proposed to contribute to\nrs1884302 genotype significantly modifies the phenotype. methods : we performed resequencing of smad6 in 795 unsolved patients with any type of craniosynostosis and genotyped rs1884302 in smad6 - positive individuals and relatives\n. we examined the inhibitory activity and stability of smad6 missense variants. results : we found 18 ( 2. 3 % ) different rare damaging smad6 variants, with the highest prevalence in metopic synostosis ( 5. 8 % ) and an 18. 3 - fold enrichment of\n. we determined the occurrence of smad6 variants in all types of craniosynostosis, evaluated the impact of different missense variants on smad6 function, and tested independently whether rs1884302 genotype significantly modifies the\nrecent genetic studies have identified several novel genes and pathways that cause nonsyndromic craniosynostosis, providing genetic evidence linking the causes of syndromic and nonsyndromic craniosynostoses, and allowing for genotype - based prediction\n. combined with eight additional variants, \u226520 / 26 were transmitted from an unaffected parent but rs1884302 genotype did not predict phenotype. conclusion : pathogenic smad6 variants substantially increase the risk of both nonsyndromic and syndromic\nidentification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis.\nthe risk of both nonsyndromic and syndromic presentations of craniosynostosis, especially metopic synostosis\nand the embryological period in which the mutation itself occurs, a type of craniosynostosis arises that may involve one or more cranial sutures.\n. it is becoming clearer that in most patients with craniosynostosis, there is regional imbalance of skull growth, which co - exists with a variety of other equally important factors, such as genetic defects, raised intracranial pressure, venous"
        },
        {
          "qas": [
            {
              "id": "5fdb4124a43ad31278000017_001",
              "question": "Is Tcf3 associated with the Wnt pathway?"
            }
          ],
          "context": "tcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\nthe transcription factor t - cell factor 3 ( tcf3 ), one component of the wnt pathway, is known as a cell - intrinsic inhibitor of many pluripotency genes in embryonic stem cells ( escs ) that influences the balance between pluripotency and differentiation.\nt - cell factor 3 ( tcf3 ) is a component of the wnt signaling and a domi \" \" t downstream effector in escs.\nbackground and objectives : transcription factor 3 ( tcf3 ) implicates wnt signaling pathway and regulates e - cadherin expression, which is involved i\nwe show that menin physically interacts with proteins involved in the canonical wnt signaling pathway, including beta - catenin, tcf3 ( tcfl1 ), and weakly with tcf4 ( tcfl2 ).\nwe also find that tcf3 phosphorylation is triggered by canonical wnt ligands, lrp6, and domi \" \" t negative mutants for axin and gsk3, indicating that this process shares the same upstream regulators with \u03b2 - catenin stabilization.\ntcf3 - mediated repression to tcf1 / lef1 - mediated enhancement of wnt signaling, constituting a positive feedback loop that facilitates neuronal differentiation.\nwe found that in contrast to es cells, where it represses wnt - pathway target genes, tcf3 promotes the expression of a subset of wnt - responsive genes in breast cancer cells while repressing another distinct target subset.\nin addition, we reveal that tcf3 is essential within the neural ectoderm to maintain anterior character and that its interaction with hesx1 ensures the repression of wnt targets in the developing forebrain.\nwnt pathway stimulation also triggers \u03b2 - catenin association at regulatory elements with classic lef / tcf motifs associated with differentiation programs."
        },
        {
          "qas": [
            {
              "id": "5e766256835f4e4777000003_001",
              "question": "Have the rotavirus vaccines changed the predominant rotavirus genotypes?"
            }
          ],
          "context": "impact of rotavirus vaccines on rotavirus disease\nthis study describes the distribution and diversity of rotavirus genotypes before and after rotavirus vaccine introduction into the australian nip.\n. genotype distribution varied based on the vaccine implemented, with g12p [ 8 ] domi \" \" t in states using rotateq, and equine - like g3p [ 8 ] and g2p [ 4 ] domi \" \" t in states and territories using rotarix.\nchange in rotavirus epidemiology in northeast florida after the introduction of rotavirus vaccine\nimpact of rotavirus vaccine on rotavirus diarrhoea in countries of east and southern africa.\na live attenuated monovalent rotavirus vaccine ( rotarix ) containing human rotavirus strain rix4414 of g1p1a p [ 8 ] specificity is being developed to meet the global need.\nwith the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine - preventable disease among children in the eu\nonly the rrv vaccine induced a low level of protection against rotavirus diarrhea mainly of serotype g1 specificity.\nwith safe and efficacious rotavirus vaccines now on the verge of widespread adoption, researchers can be vital advocates for their uptake into routine immunization programs\nclinical and immunological studies of rotavirus vaccines."
        },
        {
          "qas": [
            {
              "id": "5e323e93fbd6abf43b000059_001",
              "question": "Does head ct increase brain tumor risk?"
            }
          ],
          "context": ". converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\n. the frequency of ct exposure was proportional to the risk of developing tumors in two studies although not significantly maintained in two other studies.\ncompared with the general population, incidence of brain tumors was higher in the cohort of children with ct scans, requiring cautious interpretation of the findings.\n. tumor incidence increased with number of pediatric head cts in a dose - dependent manner, with measurable excess incidence even after a single scan\nrison of exposed and unexposed cohorts showed that there was no statistically significant increase in the risk of meningioma after exposure to ct of the head ( hr : 1. 49 ; 95 % confidence interval : 0. 97, 2. 30 ; p =. 07 ). if incident c\nrecent epidemiologic evidence from a national registry of children who underwent ct scans suggests a higher - than - expected incidence of secondary tumors.\n. the frequency of ct examination showed strong correlation with the subsequent overall risk of malig \" \" cy and benign brain tumour. conclusions : we found that paediatric head ct examination was associated with an increased incidence of benign brain\nresults : a positive correlation between exposure to ct scans and developing central nervous system tumors was evident in all cohorts. the strength of the association varied across the studies\nbackground : recent studies linking radiation exposure from pediatric computed tomography ( ct ) to increased risks of leukemia and brain tumors lacked data to control for cancer susceptibility syndromes ( css ).\nepidemiological studies consistently cited increased tumor incidence in pediatric patients ( ages 0 - 18 ) exposed to head cts."
        },
        {
          "qas": [
            {
              "id": "5e764732c6a8763d23000017_001",
              "question": "Can AGY be used as antidiuretic replacement therapy?"
            }
          ],
          "context": "preclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\noral egg yolk anti - gliadin antibody ( agy ) is a novel treatment to neutralize gluten and may improve the efficacy of the gfd.\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\nand daprodustat may become an effective alternative for treatment of anemia with ckd.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\nprevious results suggest that oxt and arginine vasopressin ( avp ) may play a role in the etiopathogenesis of asd\ndaprodustat for the treatment of anemia in patients not undergoing dialysis.\nand for high - dose diuretics ; renal function usually improved or at least stabilized.\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah )."
        },
        {
          "qas": [
            {
              "id": "5e323d79fbd6abf43b000058_001",
              "question": "Can secondary glioblastoma be caused by brain irradiation?"
            }
          ],
          "context": "the authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\nsecondary brain tumors rarely arise after cranial irradiation ; among them, meningiomas and glioblastomas are the most common and secondary oligodendroglial tumors the most rare.\nsecondary glioblastoma multiforme ( sgbm ) can occur after a long latency period following radiation treatment of various diseases including brain tumors, leukemia, and more benign disorders like tinea capitis.\nparadoxically, radiation is also a risk factor for gbm development, raising the possibility that radiotherapy of brain tumors could promote tumor recurrence or trigger secondary gliomas.\nirradiation, however, acts as an oncogenic factor as a delayed effect and it is rare that glioblastoma multiforme develops during the remission period of all.\nwe describe a case of radiation - induced glioblastoma after radiotherapy for germinoma.\nsurvivors of childhood all treated with high - dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation - induced meningioma\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\na 22 year - old - man with acute lymphoblastic leukaemia had received prophylactic cranial irradiation and intrathecal chemotherapy. eighteen years later a cerebellar glioblastoma multiforme was diagnosed.\nradiation - induced world health organization grade ii meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. three case reports."
        },
        {
          "qas": [
            {
              "id": "5e94902f2d3121100d000012_001",
              "question": "Is aggrephagy a variant of autophagy?"
            }
          ],
          "context": "the selective branch of autophagy that deals with identification, capture and degradation of protein aggregates is called aggrephagy.\nmechanistic insights into aggrephagy, a selective basal autophagy process to clear misfolded protein aggregates,\n, it is largely unknown how misfolded polypeptides form aggresomes and are eventually cleared by the aggresome - macroautophagy / autophagy pathway, so - called aggrephagy.\nautophagy is a self - eating process, in which the damaged or excessed cell organelles and misfolded protein aggregates are removed from the cellular microenvironment.\nautophagy is a homeostatic process involved in the turnover or elimination of cytoplasmic components, damaged organelles, and protein aggregates via a lysosomal degradation mechanism.\nautophagy is a cellular survival pathway that is necessary for the degradation of cellular constituents such as long - lived proteins and damaged organelles.\nautophagy is an evolutionarily conserved cellular process in which intracellular components are eliminated via lysosomal degradation to supply nutrients for organelle biogenesis and metabolic homeostasis.\nautophagy is a lysosome - associated, degradative process that catabolizes cytosolic components to recycle nutrients for further use and maintain cell homeostasis.\nautophagy is known as a catabolic process for the recycling of the cytoplasmic macromolecules.\nautophagy is important in cellular homeostasis for the cell survival mechanism."
        },
        {
          "qas": [
            {
              "id": "601d75281cb411341a000043_001",
              "question": "Is there any role of genotoxic pks + E. coli in cancer?"
            }
          ],
          "context": ". our study describes a distinct mutational signature in colorectal cancer and implies that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin - producing pks pathogenicity island.\n. escherichia coli can carry the pathogenicity island pks, which encodes a set of enzymes that synthesize colibactin3. this compound is believed to alkylate dna on adenine residues4, 5 and induces double - strand breaks in cultured cells3\nmutational signature in colorectal cancer caused by genotoxic pks +\n. here we expose human intestinal organoids to genotoxic pks + e. coli by repeated luminal injection over five months\nsuggesting that these pathways do not predispose cyld - deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and / or pro - inflammatory stress. conclusions : our findings underscore a critical tumor - suppressing role\n. in the present study we evaluated the role of intestinal epithelial cyld in colitis - associated cancer using a conditional mouse cyld inactivation model. methods : in order to evaluate the role of cyld in intestinal epithelial carcinogenesis, mice\ninactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\nunderscore a critical tumor - suppressing role for functional intestinal epithelial cyld in colitis - associated carcinogenesis\n. moreover, increased p38mapk and erk1 / 2 activities were detected in colon cancer cells from adamts18 - deficient mice\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model."
        },
        {
          "qas": [
            {
              "id": "5e44c59848dab47f26000021_001",
              "question": "Should tirilazad be used for treatment of ischemic stroke?"
            }
          ],
          "context": ". although further trials of tirilazad are now unwarranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischemic stroke.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\nconclusions : tirilazad mesylate increases death and disability by about one fifth when given to patients with acute ischemic stroke\ntirilazad did not significantly decrease unfavorable clinical outcome on the gos ( odds ratio [ or ] 1. 04, 95 % confidence interval [ ci ] 0. 89 - 1. 20 ) or cerebral infarction ( or 1. 04, 95 % ci 0. 89 - 1. 22 ).\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\ntreatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.\nconclusions : this study failed to show an efficacy of lubeluzole in the treatment of acute stroke."
        },
        {
          "qas": [
            {
              "id": "5e64f11a1af46fc130000017_001",
              "question": "Is the Paramyxovirus geneome segmented, negative-sense RNA?"
            }
          ],
          "context": "the paramyxovirus family has a genome consisting of a single strand of negative sense rna\nthe paramyxovirus genome, a nonsegmented, negative - polarity, single - stranded rna of approximately 15 kb, contains six transcription units flanked at the 3'and 5'ends by a short ( approximately 50 - to 60 - nucleotide ) extracistronic sequence, dubbed\nmembers of the paramyxoviridae such as measles, mumps, and parainfluenza viruses have pleomorphic, enveloped virions that contain negative - sense unsegmented rna genomes.\nparamyxovirus particles are pleomorphic, with a lipid envelope, nonsegmented rna genomes of negative polarity, and densely packed glycoproteins on the virion surface.\nbeilong virus, a novel paramyxovirus with the largest genome of non - segmented negative - stranded rna viruses.\nthe avian paramyxovirus type 1 ( apmv - 1 ), or newcastle disease virus ( ndv ), comprise a diverse group of viruses with a single - stranded, negative - sense rna genome.\nassembly of the nonsegmented negative - strand rna paramyxovirus simian virus 5 ( sv5 )\nunlabelled : mumps virus ( muv ) is a paramyxovirus with a negative - sense nonsegmented rna genome.\nthe replication of nonsegmented minus - strand rna genomes, like that of sendai paramyxovirus ( sev ), are controlled by the short leader regions present at each end of the linear genomes and antigenomes ; the left and right promoters ( pl and pr ),\nan alternative method to determine the 5'extremities of non - segmented, negative sense rna viral genomes using positive replication intermediate 3'tailing : application to two members of the paramyxoviridae family."
        },
        {
          "qas": [
            {
              "id": "602599251cb411341a0000b1_001",
              "question": "Does the use of bDMARDs during pregnancy impact neonatal development?"
            }
          ],
          "context": "exposure to bdmards during preg \" \" cy does not seem to interfere with post - natal development up to infancy.\nobjectives oral targeted synthetic disease - modifying anti - rheumatic drugs ( dmards ), including the janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis ( ra ).\nindeed, worldwide clinical trials of tnf inhibiting biologic disease modifying antirheumatic drugs ( bdmards ) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti - human il - 6 receptor antibody,\nother disease modifying antirheumatic drugs and biologic agents, as they became available.\nthe task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic ( cs ) dmards ( methotrexate ( mtx ), leflunomide, sulfasalazine ) ; glucocorticoids ( gcs ) ; biological ( b ) dmards ( tumour necrosis factor\nto treat moderate to severe active ra in patients with an inadequate response to synthetic disease modifying antirheumatic drugs ( sdmards ).\nthe use of methotrexate in rheumatoid arthritis.\nbiological ( b ) dmards ( tumour necrosis factor inhibitors ( adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ), abatacept, rituximab, tocilizumab, sarilumab and biosimilar ( bs ) dmards ) and targeted synthetic ( ts ) dmards ( the janus\nresponded inadequately to, or who are intolerant to one or more disease - modifying anti - rheumatic drugs ( dmards ).\nmethotrexate is generally the first - line drug for the treatment of ra, psoriatic arthritis and other forms of inflammatory arthritis, and it enhances the effect of most biologic agents in ra."
        },
        {
          "qas": [
            {
              "id": "601d46d61cb411341a000030_001",
              "question": "Do exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1)?"
            }
          ],
          "context": "to investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\nspanning exons 38 and 39 and affecting highly conserved residues cause a novel multiple malformations syndrome distinct from ks1\n. we report two additional individuals with intellectual disability, dysmorphic features, hypertrichosis, macrocephaly and the same de novo kcnt2 missense variants affecting the arg190 residue as previously described\nkcnt2 variants resulting in substitutions affecting the arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt\n. this is the first report of pathogenic variants in kcnt2 causing a developmental phenotype without epilepsy.\n. notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\n. unlike kmt2d haploinsufficiency in ks1, these mvs likely result in disease through a domi \" \" t negative mechanism.\nmissense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy.\ndkk1 has been implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic breast cancer, and osteoblastic metastases of prostate cancer.\n. circular dichroism spectroscopy indicated that these mvs perturb kmt2d secondary structure through an increased disordered to \u0251 - helical transition. conclusion : kmt2d mvs located in a specific region spanning exons 38 and 39 and affecting highly"
        },
        {
          "qas": [
            {
              "id": "601c4e5e1cb411341a000021_001",
              "question": "Is cabergoline used for treatment of the Nelson's syndrome ?"
            }
          ],
          "context": "this case demonstrates that long - term cabergoline treatment may be efficient in patients with nelson's syndrome.\nthis case demonstrated that cabergoline treatment is able to induce the remission of nelson's syndrome and may be a valid therapeutic alternative in this syndrome.\nnelson's syndrome : complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.\n. identification of d ( 2 ) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of nelson's syndrome, ectopic acth - secreting tumors, and recently cushing's disease ( cd ). objective : to evaluate the long - term\nhowever, some preliminary data suggest a potential use of cabergoline in combination with ketoconazole, or alone, in selected cases of cushing's disease or nelson's syndrome.\nidentification of d ( 2 ) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of nelson's syndrome, ectopic acth - secreting tumors, and recently cushing's disease ( cd ).\ndisease ( cd ). objective : to evaluate the long - term efficacy of cabergoline monotherapy in patients with cd. methods : retrospective analysis of non - randomized clinical therapy with cabergoline in 30 patients with cd treated in academic cente\nin our observation cabergoline at 2 mg per week seems to be efficient after a 3 and a half years follow - up, in accordance with some recent publications.\ntherefore, in addition to prolactinomas, targets of dopamine agonist therapy are somatotroph tumors, nonfunctioning pituitary tumors, corticotroph pituitary tumors, nelson's syndrome, gonadotropinomas, and thyrotropin - secreting pituitary tumors.\ndue to a rapid regrowth of the tumour, the patient did not receive gamma - knife therapy and was treated with cabergoline and somatostatin analogue for some time."
        },
        {
          "qas": [
            {
              "id": "604903551cb411341a000162_001",
              "question": "Are mucins glycosylated proteins?"
            }
          ],
          "context": "mucin is a glycoprotein that is the primary component of the mucus overlaying the epithelial tissues.\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\nmuc1 is a membrane glycoprotein, which in adenocarninomas is overexpressed and exhibits truncated o - glycosylation.\nmucin - type o - linked glycosylation\nmucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\ninflammation causes muc1 overexpression and hypoglycosylation.\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\nigg glycosylation profile was independently associated with esophageal precancerosis beyond inflammation, which could be an early biomarker for esophageal cancer.\nve - cadherin protein levels were also increased in the plasma membrane fraction."
        },
        {
          "qas": [
            {
              "id": "601d73ee1cb411341a00003f_001",
              "question": "Is carpal tunnel syndrome a type of nerve entrapment?"
            }
          ],
          "context": "entrapment neuropathies are of various types, but the most common type is carpal tunnel syndrome.\ncarpal tunnel syndrome ( cts ) is a common form of peripheral nerve entrapment, which is observed due to compression of the median nerve at the level of the carpal tunnel in the wrist.\ncarpal tunnel syndrome ( cts ) is the most common nerve entrapment neuropathy which is the result of the compression of the median nerve in the wrist.\ncarpal tunnel syndrome is the most frequently encountered peripheral nerve entrapment.\ncarpal tunnel syndrome ( cts ) is the most common type of peripheral nerve entrapment and is a significant cause of morbidity.\nthe carpal tunnel syndrome is the most frequent entrapment syndrome of peripheral nerves.\ndear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \" entrapment of median nerve in carpal tunnel \" also called \" carpal tunnel syndrome ( cts ) \" ( aydin et al., 2007 ; huisstede et al., 2010 ). this syndr\n[ carpal tunnel syndrome and other nerve entrapment syndromes ].\ncarpal tunnel syndrome is the most common of the median nerve entrapments.\ncarpal tunnel syndrome ( cts ) is a nerve entrapment disorder, involving the median nerve when it passes the carpal tunnel at the wrist."
        },
        {
          "qas": [
            {
              "id": "602905e81cb411341a000108_001",
              "question": "Is there a link between rare variants in PPARG and type 1 diabetes?"
            }
          ],
          "context": "rare variants in pparg with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.\n. the combination of large - scale dna sequencing and functional testing in the laboratory reveals that approximately 1 in 1, 000 individuals carries a variant in pparg that reduces function in a human adipocyte differentiation assay and is associated\nthe nlr family pyrin domain containing 3 ( nlrp3 ) inflammasome plays a critical role in insulin resistance and the pathogenesis of type 2 diabetes\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\nadipocyte differentiation assay and is associated with a substantial risk of t2d.\nthe behavioral effects of avp are mediated through the avp receptor 1a ( avpr1a ), making the avpr1a gene a reasonable candidate for autism susceptibility.\n. considered in aggregate ( with or without computational prediction of functional consequence ), these rare variants showed no association with t2d ( or = 1. 35 ; p = 0. 17 )\n. moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.\n. 5. 1 % / year, p < 0. 001 ). < br > < b > conclusions < / b > : plasma apelin is a novel biomarker for predicting type 2 diabetes in men. < br >\nin men at risk for diabetes ( hba1c 5. 7 - 6. 4 %, fpg 100 - 125mg / dl, or ogtt - 2h - pg 140 - 199mg / dl ), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations ( 10. 6 % / year"
        },
        {
          "qas": [
            {
              "id": "5fd78702a43ad31278000005_001",
              "question": "Does steroid 5A-Reductase deficiency lead to hermaphroditism?"
            }
          ],
          "context": "male pseudo hermaphroditism caused by steroid 5 alpha reductase deficiency is a rare autosomal recessive disorder.\nmale pseudohermaphroditism caused by steroid 5alpha - reductase deficiency is an autosomal recessive disorder.\nthe deficiency of steroid 5 alpha - reductase leads to the disturbances in sex differentiation that cause symptoms of male pseudohermaphroditism.\nsteroid 5 - alpha - reductase 2 deficiency is a rare disorder leading to male pseudohermaphroditism, a condition characterized by incomplete differentiation of male genitalia in 46, xy patients.\n5\u03b1 steroid reductase deficiency ( 5\u03b1srd ) is an autosomal recessive enzymatic deficiency and mutations in the 5\u03b1 steroid reductase type 2 gene ( srd5a2 ) result in male pseudohermaphrodism caused by decreased dihydrotestosterone ( dht ) synthesis.\ndeletion of steroid 5 alpha - reductase 2 gene in male pseudohermaphroditism.\ninherited deficiencies of 5 alpha - reductase type 2 result in a form of male pseudohermaphroditism in which the external genitalia fail to develop normally.\nthe present report describes a cluster of eight patients with male pseudohermaphroditism from a large pedigree with steroid 5 alpha - reductase 2 deficiency ( 5 alpha rd ), who reside in southern lebanon.\nwe report two cases of male pseudohermaphroditism, a true hermaphroditism and a 5 - alfa - reductase deficiency.\nn 46, xy disorders of sex development, 5\u03b1 - reductase deficiency is rare and is not usually the first - intention diagnosis in newborn ambiguous genitalia, contrary to partial androgen insensitivity syndrome."
        },
        {
          "qas": [
            {
              "id": "6026db1f1cb411341a0000cf_001",
              "question": "Has ubrogepant entered clinical phase III trials?"
            }
          ],
          "context": "two pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\nubrogepant ( mk - 1602 ) is a novel, oral, calcitonin gene - related peptide receptor antagonist in clinical development with positive phase iii outcomes for acute treatment of migraine.\ndespite the clear safety concerns, clinical trial data suggests that their intermittent use remains a viable and safe alternative, with 2 molecules remaining in clinical development ( ubrogepant and rimegepant ).\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for acute treatment of migraine, but have not yet been submitted to the fda for this indication.\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the fda for this indication.\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\nthe cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\nwe applied this strategy for another late - stage clinical program : ubrogepant ( mk - 1602 ), a novel oral calcitonin gene - related peptide receptor antagonist for acute treatment of migraine.\nubrogepant for the treatment of migraine.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine."
        },
        {
          "qas": [
            {
              "id": "6031002d1cb411341a000129_001",
              "question": "Are PDXK mutations linked to polyneuropathy?"
            }
          ],
          "context": "hereditary polyneuropathy with optic atrophy due to pdxk variant leading to impaired vitamin b6 metabolism\n. response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. results : we identified biallelic mutations in pdxk in 5 individuals from 2 unrelated families with primary axonal\nwalk independently during the first year of plp normalization. interpretation : we show that mutations in pdxk cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced pdxk enzymatic activity and low plp\n. low pdxk atp binding resulted in decreased erythrocyte pdxk activity and low pyridoxal 5'- phosphate ( plp ) concentrations\nshow that mutations in pdxk cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced pdxk enzymatic activity and low plp. we\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\naccumulated evidence implies that mutations in the gene coding for cu / zn superoxide dismutase ( sod ) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis ( als ).\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 ).\nwe previously identified fxyd1 ( encoding phospholemman ; a protein containing the motif phenylalanine - x - tyrosine - aspartate ), a gene encoding a transmembrane modulator of the na, k - atpase ( nka ) enzyme,\nmutations in the cu, zn superoxide dismutase ( sod1 ) gene have been reported in some pedigrees with familial amyotrophic lateral sclerosis ( fals )."
        },
        {
          "qas": [
            {
              "id": "601d76131cb411341a000044_001",
              "question": "Is avelumab effective for urothelial carcinoma?"
            }
          ],
          "context": ". areas covered : this article will review the pharmacological characteristics of avelumab, the efficacy studies which led to its approval, its safety profile, as well as its place within the management of urothelial carcinoma with immunotherapy.\nnivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the fda for treatment of advanced - stage urothelial carcinoma.\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\navelumab for the treatment of urothelial cancer.\nretation : avelumab showed antitumour activity in the treatment of patients with platinum - refractory metastatic urothelial carcinoma ; a manageable safety profile was reported in all avelumab - treated patients. these\nsions : mainte \" \" ce avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first - line chemotherapy\nexpert opinion : avelumab has shown clinical efficacy for metastatic and advanced uc in phase i studies after the failure of platinum - based therapy with a well - tolerated safety profile.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc.\navelumab has been approved by the u. s. fda for the treatment of metastatic merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum - based regimen.\nfive new pd - 1 / pd - l1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma ( uc ) : pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab."
        },
        {
          "qas": [
            {
              "id": "601dc46c1cb411341a000050_001",
              "question": "Is MIS-C or Multisystem  Inflammatory syndrome in children a complication of Covid-19?"
            }
          ],
          "context": "multisystem inflammatory syndrome in children ( mis - c ) associated with coronavirus disease 2019 ( covid - 19 ) is a newly recognized condition in which children with recent sars - cov - 2 infection present with a constellation of symptoms including\ndata on multisystem inflammatory syndrome in children ( mis - c ) related to coronavirus disease - 19 ( covid - 19 ) is increasing in the current covid - 19 pandemic.\nintroduction multisystem inflammatory syndrome in children ( mis - c ) is a unique clinical complication of sars - cov - 2 infection observed in pediatric patients.\nhowever, the newly described multisystem inflammatory syndrome in children ( mis - c ) associated with coronavirus disease 2019 ( covid - 19 ) has been associated with cardiac complications. m\nit includes a discussion of multisystem inflammatory syndrome in children ( mis - c ) associated with covid - 19, as well as other aspects of the covid - 19 pandemic that are affecting children and families, such as poisonings, childhood immunizations,\nmultisystem inflammatory syndrome in children ( mis - c ) is a life - threatening post - infectious complication occurring unpredictably weeks after mild or asymptomatic sars - cov2 infection in otherwise healthy children.\nthis syndrome is now known as either \" pediatric inflammatory multisystem syndrome temporally related with covid - 19 \" ( pims - ts ) ( 1 ), or multisystem inflammatory syndrome in children ( mis - c ) ( 2 ) and is currently considered a rare post - covid - 19\nthis condition, since defined as the multisystem inflammatory syndrome in children ( mis - c ), is assumed to be a delayed immune response to coronavirus disease 2019 ( covid - 19 ), and there are frequently cardiac manifestations of ventricular dysfunction\nbackground : multisystem inflammatory syndrome in children ( mis - c ), also known as pediatric inflammatory multisystem syndrome, is a new dangerous childhood disease that is temporally associated with coronavirus disease 2019 (\nbackground : recently, cases of multisystem inflammatory syndrome in children ( mis - c ) associated with covid - 19 have been reporte"
        },
        {
          "qas": [
            {
              "id": "6020010a1cb411341a00007c_001",
              "question": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?"
            }
          ],
          "context": ". co - loss of brca2 - rb1 in human prostate cancer cells induces an epithelial - to - mesenchymal transition, which is associated with invasiveness and a more aggressive disease phenotype\nin human prostate cancer cell lines ( lncap and lapc4 ), loss of brca2 leads to the castration - resistant phenotype\non multivariable competing risk regression analyses, treatment with ebrt was independently associated with the risk of developing a second primary bca ( hazard ratio : 1. 35, ci : 1. 18 - 1. 55 ; p < 0. 001 ), but not rca ( p = 0. 4 ).\nthe status of braf mutation may not affect the clinical response to rai therapy for patients with ptmc with intermediate - risk to high - risk features. more trials examining the role of braf mutation in guiding postoperative rai therapy are needed.\nthe results indicate that braf ( v600e ) mutation is correlated with a lower expression of nis in ptcs without ht, suggesting the radioiodine - refractory effects during ria therapy in these patients.\nresults : a more aggressive course of breast cancer is observed in patients exposed to radiation from the chernobyl accident under the age of 30 years ( p <. 01 ).\nwe found that loss at 6q24. 2 - 26 was significantly associated with the cluster of longer survival independently from other confounding factors ( hr = 0. 06, 95 % ci = 0. 01 - 0. 43, padj = 0. 005 )\nresults brca2 - defective cells were unable to repair the double - strand dna breaks induced by ionizing radiation.\nof brca status reflect a willingness to seek indications for poly - adp - ribose polymerase ( parp ) inhibitors beyond cancers with deleterious breast cancer 1 and breast cancer 2 mutations.\n. our results indicate that different types of mutational events in the brca1 and brca2 genes are responsible for the hereditary component of breast / ovarian cancer in the greek population"
        },
        {
          "qas": [
            {
              "id": "6028ffae1cb411341a000106_001",
              "question": "Does erenumab target the calcitonin gene-related peptide?"
            }
          ],
          "context": "four monoclonal antibodies have been developed : one targeting the calcitonin gene - related peptide receptor ( erenumab ) and three targeting the calcitonin gene - related peptide ( eptinezumab, fremanezumab, and galcanezumab ).\ncurrently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene - related peptide ( eptinezumab, galcanezumab, fremanezumab ) and the calcitonin gene - related peptide receptor ( erenumab )\neptinezumab - jjmr ( referred to as eptinezumab hereafter ; vyepti\u2122 ) is a humanised monoclonal antibody that binds to calcitonin gene - related peptide ( cgrp ) and blocks its binding to the receptor.\npurpose of review : monoclonal antibodies ( mabs ) targeting the calcitonin - gene - related peptide ( cgrp ) pathway have been developed for episodic and chronic migraine prevention, either through binding the cgrp ligand ( eptinezumab, fremanezumab,\ncalcitonin gene - related peptide ( cgrp ) receptor antagonists ( gepants - rimegepant and ubrogepant ) and serotonin 5 - ht _ _ sub _ _ 1f _ _ end _ sub _ _ receptor agonists ( ditans - lasmiditan ) have completed phase 3 clinical trials and will soon offer novel,\nfurthermore, new hope rises for the cgrp ( calcitonin - gene related peptide ) - antagonists, as the data for ubrogepant do not suggest hepatotoxicity but efficacy.\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention.\ngalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide, has demonstrated in previous phase 2 and phase 3 clinical studies ( \u22646 - month of treatment ) a reduction in the number of migraine headache"
        },
        {
          "qas": [
            {
              "id": "601c44ab1cb411341a00001c_001",
              "question": "Can radiosurgery be used for the DNET tumors?"
            }
          ],
          "context": "salvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\ntwo rare cases of intractable epilepsy caused by dysembryoplastic neuroepithelial tumours ( dnet ) are reported and their different management discussed\nstereotactic radiosurgery ( srs ) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation - induced tumors is unclear.\ncranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims ).\nproton radiation has been used safely and effectively for medulloblastoma, primitive neuro - ectodermal tumors, craniopharyngioma, ependymoma, germ cell intracranial tumors, low - grade glioma, retinoblastoma, rhabdomyosarcoma and other soft tissue\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\ndiagnoses included medulloblastoma, craniopharyngioma, ependymoma, glial tumors, germ cell tumors, and others.\n. the patients had originally received radiation therapy for three reasons : ( a ) cranial irradiation for acute lymphoblastic leukemia ( all ), ( b ) definitive treatment of cns neoplasia, and ( c ) treatment of benign disease ( mostly cutaneous infections ).\nreports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull - base sarcomas, and unresectable meningiomas. conclusions : use of proton beam th\nxternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting."
        },
        {
          "qas": [
            {
              "id": "6026754f1cb411341a0000c8_001",
              "question": "Should minocycline be used for mild Alzheimer disease?"
            }
          ],
          "context": "conclusions and relevance : minocycline did not delay the progress of cognitive or functional impairment in people with mild ad during a 2 - year period.\na recent publication of the results of a clinical trial of minocycline in 412 als patient has aroused considerable controversy in the als scientific community.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\ndiscussion : intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild - to - moderate ad dementia patients.\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\ninterpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease.\nthis pilot study shows that minocycline and riluzole can be taken safely together. further trials are needed to assess efficacy of such treatment."
        },
        {
          "qas": [
            {
              "id": "60290a131cb411341a000109_001",
              "question": "Is there an association of alterations in ADCY7 and ulcerative colitis?"
            }
          ],
          "context": ". we discovered a 0. 6 % frequency missense variant in adcy7 that doubles the risk of ulcerative colitis\nunderscore a critical tumor - suppressing role for functional intestinal epithelial cyld in colitis - associated carcinogenesis\ninactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\nto further resolve the genetic architecture of the inflammatory bowel diseases ulcerative colitis and crohn's disease, we sequenced the whole genomes of 4, 280 patients at low coverage and compared them to 3, 652 previously sequenced population\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. two cases of pv associated with ibd - - one with crohn's disease ( cd ) and the other with ulcerative colitis ( uc ) are reported.\n. it is a highly specific marker for inflammatory bowel disease and its correct recognition may lead to the diagnosis of ulcerative colitis or crohn's disease.\n. in aom / dss - induced colitis - associated colorectal cancer, the deficiency of adamts18 in mice resulted in enhanced tumorigenesis and colon inflammation that could be attributed in part to enhanced nuclear translocation of \u03b2 - catenin and elevated\nof relapsing multiple sclerosis and ulcerative colitis\n. in the present study we evaluated the role of intestinal epithelial cyld in colitis - associated cancer using a conditional mouse cyld inactivation model. methods : in order to evaluate the role of cyld in intestinal epithelial carcinogenesis, mice"
        },
        {
          "qas": [
            {
              "id": "604906ed1cb411341a000163_001",
              "question": "Are mucin overexpression associated with disease?"
            }
          ],
          "context": "mucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\nmucin is a glycoprotein that is the primary component of the mucus overlaying the epithelial tissues.\nmuc1 is a membrane glycoprotein, which in adenocarninomas is overexpressed and exhibits truncated o - glycosylation.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\naltered glycoprotein expression has been demonstrated in tissue from patients with barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.\ninflammation causes muc1 overexpression and hypoglycosylation.\nmucin - type o - linked glycosylation\nof cell and tissue types related to pathological states\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis."
        },
        {
          "qas": [
            {
              "id": "6025fdf41cb411341a0000c0_001",
              "question": "Should nerinetide be used for treatment of ischaemic stroke?"
            }
          ],
          "context": ". serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\ntreatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.\n. although further trials of tirilazad are now unwarranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischemic stroke.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nin this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months."
        },
        {
          "qas": [
            {
              "id": "6026de661cb411341a0000d1_001",
              "question": "Are there small molecule CGRPs under development for the treatment of migraine?"
            }
          ],
          "context": "meanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\narea covered : this review reports on compounds currently under development for the oral treatment of acute migraine attacks, focusing on calcitonin - gene - related - peptide receptor antagonists, specifically ubrogepant and rimegepant.\nrecently, orally administered next - generation small molecule cgrp - ras have been shown to have safety and efficacy in acute treatment ( ubrogepant and rimegepant ) and prevention ( atogepant ) of migraine, giving additional cgrp - based therapeutic options\ncgrp receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against cgrp ( eptinezumab, fremanezumab and galcanezumab ) or the cgrp receptor ( erenumab ) effectively prevent migraine\nfour monoclonal antibodies ( mabs ) targeting the cgrp pathway are currently under evaluation for the prevention of episodic and chronic migraine : eptinezumab ( ald403 ), fremanezumab ( tev - 48125 ), galcanezumab ( ly2951742 ), and erenumab ( amg334 ).\nthe cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\ngiving additional cgrp - based therapeutic options for migraine patients.\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention.\npurpose of review : monoclonal antibodies ( mabs ) targeting the calcitonin - gene - related peptide ( cgrp ) pathway have been developed for episodic and chronic migraine prevention, either through binding the cgrp ligand ( eptinezumab, fremanezumab,\nthe efficacy and safety of calcitonin gene - related peptide monoclonal antibody for episodic migraine : a meta - analysis. based on the results of this meta - analysis, cgrp monoclonal antibodies significantly reduced the monthly migraine days and acute"
        },
        {
          "qas": [
            {
              "id": "6026ee821cb411341a0000d3_001",
              "question": "Is eptinezumab a small molecule?"
            }
          ],
          "context": "eptinezumab - jjmr ( referred to as eptinezumab hereafter ; vyepti\u2122 ) is a humanised monoclonal antibody that binds to calcitonin gene - related peptide ( cgrp ) and blocks its binding to the receptor.\ncurrently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene - related peptide ( eptinezumab, galcanezumab, fremanezumab ) and the calcitonin gene - related peptide receptor ( erenumab )\nfour monoclonal antibodies have been developed : one targeting the calcitonin gene - related peptide receptor ( erenumab ) and three targeting the calcitonin gene - related peptide ( eptinezumab, fremanezumab, and galcanezumab ).\nimportance galcanezumab ( ly2951742 ), a monoclonal antibody against calcitonin gene - related peptide ( cgrp ), is one of a novel class of new medicines for migraine prevention.\npurpose of review : monoclonal antibodies ( mabs ) targeting the calcitonin - gene - related peptide ( cgrp ) pathway have been developed for episodic and chronic migraine prevention, either through binding the cgrp ligand ( eptinezumab, fremanezumab,\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\nthe efficacy and safety of calcitonin gene - related peptide monoclonal antibody for episodic migraine : a meta - analysis. based on the results of this meta - analysis, cgrp monoclonal antibodies significantly reduced the monthly migraine days and acute\ngalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide, has demonstrated in previous phase 2 and phase 3 clinical studies ( \u22646 - month of treatment ) a reduction in the number of migraine headache\nwithin the past few years, new and promising drugs such as more specific 5 - ht 1f receptor agonists ( that is, lasmiditan ) and monoclonal calcitonin gene - related peptide ( cgrp ) receptor antibodies entered advanced development phases while non - invasive\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab )."
        },
        {
          "qas": [
            {
              "id": "60324b771cb411341a000139_001",
              "question": "Is the apilimod inhibitor effective against SARS-CoV-2?"
            }
          ],
          "context": ". these include the pikfyve kinase inhibitor apilimod, cysteine protease inhibitors mdl - 28170, z lvg chn2, vby - 825, and ono 5334, and the ccr1 antagonist mln - 3897\nis a monoclonal antibody that works directly against the spike protein of sars - cov - 2 to block its attachment and entry into a human cell.\nsurface inhibitory molecules such as siglec - 8, anti - il - 1s such as canakinumab, bruton kinase ( btk ) inhibitors such as gdc - 0853 and anti - il - 5s such as benralizumab and mepolizumab. summary : the ongoing clinical trials on new targets of treatment hold\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nto identify therapeutics that can be repurposed as sars - cov - 2 antivirals, we profiled a library of known drugs encompassing approximately 12, 000 clinical - stage or fda - approved small molecules\ntecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\nici, such as the pd - 1 inhibitors nivolumab and pembrolizumab and the pd - l1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced nsclc.\n. since many of these molecules have advanced into the clinic, the known pharmacological and human safety profiles of these compounds will accelerate their preclinical and clinical evaluation for covid - 19 treatment.\nby the emergence of modern immunotherapies with active agents like pd - 1 ( nivolumab, pembrolizumab ) and pd - l1 immune checkpoint blockers ( atezolizumab, avelumab, durvalumab ), new therapeutic options have become available for the treatment of patients"
        },
        {
          "qas": [
            {
              "id": "602673e91cb411341a0000c7_001",
              "question": "Is Lanabecestat effective for Alzheimer's disease?"
            }
          ],
          "context": "conclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nconclusions : this study failed to show an efficacy of lubeluzole in the treatment of acute stroke.\nverubecestat, a bace1 inhibitor that reduces a\u03b2 levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial ( epoch ) of mild - to - moderate ad and was associated with adverse events.\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\ninterpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease."
        },
        {
          "qas": [
            {
              "id": "601c46f61cb411341a00001d_001",
              "question": "Was golimumab tested for diabetes?"
            }
          ],
          "context": "golimumab and beta - cell function in youth with new - onset type 1 diabetes\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\nclinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\ntreatment of type 1 diabetes with teplizumab : clinical and immunological follow - up after 7 years from diagnosis.\nthe results from the tn - 10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a fcr non - binding monoclonal antibody to cd3 in people at high risk for disease.\nconclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm.\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\nteplizumab ( anti - cd3 mab ) treatment preserves c - peptide responses in patients with new - onset type 1 diabetes in a randomized controlled trial : metabolic and immunologic features at baseline identify a subgroup of responders.\nalthough treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit."
        },
        {
          "qas": [
            {
              "id": "604fc22894d57fd879000008_001",
              "question": "Is G3BP1 found in stress granules?"
            }
          ],
          "context": "ras gtpase - activating protein - binding protein ( g3bp1 ) is an rna - binding protein that is essential for assembling stress granules.\n. nup358 localizes to the nuclear pore complex and to the cytoplasmic annulate lamellae ( al ), and these structures dynamically associate with two mrnp granules : processing bodies ( p bodies ) and stress granules ( sgs ).\nwithin sgs, single - molecule localization microscopy revealed distributed hotspots of immobilized g3bp1 and imp1 that reflect the presence of relatively immobile \" \" ometer - sized \" \" ocores.\nusing super - resolution and expansion microscopy, we find that the sg component ubap2l [ 11, 12 ] and the core protein g3bp1 [ 5, 11 - 13 ] occupy different domains inside sgs.\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\ncation stress and glucose starvation selectively caused chromatin structure alteration around cre - like sequences in cta3 ( + ) and fbp1 ( + ) promoters, respectively, in correlation with transcriptional activation.\nantisense transcripts from the fission yeast fbp1 locus ( fbp1 - as ) are expressed in glucose - rich conditions and anticorrelated with transcription of metabolic stress - induced lncrna ( mlonrna ) and mrna on the sense strand during glucose starvation.\nbscr is also associated with endoplasmic reticulum aminopeptidase 2 ( erap2 ), an enzyme involved in processing hla class i ligands, thus implicating the a * 29 : 02 peptidome in this disease.\nwe herein show that the chromatin configuration is altered into an accessible state within 290 bp downstream from the initiation site of metabolic - stress - induced lncrnas ( mlonrnas ) in the promoter of the fission yeast fbp1 gene, whose transcription\n. the stress - activated protein kinase ( sapk ) pathway and its effectors, sty1 mapk and transcription factor atf1, play a critical role in the adaptation of fission yeast to grow on alternative non - fermentable carbon sources by inducing the expression"
        },
        {
          "qas": [
            {
              "id": "5fdb4290a43ad31278000024_001",
              "question": "Do polycomb group proteins (PcG) mediate the formation of chromatin loops?"
            }
          ],
          "context": "repressive loops within polycomb domains are formed after the midblastula transition between polycomb response elements by the action of gaga factor and polycomb proteins.\npcg proteins, dna methylation, and gene repression by chromatin looping.\npolycomb - mediated chromatin loops revealed by a subkilobase - resolution chromatin interaction map.\niation to proliferation control. our results revealed a chromatin looping mechanism of long - range control and argue against models involving homogeneous spreading of pcg silencers\npolycomb action at a distance can be organized by local chromatin topology\npolycomb repressive complex 2 is recruited through the interaction of ctcf\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\n. in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\nthese structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation."
        },
        {
          "qas": [
            {
              "id": "5fe31319a43ad31278000046_001",
              "question": "Can ATAC-Seq be employed in single-cell mode?"
            }
          ],
          "context": "single - cell atac - seq ( scatac - seq ) technology has also been developed to study cell type - specific chromatin accessibility in tissue samples containing a heterogeneous cellular population.\nsingle - cell atac - seq ( scatac - seq ) maps from hundreds of single cells in aggregate closely resemble accessibility profiles from tens of millions of cells and provide insights into cell - to - cell variation.\nthis paper presents scasat ( single - cell atac - seq analysis tool ), a complete pipeline to process scatac - seq data with simple steps.\nsingle - cell atac - seq : strength in numbers.\nsingle - cell sequencing assay for transposase - accessible chromatin ( scatac - seq ) is the state - of - the - art technology for analyzing genome - wide regulatory landscapes in single cells.\nchroma can analyze single cell atac - seq data, correcting many biases generated by the sparse sampling inherent in single cell technologies.\nhere, we introduce a method for analyzing scatac - seq data, called single - cell atac - seq analysis via latent feature extraction ( scale ).\n. existing chromatin profiling methods such as atac - seq and dnase - seq, applied to islets in bulk, produce aggregate profiles that mask important cellular and regulatory heterogeneity. methods : we present genome - wide single - cell chromatin accessibility\nthods : we present genome - wide single - cell chromatin accessibility profiles in > 1, 600 cells derived from a human pancreatic islet sample using single - cell combinatorial indexing atac - seq ( sci - atac - seq ). w\npredictions based on single - cell rna - seq ( scrna - seq ) can more accurately reconstruct bulk chromatin accessibility than using scatac - seq."
        },
        {
          "qas": [
            {
              "id": "5fdb42fba43ad31278000027_001",
              "question": "Are there negative enhancers?"
            }
          ],
          "context": "enhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\nenhancers are cis - regulatory elements in the genome that cooperate with promoters to control target gene transcription\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\nenhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\nthe site was similar to silencers, or negative enhancers, in that it acted to repress transcription from outside the transcribed region, but was distinct in that the function of a canonical silencer was independent of orientation.\nepigenetic profiling of different tissues and cell - types has identified a large number of non - coding epigenetic regulatory elements ('enhancers') that can be located far away from coding genes.\nenhancer elements are essential for tissue - specific gene regulation during mammalian development\n. unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors."
        },
        {
          "qas": [
            {
              "id": "5fdb42b7a43ad31278000025_001",
              "question": "Are super enhancers structurally insulated in chromatin loops?"
            }
          ],
          "context": ". in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\ndissecting super - enhancer hierarchy based on chromatin interactions\nthe term'super - enhancer'has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of mediator binding, as measured by chromatin immunoprecipitation and sequencing ( chip - seq ).\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\n. over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.\nnucleosome depletion at 5'- hs4 was dependent on interaction of the insulator protein ccctc - binding factor ( ctcf ) and was required for enhancer blocking.\na number of studies have recently demonstrated that super - enhancers, which are large cluster of enhancers typically marked by a high level of acetylation of histone h3 lysine 27 and mediator bindings, are frequently associated with genes that control\nhese differences extend to histone variants ( h2a. z ) and marks ( h3k4 methylation ), as well as insulator binding ( such as ctcf ), independent of the expression levels of affected genes.\nsuper - enhancers and preventing cross talk between distinct regulatory elements.\nthese structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion."
        },
        {
          "qas": [
            {
              "id": "6060e1a094d57fd879000049_001",
              "question": "Does IL18 signaling have a role in thymus?"
            }
          ],
          "context": "collectively, this study provides a detailed characterization of the mature treg subsets in the mouse thymus and identifies a key role of il18 signaling in controlling the ccr6 - ccl20 - dependent migration of tregs into the thymus.\nimmune system and plays a role as a signaling and costimulatory molecule on t lymphocytes.\nalthough au - rich elements ( ares ) in the 3'utr of interleukin - 6 ( il - 6 ) mrna dictate mrna degradation, the role of ttp in the post - transcriptional regulation of il - 6 gene expression is unclear.\ndevelopment, differentiation, and function of thymocytes and cd4 ( + ) and cd8 ( + ) t cells are controlled by a multitude of secreted and intracellular factors\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nin the thymus, mature cd4 + cd8 - and cd4 - cd8 + t cells expressing alpha beta t - cell antigen receptors ( tcr ) develop from immature thymocytes through cd4 + cd8 + alpha beta tcr + intermediates.\nto t cell subsets, interleukin ( il ) - 17a, and biomarkers associated with arterial damage.\ntfii - i is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. tfii - i has been implicated in neuronal and immunologic diseases as well as in thymic epithelial cancer\ncd4 + cd8 + progenitor thymocytes undergo selection following interaction with mhc class i and class ii molecules bearing peptide self - antigens, giving rise to cd8 + cytotoxic and cd4 + helper or regulatory t cell lineages, respectively.\nactivated pscs expressed il - 33 in the nucleus, and the expression was increased by il - 1\u03b2, tnf - \u03b1, pdgf - bb, and ifn - \u03b3, but not tgf - \u03b21."
        },
        {
          "qas": [
            {
              "id": "601c18921cb411341a00000f_001",
              "question": "Does an antiphlogistic promotes inflammation?"
            }
          ],
          "context": "the antiphlogistic ibuprofen incorporated in liposomes caused a decrease of the inflammatory edema induced by carragee in the distal part of the rat's hind leg after both the intramuscular and percutaneous administration.\nantiphlogistics were found to enhance the membrane viscosity both in control and under inflammation.\nanalgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\n. some studies revealed changes in certain immune response parameters post - vaccination when analgesics / antipyretics were used either prophylactically or therapeutically. still, there is no evidence that these changes impact vaccine efficacy\nthe aim of this study was to analyze the formation of the most relevant inflammation mediators including proteins and lipids in human fibroblasts upon inflammatory stimulation and subsequent treatment with dexamethasone, a powerful antiphlogistic\nenhancement of the immunoreactivity inhibition caused by the drugs was not proportional to the increase in their antiphlogistic effects determined by the selye model of inflammation.\nanimals in which antiphlogistic action is highest a decrease of 5 - ht was observed.\nwhile antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.\nantiinflammatory agents : new series of n - substituted amino acids with complex pyrimidine structures endowed with antiphlogistic activity.\nwith dexamethasone, a powerful antiphlogistic drug."
        },
        {
          "qas": [
            {
              "id": "6020ad161cb411341a000082_001",
              "question": "Is liraglutide effective for weight reduction?"
            }
          ],
          "context": "liraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials.\nconclusions : low - dose liraglutide still has high efficacy in weight reduction in taiwanese people, especially for those of younger age.\n. pharmacological monotherapies focus mainly on a single protein target and include orlistat, lorcaserin and liraglutide while the combination molecules propose a multitarget approach and include phentermine / topiramate and naltrexone / bupropion.\nconclusion : liraglutide ( monotherapy or added to metformin ) significantly reduced fat mass and fat percentage vs. glimepiride in patients with t2d.\nconclusion : in patients with t1d, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.\nconclusions : in adolescents with obesity, the use of liraglutide ( 3. 0 mg ) plus lifestyle therapy led to a significantly greater reduction in the bmi standard - deviation score than placebo plus lifestyle therapy.\n( - 6. 8 % ) liraglutide ( - 5. 4 % ), naltrexone / bupropion ( - 4. 0 % ), lorcaserin ( - 3. 1 % ), and orlistat ( - 2. 9 % ).\nliraglutide ( lira ) treatment is associated with the dose - dependent reduction of weight. hig\nconclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\ndemonstrated that treatment intensification with liraglutide offers effective glycemic control, weight reduction, and a lower risk of hypoglycemia compared to treatment intensification with insulin or additional oads."
        },
        {
          "qas": [
            {
              "id": "6020b0e21cb411341a000085_001",
              "question": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?"
            }
          ],
          "context": "eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis\n0. 71 ( 95 % confidence interval [ ci ], 0. 39 to 1. 32 ) for eflornithine - sulindac as compared with sulindac ( p = 0. 29 ) and 0. 66 ( 95 % ci, 0. 36 to 1. 24 ) for eflornithine - sulindac as compared with eflornithine.\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\nseveral new drugs have been approved to treat rare genetic disorders : setmelanotide for certain conditions causing obesity ; lumasiran for primary hyperoxaluria type 1, a kidney disorder ; and lonafarnib for two diseases that cause premature aging.\noral niraparib, a highly - selective, potent poly ( adp - ribose ) polymerase ( parp ) - 1 and parp - 2 inhibitor, is approved in the usa for the mainte \" \" ce treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer\npirfenidone and nintedanib are emerging agents that exert pleiotropic effects, reflective of the multiple mechanistic pathways of ipf.\nniraparib slows ovarian cancer progression.\nrecent findings : the approval of several parpi ( olaparib, rucaparib, and niraparib ) has driven the focus of anticancer treatment on synthetic lethality in prostate cancer too.\nin a phase ii study, researchers found that the parp inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in brca1 or brca2."
        },
        {
          "qas": [
            {
              "id": "602498cb1cb411341a00009e_001",
              "question": "Is Olaparib effective for prostate cancer?"
            }
          ],
          "context": "in prostate cancer, two parpi, rucaparib and olaparib, have been fda approved for the treatment of metastatic castration - resistant prostate cancer ( mcrpc ).\npatient summary : a large clinical study concluded that treatment with the parp inhibitor olaparib benefits men with metastatic castration - resistant prostate cancer whose tumors harbor alterations in 15 different dna repair genes.\nrecent clinical studies show favorable results for the parp inhibitor olaparib used as single agent for treatment of metastatic castration - resistant pca.\nthe parp inhibitor ( parpi ) olaparib received fda breakthrough designation for treatment of metastatic castration - resistant prostate cancers ( crpc ) carrying mutations in brca1 / 2 or atm genes.\nof note is the recent u. s. food and drug administration breakthrough therapy designation of olaparib for the treatment of brca1 / 2 - or atm - mutated metastatic castration - resistant prostate cancer.\nexperience with olaparib for prostate cancer at a comprehensive cancer center, and future directions of olaparib for the treatment of mcrpc.\nin a phase ii study, researchers found that the parp inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in brca1 or brca2.\nolaparib targets some advanced prostate cancers.\nin phase ii clinical trials, including patients with advanced castration - resistant pc, olaparib seems to be efficacious and well tolerated.\ninterpretation : olaparib has antitumour activity against metastatic castration - resistant prostate cancer with ddr gene aberrations, supporting the implementation of genomic stratification of metastatic castration - resistant prostate cancer in clinical"
        },
        {
          "qas": [
            {
              "id": "6025fd261cb411341a0000bf_001",
              "question": "Is isradipine effective for Parkinson's disease?"
            }
          ],
          "context": "however, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\nthese findings suggest that greater exposure to isradipine might slow disease progression.\nresults : isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy - adjusted unified parkinson's disease rating scale parts i - iii score over 36 months ( spearman rank correlation coefficient, rs :\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nit has been demonstrated to be efficacious, well tolerated and safe for the treatment of pdp.\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\npimavanserin : a novel therapeutic option for parkinson disease psychosis. while pimavanserin appears to be a safe, effective, and well - tolerated therapeutic option for pdp, additional clinical trials and open - label extension studies are needed to\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )"
        },
        {
          "qas": [
            {
              "id": "6026c1071cb411341a0000cb_001",
              "question": "Is MK-1602 a CGRP antagonist?"
            }
          ],
          "context": "the cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\nwe applied this strategy for another late - stage clinical program : ubrogepant ( mk - 1602 ), a novel oral calcitonin gene - related peptide receptor antagonist for acute treatment of migraine.\nubrogepant ( mk - 1602 ) is a novel, oral, calcitonin gene - related peptide receptor antagonist in clinical development with positive phase iii outcomes for acute treatment of migraine.\ncalcitonin gene - related peptide ( cgrp ) receptor antagonists ( gepants - rimegepant and ubrogepant ) and serotonin 5 - ht _ _ sub _ _ 1f _ _ end _ sub _ _ receptor agonists ( ditans - lasmiditan ) have completed phase 3 clinical trials and will soon offer novel,\narea covered : this review reports on compounds currently under development for the oral treatment of acute migraine attacks, focusing on calcitonin - gene - related - peptide receptor antagonists, specifically ubrogepant and rimegepant.\nrecently, orally administered next - generation small molecule cgrp - ras have been shown to have safety and efficacy in acute treatment ( ubrogepant and rimegepant ) and prevention ( atogepant ) of migraine, giving additional cgrp - based therapeutic options\nfurthermore, new hope rises for the cgrp ( calcitonin - gene related peptide ) - antagonists, as the data for ubrogepant do not suggest hepatotoxicity but efficacy.\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\ncgrp receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against cgrp ( eptinezumab, fremanezumab and galcanezumab ) or the cgrp receptor ( erenumab ) effectively prevent migraine"
        },
        {
          "qas": [
            {
              "id": "6027dc011cb411341a0000eb_001",
              "question": "Does inactivation of CYLD help in colorectal cancer?"
            }
          ],
          "context": "inactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\n. in the present study we evaluated the role of intestinal epithelial cyld in colitis - associated cancer using a conditional mouse cyld inactivation model. methods : in order to evaluate the role of cyld in intestinal epithelial carcinogenesis, mice\n. cyld expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.\n. the tumor - suppressing function of cyld is associated with its deubiquitinating activity, which maps to the carboxyl - terminal region of the protein\nsuggesting that these pathways do not predispose cyld - deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and / or pro - inflammatory stress. conclusions : our findings underscore a critical tumor - suppressing role\nunderscore a critical tumor - suppressing role for functional intestinal epithelial cyld in colitis - associated carcinogenesis\n. inactivation of cyld in intestinal epithelial cells did not affect the classical nuclear factor - kappab ( nf - \u03bab ) and c - jun kinase ( jnk ) activation pathways under physiological conditions, suggesting that these pathways do not predispose\ntogether, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity. < br >\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells."
        },
        {
          "qas": [
            {
              "id": "60290c2b1cb411341a00010a_001",
              "question": "Is there high nucleotide diversity in the Drosophila suzukii species?"
            }
          ],
          "context": ". our results indicate high levels of nucleotide diversity in this species and suggest that the recent invasions of europe and the continental united states are independent demographic events.\n. here, we investigate the genetic population structure of this invasive fruit fly, with a focus on the eastern united states. we sequenced six x - linked gene fragments from 246 individuals collected from a total of 12 populations\n. here we used natural genetic variation across a panel of 81 drosophila lines to measure changes in transcriptional start site ( tss ) usage, identifying thousands of genetic variants affecting transcript levels ( strength ) or the distribution of tsss\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\n. in drosophila, the dna - binding protein zelda ( also known as vielfaltig ) is required for this transition and for transcriptional activation of the zygotic genome.\nnative to asia, the soft - skinned fruit pest drosophila suzukii has recently invaded the united states and europe\nmining apis mellifera sequences made it possible to identify the honey bee subspecies both at the mitochondrial and nuclear genome levels.\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\n. we find that the elevated nucleotide diversity of mae genes is also associated with greater allelic age : variants in these genes tend to be older and are enriched in polymorphisms shared by neanderthals and chimpanzees\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences."
        },
        {
          "qas": [
            {
              "id": "60327e541cb411341a00013e_001",
              "question": "Is Hunter's disease is associated with the X Chromosome?"
            }
          ],
          "context": "introduction : hunter syndrome, or mucopolysaccharidosis type ii, is an inherited disease linked to the x chromosome that is caused by a deficit of the enzyme iduronate - 2 - sulfatase and its main symptoms affect the bones, neurological system and the\nhunter disease ( mucopolysaccharidosis type ii ) associated with unbalanced inactivation of the x chromosomes in a karyotypically normal girl.\nmucopolysaccharidosis type ii ( mps ii, hunter disease ) is an x chromosome - linked inherited metabolic disease caused by mutations resulting in deficiency of activity of iduronate - 2 - sulfatase ( ids ) and accumulation of undegraded glycosaminoglycans\nwe report the results of studies on the characterization of the mutation associated with marked unbalanced expression of the mutant x chromosome in a karyotypically normal girl with hunter disease ( mucopolysaccharidosis type ii ). so\nbackground : hunter syndrome ( mucopolysaccharidosis type ii ) is a recessive x - linked disorder due to mutations in the iduronate 2 - sulfatase ( ids\nfamilial x - chromosome inactivation ( xci ) skewing was investigated in a family in which a female mucopolysaccharidosis type ii ( mps ii ) ( hunter syndrome, an x - linked genetic disease ) occurred. among e\nhunter disease is an x - linked recessive mucopolysaccharide storage disorder caused by iduronate - 2 - sulfatase deficiency and is rare in females.\nhunter disease or mucopolysaccharidosis type ii is an x - linked disease caused by the deficiency of the lysosomal enzyme iduronate - 2 - sulfatase ( ids ). th\nall mucopolysaccharidosis are autosomal recessive disorders, except for hunter's syndrome that is x - linked and recessive.\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation."
        },
        {
          "qas": [
            {
              "id": "60328f351cb411341a000145_001",
              "question": "Can Freund's complete adjuvant induce arthritis?"
            }
          ],
          "context": "rheumatoid arthritis ( ra ) was induced by freund's complete adjuvant ( fca ; 1 mg / 0. 1 ml paraffin oil ), injected subcutaneously on days 0, 30 and 40\ncomplete freund's adjuvant ( cfa ) induced ra\nthe ra model was established using freund's complete adjuvant,\nthe rats were made arthritic using a subcutaneous injection with 0. 1 ml complete freund's adjuvant ( cfa ) into the footpad of the left hind paw.\nthe use of methotrexate in rheumatoid arthritis.\n( sjia ) and polyarticular juvenile idiopathic arthritis ( pjia ).\nin rheumatoid arthritis ( ra ) treatment, the concomitant use of methotrexate has been shown to reduce the incidence of antibodies to infliximab ( ati ), on the other hand, it is unclear whether azathioprine can reduce ati production. we enro\n. however, upon challenge with a combination of genotoxic ( aom ) and pro - inflammatory ( dss ) agents we found that the number of adenomas in the iec - cyld ( \u03b49 ) mice was dramatically increased compared to the control mice\nin patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.\npyostomatitis vegetans, and bowel - associated dermatosis - arthritis syndrome."
        },
        {
          "qas": [
            {
              "id": "603291f21cb411341a000146_001",
              "question": "Can saponins be used as adjuvant?"
            }
          ],
          "context": ". these results confirm that momordica saponins are a viable natural source to provide potent saponin adjuvants\nwe report the design, synthesis, immunological evaluation, and conformational analysis of new saponin variants as promising vaccine adjuvants\na saponin - based matrix - m\u2122 adjuvant\nthe purified active fraction of albizia julibrissin saponin ( ajsaf ) is an ideal adjuvant candidate\nbalb / c mice immunized with subcutaneous injections of the recombi \" \" t protein with or without liposome / saponin ( lip / sap ) as an adjuvant.\nfrom clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate.\nanalgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\nwhile antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.\nantiphlogistics were found to enhance the membrane viscosity both in control and under inflammation.\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species."
        },
        {
          "qas": [
            {
              "id": "603bc16b1cb411341a000158_001",
              "question": "Is erabutoxin b usually found in plants?"
            }
          ],
          "context": "the study has established complete structural identity of the two sea - snake venom toxins, erabutoxin b and neurotoxin b, isolated from laticauda semifasciata snakes taken in different pacific ocean waters.\nerabutoxin c, a minor neurotoxic component of the venom of a sea snake laticauda semifasciata, was isolated in pure form by repeated column chromatography on cm - cellulose columns.\nthe three - dimensional structure of erabutoxin b, a neurotoxin in the venom of the sea snake laticauda semifasciata, has been determined from a 2. 75 a resolution electron density map.\nthe three - dimensional structure of erabutoxin b, a short - chain neurotoxic peptide purified from the venom of the sea snake laticauda semifasciata,\na systematic computer search of the three - dimensional structure of erabutoxin b ( an alpha - neurotoxin from the false sea snake laticauda semifasciata ) was performed to identify the locality that most closely matched the amino acid compositions of the\nstudies on sea - snake venoms. crystallization of erabutoxins a and b from laticauda semifasciata venom.\nthe characteristic feature of the crystal structure of erabutoxin b, a short neurotoxin from laticauda semifasciata, and alpha - cobratoxin, a long neurotoxin from naja naja siamensis, is the presence of a triple - stranded antiparallel pleated\nthe method was applied to a study of erabutoxin b molecule, a neurotoxic protein from a sea snake, to analyze the microenvironments of its single tryptophan and tyrosine residues.\nhere we examine the actions of six snake neurotoxins ( alpha - cobratoxin from naja naja siamensis, erabutoxin - a and b from laticauda semifasciata ; cm12 from n. haje annulifera, toxin iii 4 from notechis scutatus and a long toxin from n\nthe variants are the curaremimetic toxin alpha from naja nigricollis and erabutoxin a or b from laticauda semifasciata"
        },
        {
          "qas": [
            {
              "id": "603285861cb411341a000141_001",
              "question": "Are Toll-like receptors (TLRs) induced by microbes?"
            }
          ],
          "context": "the c - type lectin receptor clec4e and toll - like receptor tlr4 expressed by host cells are among the first line of defense in encountering pathogens.\ntoll - like receptor 9 ( tlr9 ) activation is attributed to delivery of bacterial dna\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\ngram - negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via toll - like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor - \u03b1 and to activate nlrp3 inflammasome, a multiprotein\nin response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\ntlr2 activators are found in many common foods, but the role of tlr2 in oral tolerance and allergic sensitization to foods is not well understood.\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\nthese ctls recognize short peptides derived from tumour - associated antigens in conjunction with class i molecules expressed on tumour cells.\nmembranes of the bacterial phagosome are enriched with ubiquitinated proteins in a way that requires its dot / icm type iv secretion system, suggesting the involvement of effectors in the manipulation of the host ubiquitination machinery.\naccumulating evidence has demonstrated that naturally occurring cd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are critical for mainte \" \" ce of immunological tolerance and have been shown to be important in regulating the immune responses in many diseases"
        },
        {
          "qas": [
            {
              "id": "603e43d51cb411341a00015e_001",
              "question": "Is Ixodes a species of tick?"
            }
          ],
          "context": "biology of ixodes species ticks in relation to tick - borne zoonoses.\nthe ixodes ricinus species complex is a group of ticks distributed in almost all geographic regions of the world.\nixodid tick fauna consists of 241 species in the genus ixodes and 442 species in the genera amblyomma, anomalohimalaya, bothriocroton, cosmiomma, dermacentor, haemaphysalis, hyalomma, margaropus, nosomma, rhipicentor and rhipicephalus in the family\ntick, ixodes ricinus\nin 1. 5 % of ixodes species ticks and 3. 6 % of small mammals.\nspecies and subgenera of ixodes ticks with a sequence divergence ranging from 13. 6 % to 62. 9 %.\nixodes ricinus, ixodes scapularis, ixodes texanus, and rhipicephalus sanguineus sensu lato ( s. l. ).\ne following 16 ixodid tick species were identified : ixodes fuscipes, amblyomma auricularium, amblyomma coelebs, amblyomma dubitatum, amblyomma geayi, amblyomma humerale, amblyomma latepunctatum, amblyomma longirostre, amblyomma naponense, amblyomma\namong the various species of hard ticks, ixodes ricinus is the most frequently found tick throughout europe.\nherein, we report these ticks to represent three different species : ixodes catarinensis n. sp."
        },
        {
          "qas": [
            {
              "id": "60367f5e1cb411341a000157_001",
              "question": "Is HbA1c an ideal biomarker of well-controlled diabetes?"
            }
          ],
          "context": "hba1c is a biomarker with a central role in the diagnosis and follow - up of patients with diabetes, although not a perfect one\n. 5. 1 % / year, p < 0. 001 ). < br > < b > conclusions < / b > : plasma apelin is a novel biomarker for predicting type 2 diabetes in men. < br >\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nin men at risk for diabetes ( hba1c 5. 7 - 6. 4 %, fpg 100 - 125mg / dl, or ogtt - 2h - pg 140 - 199mg / dl ), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations ( 10. 6 % / year\n. covid - 19 pandemic poses a pressing challenge for the diabetic population, since maintaining optimal blood glucose control is key to reduce morbidity and mortality rates.\ndiscovery and validation of hsa _ circ _ 0001953 as a potential biomarker for proliferative diabetic retinopathy in human blood.\nfive weeks of treatment with the glp - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.\nc - peptide ) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.\nc - peptide ) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.\nwise regression analysis demonstrated that baseline bmi and previous insulin dose were positively associated with body weight reduction and baseline hba1c was positively associated with reduction of hba1c at 2 years after liraglutide"
        },
        {
          "qas": [
            {
              "id": "6057003594d57fd879000020_001",
              "question": "Are the major royal jelly proteins similar to the yellow proteins?"
            }
          ],
          "context": "major royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\nanalysis of drosophila yellow - b cdna reveals a new family of proteins related to the royal jelly proteins in the honeybee\njelleines, isolated as novel antibacterial peptides from the royal jelly ( rj ) of bees, exhibit broad - spectrum protection against microbial infections.\nnutrients such as 24 - methylenecholesterol, major royal jelly proteins, and 10 - hydroxy - 2 - decenoic acid.\nwe observed differences in the metabolome, proteome, and phytosterol compositions of royal jelly synthesized by nurse bees from multi - pesticide exposed colonies, including significant reductions of key nutrients such as 24 - methylenecholesterol, major\ntwo - dimensional electrophoresis was used for the fractionation of royal jelly proteins\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\nthe highly structured ( 64 % gc ) covalently closed circular ( ccc ) rna ( 220 nt ) of the virusoid associated with rice yellow mottle virus codes for a 16 - kda highly basic protein using novel modalities for coding, translation, and gene expression"
        },
        {
          "qas": [
            {
              "id": "6057014c94d57fd879000022_001",
              "question": "Is the Apis mellifera genome available?"
            }
          ],
          "context": "mining apis mellifera sequences made it possible to identify the honey bee subspecies both at the mitochondrial and nuclear genome levels.\nwe have mined histone methyltransferases and demethylases from the whole genome sequence of aedes aegypti ( diptera ), the pea aphid acyrthosiphon pisum, the triatomid bug rhodnius prolixus ( hemiptera ), the honeybee apis mellifera ( hymenoptera ),\nwe show that the honeybee genome is structured with respect to plasticity ; genes that respond to an environmental trigger are colocated in the honeybee genome in a series of gene clusters, many of which have been assembled in the last 80 my during\nthe genome release and ccd had quantitively only minor effects, mainly on honey bee health - related topics post - 2006.\n. here, we investigate the genetic population structure of this invasive fruit fly, with a focus on the eastern united states. we sequenced six x - linked gene fragments from 246 individuals collected from a total of 12 populations\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nthods : we present genome - wide single - cell chromatin accessibility profiles in > 1, 600 cells derived from a human pancreatic islet sample using single - cell combinatorial indexing atac - seq ( sci - atac - seq ). w\n. we have combined available genomics data with a comprehensive proteomics approach to get the annotated olive tree ( olea europaea l. ) pollen proteome and define its complex allergenome."
        },
        {
          "qas": [
            {
              "id": "60570af094d57fd879000025_001",
              "question": "Has the olive tree pollen proteome been studied?"
            }
          ],
          "context": ". we have combined available genomics data with a comprehensive proteomics approach to get the annotated olive tree ( olea europaea l. ) pollen proteome and define its complex allergenome.\nolive pollen is a major allergenic source worldwide due to its extensive cultivation\noleuropein, a phenolic secoiroid glycoside, is the main polyphenol in the olive oil\nmining apis mellifera sequences made it possible to identify the honey bee subspecies both at the mitochondrial and nuclear genome levels.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\n. it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\nthe major alpha - amylase in honey was characterized.\nanalysis of drosophila yellow - b cdna reveals a new family of proteins related to the royal jelly proteins in the honeybee\nthe yeast system has provided considerable insight into the biology of amyloid and prions."
        },
        {
          "qas": [
            {
              "id": "6060c7c094d57fd879000046_001",
              "question": "Is cadherin a plasma membrane marker?"
            }
          ],
          "context": "ve - cadherin protein levels were also increased in the plasma membrane fraction.\nthe plasma membrane - bound e - cadherin protein\nrecycling of ve - cadherin to the plasma membrane,\n( vcam - 1 ), platelet - endothelial cell adhesion molecule - 1 ( pe - cam - 1 ), and mucosal addressin cell adhesion molecule - 1 ( madcam - 1 ).\nintercellular adhesion molecule - 1 ( icam - 1 ), vascular cell adhesion molecule - 1 ( vcam - 1 ) and platelet - endothelial cell adhesion molecule - 1 ( pecam - 1 ) are members of the immunoglobulin super - family which are present on the surface of endothelial cells.\ne - cadherin, a central component of the adherens junction ( aj ), is a single - pass transmembrane protein\nintracellular adhesion molecule 1 ( icam - 1 ) is an adhesion - related molecule belonging to the immunoglobulin superfamily.\nit has now been shown that adhesion molecules, particularly those of the immunoglobulin super family ( e. g. icam - 1, vcam - 1 and pecam - 1 ),\nintercellular adhesion molecules ( icams ) belong to the immunoglobulin superfamily and participate in diverse cellular processes including host - pathogen interactions.\nmembers of the immunoglobulin superfamily of endothelial adhesion molecules, vascular cell adhesion molecule ( vcam - 1 ) and intercellular cell adhesion molecule ( icam - 1 ), participate in leukocyte adhesion to the endothelium and play an important role"
        },
        {
          "qas": [
            {
              "id": "5fe31304a43ad3127800003a_001",
              "question": "Is methotrexate used for the treatment of Rheumatoid Arthritis (RA)?"
            }
          ],
          "context": "methotrexate has been used in treatment of rheumatoid arthritis ( ra ) since the 1980s and to this day is often the first line medication for ra treatment.\nthe use of methotrexate in rheumatoid arthritis.\nalthough rheumatologists have been using methotrexate in the treatment of ra for some time, controlled studies have been needed to establish the safety and efficacy of this agent.\nmethotrexate ( mtx ) is currently the most frequently used drugs in the treatment of rheumatoid arthritis ( ra ).\nmethotrexate is generally the first - line drug for the treatment of ra, psoriatic arthritis and other forms of inflammatory arthritis, and it enhances the effect of most biologic agents in ra.\nmethotrexate ( mtx ) is the anchor treatment for rheumatoid arthritis ( ra ) and has been very thoroughly studied in many different patient populations, as monotherapy and in combination with various other disease modifying antirheumatic drugs and\nmethotrexate ( mtx ) has been the anchor treatment in rheumatoid arthritis ( ra ) over the last 15 years, and is used in combination with biologic agents to enhance efficacy over the last decade or so.\nthe rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.\na number of studies show the efficacy of methotrexate ( mtx ) for rheumatoid arthritis ( ra ) in general.\nmethotrexate ( mtx ) is currently under study for use in juvenile rheumatoid arthritis."
        },
        {
          "qas": [
            {
              "id": "605e3c8294d57fd879000037_001",
              "question": "Is atenolol metabolized by CYP2D6?"
            }
          ],
          "context": "metoprolol and carvedilol are metabolised by cyp2d6.\nor ssris without significant cyp2d6 inhibition ( citalopram / escitalopram / sertraline ), and the related prescribing of cyp2d6 - independent comparator drugs ( atenolol, rivastigmine, propoxyphene, anastrozole ).\namong these beta - blockers atenolol is mainly eliminated by renal excretion, bisoprolol is in part excreted as parent compound via the renal route ( 50 % ), the other 50 % are hepatically metabolised, whereas metoprolol and carvedilol are metabolised by\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\nthe study analysed the prescribing and dispensing of cyp2d6 drugs ( metoprolol, donepezil, galantamine, codeine, tamoxifen ) together with cyp2d6 - blocking ssris ( paroxetine / fluoxetine ) or ssris without significant cyp2d6 inhibition\nthe results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets."
        },
        {
          "qas": [
            {
              "id": "606b3b6794d57fd879000064_001",
              "question": "Is the glucocorticoid receptor a transcription factor?"
            }
          ],
          "context": "the glucocorticoid receptor ( gr ) is a ligand - activated transcription factor that translocates to the nucleus upon hormone stimulation and distributes between the nucleoplasm and membraneless compartments named nuclear foci.\nthe glucocorticoid receptor ( gr ) is a ligand - binding dependent transcription factor that ultimately regulates vital biological processes and inflammation response through specific gene expression control, thus representing a notable drug target to\npioneer transcription factors recognise and bind their target sequences in inaccessible chromatin to establish new transcriptional networks throughout development and cellular reprogramming.\ngr and klf4, both pioneer transcription factors,\ntfii - i is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. tfii - i has been implicated in neuronal and immunologic diseases as well as in thymic epithelial cancer\nthe transcription factor grainyhead - like 2 ( grhl2 ) plays a crucial role in various developmental processes\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\n. the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\nfoxa1 is a key determi \" \" t of estrogen receptor function and endocrine response."
        },
        {
          "qas": [
            {
              "id": "601fff6a1cb411341a00007b_001",
              "question": "Are there sex differences in oncogenic mutational processes?"
            }
          ],
          "context": "sex differences in oncogenic mutational processes.\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\n. the same mutational signature was detected in a subset of 5, 876 human cancer genomes from two independent cohorts, predomi \" \" tly in colorectal cancer\n. our study describes a distinct mutational signature in colorectal cancer and implies that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin - producing pks pathogenicity island.\n. our results indicate that different types of mutational events in the brca1 and brca2 genes are responsible for the hereditary component of breast / ovarian cancer in the greek population\nrecent studies have shown that tad disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.\nbackground induction of dna double strand breaks and alterations in the repair of these breaks is implicated in breast carcinogenesis.\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes.\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet\nfor breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the chernobyl accident."
        },
        {
          "qas": [
            {
              "id": "606a232a94d57fd87900004c_001",
              "question": "Is metoprolol metabolized by CYP2D6?"
            }
          ],
          "context": "metoprolol and carvedilol are metabolised by cyp2d6.\namong these beta - blockers atenolol is mainly eliminated by renal excretion, bisoprolol is in part excreted as parent compound via the renal route ( 50 % ), the other 50 % are hepatically metabolised, whereas metoprolol and carvedilol are metabolised by\nthe study analysed the prescribing and dispensing of cyp2d6 drugs ( metoprolol, donepezil, galantamine, codeine, tamoxifen ) together with cyp2d6 - blocking ssris ( paroxetine / fluoxetine ) or ssris without significant cyp2d6 inhibition\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\nor ssris without significant cyp2d6 inhibition ( citalopram / escitalopram / sertraline ), and the related prescribing of cyp2d6 - independent comparator drugs ( atenolol, rivastigmine, propoxyphene, anastrozole ).\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nhe vascular endothelium metabolizes arachidonic acid by cytochrome p450 epoxygenases to epoxyeicosatrienoic acids or eets.\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\nanother enzymatic pathway, the cytochrome p450 ( cyp ) system.\nepoxygenases metabolize arachidonic acid to four regioisomeric epoxyeicosatrienoic acids ( eets ) and selected monohydroxyeicosatetraenoic acids ( hetes )."
        },
        {
          "qas": [
            {
              "id": "60292e1b1cb411341a000111_001",
              "question": "Does Curare function by stimulating the acetylcholine receptor?"
            }
          ],
          "context": "usual clinical concentrations of curare cause competitive inhibition of muscle nicotinic acetylcholine receptors while higher concentrations may induce open channel blockade.\nin aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ach receptor, but rather to be a specific blocking agent for a class of receptor - activated na + and cl - responses.\nthe mode of action of curare, a well - known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique.\nwe applied ach alone ; the nicotinic acetylcholine receptor ( nachr ) antagonist curare, either alone or in the presence of ach ; and the muscarinic acetylcholine receptor ( machr ) antagonist atropine, either alone or in the presence of ach.\nently, however, it has been shown that curare can also block the channels opened by ach at the frog neuromuscular junction as well as on rat and aplysia neurones ; moreover, curare is able to depolarize rat myotubes and thus behaves as an agonist for\ncurare action on nicotinic acetylcholine receptors has a number of facets, of which the best known is competitive antagonism.\none site, competitively blocked by bungarotoxin and by curare, is presumably the acetylcholine receptor.\ncurare binding and the curare - induced subconductance state of the acetylcholine receptor channel.\nnicotinic acetylcholine receptor ( nachr ) - blocking agents [ e. g., curare or alpha - bungarotoxin ( alpha - btx )\nthe short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor"
        },
        {
          "qas": [
            {
              "id": "5fdb2ee4a43ad3127800000f_001",
              "question": "Are somatic mutations positioned towards the nuclear periphery?"
            }
          ],
          "context": "we found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\n. for instance, smoking and uv - related signatures, as well as substitutions at certain motifs, were more enriched in the nuclear periphery.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\nthe chromosomal regions at the nuclear periphery have distinct structural, functional and evolutionary characteristics compared to their centromeric - proximal counterparts\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet\nrecent advances in our understanding of the three - dimensional organization of the eukaryotic nucleus have rendered the spatial distribution of genes increasingly relevant\n. in total, a pathogenic mutation was identified in 12. 9 % of 898 families analyzed. of the 116 mutations identified in total 9 % were novel and 14. 7 % were large genomic rearrangements\nour findings establish that nuclear actin - based mobility shapes chromatin organization by generating repair domains that are essential for homology - directed repair in eukaryotic cells.\nin many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by pr domain - containing protein 9 ( prdm9 ).\n. a likely explanation for the reduction of or transcription is the striking reorganization of nuclear architecture observed in the osn lineage, which disrupts multi - chromosomal compartments regulating or expression in humans and hamsters"
        },
        {
          "qas": [
            {
              "id": "6020ab801cb411341a000081_001",
              "question": "Is belimumab effective for the lupus nephritis?"
            }
          ],
          "context": "a secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.\ncent findings : recently, the belimumab in subjects with systemic lupus erythematosus - lupus nephritis trial tested belimumab, an inhibitor of b - cell activating factor, as an add - on therapy to steroids and either mycophenolate mofetil ( mmf ) or\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\ndurable renal response and safety with add - on belimumab in patients with lupus nephritis in real - life setting ( berliss - ln ).\ns end, there is limited post - hoc randomized evidence to suggest beneficial effect of belimumab, administered on top of standard - of - care, during mainte \" \" ce therapy in lupus nephritis. type i\nst implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with sle, specifically lupus nephritis. by targ\nbelimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis ( including dialysis and transplanted patient ).\nin this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add - on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase iii clinical trials.\nfollowing treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. belimumab might hold promise for this indication.\nbelimumab and low - doses of mycophenolate mofetil as induction therapy of class iv lupus nephritis : case series and literature review."
        },
        {
          "qas": [
            {
              "id": "5fdb4311a43ad31278000028_001",
              "question": "Are enhancers directional in their targeting of gene promoters?"
            }
          ],
          "context": ". unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.\nenhancers function independently of their distance and orientation to the promoters of target genes.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n. over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.\nenhancers are cis - regulatory elements in the genome that cooperate with promoters to control target gene transcription\nuntil recently, identifying each gene's enhancers had been challenging because enhancers do not occupy prescribed locations relative to their target genes.\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\ncomputational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features.\npromoter as well as heterologous promoters in an orientation - independent manner"
        },
        {
          "qas": [
            {
              "id": "606b718994d57fd87900006b_001",
              "question": "Has dupilumab been FDA approved for atopic dermatitis?"
            }
          ],
          "context": "dupilumab is the first us fda approved biologic for treatment of atopic dermatitis.\nin march of 2017, the united states food and drug administration ( fda ) approved dupilumab for the treatment of moderate - to - severe atopic dermatitis in adults that is uncontrolled with topical medications, becoming the first biologic agent approved to\ndupilumab is the first biological treatment approved for moderate - to - severe atopic dermatitis ( ad ).\nin addition, dupilumab is currently under phase iii development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients.\nthe efficacy and safety profile of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and\ndupilumab : a novel treatment for asthma.\nbackground dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\ndupilumab inhibits interleukin - 4 ( il - 4 ) and interleukin - 13 ( il - 13 ) signaling and was previously found to be effective in asthma.\nexpert opinion : supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.\n. new fda - approved therapies for ad are crisaborole and dupilumab."
        },
        {
          "qas": [
            {
              "id": "6025dd0c1cb411341a0000b9_001",
              "question": "Should cerebrolysin be used for aneurysmal subarachnoid hemorrhage?"
            }
          ],
          "context": "conclusion : cerebrolysin injection during the acute period of sah appeared to reduce the mortality rate, especially in poor - grade patients. this study suggests the potential of cerebrolysin for treating aneurysmal sah\n. similarly, there was no difference in moca neurocognitive performance ( p - value : 0. 75 ) and in the incidence of dci ( or : 0. 85 95 % ci : 0. 28 - 2. 59 ). conclusions : use of cerebrolysin in addition to standard - of - care management of aneurysmal sah is safe,\nand mortality in patients with acute aneurysmal subarachnoid hemorrhage.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\nconclusions high - dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage.\nconclusions simvastatin showed no benefits in decreasing the incidence of vasospasm, dci, or all - cause mortality after aneurysmal sah. we conclude that patients with sah should not be treated routinely with simvastatin during the acute stage.\nhigh - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nrandomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent dci or improve functional outcomes after aneurysmal subarachnoid hemorrhage ( asah ).\nstay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage."
        },
        {
          "qas": [
            {
              "id": "603213ea1cb411341a000131_001",
              "question": "Do bacteria release extracellular vesicles?"
            }
          ],
          "context": "release of extracellular vesicles ( evs ) is a common feature among eukaryotes, archaea, and bacteria. however, the biogenesis and downstream biological effects of evs released from gram - positive bacteria remain poorly characterized.\nbacteria derived - extracellular vesicles\nbacterial extracellular vesicles ( evs ) are bilayered lipid membrane structures, bearing integral proteins and able to carry diverse cargo outside the cell to distant sites.\nknowledge of the structure, molecular cargo and function of bacterial extracellular vesicles ( bevs ) is primarily obtained from bacteria cultured in laboratory conditions.\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwe are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nmembranes of the bacterial phagosome are enriched with ubiquitinated proteins in a way that requires its dot / icm type iv secretion system, suggesting the involvement of effectors in the manipulation of the host ubiquitination machinery.\nhere we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta\nour findings provide new insight into the role of evs from gram - positive oral bacteria in periodontal diseases."
        },
        {
          "qas": [
            {
              "id": "6025ddde1cb411341a0000ba_001",
              "question": "Is Tranexamic acid effective for intracerebral haemorrhage?"
            }
          ],
          "context": "interpretation : functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events.\n. three observational studies ( n = 281 ) suggested less haematoma growth with rapid tranexamic acid infusion.\nconclusions : tranexamic acid did not affect a patient's functional status at 90 days after ich, despite there being significant modest reductions in early death ( by 7 days ), haematoma expansion and saes, which is consistent with an antifibrinolytic\n. none of the deaths was considered related to study medication. interpretation : our study does not provide evidence that tranexamic acid prevents intracerebral haemorrhage growth, although the treatment was safe with no increase in thromboembolic\nthe primary outcome was not different between the two groups : 26 ( 52 % ) patients in the placebo group and 22 ( 44 % ) in the tranexamic acid group had intracerebral haemorrhage growth ( odds ratio [ or ] 0 \u00b7 72 [ 95 % ci 0 \u00b7 32 - 1 \u00b7 59 ], p = 0 \u00b7 41 )\ntranexamic acid did not increase the risk of post - intracerebral haemorrhage seizures in the first 90 days.\nof these, two randomised controlled trials ( rcts ) comparing intravenous tranexamic acid to placebo ( n = 54 ) reported no significant difference in death or dependency\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\nconclusions - prehospital treatment with gtn worsened outcomes in patients with intracerebral hemorrhage.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume."
        },
        {
          "qas": [
            {
              "id": "60490dc71cb411341a000167_001",
              "question": "Are interferons defensive proteins?"
            }
          ],
          "context": "the innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\nin response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\nthe interferon - induced gtp - binding protein mx is responsible for a specific antiviral state against a broad spectrum of viral infections that are induced by type - i interferons ( ifn \u03b1 / \u03b2 ) in different vertebrates\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\n. our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of covid - 19.\npossible to construct a suppressive anti - viral regimen.\nsecondly, the degradation of some mrnas related to immune responses has been reported to be regulated by binding of rna - binding proteins to adenylate uridylate - rich elements ( au - rich elements, ares ) located in the 3'- untranslated region ( 3'- utr ).\nthe c - type lectin receptor clec4e and toll - like receptor tlr4 expressed by host cells are among the first line of defense in encountering pathogens.\ns viral glycoprotein cytoplasmic domains may play a role in this coordination, we have investigated the importance of the hemagglutinin - neuraminidase ( hn ) protein cytoplasmic domain in the assembly of the nonsegmented negative - strand rna"
        },
        {
          "qas": [
            {
              "id": "60354a7b1cb411341a000154_001",
              "question": "Do honey contain diastases/amylases?"
            }
          ],
          "context": "the major alpha - amylase in honey was characterized.\nseparation of honey amylase\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\na new rapid method for the determination of honey diastase activity using direct potentiometric principles has been proposed.\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nlysozyme present in the natural tear\ngluconeogenic enzymes such as phosphoenolpyruvate carboxykinase, glucose 6 - phosphatase, and fructose 1, 6 - bisphosphatase.\nlysozyme ( lzm ) is a natural anti - bacterial protein that is found in the saliva, tears and milk of all mammals including humans.\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\nlysozyme in tears, saliva, sweat, and other body fluids,"
        },
        {
          "qas": [
            {
              "id": "601ecab41cb411341a000065_001",
              "question": "Is adenosine signaling prognostic for cancer outcome?"
            }
          ],
          "context": "adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response.\nof a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development.\n. finally, adenosine signaling is associated with reduced efficacy of anti - pd1 therapy in published cohorts ( hr = 0. 29, p = 0. 00012 ). conclusions : these data support the adenosine pathway as a mediator of a successful antitumor immune response,\n. however, it is challenging to measure tumor adenosine levels at scale, thus novel, clinically tractable biomarkers are needed. experimental design : we generated a gene expression signature for the adenosine signaling using regulatory networks\n. further, adenosine signaling is associated with reduced os ( hr = 0. 47, p < 2. 2e - 16 ) and pfs ( hr = 0. 65, p = 0. 0000002 ) in cd8 + t - cell - infiltrated tumors\nthe adenosine signaling using regulatory networks derived from the literature and validated this in patients\n. we applied the signature to large cohorts of disease from the cancer genome atlas ( tcga ) and cohorts of immune checkpoint inhibitor - treated patients. results : the signature captures baseline adenosine levels in vivo ( r 2 = 0. 92, p = 0. 018 ), is\n. analysis of tcga confirms a negative association between adenosine and overall survival ( os, hr = 0. 6, p < 2. 2e - 16 ) as well as progression - free survival ( pfs, hr = 0. 77, p = 0. 0000006 )\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\n. mutation of tgf\u03b2 superfamily members is associated with enhanced adenosine signaling and worse os ( hr = 0. 43, p < 2. 2e - 16 )"
        },
        {
          "qas": [
            {
              "id": "5e67cd6b1af46fc13000001e_001",
              "question": "Does AZD3759 cross the blood brain barrier?"
            }
          ],
          "context": "we report the discovery and early clinical development of azd3759, a selective egfr inhibitor that can fully penetrate the blood - brain barrier ( bbb ),\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nthe results showed the bbb penetration of azd3759 was decreased within 24 hr after radiation, however, the free concentration of azd3759 in brain kept at a high level in the context of radiation.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\nthe next generation egfr tkis osimertinib and azd3759 have improved bbb penetration and the bloom study of osimertinib and azd3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically\n. azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay\nazd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\nseveral brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro bbb model.\nthe blood - brain barrier ( bbb ) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells."
        },
        {
          "qas": [
            {
              "id": "5fe0c141a43ad31278000035_001",
              "question": "Is the zelda transcription factor a chromatin remodeller?"
            }
          ],
          "context": "zelda binds cis - regulatory elements ( tagteam heptamers ), making chromatin accessible for gene transcription.\nthe zinc - finger tf zelda ( zld ) is essential for the maternal - to - zygotic transition ( mzt ) in drosophila melanogaster, where it directly binds over thousand cis - regulatory modules to regulate chromatin accessibility.\nwe demonstrate that zelda is essential for hundreds of regions of open chromatin.\nzld facilitates binding of dl to regulatory dna, and that this is associated with increased chromatin accessibility.\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\nwe postulate that zrf1 operates in conjunction with cellular remodeling machines and suggest that on - site remodeling might be a hallmark of many chromatin - associated signaling pathways.\ntranscription factors and chromatin - remodeling complexes are key determi \" \" ts of embryonic stem cell ( esc ) identity.\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\nthese different timing classes each associate with binding sites for two transcription factors, gaga - factor and zelda, previously implicated in controlling chromatin accessibility at zga.\n. in drosophila, the dna - binding protein zelda ( also known as vielfaltig ) is required for this transition and for transcriptional activation of the zygotic genome."
        },
        {
          "qas": [
            {
              "id": "6025db0e1cb411341a0000b8_001",
              "question": "Is capmatinib effective for glioblastoma?"
            }
          ],
          "context": "however, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\npacritinib ( pac ), a multi - kinase inhibitor with specificity for jak2, flt3, and irak1 but sparing jak1, has demonstrated clinical activity in mf with minimal myelosuppression.\npacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.\ninterpretation : selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common braf aberrations and nf1 - associated paediatric low - grade glioma.\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nalthough further research is needed, cyclin - dependent kinase 4 / 6 inhibitors represent intriguing developments in the treatment of various malig \" \" cies, including those with such poor prognoses as glioblastoma multiforme, mantle cell lymphoma, and"
        },
        {
          "qas": [
            {
              "id": "6057151094d57fd879000027_001",
              "question": "Are there antimicrobial proteins in royal jelly?"
            }
          ],
          "context": "jellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\njelleines, isolated as novel antibacterial peptides from the royal jelly ( rj ) of bees, exhibit broad - spectrum protection against microbial infections.\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\nnutrients such as 24 - methylenecholesterol, major royal jelly proteins, and 10 - hydroxy - 2 - decenoic acid.\nlysozyme ( lzm ) is a natural anti - bacterial protein that is found in the saliva, tears and milk of all mammals including humans.\n. this antimicrobial enzyme forms the part of the innate defense system of nearly all animals and exists in their somatic discharges such as milk, tears, saliva and urine.\nwe observed differences in the metabolome, proteome, and phytosterol compositions of royal jelly synthesized by nurse bees from multi - pesticide exposed colonies, including significant reductions of key nutrients such as 24 - methylenecholesterol, major\nit is also the most studied bee product, aimed at unravelling its bioactivities, such as antimicrobial, antioxidant, anti - aging, immunomodulatory, and general tonic action against laboratory animals, microbial organisms, farm animals, and clinical"
        },
        {
          "qas": [
            {
              "id": "6025e2641cb411341a0000bb_001",
              "question": "Can thiotepa be recommended for treatment of osteosarcoma?"
            }
          ],
          "context": "conclusion. the use of hd thiotepa and asct is feasible in patients with relapsed osteosarcoma. a randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.\n. despite a trend of prolonged survival and an acceptable toxicity, thiotepa cannot be recommended. key message : hdtp and autologous transplantation added to sct did not improve os and pfs in patients with resectable relapsed osteosarcomas\n. despite a trend of prolonged survival, thiotepa cannot be recommended.\nosteosarcoma after radiotherapy for prostate cancer.\nextraskeletal osteosarcoma occurring following radiotherapy for thyroid cancer, and the only case reported in the soft tissue of the head and neck region.\nas the prognosis of radiation - induced osteosarcoma is poorer than that of primary osteo - sarcoma, careful attention is required for consideration of the long - term survival of patients with glioma.\nosteosarcoma following radiotherapy : a case report.\nconclusion : adjuvant hdtp failed to significantly improve os and pfs in resectable relapsed osteosarcomas\npotential immunomodulatory, antiinflammatory, anti - angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma.\ntemozolomide does not improve os and has higher hematological toxicity."
        },
        {
          "qas": [
            {
              "id": "601db7fb1cb411341a00004a_001",
              "question": "Does a comet assay measure radiation induced mutations?"
            }
          ],
          "context": "the comet assay is recognized as a rapid and sensitive method in quantifying radiation induced dna damage.\nthe comet assay is frequently used to measure dna damage in individual cells.\nthis paper attempts a correlation between the induction and repair of dna damage measured in the comet assay and the clinical observed reaction in order to evaluate the suitability of the comet assay for prediction of radiation sensitivity.\na wide variety of mutagens have been shown to cause dna alterations detectable with the comet assay, but it is not yet clear whether a relationship exists between the dna effects and the induction of mutations.\nreliable comet assay measurements for detecting dna damage induced by ionising radiation and chemicals.\nthe relationship between cellular radiosensitivity and radiation - induced dna damage measured by the comet assay.\npurpose : the deoxyribonucleic acid ( dna ) comet assay, being a quick, simple, sensitive, reliable and fairly inexpensive method for measuring dna strand breaks, has been used to assess dna damage caused by gamma radiation in developmental stages of\nevaluation of primary dna - damage is one way to identify potential genotoxic agents and for this purpose the comet assay has, for the last decades, been used to monitor dna single strand and double strand breaks in individual cells\nthe single - cell electrophoresis ( comet ) assay is an established method for measuring radiation - induced strand breaks in dna.\nthe comet assay is a potential tool for use in neutron therapy, as well as a method for the rapid screening of samples from individuals accidentally exposed to radiation."
        },
        {
          "qas": [
            {
              "id": "606c017294d57fd879000076_001",
              "question": "Has the companion diagnostic HercepTest received FDA approval?"
            }
          ],
          "context": "her2 fluorescence in situ hybridization ( fish ) and immunohistochemistry ( ihc ) tests were performed on 52 cases using a us food and drug administration ( fda ) - approved kit ( herceptest, fda kit ) and a laboratory - developed test ( ldt ) with the herceptest\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\ntest ( ldt ) with the herceptest antibody and a leica bond automated stainer.\nreceived marketing approval in the united states and japan for the treatment of ssc - ild.\ntecovirimat : first global approval.\napremilast is now approved for the treatment of oral ulcer of behcet syndrome in the united states.\nbased on positive results from a phase i / ii clinical trial\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\ndesign and testing of a cabotegravir implant for hiv prevention.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia."
        },
        {
          "qas": [
            {
              "id": "6033f5541cb411341a00014c_001",
              "question": "Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis?"
            }
          ],
          "context": "the gluconeogenesis key enzymes pepck ( phosphoenolpyruvate carboxykinase )\nphosphoenolpyruvate carboxykinase ( pepck ) is a metabolic enzyme in the gluconeogenesis pathway,\npck1 is a rate - limiting gluconeogenic enzyme, where its deficiency or mutation contributes to serious clinical situations as neonatal hypoglycemia and liver failure.\ngluconeogenic enzymes such as phosphoenolpyruvate carboxykinase, glucose 6 - phosphatase, and fructose 1, 6 - bisphosphatase.\npepck, a key enzyme involved in gluconeogenesis associated with a decrease in the expression of master genes involved in the vldl synthesis\nthe schizosaccharomyces pombe fbp1 gene, which encodes fructose - 1, 6 - bis - phosphatase, is transcriptionally repressed by glucose through the activation of the camp - dependent protein kinase a ( pka ) and transcriptionally activated by glucose starvation\ntranscriptome analysis of rate - limiting enzymes involved in hepatic gluconeogenesis revealed that moxifloxacin and gatifloxacin at a concentration of 1000 \u03bcm did not affect the expression of key gluconeogenic enzymes such as phosphoenolpyruvate\ncarbon sources by inducing the expression of fbp1 + gene, coding for the gluconeogenic enzyme fructose - 1, 6 - bis\nthe selenoenzyme gpx4 is essential for early embryogenesis and cell viability for its unique function to prevent phospholipid oxidation.\nanother enzymatic pathway, the cytochrome p450 ( cyp ) system."
        },
        {
          "qas": [
            {
              "id": "605265ee94d57fd87900000d_001",
              "question": "Has FTY720  been considered for the treatment of stroke?"
            }
          ],
          "context": ". in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment.\n. although the mechanism of fty720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials\nmany researchers have recognized the positive effects of fty720 and launched basic and clinical experiments to test the use of this agent against stroke\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\ntreatment with a murine anti - icam - 1 antibody ( enlimomab ) has been investigated in patients with acute ischemic stroke in the enlimomab acute stroke trial ( east )\nbased on our knowledge of pathophysiology, three therapeutic strategies are proposed : anti - inflammatory ( ocrelizumab, siponimod \u2026 ) ; remyelinating ( opicinumab ) ; and neuroprotective ( high - dose biotin, ibudilast, simvastatin \u2026 ).\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nas immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases\n. the larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients."
        },
        {
          "qas": [
            {
              "id": "6081af3c4e6a4cf630000008_001",
              "question": "Is colistin an antibiotic?"
            }
          ],
          "context": "all antibiotics tested, apart from colistin,\ncefmetazole, cephalosporin c, aztreonam, piperacillintazobactam, mezlocillin ), 3 tetracycline antibiotics ( meclocycline, doxycycline, tetracycline ), 2 membrane - acting agents ( colistin and clofoctol ),\nmice received an antibiotic cocktail ( kanamycin, gentamicin, colistin, metronidazole, and vancomycin ) for 96 h.\n. colchicine, an inhibitor of nlrp3 inflammasome formation, and il - 1 - targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.\n. this antimicrobial enzyme forms the part of the innate defense system of nearly all animals and exists in their somatic discharges such as milk, tears, saliva and urine.\namong the selected antibiotics, there were 12 fluoroquinolone antibiotics ( tosufloxacin, levofloxacin, sparfloxacin, clinafloxacin, pazufloxacin, gatifloxacin, enrofloxacin, lomefloxacin, norfloxacin, fleroxacin, flumequine, ciprofloxacin ), 15\nfleroxacin, flumequine, ciprofloxacin ), 15 beta - lactam or cephalosporin antibiotics ( cefmenoxime, cefotaxime, ceftizoxime, cefotiam, cefdinir, cefoperazone, cefpiramide, cefamandole, cefixime, ceftibuten, cefmetazole, cephalosporin c, aztreonam,\nimportance : ozenoxacin, a novel topical antibacterial agent with potent bactericidal activity against gram - positive bacteria, has been developed as a cream with 1 % active drug for the treatment of impetigo, a highly contagious bacterial skin\ngsk2140944 is a novel bacterial topoisomerase inhibitor in development for the treatment of bacterial infections.\nfrom clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate."
        },
        {
          "qas": [
            {
              "id": "602e84e61cb411341a000126_001",
              "question": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?"
            }
          ],
          "context": "tocilizumab / actemra is an anti - il - 6r antibody, which can competitively block il - 6 binding to the il - 6r.\ntocilizumab ( roactemra or actemra ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin ( il ) - 6 receptor antagonist.\ntocilizumab ( tcz ; roactemra\u00ae or actemra\u00ae ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin 6 ( il - 6 ) receptor antagonist.\ntocilizumab ( roactemra ( \u00ae ) ; actemra ( \u00ae ) ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin - 6 receptor antagonist.\ntocilizumab ( actemra ; genentech, inc ) is the first biologic therapy targeting the cytokine interleukin 6 ( il - 6 ).\nin 2009 the us food and drug administration accepted a complete - response submission for the use of actemra ( tocilizumab ), the first humanized il - 6 receptor - inhibiting monoclonal antibody, for the treatment of ra.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\nincrease the number of cycles of antigen binding and lysosomal degradation, we engineered tocilizumab ( actemra ), an antibody against the il - 6 receptor ( il - 6r ), to rapidly dissociate from il - 6r within the acidic environment of the endosome ( ph 6. 0 )\nroche is co - developing tocilizumab ( actemra, roactemra ), a humanized anti - interleukin - 6 receptor ( il - 6r ) monoclonal antibody, with chugai pharmaceutical. tocili\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor."
        },
        {
          "qas": [
            {
              "id": "5cebe41ea49efeb44c000006_001",
              "question": "Is the process of DNA loop-extrusion independent of ATP?"
            }
          ],
          "context": "these structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\nthe identification and quantification of further initiation steps - - atp binding and extrusion of an initial dna loop - - allowed us to deduce a complete kinetic reinitiation scheme.\nin support of this model, single - molecule imaging experiments indicate that saccharomyces cerevisiae condensin complexes can extrude dna loops in an atp - hydrolysis - dependent manner in vitro.\nwe observed that a single condensin complex is able to extrude tens of kilobase pairs of dna at a force - dependent speed of up to 1500 base pairs per second, using the energy of adenosine triphosphate hydrolysis\nthe dna - organizing mechanism of condensin depends on the energy of atp hydrolysis but how this activity specifically promotes proper compaction and segregation of chromosomes during mitosis remains poorly understood.\n. in addition, the supercoiling - driven loop extrusion mechanism is consistent with earlier explanations proposing why tads flanked by convergent ctcf binding sites form more stable chromatin loops than tads flanked by divergent ctcf binding sites.\nour model explains what can be the driving force of chromatin loop extrusion and how it can be ensured that loops grow quickly and in a good direction\ndna compaction by cohesin requires adenosine triphosphate ( atp ) hydrolysis and is force sensitive.\nhowever, the model requires a motor to generate the loops, and although cohesin is a strong candidate for the extruding factor, a suitable motor protein ( or a motor activity in cohesin itself ) has yet to be found\nwe suggest that loading and translocation are mediated by conformational changes in cohesin's hinge driven by cycles of atp hydrolysis."
        },
        {
          "qas": [
            {
              "id": "6060df1e94d57fd879000047_001",
              "question": "Is there an upper limit on the functional fraction of the human genome?"
            }
          ],
          "context": "mutational load considerations lead to the conclusion that the functional fraction within the human genome cannot exceed 25 %, and is probably considerably lower.\n. we estimate that, genome - wide, 1 - 3 % of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain - active regulatory elements and that only 0. 15 % of all possible mutations within highly conserved fetal\nan order of magnitude. conclusions : using bagel, we identify ~ 2000 fitness genes in pooled library knockout screens in human cell lines at 5 % fdr, a major advance over competing platforms\ngenome - wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or dna mutations, only explained a minority of the expected heritable fraction\n. in total, a pathogenic mutation was identified in 12. 9 % of 898 families analyzed. of the 116 mutations identified in total 9 % were novel and 14. 7 % were large genomic rearrangements\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\n. the combination of large - scale dna sequencing and functional testing in the laboratory reveals that approximately 1 in 1, 000 individuals carries a variant in pparg that reduces function in a human adipocyte differentiation assay and is associated\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\nsynostosis ( 5. 8 % ) and an 18. 3 - fold enrichment of loss - of - function variants comparedwith gnomad data ( p < 10 - 7 )\nempirical data shows that whole - genome duplications ( wgds ) are more likely to be retained than small - scale duplications ( ssds ), though their relative contribution to the functional fate of duplicates remains unexplored."
        },
        {
          "qas": [
            {
              "id": "601ec5661cb411341a000063_001",
              "question": "Is SLIC-CAGE used for quantification of translation?"
            }
          ],
          "context": ". in addition, active enhancers can be detected through signatures of bidirectional transcription initiation. described here is a protocol for performing super - low input carrier - cage ( slic - cage )\ncap analysis of gene expression ( cage ) is a methodology for genome - wide quantitative mapping of mrna 5'ends to precisely capture transcription start sites at a single nucleotide resolution\ntranscription start site mapping using super - low input carrier - cage.\n. here, we present slic - cage, a super - low input carrier - cage approach to capture 5'ends of rna polymerase ii transcripts from as little as 5 - 10 ng of total rna\n. in combination with high - throughput sequencing, cage has revolutionized our understanding of the rules of transcription initiation, led to discovery of new core promoter sequence features, and discovered transcription initiation at enhancers\n. we demonstrate the ability of slic - cage to generate data for genome - wide promoterome with 1000 - fold less material than required by existing cage methods, by generating a complex, high - quality library from mouse embryonic day 11. 5 primordial germ\n. this slic adaptation of the cage protocol minimizes rna losses by artificially increasing the rna amount through use of an in vitro transcribed rna carrier mix that is added to the sample of interest, thus enabling library preparation from\n. the biggest limitation of cage is that even the most recently improved version ( nant - icage ) still requires large amounts of total cellular rna ( 5 \u00b5g ), preventing its application to scarce biological samples such as those from early embryonic\n. here we used natural genetic variation across a panel of 81 drosophila lines to measure changes in transcriptional start site ( tss ) usage, identifying thousands of genetic variants affecting transcript levels ( strength ) or the distribution of tsss\nsingle - cell sequencing assay for transposase - accessible chromatin ( scatac - seq ) is the state - of - the - art technology for analyzing genome - wide regulatory landscapes in single cells."
        },
        {
          "qas": [
            {
              "id": "6025fa371cb411341a0000be_001",
              "question": "Does hypofractionated radiotherapy offers any benefit for DIPG?"
            }
          ],
          "context": "xternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nconclusions : hypofractionated radiotherapy offers lesser burden on the patients, their families and the treating departments, with nearly comparable results to conventional fractionation, though not fulfilling the non - inferiority assumption.\nconclusions : the results of this meta - analysis suggest that cfrt and hfrt provide similar survival outcomes for patients with dipg.\n. 28 % ( n = 5 ) patients in the experimental arm developed grade 3 or 4 hematological toxicity. conclusion : the above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve os and has higher\nsalvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\ndid not improve survival in patients with borderline resectable or locally advanced unresectable pdac receiving soc neoadjuvant chemotherapy and chemoradiation.\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nconclusion : adjuvant hdtp failed to significantly improve os and pfs in resectable relapsed osteosarcomas\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nthe radiotherapy dose for this patient is lower than classically reported for radiation induced sarcomas."
        },
        {
          "qas": [
            {
              "id": "601d72e61cb411341a000039_001",
              "question": "Is progeria caused by an autosomal recessive gene?"
            }
          ],
          "context": "hutchinson - gilford progeria syndrome ( hgps ) is a rare autosomal domi \" \" t genetic disease that is caused by a silent mutation of the lmna gene encoding lamins a and c ( lamin a / c ).\nhutchinson - gilford progeria causing premature aging of children is a genetic disease and according to most authors has an autosomal domi \" \" t inheritance.\nevidence for autosomal recessive inheritance of progeria ( hutchinson gilford ).\nhutchinson - gilford progeria syndrome ( hgps ) is an autosomal - domi \" \" t genetic disease that leads to accelerated aging and often premature death caused by cardiovascular complications.\nhutchinson - gilford progeria syndrome is an autosomal domi \" \" t, rare, fatal pediatric segmental premature aging disease.\ncontext : hutchinson - gilford progeria syndrome ( hgps ) and mandibuloacral dysplasia are well - recognized allelic autosomal domi \" \" t and recessive progeroid disorders, respectively, due to mutations in lamin a / c ( lmna ) gen\namong them, the most studied is werner's syndrome, \" adult progeria \", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in dna repair.\nhomozygous lmna mutation r527c in atypical hutchinson - gilford progeria syndrome : evidence for autosomal recessive inheritance.\npattern of inheritance of non - classical progeria is most probably autosomal recessive.\nprogeria is an autosomal domi \" \" t, premature aging syndrome."
        },
        {
          "qas": [
            {
              "id": "601d73c71cb411341a00003e_001",
              "question": "Is acupotomy used to treat muscle stiffness?"
            }
          ],
          "context": "acupotomy, a biomechanical therapy guided by traditional chinese medicine theory, alleviates cartilage degradation and is widely used in the clinic to treat koa by correcting abnormal mechanics.\nbackground : acupotomy has been widely used to treat nerve entrapment syndrome.\nboth acupotomy and acupuncture have been widely used clinically to treat csr in china with satisfied efficacy.\n. all the included studies reviewed musculoskeletal disorders and reported a significantly higher total effective and cure rates in the acupotomy group for frozen shoulder, cervical spondylosis, third lumbar vertebrae transverse process syndrome,\nacupotomy alleviates energy crisis at rat myofascial trigger points\nlumbar vertebrae transverse process syndrome, trigger finger, knee osteoarthritis, and lumbar spinal stenosis, compared to the other active control groups. conclusion : acupotomy showed promising results for some musculoskeletal disorders ; however,\nacupotomy has been widely used to treat calcaneodynia.\n[ percutaneous dynamic release in stress position by acupotomy in treating severe scapulohumeral periarthritis ].\nto evaluate the clinical efficacy and safety of acupotomy in treatment of knee osteoarthritis\nto observe the clinical efficacy of minimally invasive acupotomy - injection technique with targeted three - point in the treatment of frozen shoulder. m"
        },
        {
          "qas": [
            {
              "id": "60234bd51cb411341a000093_001",
              "question": "Is ofatumumab effective for multiple sclerosis?"
            }
          ],
          "context": "conclusions : among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.\nofatumumab offers beneficial outcomes for rms by reducing relapse and disability progression risk.\nconclusion : imaging showed that all subcutaneous ofatumumab doses demonstrated efficacy ( most robust : cumulative doses \u226530 mg / 12 wk ), with a safety profile consistent with existing ofatumumab data.\nareas covered : in this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti - cd20 therapies for ms, including rituximab, ocrelizumab, and ofatumumab.\ncurrently, new therapies are emerging that promise more convenience and an improved safety profile ( ofatumumab ) or remyelinating potential with clinical improvement ( opicinumab ).\nanti - cd20 agents for multiple sclerosis : spotlight on ocrelizumab and ofatumumab.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nibudilast for the treatment of multiple sclerosis.\ntofacitinib 10 mg + methotrexate ( mtx ) and baricitinib 4 mg + mtx were among the most effective treatments for active ra with an inadequate dmard or biologic response, followed by baricitinib 2 mg + mtx, tofacitinib 5 mg + mtx, and adalimumab + mtx.\nof relapsing multiple sclerosis and ulcerative colitis"
        },
        {
          "qas": [
            {
              "id": "60206bae1cb411341a00007d_001",
              "question": "Is there a role for Dickkopf-1 (DKK1) in prostate cancer?"
            }
          ],
          "context": "the wnt inhibitor dickkopf - 1 ( dkk - 1 ) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis.\n. epigenetic studies were carried out in a rapid autopsy cohort. results : dickkopf - 1 ( dkk1 ) expression is increased in dnpc relative to prostate - specific antigen ( psa ) - expressing mcrpc in the stand up to cancer / prostate cancer foundation discovery\nckkopf - 1 ( dkk1 ) expression is increased in dnpc relative to prostate - specific antigen ( psa ) - expressing mcrpc in the stand up to cancer / prostate cancer foundation discovery cohort ( 11. 2 v 0. 28 reads per kilobase per million mapped reads ; q < 0. 05 ; n =\nresults support dkk1 as a contributor to the immunosuppressive tumor microenvironment of dnpc\ndkk1 has been implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic breast cancer, and osteoblastic metastases of prostate cancer.\n. dkk1 expression can be regulated by activated wnt signaling in vitro and correlates with activating canonical wnt signaling mutations and low psa mrna in mcrpc biopsies ( p <. 05 )\ndickkopf - 1 protein secretion was documented in breast, prostate and lung cancer lines, but was negligible in melanoma.\n. growth inhibition of the human pca model pc3 by the anti - dkk1 monoclonal antibody dkn - 01 depends on the presence of nk cells in a severe combined immunodeficient xenograft mouse model. conclusion : these results support dkk1 as a contributor to the\n. these data have provided the rationale for a clinical trial targeting dkk1 in mcrpc ( clinicaltrials. gov identifier : nct03837353 ).\nalong with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1epsilon can modulate wnt signaling in vivo by regulating both the beta - catenin - tcf3 and the gbp - dsh interfaces."
        },
        {
          "qas": [
            {
              "id": "602c28551cb411341a000123_001",
              "question": "Has AZD9668 been tested in clinical trials?"
            }
          ],
          "context": "efficacy, safety and tolerability of azd9668 ( 5, 20 and 60 mg bid ) were compared with placebo in a randomised, double - blind, placebo - controlled, 12 - week, phase iib trial ( nct00949975 : approved by an investigational review board ), in patients with\nazd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\n. additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\na randomized, double - blind, placebo - controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis.\nthe study was a 4 - week phase ib multiple ascending dose, randomized, double - blind, placebo - controlled trial of azd0530 in ad patients with mini - mental state examination ( mmse ) scores ranging from 16 to 26.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\n. a global test statistic confirmed that lubeluzole - treated patients had a more favorable clinical outcome at 12 weeks ( p =. 041 ).\neteplirsen - treated patients experienced a statistically significant longer median time to loa by 2. 09 years ( 5. 09 vs. 3. 00 years, p < 0. 01 ) and significantly attenuated rates of pulmonary decline vs. natural history patients ( fvc % p change : - 3. 3 vs\nconclusions : there was a high rate of continued study participation and long - term benefit with ozanimod hcl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active uc in the touchstone ole"
        },
        {
          "qas": [
            {
              "id": "5fdb415ba43ad31278000019_001",
              "question": "Is Nanog repressed in pluripotent stem cells?"
            }
          ],
          "context": "maintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\nnanog, oct4, and sox2 form the core of a transcription factor network that maintains embryonic stem cells in the pluripotent state in both humans and mice.\ncurrent evidence suggests that es cells maintain their pluripotent state by expressing a battery of transcription factors including oct4 and nanog.\nnanog safeguards pluripotency in mouse embryonic stem cells ( mescs ).\nnotably, the expression of nanog, a key pluripotency regulator and repressor of extraembryonic endoderm specification in es cells, was significantly reduced in zic3 knockdown cells.\nnanog maintains pluripotency of mouse embryonic stem cells by inhibiting nfkappab and cooperating with stat3.\nnanog is a newly identified transcriptional factor bearing a homeodomain and expressed in pluripotential cells of preimplantation and early postimplantation embryos, and embryonic stem ( es ) and embryonic germ ( eg ) cells.\nnanog, oct4 and repressor proteins co - occupy nanog - target genes in mouse es cells, suggesting that nanog and oct4 together may communicate with distinct repression complexes to control gene transcription.\nboth tcf3 depletion and wnt pathway activation cause increased expression of oct4, nanog, and other pluripotency factors and produce es cells that are refractory to differentiation.\nhe main finding of this study is that knockdown of trp53 and pten independently resulted in significantly higher expression levels of the pluripotency - associated gene nanog, and we hypothesize that trp53 and pten mediated repression is important for"
        },
        {
          "qas": [
            {
              "id": "6060e03394d57fd879000048_001",
              "question": "Are synonymous sites in primates and rodents functionally constrained?"
            }
          ],
          "context": ". after controlling for the effects of gc content, our results were similar to those from previous studies, i. e., synonymous sites in primates exhibited evidence for higher selective constraint that those in rodents\n. specifically, our results indicated that in primates up to 24 % of synonymous sites could be under purifying selection, while in rodents synonymous sites evolved neutrally.\nto resolve this contradiction between expectations and observations, we used processed pseudogenes as a model for strict neutral evolution, and estimated selective constraint on synonymous sites using the rate of substitution at pseudosynonymous and\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\n. both synonymous and nonsynonymous alleles of mae genes have elevated average population frequencies. we also observed strong enrichment of the mae signature among genes reported to evolve under balancing selection\n. mice carrying a heterozygous loss - of - function mutation of the orthologous gene exhibit alterations in axonal branching and cortical synaptic dynamics accompanied by working memory deficits\nthese selected pairs, both wgd and ssd, tend to have decelerated functional evolution, have higher propensities of co - clustering into the same protein complexes, and share common interacting partners.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\n. here, we show that clusters of cnes strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains ( tads ) in human and drosophila\n. we also demonstrate the utility of this web server based on two case studies, focusing on the relevance of evolutionary conservation of morf regions."
        },
        {
          "qas": [
            {
              "id": "6027f7171cb411341a0000ec_001",
              "question": "Is there a role for TFII-I in megakaryopoiesis?"
            }
          ],
          "context": ". the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\ntfii - i is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. tfii - i has been implicated in neuronal and immunologic diseases as well as in thymic epithelial cancer\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\nin humans, hematopoietic erythroid precursor cells express high levels of tfr1 and specifically take up the fth homopolymer ( h - ferritin ).\nthe signaling functions of both tfr1 and tfr2 in erythroid cells were unexpected and these recent findings open a new field of research regarding the last steps of erythroid differentiation and their regulation.\n. our data indicate that tet proteins regulate inkt cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the t cell antigen receptor ( tcr ).\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\n. a subset of wbs patients has recently been shown to present with macrocytosis, a mild anemia characterized by enlarged erythrocytes. we conditionally deleted the tfii - i / gtf2i gene in adult mice by tamoxifen induced cre - recombination\n. thus, gata - 1 deacetylation and its interaction with hdac1 modulates gata - 1 chromatin binding and transcriptional activity that control erythroid / megakaryocyte commitment and differentiation.\nits role as tumor - suppressor gene from solid tumors to hematopoietic malig \" \" cies."
        },
        {
          "qas": [
            {
              "id": "604915581cb411341a00016a_001",
              "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?"
            }
          ],
          "context": "recently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\nykl - 40 appears to be a more reliable biomarker in neurological diseases than nse.\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\nneurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with alzheimer's dementia, and psychiatric disorders.\nneurofilament light chain ( nfl ) has recently been proposed as a promising biomarker in frontotemporal dementia ( ftd )\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\naqueous humor of glaucoma patients, indicating a promising biomarker for the disease.\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nneuroprotective agents are screened for use in patients with als."
        },
        {
          "qas": [
            {
              "id": "601c3f041cb411341a000018_001",
              "question": "Can propofol cause green urine?"
            }
          ],
          "context": "the green colour of urine due to propofol occurs when clearance of propofol exceeds hepatic elimination, and extrahepatic elimination of propofol occurs.\nthis phenomenon is due to metabolism of propofol which may lead to a phenolic green chromophore which is conjugated in the liver and excreted in the urine.\nclinical significance of rare and benign side effects : propofol and green urine.\nwhat is known and objective : propofol, a commonly used sedative, has on rare occasions, been reported to discolour urine green\ntwo days after admittance, we observed a green discoloration of the urine. this is a rare and benign side effect of propofol.\n. although previously documented in humans, this appears to be the first report of green urine in a dog following propofol use.\nseveral substances in literature have been associated with green urine including propofol, biliverdin, metoclopramide, methylene blue, indigo blue, amitriptyline, methocarbamol, indomethacin, promethazine, cimetidine and food colourings.\ngreen discolouration of urine following propofol infusion in a dog.\nwe discuss a case of a benign cause of green discoloration of urine caused by propofol infusion, which reversed following its discontinuation.\ngreen urine is also caused by medications such as propofol and infections such as pseudomonas."
        },
        {
          "qas": [
            {
              "id": "6032187e1cb411341a000132_001",
              "question": "Are Gram positive bacteria able to release extracellular vesicles?"
            }
          ],
          "context": "release of extracellular vesicles ( evs ) is a common feature among eukaryotes, archaea, and bacteria. however, the biogenesis and downstream biological effects of evs released from gram - positive bacteria remain poorly characterized.\nbacteria derived - extracellular vesicles\nbacterial extracellular vesicles ( evs ) are bilayered lipid membrane structures, bearing integral proteins and able to carry diverse cargo outside the cell to distant sites.\nour findings provide new insight into the role of evs from gram - positive oral bacteria in periodontal diseases.\nknowledge of the structure, molecular cargo and function of bacterial extracellular vesicles ( bevs ) is primarily obtained from bacteria cultured in laboratory conditions.\ngram - negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via toll - like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor - \u03b1 and to activate nlrp3 inflammasome, a multiprotein\nmembranes of the bacterial phagosome are enriched with ubiquitinated proteins in a way that requires its dot / icm type iv secretion system, suggesting the involvement of effectors in the manipulation of the host ubiquitination machinery.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nsuch bacteria are either obligate anaerobic bacteria like clostridium or bifidobacterium or facultative anaerobic like escherichia coli or salmonella.\n. several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),"
        },
        {
          "qas": [
            {
              "id": "6025d88c1cb411341a0000b6_001",
              "question": "Is vocimagene amiretrorepvec effective for glioblastoma?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nof glioblastoma or anaplastic astrocytoma, administration of toca 511 and toca fc, compared with soc, did not improve overall survival or other efficacy end points.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\nconclusion : the combination of inc280 / buparlisib resulted in no clear activity in patients with recurrent pten - deficient glioblastoma.\nthe proteasome inhibitor bortezomib is effective for a variety of tumors, but not for gbm.\nirradiation, however, acts as an oncogenic factor as a delayed effect and it is rare that glioblastoma multiforme develops during the remission period of all.\nexpert opinion : sacituzumab govitecan has promising anti - cancer activity in patients with metastatic tnbc previously treated with at least two prior lines of systemic therapy based on a single arm phase i / ii clinical trial.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial."
        },
        {
          "qas": [
            {
              "id": "601cb7a61cb411341a000026_001",
              "question": "Can Panitumumab cause trichomegaly?"
            }
          ],
          "context": "eyelash trichomegaly is an uncommon drug - associated sequelae experienced during treatment with epidermal growth factor receptor ( egfr ) inhibitors\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\ntrichomegaly of the eyelashes is a rare adverse effect of egfr inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes.\nadding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.\nrepens, hypertrichosis lanuginosa acquisita, papuloerythroderma of ofuji, tripe palms, and multicentric reticulohistiocytosis )\nthe insulin - like growth factor receptor ( igf - 1r ) monoclonal antibody figitumumab, while initially promising, appears to increase toxicity and death in combination with chemotherapy in the treatment of patients with nsclc of squamous histology ;\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nfinally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically - diverse malig \" \" cies ( leser - trelat syndrome, trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita,\npten is a potent tumour suppressor\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract"
        }
      ],
      "title": "BioASQ11b"
    }
  ],
  "version": "BioASQ11b"
}